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Abstract 
Canonical WNT signalling plays a critical role in the regulation of ovarian development 
during embryogenesis; dysregulation of this pathway in adult ovary is associated with 
subfertility and tumourigenesis. The aim of the current study was to elucidate the previously 
unexplored roles of Adenomatous polyposis coli 2 (APC2), a WNT signalling pathway 
regulator, in the ovary using an Apc2 constitutive knockout mouse. For the first time, the 
current work demonstrated essential roles of APC2 in regulating ovarian WNT signalling and 
ovarian homeostasis. In early adulthood, APC2-deficiency resulted in WNT signalling 
activation and sub-fertility driven by intra-ovarian defects. Follicular growth was perturbed, 
resulting in a reduced rate of ovulation and corpora lutea formation, which was not rescued by 
administration of gonadotrophins.  
The current study provides fundamental new knowledge on the role of APC2 in ovarian 
tumourigenesis. APC2-deficiency (on the background of a hypomorph Apc- allele) resulted in 
a predisposition to granulosa cell tumour (GCT) formation, accompanied by acute tumour-
associated WNT-signalling activation and expression of a histologic pattern and molecular 
signature seen in human adult GCTs. Hence, APC2 has an important tumour-suppressor 
activity within ovarian granulosa cells. 
However, APC2 is dispensable for ovarian surface epithelium (OSE) homeostasis. 
APC2 loss on its own, or combined with PTEN or APC loss in the OSE, failed to cause tumour 
development. Introducing APC2-deficiency to an ovarian endometrioid adenocarcinoma 
(OEA) mouse model, driven by loss of PTEN and APC in the OSE, resulted in early initiation 
of tumourigenesis, but attenuated tumour growth. This attenuation was accompanied by 
squamous metaplasia, decreased mitosis, decreased p-ERK1/2 expression and disrupted 
immune/inflammatory signalling. Thus, for the first time, an APC2 functional dualism in 
initiation and progression of WNT-driven OEA in mice is reported. RNA sequence analysis 
unraveled 2 transcripts (HAL and HUNK) associated with OEA progression and should be 
considered for future research.    
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1. Introduction 
1.1. The ovary 
1.1.1. Ovarian biology 
The ovary is the female reproductive organ responsible for the production and release 
of oocytes during ovulation. It also acts as an endocrine gland, secreting the steroidal hormones 
estradiol and progesterone. Histologically, the ovary is formed of an outer cortex and an inner 
medulla. The cortex is composed of ovarian follicles embedded in connective tissue stroma. 
The medulla is formed of loose connective tissue stroma containing blood vessels, lymphatic 
vessels and nerves. The ovarian surface is lined with a single layer of epithelium, the ovarian 
surface epithelium (OSE), formerly known as the germinal epithelium, which is weakly 
attached to a basement membrane. Immediately under the OSE is a layer of fibrous connective 
tissue, the tunica albuginea, which separates the OSE from the ovarian stroma (Figure 1.1) 
(Orsi et al. 2014). 
 
Figure 1.1: The structure of the ovary. (a) Schematic diagram of the ovary showing the different 
functional compartments and follicular developmental stages. (b) Structure of Graafian (pre-
ovulatory) follicle. Copyright © 2004 Pearson education, Inc. publishing. 
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During embryogenesis, the ‘bipotential gonad’ is formed of the gonadal ridge and 
migrating primordial germ cells. The gonadal ridge is formed of a projection from the 
mesothelium, while primordial germ cells are derived from the epiblast, and migrate to the 
gonadal ridge forming ‘oogonia’. Differentiation into an ovary is governed by sex 
chromosomes (absence of Y chromosome), and activation of β-catenin signalling by 
Rspondin1 and Wnt4. Oogonia proliferate by mitosis and then undergo meiosis at embryonic 
day E12.5, when they become oocytes and are arrested at the diploid prophase of meiosis I. 
These oocytes are found in nests, which break down during foetal development, when most of 
them degrade by apoptosis. Surviving oocytes are surrounded by single layer of squamous pre-
granulosa cells, in the second half of foetal development and in early post-natal days, giving 
rise to a ‘finite pool’ of primordial follicles, which are recruited in ‘groups’ throughout life 
until they become completely depleted at menopause (Edson et al. 2009).  
Primordial follicles start to be recruited to grow into primary follicles as early as their 
formation. This ‘initial recruitment’ causes follicles to grow up to the antral stage and then 
undergo atresia. However, after puberty another recruitment, the ‘cyclic recruitment’, happens 
every cycle where a number of primordial follicles are recruited to grow, reaching the antral 
stage but acquiring a different fate (McGee and Hsueh 2000). Puberty-onset happens when 
pulses of gonadotrophin-releasing hormone (GnRH) from the hypothalamus induce the rise of 
follicle-stimulating hormone (FSH) and luteinizing hormone (LH) produced by the pituitary 
gland (Chamberlain et al. 2013). Rising levels of FSH rescues some antral follicles from 
atresia, allowing them to grow further. In humans, one follicle grows faster than the remaining 
follicles, producing high levels of estradiol and inhibin, which by negative feedback inhibits 
FSH production by the pituitary gland, causing the remaining follicles to degenerate (McGee 
and Hsueh 2000). With LH surge before ovulation, the oocyte completes meiosis I, giving 2 
haploid daughter cells (secondary oocyte and polar body). Following this, the secondary oocyte 
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enters meiosis II when it is arrested at metaphase until fertilization occurs (Rodriguez and 
Pangas 2016). 
1.1.1.1. Mouse vs. Human ovary 
Anatomical and physiologic differences exist between mouse and human ovary. For 
instance, while the human ovarian surface is exposed to the surrounding tissue in the  peritoneal 
cavity, the mouse ovary is enclosed in a membrane-like balloon, the bursa  (Treuting and 
Dintzis 2011). Physiologically, the ovary is an active organ with cyclic changes happening 
every 28 days in human, and every 4-5 days in the mouse (Byers et al. 2012). Starting from 
puberty, a certain number of primordial follicles are recruited for follicular growth into 
primary, secondary and one fully mature pre-ovulatory (Graafian) follicle. During maturation, 
both the oocytes and the follicles enlarge, and the follicular cells become small cuboidal 
basophilic granulosa cells, which are surrounded by theca cells. The main function of theca 
cells is the production of androgens; the precursors of estradiol produced by the granulosa cells 
of follicles. On ovulation, the mature Graafian follicle is ruptured along with the adjacent part 
of the OSE, and the oocyte is released from the ovary. In the mouse, several follicles are fully 
mature at the time of ovulation, all of which rupture during ovulation (Treuting and Dintzis 
2011).  
Following ovulation, the remaining somatic granulosa cells of the ovulated follicle form 
the corpus luteum, which is responsible for progesterone secretion and maintenance of 
pregnancy after fertilization of the oocyte. In the absence of fertilization, the corpus luteum 
degenerates and is converted to the non-functional corpus albicans in human. In contrast, the 
corpora lutea from previous cycles do not degenerate in the mouse, with the ovary containing 
both mature corpora lutea from previous ovulations and immature corpora lutea from the most 
recent ovulation. The mature corpora lutea are characterized by large eosinophilic cells and are 
mostly located deeper in the ovarian medulla. The immature recently-developed corpora lutea 
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are characterized by smaller basophilic cells, similar to granulosa cells, and are embedded in 
the ovarian cortex (Dixon et al. 2014). 
1.1.1.2. The ovarian surface epithelium 
The biology and functions of OSE are not as well characterized as the remaining 
structures of the ovary. OSE functions in transporting molecules to and from the peritoneal 
cavity. It plays important roles in ovulation and post-ovulatory wound repair (Murdoch and 
McDonnel 2002). Histologically, the OSE is formed of squamous to cuboidal epithelial cells 
which tend to assume columnar shapes upon metaplastic transformation (Okamoto et al. 2009). 
With age, OSE irregularities form leading to OSE-lined surface invaginations (clefts) and 
epithelial inclusion cysts within the ovarian cortex. These clefts and inclusion cysts have 
historically been thought to be the preferred sites of neoplastic progression (Auersperg et al. 
2001). OSE is a modified pelvic mesothelium, which is less differentiated than other pelvic 
epithelia. OSE displays both epithelial and mesenchymal features but retains the ability of other 
coelomic epithelium to differentiate under pathologic condition (Auersperg et al. 2001). OSE 
shifts to the differentiated epithelial phenotype during neoplastic transformation via 
mesenchymal to epithelial transition (Ahmed et al. 2007). On the other hand, OSE acquires 
mesenchymal phenotype during metastasis by epithelial to mesenchymal transition (Lili et al. 
2013).  
1.1.2. Regulation of ovarian functions 
The complicated biological processes taking place during folliculogenesis and 
ovulation are tightly regulated by endocrine, autocrine and paracrine signals (Orsi et al. 2014). 
The extra-ovarian regulation of ovarian functions is controlled by the hypothalamus and the 
pituitary gland via the hypothalamic-pituitary-ovarian axis. The autocrine and paracrine 
regulation of ovarian functions is controlled mainly by members of TGF-β transcription 
superfamily (Knight and Glister 2006). 
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1.1.2.1. Hypothalamic-pituitary-ovarian axis  
  The pulsatile release of GnRH from the hypothalamus triggers the production and 
secretion of FSH and LH from the pituitary gland. The cyclic changes in levels of these 
hormones control follicular growth and ovulation as well as secretion of estradiol and 
progesterone from the ovary (Figure 1.2a). The hypothalamic and pituitary hormonal secretion 
is tightly regulated by feedback loops governed by ovarian hormones (Figure 1.2b). As their 
names imply, FSH controls follicular growth and maturation, while the main function of LH is 
the luteinisation of ovarian follicles after ovulation. A surge in both LH and FSH is needed for 
ovulation. During folliculogenesis, LH stimulates theca cells to produce androgens, while FSH 
stimulates granulosa cells to produce estradiol. After ovulation, LH controls the development 
and functional activities of the corpus luteum, most critically progesterone secretion (Orsi et 
al. 2014).   
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Figure 1.2: Schematic representation of (a) Hormonal cyclic changes (Gray 2013), and (b) 
Feedback mechanisms regulating the hypothalamic-pituitary-ovarian axis (Sun et al. 2013). (+) 
represents positive feedback. (-) represents negative feedback.  
1.1.2.2. Biosynthesis of ovarian hormones 
Progesterone is considered the precursor of all other hormones synthesized in the ovary. 
Progesterone biosynthesis requires only 2 enzymes, cholesterol side chain cleavage enzyme 
and 3 beta-hydroxysteroid dehydrogenase, both present in granulosa cells, theca cells and luteal 
cells of growing follicles and corpora lutea, respectively. Estradiol, the key female sex hormone 
responsible for follicle growth and maturation, is secreted from granulosa cells in response to 
FSH. According to the two-cell theory of estradiol biosynthesis, the enzymatic machinery 
needed to synthesize progesterone from cholesterol is present in both theca cells and granulosa 
cells. However, the enzymes responsible for the synthesis of androstenedione and testosterone, 
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namely 17α-hydroxylase and C17,20-lyase, are only present in theca cells. On the other hand, 
the aromatase enzyme, which is responsible for the synthesis of estradiol from these 2 
androgens, is only present in the granulosa cells. This  necessitates the transport of androgens 
to granulosa cells prior to their conversion to estradiol (Figure 1.3) (Orsi et al. 2014).  
 
Figure 1.3: Biosynthesis of steroid hormones in the ovary. SCC: cholesterol side chain cleavage 
enzyme, 3β-HSD: 3β-hydroxysteroid dehydrogenase (Griffin and Ojeda 1992) 
1.1.2.3. Autocrine and paracrine regulators 
Due to the complexity of folliculogenesis, hormonal regulation is not considered 
enough to explain processes such as follicle recruitment and selection of dominant follicles. 
Autocrine and paracrine regulators, proteins which are endogenously secreted by ovarian cells 
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and act locally on the producer cell or on nearby cells, are believed to modulate and interact 
with gonadotrophins during folliculogenesis (Canipari et al. 2012). The most studied ovarian 
autocrine and paracrine regulators are the transforming growth factor β superfamily of 
transcription factors (TGF-β)(Knight and Glister 2006), the forkhead box family of 
transcription factors (FOX) (Uhlenhaut and Treier 2011), the insulin-like growth factor system  
(IGF) (Silva et al. 2009), and interleukins (Smolikova et al. 2012).  
1.1.2.3.1. TGF-β superfamily 
Activin, inhibin and anti-müllerian hormone (AMH) are members of the TGF-β 
transcription superfamily that are secreted by granulosa cells of growing follicles. Activin is 
secreted from granulosa cells of pre-antral follicles, and functions to increase FSH secretion 
from the pituitary gland via a positive feedback loop. In addition, it has been shown to increase 
the responsiveness of growing follicles to FSH by inducing the expression of FSH receptors 
(Katayama et al. 2000). Induction of aromatase expression by activin augments the FSH-
induced estradiol secretion, resulting in the stimulation of granulosa cell proliferation and 
follicular growth (Nomura et al. 2013). 
 Inhibin is produced by granulosa cells of antral and pre-ovulatory follicles, and is 
believed to have opposite biological functions to those of activin. Inhibin decreases the 
synthesis and secretion of FSH from the pituitary gland in a negative feedback fashion (Childs 
et al. 1997). In this manner, inhibin prevents the proliferation of granulosa cells of antral 
follicles, hampering their further growth apart from the dominant ‘selected’ follicle (Geng et 
al. 2008).  
AMH, the third member of TGF-β transcription superfamily, is produced by granulosa 
cells of pre-antral follicles. Its main function is to limit the recruitment of primordial follicles 
for folliculogenesis, stimulated by FSH. In this manner, AMH spares the primordial follicle 
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pool throughout the female fertile/reproductive period by preventing their early depletion 
(Durlinger et al. 1999). 
1.1.2.3.2. FOX family 
FOXL2, one of the FOX transcription factor proteins, gained a lot of interest recently 
after the discovery of a somatic missense mutation in 97% of adult granulosa cell tumour 
(GCT) patients (Kalfa et al. 2009). It plays an important role in maintaining the identity of 
granulosa cells (Schmidt et al. 2004), as well as regulating expression of the steroidogenic 
enzyme machinery (Caburet et al. 2012).  
The FOXO family members FOXO1, FOXO3 and FOXO4 are all expressed in the 
ovary (Uhlenhaut and Treier 2011). FOXO3 is expressed in granulosa cells as well as oocytes 
(Liu et al. 2013), and has been shown to reserve the primordial follicle pool from early 
depletion in mice (Pelosi et al. 2013). Activation of FOXO3 causes granulosa cell apoptosis, 
and has been linked to polycystic ovary syndrome (PCOS) in humans (Mikaeili et al. 2016). 
FOXO1 protein is primarily expressed in ovarian granulosa cells of activin-high growing 
follicles, as well as in atretic follicles (Liu et al. 2013).  FOXO1 has been shown to 
downregulate follicular steroidogenesis (Liu et al. 2009), repress LH receptor expression in the 
ovary (Law et al. 2013), and activate apoptosis of granulosa cells (Zhang et al. 2016). FOXO1 
expression is controlled by FSH, causing downregulation of FOXO1 and inhibition of FOXO1-
dependent apoptosis of ovarian granulosa cells (Shen et al. 2014). Although FOXO4 is 
expressed in granulosa cells of ovarian follicles, its deletion does not affect viability or fertility, 
leaving its ovarian function unidentified (Hosaka et al. 2004). 
1.1.2.3.3. IGF 
The IGF system consists of IGF binding proteins (IGFBP1-6), IGF and insulin 
receptors, in addition to the ligands insulin, IGF-1 and IGF-2 (Silva et al. 2009).  IGF-1 and 
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gonadotrophins mutually regulate each other, and IGF-1 has been shown to potentiate the 
response to gonadotrophins by ovarian follicles (Mani et al. 2010). IGF-1 induces follicular 
growth, and its intra-ovarian levels are regulated by gonadotrophins (Checura et al. 2010). 
IGF-2 is thought to function in the selection and maintenance of the dominant follicle, 
by increasing the proliferation of granulosa cells (Livingstone and Borai 2014). In addition, it 
has been reported that it increases the production of androgens from theca cells, and estradiol 
from granulosa cells of follicles (Livingstone and Borai 2014). 
1.1.2.3.4. Interleukins  
Interleukins are a subset of cytokines, which are preferentially produced in 
reproduction-related fluids and all types of follicular cells (Smolikova et al. 2012). They are 
believed to play an autocrine role in the regulation of follicular growth and ovulation; a process 
which is mediated by and results in an inflammatory response (Gerard et al. 2004). Most 
research has been directed towards elucidating the regulatory effects of interleukin-1 (IL-1) on 
ovarian functions. It has been shown to increase the growth of the dominant follicle and the 
maturation of the oocyte (Caillaud et al. 2005). In addition, it is believed to stimulate ovulation 
by inducing the secretion of inflammatory mediators such as prostaglandins, nitric oxides as 
well as proteolytic enzymes (Gerard et al. 2004), as well as regulating steroidogenesis in pre-
ovulatory follicles by inducing progesterone synthesis and inhibiting estradiol synthesis 
(Caillaud and Gerard 2009).  
1.1.3.  Ovarian stem cells 
Stem cells are rare undifferentiated somatic cells which have the ability to indefinitely 
self-renew and differentiate (Mayani 2003). Much effort has been recently directed towards 
characterizing this population in the ovary, following the identification of cellular markers for 
this population. However, no stem cells have been identified in granulosa cells or theca cells 
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(Ng and Barker 2015). Controversy exists about the presence of ovarian germ stem cells (Pan 
et al. 2016). However, success has been achieved in identifying the stem cell pool in the OSE 
(Flesken-Nikitin et al. 2013; Ng et al. 2014). 
The hypothesis for the presence of stem cells in the OSE stems from the efficient 
regeneration and repair of OSE after the rupture caused by ovulation. These stem cells were 
recently characterized in the adult mouse by two groups. Nikitin and colleagues proposed the 
presence of a stem cell niche at the ovarian hilum; the site of entry of blood vessels and nerves 
to the ovary and the junctional area between OSE, mesothelium and oviductal epithelium 
(Flesken-Nikitin et al. 2013). Ng and colleagues showed that, in addition to the hilum, the stem 
cells are also present at the cleft regions between growing follicles or corpora lutea, and are 
abundant at the ovulatory rupture sites (Ng et al. 2014).   
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1.2. Ovarian cancer  
1.2.1. Ovarian cancer statistics 
Ovarian cancer (OC) is a term used to describe a heterogeneous group of malignancies, 
which arise from or involve the ovaries. OC is the second most common gynaecological 
malignancy and the deadliest of them (Marcus et al. 2014). The prevalence of OC is 
continuously rising, with nearly 239 000 new cases diagnosed worldwide in 2012 (Ferlay et al. 
2015). In the UK, OC is the fifth most prevalent cancer in women, with 7378 new cases 
diagnosed in 2014 (4% of all female cancer cases)(CancerResearchUK 2017).  
OC survival rates have changed a little over the last 20 years despite advances in 
treatment. In particular, poor patient survival is related to a lack of specific symptoms, leading 
to late diagnosis, the risk of relapse and development of chemoresistance (Bonome et al. 2008). 
Although one-year survival rates for OC are greater than 70%, 5-year survival rates are less 
than 45% (Siegel et al. 2015). It is the fifth highest cause of cancer deaths in women in the UK, 
accounting for 4128 deaths in 2014 (5% of cancer deaths in women) (CancerResearchUK 
2017). 
OC is considered a disease of the elderly, with 53% of cases diagnosed at the age of 65 
and over. Incidence rates start to rise after the age of 30, and peak in women aged 65-69 
(CancerResearchUK 2017). 
1.2.2. Risk factors 
Some factors might increase the risk of developing OC. It is believed that women who 
ovulate more tend to have higher risk of developing OC. It is well established that increasing 
parity, breast-feeding or oral contraceptive use reduces the risk of OC. On the other hand, 
infertility or hormone replacement therapy use increases OC risk (Doufekas and Olaitan 2014).  
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Lifestyle is considered a potentially controllable risk factor for OC, estimated to relate 
to 21% of OC cases in UK. Smoking tobacco causes OC, with 3% of cases diagnosed in UK 
believed to be linked to smoking (CancerResearchUK 2017). Obesity, talcum powder used in 
the genital area, occupational exposure to asbestos and radiation exposure have been linked to 
OC, although stronger evidence is still needed to confirm these links (Huncharek and Muscat 
2011; Bounin et al. 2014; Usset et al. 2016). 
About 10% of OC cases are caused by familial genetic mutations. BRCA1 and BRCA2 
gene mutations account for 90% of inherited predispositions to OC (Randall and Pothuri 2016). 
Women with endometriosis or a history of breast cancer also have increased risk of OC 
(Munksgaard and Blaakaer 2011). Other medical conditions which have been linked to OC 
include diabetes and Lynch syndrome (Hereditary non-polyposis colorectal cancer) 
(CancerResearchUK 2017). 
1.2.3. Types and origins of OC 
According to the historic histologic classification of OC based on the cell of origin, 
OCs are classified into epithelial, sex-cord stromal and germ cell tumours (Figure 1.4). The 
most prevalent OCs are epithelial tumours, accounting for 90% of cases, followed by sex-cord 
stromal tumours (7%) and germ cell tumours (3%) (Bidus et al. 2012). 
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Figure 1.4: Schematic representation showing the cell of origin of the major types of ovarian 
cancer.  Diagram © Commenwealth of Australia 2016 
1.2.3.1. Epithelial ovarian cancer (EOC) 
 EOC includes histologic subtypes, which differ in their proposed origin, 
pathogenesis and molecular alterations. Histologically, EOCs are classified as serous (30-
70%), endometrioid (10-20%), mucinous (5-20%) and clear cell (3-10%) and undifferentiated 
carcinomas (1%) (Rosen et al. 2009). 
Serous carcinomas show a broad range of histologic features, in contrast to other 
ovarian carcinomas, which have less morphological variations. Serous carcinomas resemble 
cells of the tubal epithelium and display papillary architecture with focal slit-like spaces and 
irregular luminal contours. Ovarian endometrioid adenocarcinomas (OEA) resemble 
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endometrial glands with tubular sheet-like growth and papillae (Przybycin and Soslow 2011). 
Mucinous OC cells resemble gastrointestinal or endocervical epithelial cells, with 
intracytoplasmic mucin, and composed of closely packed glands and cysts (Lee and Nucci 
2003). Clear cell carcinomas (CCC) demonstrate a limited architecture composed of ‘hobnail 
cells’ with clear cytoplasm, which resemble cells found in nests in the vagina (Przybycin and 
Soslow 2011). Undifferentiated carcinomas lack histological differentiating features. 
Different theories have been proposed to define the cell of origin of EOC (Figure 1.5). 
Different histologic types of EOC have historically been thought to be derived from the OSE 
following metaplastic changes, leading to the development of different histotypes whose 
epithelium resembles müllerian duct-derived epithelium. These metaplastic changes are 
believed to be associated with ovulation, which contributes to increased risk for genetic 
aberrations to the OSE in response to repeated rupture and repair (Fleming et al. 2006).  In this 
model, OSE clefts and inclusion cysts are the preferred sites for neoplastic progression of OSE. 
This may be attributed to the fact that the epithelial cells in the cleft and cysts are not separated 
from the underlying stroma, enhancing their access to stromal-derived cytokines and hormones, 
which promote neoplastic progression (Deligdisch et al. 1995).  
With the recent advances in the identification and isolation of stem cells from the OSE, 
it could be suggested that OSE stem cells, when trapped inside the ovary, can initiate EOC and 
differentiate into any of the müllerian tumour lineages (Ng and Barker 2015).  
An alternative theory proposes that tumours with a müllerian phenotype (serous, 
endometrioid or clear cell) are derived from müllerian-type tissue not the OSE mesothelium. 
These tumours can be derived from para-ovarian and para-tubal microscopic structures, 
collectively known as ‘secondary müllerian system’ (Dubeau 1999). Another hypothesis is that 
these cells are derived from epithelial cells of the uterine endometrium (endometrioid and clear 
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cell histotypes) or fallopian tube (serous histotype) by retrograde menstruation, following their 
travel up to the ovary and shedding from the distal part of the fallopian tube (fimbria) into the 
ovary at the site of rupture post ovulation (Kurman and Shih 2016). 
More recently a third theory has been advanced which argues that the majority of 
ovarian carcinomas, the high grade serous carcinomas, arise primarily in the fallopian tube as 
serous tubal intraepithelial carcinomas, which then spread to the ovary (Seidman et al. 2011).  
 
Figure 1.5: Schematic outline of different theories proposed to define epithelial ovarian cancer 
EOC cell of origin.  
1.2.3.1.1. Ovarian cancer stem cells 
 Cancer stem cells (CSCs) represent a very small subgroup of tumour cells 
characterized by their capacity of self-renewal, differentiation and tumour initiation (Wicha et 
al. 2006). Unlike rapidly dividing cancerous cells, CSCs are quiescent, thus escaping the effects 
of current cytotoxic therapies designed to destroy rapidly dividing cells. CSCs may have 
upregulated DNA repair capacity, be resistant to apoptosis and over-express ATP-binding 
cassette (ABC) drug efflux transporters. They are thus believed to play a crucial role in tumour 
development, chemo-resistance and relapse after initial treatment (Tomao et al. 2014). 
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CSCs from OC were first isolated from malignant ascites (Bapat et al. 2005), and 
thereafter from primary human ovarian tumours and OC cell lines (Lin et al. 2011; Wang et al. 
2012). Ovarian CSCs are regulated by a variety of genes, micro RNAs and the surrounding 
tumour microenvironment (termed ‘CSC niche’). Developmental signalling pathways, 
including Notch, WNT, Hedgehog and TGF-β have been implicated in the regulation of CSCs 
including ovarian CSCs (Kwon and Shin 2013).  
1.2.3.2. Non- epithelial ovarian tumours 
Sex-cord stromal tumours originate from the stromal cells or somatic cells of the 
growing follicles. Granulosa cell tumours are the most prevalent histotype in this group, 
representing about 5% of all OC cases. Other types in this group are thecoma (from theca cells), 
fibroma (from fibroblasts), luteoma (from luteal cells) and androblastoma (Sertoli-Leydig cell 
phenotype) (Horta and Cunha 2015).  
Germ cell tumours, arising from the germinal cells (which give rise to the oocyte), are 
the least prevalent. These tumours are further classified into dysgerminoma, teratoma and yolk 
sac tumours (Shaaban et al. 2014). 
1.2.4. Molecular pathogenesis of OC 
The molecular pathogenesis of OC differs from one histotype to another. In high-grade 
serous ovarian carcinoma (HGSOC), mutations in TP53 and genomic instability predominate 
in 95% of cases, with frequent germline (9%) and somatic (3%) mutations in BRCA1 and 
BRCA2 (CGARN 2011). Low-grade serous ovarian carcinoma (LGSOC) often harbours 
activating mutations in KRAS and its downstream mediator BRAF (Singer et al. 2003).  
Aberrant activation of Wnt/β-catenin signalling, mainly via activating mutations of 
catenin β1 (CTNBB1) gene and microsatellite instability, are characteristic of ovarian 
endometrioid adenocarcinoma (OEA) (Wu et al. 2001; Tanwar et al. 2013). Somatic 
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inactivating mutations in the chromatin remodelling gene ARID1A, together with inactivating 
mutations of PTEN or activating mutations in PIK3CA, are common in both OEA and clear 
cell carcinoma (CCC) (Fujiwara et al. 2016). Recently, increased promoter methylation of 
genes involved in the estrogen receptor α (ERα) pathway have also been identified in CCC, in 
addition to loss of promoter methylation in genes of the hepatocyte nuclear factor 1 pathway 
(Yamaguchi et al. 2014).  
In the remaining histologic subtypes, KRAS activating mutations along with 
amplification of its signalling activator HER2 and the downstream target BRAF, are present in 
90% of mucinous carcinomas (Anglesio et al. 2013). Frequent mutations in TP53 are present 
in mucinous carcinomas and recently another inactivating mutation, the RNF43 mutation, has 
also been identified (Ryland et al. 2013). In adult granulosa cell tumours, FOXL2 somatic 
missense mutation has been identified in 97% of tumours (Shah et al. 2009). DICER1 
mutations are present in 60% of Sertoli-Leydig cell tumours of the ovary (Wang et al. 2015b). 
1.2.5. Grading EOC 
Kurman and Shih have proposed a dualistic model that categorizes EOC into low grade 
Type I and high grade Type II (Figure 1.6) (Kurman and Shih Ie 2010; Kurman and Shih 2016). 
Type I tumours make up 10-20% of EOC, are diagnosed in an early stage and have better 
prognosis. They include mucinous, clear cell, and low-grade serous and endometrioid 
histotypes. These tumours are genetically more stable and are characterized by the presence of 
somatic mutations in one or more of KRAS, BRAF, ERBB2 (HER2) , CTNNB1, PTEN, PIK3CA 
and ARID1A genes. Type II tumours are more aggressive, always diagnosed at an advanced 
stage and with poor prognosis. They include HGSOC, high-grade OEA, and undifferentiated 
cancers. They are characterized by marked chromosomal instability with a very high frequency 
of TP53 mutations. 
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Figure 1.6: Dualistic model of grading EOC as proposed by Kurman and Shih (Kurman and 
Shih 2016). ARID1A: AT-rich interaction domain 1A; BRAF: B-Raf proto-oncogene; CCNE1: 
cyclin E1; ERRB2: estrogen-related receptor β2; HR DDR: homologous recombination-
mediated DNA damage repair; KRAS: Kirsten rat sarcoma viral oncogene homologue; MEK: 
mitogen-activated protein (MAP) extracellular signal-related kinase (ERK) kinase; MMR: 
DNA mismatch repair; NF1: nuclear factor 1; PI3K: phosphatidylinositol 3-kinase; PTEN: 
phosphatase and tensin homologue; Rb: retinoblastoma protein. 
1.2.6. Staging OC 
Staging of gynaecological cancers, including OC, has been standardized by The 
International Federation of Gynaecologists and Obstetricians (FIGO) (Prat 2013). OC, together 
with primary fallopian tube and primary peritoneal cancer, are staged surgically and 
pathologically into 4 stages (Prat 2013). 
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Stage I: Tumour confined to ovaries or fallopian tube(s). Most OC patients are 
diagnosed beyond this stage, apart from GCT patients, who are mostly diagnosed at this stage 
(Mangili et al. 2013), with overall 15% OC patients being diagnosed at this stage (Jelovac and 
Armstrong 2011) 
Stage II: Tumour involves one or both ovaries or fallopian tubes spreading to the 
fallopian tube or uterus (IIA) or is associated with primary pelvic intraperitoneal cancer (IIB). 
17% of cases are diagnosed at this stage (Jelovac and Armstrong 2011) 
Stage III: Tumour involves one or both ovaries or fallopian tubes, or primary pelvic 
intraperitoneal cancer, with confirmed cytological or histological spread to the peritoneum 
outside the pelvis, and/or metastasis to the retroperitoneal lymph nodes. The majority of OC 
patients (62%) are presented at this stage (Jelovac and Armstrong 2011) 
Stage IV: Ovarian tumours with distant metastasis excluding peritoneal metastases. 
This includes pleural effusion with positive cytology (IVA) or liver, spleen and extra-
abdominal metastases (IVB). Less than 10% of patients are diagnosed at this stage (Cormio et 
al. 2003) 
1.2.7. EOC screening 
One of the major problems with EOC is being asymptomatic in early stages of the 
disease. The most common symptoms of EOC are related to abdominal discomfort, back pain 
and urgency to urinate, which could easily be mistaken for irritable bowel syndrome or pre-
menstrual syndrome. Given that EOC is located deep within the pelvis, and a lack of effective 
diagnostic methods, more than 60% of patients are diagnosed at advanced stages. Therefore, it 
is important to develop early detection markers to be used for screening and following up 
patients with EOC. 
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There is currently no screening test reliable enough to detect early stage EOC patients. 
Cancer antigen 125 (CA125) is the most widely studied biomarker for EOC, as it tends to be 
higher in women with EOC. However, it can be increased in many other conditions unrelated 
to OC (e.g. abdominal disorders, lung diseases and non-malignant gynaecological diseases) as 
well as in other cancers, decreasing its specificity (Buamah 2000). Its sensitivity as a screening 
tool to identify early stage disease is limited, with only 50% of patients with stage I ovarian 
cancer showing elevated levels (Nossov et al. 2008).   
Another useful biomarker is the human epididymis protein 4 (HE4), which shows better 
sensitivity compared to CA125 (mainly for early-stage EOC), and the ability to differentiate 
between benign and malignant tumours (Simmons et al. 2013). Multiplex screening using a 
panel of serum biomarkers, including CA125 and HE4, has proved to have better sensitivity, 
specificity and reliability compared to any individual biomarker (Moore et al. 2009). 
It is therefore vital to identify and validate new diagnostic biomarkers for early 
diagnosis of EOC. Various gene- and microRNA-based OC biomarkers have been recently 
identified and might be promising in early detection of the different histotypes of EOC, but 
their clinical utility is still under investigation (Zhang et al. 2011a; Pal et al. 2015). 
1.2.8. EOC diagnosis 
According to the National Institute for Health and Care Excellence (NICE) guidelines, 
any female patient (especially older than 50) suffering from abdominal bloating, pelvic pain or 
increased frequency to urinate should have a CA125 serum measurement test. If CA125 levels 
are higher than 35 IU/ml, an ultrasound scan of the abdomen and pelvis should be arranged. 
The same applies for any woman with ascites, pelvic or abdominal mass during physical 
examination (NICE 2011).  
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If the ultrasound, together with physical examination and elevated CA125 levels 
suggest EOC, a computerized tomography (CT) scan for pelvis and abdomen should be 
performed. If confirmed, the disease should be identified and staged histologically by 
examining a tumour specimen either after surgical resection or on a biopsy obtained via 
percutaneous image-guided biopsy (NICE 2011). 
1.2.9. EOC treatment 
1.2.9.1.Management of EOC patients  
The current gold standard treatment strategy for EOC is surgical resection, followed by 
platinum or taxane therapy (Fujiwara et al. 2013), which reduces tumour burden and causes 
cancer cell death via DNA and cytoskeletal damage responses (Abubaker et al. 2014). In 
patients with early disease (FIGO stage I-II), surgery is able to cure the disease without 
adjuvant chemotherapy and the 5-year survival rate is around 90%. However, only 30% of OC 
cases are diagnosed at this early stage. In patients diagnosed with FIGO (III-IV) OC, maximal 
surgical cytoreduction (total abdominal hysterectomy, bilateral salpingo-oophorectomy, pelvic 
and para-aortic lymphadenectomy and omentectomy) followed by systemic platinum-based 
chemotherapy, is the standard treatment strategy, with a 5-year survival of 10-30% (Kim et al. 
2012). This low survival is due to the fact that approximately 80% of women with advanced 
OC (stage III and IV) will have tumour recurrence.  This is usually eventually fatal due to the 
emergence of drug resistance in the microscopic residual disease persisting after the first line 
chemotherapy (Luvero et al. 2014).  
1.2.9.2. Chemoresistance to cytotoxic agents 
The development of chemoresistance in EOC is poorly understood, although many 
different theories have been proposed to explain the origin of chemoresistant cells. One theory 
proposes cytotoxicity-induced mutations occurring within the tumour population, that lead to 
chemoresistance (Fraser et al. 2003). Another suggests that genetically heterogeneous clones 
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exist in the tumour that differentially respond to the cytotoxic therapy, with the chemosensitive 
clones eradicated post-treatment, thus leaving the resistant clones to survive after therapy 
(Cunnea and Stronach 2014). Those chemoresistant tumour cells express high levels of 
multidrug resistance transporters, proliferate slowly and can repair damaged DNA, a phenotype 
that is commonly displayed by CSCs (Ahmed et al. 2013). A recent theory relates 
chemoresistance to the metabolic interaction between tumour cells and their 
microenvironment, which can cause tumour cells to become quiescent, thereby escaping 
cytotoxic effects (Suh et al. 2014). Targeting molecular pathways and mechanisms responsible 
for chemoresistance could lead to better prognosis. 
1.2.9.3. Targeting OC microenvironment 
It is now widely accepted that cells (tumour, stromal and inflammatory cells) and 
molecules present in the tumour microenvironment affect tumourigenesis, mainly through 
promoting angiogenesis and modulating stromal invasion and metastasis. Antiangiogenic 
agents, targeting endothelial cells, are currently undergoing clinical trials for use as single 
agents or in combination therapy with platinum or taxanes, and the results published so far are 
promising, as reflected by improved progression-free survival and objective response rate 
(Luvero et al. 2014). Bevacizumab, a recombinant antibody targeting vascular endothelial 
growth factor (VEGF), is approved by the European Medicines Agency for use in treating 
primary OC patients with tumour stage beyond FIGO stage IIIA, and in recurrent OC cases 
(Lokadasan et al. 2016). 
Cancer-associated fibroblasts (CAFs) have been shown to play important roles in EOC 
progression and metastasis. Targeting fibroblast growth factor receptor (FGFR) appears to be 
an attractive intervention, and several clinical trials are testing the efficacy of non-specific 
targeting of FGFR using receptor tyrosine kinase inhibitors in solid tumours (Hansen et al. 
2016). Of interest are the clinical trials on nintedanib, a non-specific receptor tyrosine kinase 
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inhibitor, which targets FGFR in addition to VEGFR and platelet-derived growth factor 
receptors. It is now undergoing phase III clinical trials as a single agent or in combination with 
platinum/taxane treatment in primary or recurrent EOC patients, and the results published so 
far are promising, showing an increase in progression-free survival (du Bois et al. 2016).  
Inflammation has historically been hypothesized as an initiator of EOC. Inflammatory 
mediators have been shown to promote tumour progression and metastasis (Knutson et al. 
2015), and targeting such molecules in the microenvironment is an attractive alternative. Some 
success was reported by targeting the pro-inflammatory tumour necrosis factor-α (TNF-α) and 
interleukin-6 (IL-6). Targeting TNF-α prolonged disease stabilization in 20% of patients 
undergoing phase II clinical trial, and  targeting interleukin-6 (IL-6) in a phase II clinical trial 
(in combination therapy) resulted in 1/18 patient with a partial response and 7/18 with periods 
of disease stabilization. TNF-α antagonists etanercept and infliximab are currently undergoing 
clinical trials for their use in OC patients (Coward et al. 2015). 
1.2.9.4. Targeting signalling pathways in EOC 
Targeting PTEN/PI3K/AKT could be useful in many type I EOC patients, where 
inactivating mutations of PTEN or activating mutations in PIK3CA, are common (Fujiwara et 
al. 2016). Clinical trials have been conducted for a range of mTOR inhibitors, either as a single 
agent or in combination with other agents, but the results were disappointing because of low 
response rates (Cheaib et al. 2015). More promising results were encountered with AKT 
inhibitors and PI3K inhibitors, showing higher response rates in combination therapy with 
cytotoxic agents, and are undergoing phase II clinical trials (Cheaib et al. 2015). 
WNT signalling has been previously shown to play important roles in EOC 
tumourigenesis, chemoresistance and activation of ovarian CSCs (Nagaraj et al. 2015). Early-
stage clinical trials for targeting WNT signalling in many solid tumours, including OC, are 
  
25 
 
currently ongoing (Masuda et al. 2015). Several approaches are under investigation, including 
targeting extracellular secretion of Wnt proteins using porcupine inhibitor, targeting Frizzled 
(FZD) receptors using monoclonal antibodies (e.g. vanituctumab) and targeting β-catenin co-
activators (e.g. PRI-724) (Zhang and Hao 2015).  
WNT signalling activation contributes to the tumorigenicity of CSCs. A new Wnt 
antagonist, OMP-54F28, was recently developed. Preclinical studies showed reduced tumour 
growth and decreased CSC frequency when OMP-54F28 was used as a single agent or in 
combination with other chemotherapeutic agents. A phase 1B trial is ongoing to study OMP-
54F28 in combination with paclitaxel and carboplatin in OC patients (Le et al. 2014). 
Targeting KRAS/BRAF could be an effective strategy for treating patients with low-
grade serous or mucinous OC. Some success was achieved using MEK inhibitors for treating 
low-grade serous carcinoma (Coward et al. 2015). A phase II/III clinical trial is currently 
ongoing in the UK for assessing the efficacy of the MEK inhibitor trametinib (GSK 1120212) 
in patients with recurrent or progressive low-grade serous OC or peritoneal cancer (Coward et 
al. 2015). 
HGSOC patients with BRCA1 or BRCA2 mutations could benefit from poly adenosine 
diphosphate (ADP)-ribose polymerase (PARP) inhibitors. Food and Drug Administration 
(FDA) has recently approved the use of olaparib, the leading PARP inhibitor, as a fourth-line 
therapy in recurrent HGSOC BRCA-mutated patients (Meehan and Chen 2016). 
1.2.9.5.Targeting CSCs 
Targeting CSCs, the cell population thought to be responsible for chemoresistance and 
relapse, appears attractive (Walters Haygood et al. 2014), and several approaches are currently 
being developed. One is to target regulatory signalling pathways of CSCs e.g. WNT signalling. 
Another approach is to use immunologic therapy, with antibodies to CSC-surface markers. 
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Hyaluronic acid-cisplatin and hyaluronic acid-paclitaxel conjugates were both tested to target 
CD44-positive cancer cells in a xenograft EOC model (Li and Howell 2010; Lee et al. 2012). 
Both interventions reduced tumour growth when compared to free unconjugated cytotoxic 
treatment. A third approach is to target the metabolic interaction between CSCs and their 
microenvironment; modulating the energy metabolism in ovarian CSCs using metformin was 
shown to restrict the growth and proliferation of ovarian cancer stem cells in vitro and in vivo 
(Kim et al. 2014b).  
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1.3. Signalling pathways dysregulated in OEAs  
1.3.1. WNT signalling 
WNT signalling is a highly conserved developmental signalling pathway that is known 
to play several roles during embryogenesis, adulthood and tumourigenesis, through the  
regulation of cell fate, proliferation, migration and stem cell activity (Smalley and Dale 1999). 
Wnt is a family of secreted glycoproteins with 19 identified members, which bind mainly with 
the FZD receptor to transduce the signal intracellularly via Dishevelled (Dvl) and initiate the 
response via activating downstream signalling cascades (Anastas and Moon 2013). These 
signalling cascades are classified into canonical (Wnt/B-catenin) and non-canonical WNT 
signalling cascades, the latter of which includes planar cell polarity (PCP) and Wnt/calcium 
signalling pathways (Figure 1.7)(Inestrosa and Varela-Nallar 2015). 
1.3.1.1. Non-canonical WNT signalling 
Calcium-dependent WNT signalling transduces the signal via increasing the 
intracellular concentration of calcium. This subsequently leads to the repression of cyclic 
guanosine monophosphate (cGMP) and activation of NEAT transcription factor, and protein 
kinases including protein kinase C (PKC) and calcium/calmodulin-dependent protein kinase II 
(CaMKII) (Inestrosa and Varela-Nallar 2015).    
Unlike calcium-dependent and canonical WNT signalling cascades, the PCP pathway 
does not activate gene transcription. Instead, Wnt glycoproteins bind to FZD receptors (and/or 
RYC, ROR receptors) to phosphorylate Dvl, causing activation of small GTPases RHO and 
RAC, which subsequently activate JNK proteins, known regulators of cytoskeletal 
arrangement, cell migration and cell polarity (Inestrosa and Varela-Nallar 2015). 
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Figure 1.7: Schematic illustration of WNT signalling pathway: Canonical WNT signalling, 
calcium-dependent pathway (Wnt/Ca+2), and planar cell polarity (PCP) pathway. Frizzled 
(FZD). Low density lipoprotein-related protein 5 or 6 (LRP5/6). Dishevelled (Dvl). Glycogen 
synthase kinase-3β (GSK-3β). Adenomatous polyposis coli (APC). Phospholipase C (PLC). 
Inositol triphosphate (IP3). Endoplasmic reticulum (ER). Calcium/calmodulin-dependent 
protein kinase II (CamKII). Protein kinase C (PKC). Rho-associated protein kinase (ROCK). 
Jun N-terminal kinase (JNK). (Inestrosa and Varela-Nallar 2015) 
Historically, Wnt glycoproteins were classified as canonical or non-canonical (Du et 
al. 1995). However, it has been shown that some Wnt glycoproteins can interact with both 
cascades in different manners, and their interaction is context-specific. For example, Wnt11 
has been shown to activate both canonical and non-canonical WNT signalling (Cha et al. 2008). 
Conversely, Wnt5a which activates non-canonical WNT signalling, has been shown to both 
activate and repress canonical WNT signalling (van Amerongen et al. 2012). 
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1.3.1.2. Canonical WNT signalling 
This signalling cascade regulates the transcription of genes controlling cell 
proliferation, differentiation and fate. In the absence of Wnt glycoprotein, a β-catenin 
destruction complex is formed of the scaffolding protein AXIN1, adenomatous polyposis coli 
(APC), glycogen synthase kinase-3 (GSK3) and casein kinase-1 (CK1) proteins, resulting in 
phosphorylation of β-catenin, marking it for ubiquitination and degradation. This keeps the 
cytoplasmic β-catenin concentration low, thus preventing its translocation to the nucleus. 
Conversely, after the binding of Wnt glycoproteins to FZD receptors and LRP co-receptors, 
Dvl is phosphorylated and recruited to interact with AXIN1, causing the destruction complex 
to fall apart. This prevents phosphorylation of β-catenin, leading to its accumulation in the 
cytoplasm and subsequent translocation to the nucleus, where β-catenin initiates the 
transcription of Wnt target genes upon binding with TCF (Figure 1.8)(Clevers 2006). 
 
Figure 1.8: Schematic representation of canonical WNT signalling pathway (Clevers 2006). 
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Canonical WNT signalling was previously reported to regulate female gonadal 
differentiation and development during embryogenesis (Pellegrino et al. 2010). In addition, 
WNT signalling functions in regulating follicular development, corpus luteum maturation and 
ovarian steroidogenesis (Richards and Pangas 2010; Lapointe and Boerboom 2011; Pan et al. 
2014).  It has been suggested that WNT signalling is important for the differentiation of OSE, 
and that WNT signalling deregulation in the OSE plays a functional role in tumourigenesis. 
However, the exact mechanisms are not yet defined (Usongo 2013). 
Aberrant WNT signalling is involved in tumour initiation and progression in many 
epithelial tumours, including EOC (Arend et al. 2013; Voloshanenko et al. 2013; Jiang et al. 
2014). WNT signalling is considered to play an important role in epithelial to mesenchymal 
transition (EMT) in EOC, a process implicated in chemoresistance and metastasis (Ford et al. 
2014). WNT signalling is one of the important signalling pathways deregulated in cancer stem 
cells, driving their self-renewal and differentiation (Holland et al. 2013). With the exception of 
OEA, mutations in WNT signalling genes are considered rare in EOC. It was believed that 
WNT signalling is implicated in the pathogenesis of OEA subtype only. However, emerging 
data shows that WNT signalling is involved in the tumorigenesis of other histotypes of EOC 
(Maria and Rebecca 2011). 
1.3.1.3. Adenomatous polyposis coli APC 
Adenomatous polyposis coli (APC) is a tumour suppressor protein which negatively 
regulates canonical WNT signalling, being a part of the β-catenin destruction complex 
(Benchabane and Ahmed 2009). APC protein function is attenuated by mutations of one or 
both APC alleles or by promoter methylation, leading to tumourigenesis, mainly in colorectal 
cancer (TCGA 2012), but also in hepatocellular carcinoma (Xu et al. 2014) and ovarian cancer 
(Shen et al. 2016).  
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APC is a large multifactorial protein widely expressed in all body tissues, formed of 
2843 amino acids encoded by 16 exons (Crist et al. 2010). APC is formed of different domains 
which function in the control of cell migration, adhesion, proliferation, differentiation, 
chromosomal segregation and stabilization of microtubules (Figure 1.9) (Aoki and Taketo 
2007). Point mutations mostly occur in the mutational cluster region, causing truncation of the 
protein C-terminal (including β-catenin binding domains) and subsequently causing canonical 
WNT signalling activation leading to upregulation of downstream oncoproteins such as MYC 
and Cyclin D1 (Aoki and Taketo 2007). 
 
Figure 1.9: Schematic representation of APC protein domains and their functions. APC 
armadillo repeats bind to Asef1 and Asef2 to stimulate cell migration. APC controls cell 
adhesion via controlling β-catenin membranous and cytoplasmic distribution. APC inhibits 
transcription of β-catenin target genes. APC controls chromosomal segregation via kinetochore 
binding and suppression of canonical WNT signalling. (Aoki and Taketo 2007) 
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1.3.1.4. Adenomatous polyposis coli 2 APC2 
Adenomatous polyposis coli 2 (APC2), formerly known as APC-like (APCL), is a 
tumour suppressor protein homologous to APC. In humans, the  protein is encoded by the APC2 
gene, present on chromosome 19 and formed of 17 exons (Van Es et al. 1999). The Mouse 
Apc2 gene is homologous to the human APC2 gene, is located on chromosome 10, spans 14 
kb and is formed of 14 exons (Figure 1.10)(Bell et al. 1999). The highest expression of APC2 
has been detected in the foetal and adult brain respectively (Van Es et al. 1999). Low levels of 
APC2 are expressed in a wide range of tissues, including the ovary (Jarrett et al. 2001). 
Most of the studies carried out to functionally characterize APC2 have been performed 
in Drosophila or mammalian cell lines. Using a mammalian carcinoma cell line, it was shown 
that APC2 downregulates β-catenin and regulates the formation of β-catenin-TCF complexes, 
suggesting that it plays a role in the Wnt/β-catenin signalling pathway (Van Es et al. 1999). 
This role was confirmed in a study with cell lines and Drosophila embryos, showing that 
APC2’s regulation of WNT signalling is independent of its cytoplasmic localization or ability 
to enter the nucleus (Roberts et al. 2012). 
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Figure 1.10: Schematic representation showing similarities between human (A) APC and (B) APC2 proteins.(McCartney et al. 2006) 
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Biochemical and localization studies in Drosophila suggested that APC2 has a role in 
cytoskeleton regulation and microtubule association (McCartney et al. 1999). APC2 plays a 
role in spindle anchoring during mitosis in the Drosophila embryo, and participates with 
armadillo and β-catenin in linking mitotic spindles to cortical actin (McCartney et al. 2001). 
These findings were confirmed in work using ovarian cancer cell lines, showing that APC2 
colocalizes with the Golgi apparatus and actin filaments (Jarrett et al. 2001).  These findings 
suggest that the APC2 interaction with actin filaments could influence cell motility and 
adhesion. Using a chick retinotectal topographic projection system, APC2 was shown to induce 
the stabilization of microtubules, affecting axonal projections and influencing nervous system 
development (Shintani et al. 2009). Using mammalian cell lines, APC2 was shown to 
colocalize with p53 binding protein 2 in the perinuclear region, and it was suggested that APC2 
might regulate the p53/Bcl2-linked pathway of cell-cycle progression and apoptosis 
(Nakagawa et al. 2000a). 
Little is known about how APC2 functions in adult ovaries, but APC2 loss has been 
reported in EOC. APC2 allelic imbalance was reported in 19 of 20 human ovarian cancers 
screened (Jarrett et al. 2001). APC2 genomic copy number alterations (deletions) have also 
been reported in human high grade serous carcinoma (Perets et al. 2013). A study in the 
Drosophila ovary has shown that APC2 controls stem cell niche size, architecture and stem 
cell numbers through negative regulation of WNT signalling, and regulation of cortical actin 
(Oliver and McCartney 2014). A recent study supported this hypothesis, showing that miR-
939, which functions via downregulation of APC2 and subsequently deregulates Wnt/β-catenin 
signalling, is a potential tumour promotor in the ovaries (Ying et al. 2015). However, it is still 
unknown whether APC2 loss contributes to tumourigenesis or occurs passively during tumour 
progression. 
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1.3.2. PTEN/PI3K/AKT signalling  
PTEN is the first tumour suppressor protein discovered to have phosphatase activity. 
Because of its homology to tensin protein, its phosphatase activity towards protein substrates 
and lipids, and the frequent mutations of PTEN gene (located on chromosome 10 in humans) 
in cancers, it gained its name PTEN (Phosphatase and tensin homologue, mutated on 
chromosome 10; also known as MMAC1 and TEP1) (Li et al. 1997). 
PTEN directly antagonizes phosphatodylinositol-3-kinase (PI3K) function. While 
PI3K catalyses the conversion of phosphatidylinositol-4,5-biphosphate (PIP2) to 
phosphatidylinositol-3,4,5-triphosphate (PIP3), PTEN dephosphorylates PIP3 converting it 
back to PIP2 (Maehama and Dixon 1998). 
PI3K is normally present in a catalytically inactive state in the cytoplasm. However, 
activation of receptor tyrosine kinase (RTK) by growth factors or activated RAS signalling 
activates the catalytic subunit of PI3K; the p110 subunit (Vivanco and Sawyers 2002). 
Subsequently, PIP2 is converted to PIP3, which activates AKT by phosphorylation at threonine 
308 and serine 473 residues. Phosphorylated AKT (p-AKT) phosphorylates a range of 
downstream target proteins, causing the deactivation of apoptosis-effector proteins (e.g. BAD-
FOXO proteins) and evasion of cell death, one of the hallmarks of cancer (Kandel and Hay 
1999). In addition, p-AKT activates the mammalian target of rapamycin (mTOR) signalling 
pathway, causing activation of ribosomal biogenesis, increased cellular growth, upregulation 
of anabolic processes and downregulation of autophagy and catabolic processes (Figure 
1.11)(Wullschleger et al. 2006). 
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Figure 1.11: Schematic representation of PTEN/PI3K/AKT pathway. p-AKT phosphorylates a 
group of proteins including p21 ,p27, GSK3 and FOXO, which causes evasion of apoptosis, 
cell cycle progression and cell proliferation. In addition, p-AKT activates mTOR signalling. 
(Hollander et al. 2011) 
In the ovary, PTEN functions mainly to regulate recruitment of primordial follicles 
during folliculogenesis (Reddy et al. 2008). In addition, it has been shown to regulate 
steroidogenesis in theca cells (Lan et al. 2017), OSE hyperplasia and papillary growth (Bajwa 
et al. 2016), and terminal differentiation of granulosa cells into luteal cells (Goto et al. 2009). 
Stemming from these functions, PTEN has been shown to play a role in polycystic ovary 
syndrome (Ouyang et al. 2013), premature ovarian failure (Kuang et al. 2009), ovarian 
endometriosis (King et al. 2016), and ovarian tumours. Deletion of PTEN or activation of PI3K 
has been shown to contribute to the progression of ovarian GCTs (Richards et al. 2012; Liu et 
al. 2013), and ovarian epithelial tumours including serous (Mullany et al. 2011; Kinross et al. 
2012; Perets et al. 2013), endometrioid (Obata et al. 1998; Dinulescu et al. 2005; Castiblanco 
et al. 2006; Wu et al. 2007; Tanwar et al. 2013), and clear cell carcinomas (Castiblanco et al. 
2006; Hashiguchi et al. 2006; Chandler et al. 2015). 
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1.4. Mouse models of EOC 
Modelling EOC is a challenge due to the complexity of the disease and the limited 
understanding of OSE biology. However, mouse models can provide better understanding of 
tumour biology in terms of progression, regression and relapse. In addition, they can be used 
for identifying new biomarkers and investigating the efficacy of new treatments. 
1.4.1. Carcinogen-induced models 
The first trial to model ovarian cancer was done as early as 1954 by applying 
dimethylbenz[a]antrhracene (DMBA) oil solution externally on the ventral surface of female 
mice fortnightly. However, this only resulted in the development of ovarian GCTs (Howell et 
al. 1954).  Changing the route of administration, by implanting a sterile silk immersed in melted 
DMBA on the ovary, induced the development of adenocarcinomas in 50% of the experimental 
animals investigated (Wang et al. 2008). Carcinogen-induced ovarian mouse models, although 
efficient in developing different histotypes of ovarian tumours, had an important drawback; 
those carcinogens used are not known to be associated with OC etiology. 
1.4.2. Xenografts   
Attempting a different technique, xenografting tumour cells from human OC cell lines 
or fresh tumour fragments from individual patients, proved to be successful and was previously 
reviewed (Connolly and Hensley 2009; House et al. 2014). Tumour cells were transplanted 
subcutaneously, intraperitoneally or orthotopically into the ovaries of immune compromised 
mice. This resulted in the formation of tumour grafts, which were able to recapitulate the 
histopathology, heterogeneity, genetic alterations and biological behaviour of the original 
tumour. These characteristics rendered tumour grafts a suitable model for testing the efficacy 
of promising new therapies. They can also be used to study the implications of altered gene 
expression on tumour behaviour and pathogenesis, by genetically manipulating the cells in 
vitro before transplantation.  
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Comparing and contrasting the different techniques used in xenografting, it is obvious 
that subcutaneous xenografts are very useful in accurately measuring tumour volume, and 
subsequently in assessing the efficacy of treatments in reducing tumour burden (Abubaker et 
al. 2014). However, tumours grow away from their natural anatomical site, and thus the effect 
of interaction between the tumour and its microenvironment cannot be achieved. Implanting 
tumour cells intraperitoneally or orthotopically allows the study of tumour growth in a more 
relevant microenvironment. In vitro manipulation of tumour cells, by introducing luminescent 
or fluorescent reporter genes before transplantation, allows the quantitative assessment of 
tumour growth. Although grafting fresh patient-isolated tumour cells are more promising than 
cell lines in predicting therapeutic responses, it is challenging to access the patients’ samples 
and to efficiently process them (Connolly and Hensley 2009).   
Although xenografts are generally valuable, especially for evaluating tumourigenesis 
in a timely fashion, they have some limitations. The main one is the use of immune-
compromised mice, rendering the model unsuitable to study the inherent immune responses or 
to test immunotherapies. Results taken from these models should be dealt with cautiously, as 
they may not accurately represent disease progression and therapeutic responses in immune-
competent cases. It would thus be more useful to use immune-competent mice to model EOC. 
1.4.3. Syngeneic models 
Syngeneic models were developed to generate EOC mouse models by combining in 
vitro and in vivo techniques. In these models, mouse OSE cells are transformed in vitro before 
being transplanted into immune-competent mice (Testa et al. 1994).  Roby et al. established 
the technique, using multiple passaging of mouse OSE cells in vitro to induce their 
transformation before injecting them intraperitoneally or subcutaneously into female mice 
(Roby et al. 2000). Subcutaneous injection resulted in localized tumour formation over a period 
of 4 months, while intraperitoneal injection caused ascites accumulation and multiple tumour 
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formation 30 days post-injection. These tumours were histologically characterized by the 
presence of anaplastic malignant carcinomatous and sarcomatous cells (Roby et al. 2000).  
Although syngeneic mice provide a model where immune interactions in the 
establishment, progression and treatment of OC could be studied, they have the drawback of 
requiring ex vivo manipulations, which is different from the pathogenesis of OC. In addition, 
they cannot be used as a pure model for EOC, due to the mixed phenotype of the malignant 
cells observed. 
1.4.4. Genetically-engineered mouse models 
Genetically-engineered mouse models (GEMMs), are the most efficient way to study 
the function of a gene and characterize its associated phenotypes. GEMMs are immune-
competent mice with one or more genetic defects that are introduced via inducible gene 
expression or viruses. These genetic defects can be expressed in all the cells of the mouse using 
germ-line mutations (constitutive models), or can be limited to a specific tissue via the use of 
tissue-specific promoters (conditional models) (Sharpless and Depinho 2006). 
In EOC, a complex disease whose etiology is not fully understood, GEMMs can be 
useful in elucidating the site of origin, pathogenesis, early events and biological behaviour of 
tumours. They can be equally valuable in identifying biomarkers for early diagnosis and testing 
pathway-targeted therapy, thus accelerating the most promising therapies from preclinical 
laboratory investigations into clinical trials. Many GEMMs are available for low and high 
grade serous histotype (Hasan et al. 2015), but only one model was developed for clear cell 
carcinoma (Chandler et al. 2015), and one model for the mucinous EOC (Ren et al. 2016). In 
the following sections, GEMMs available for the ovarian endometrioid adenocarcinoma (OEA) 
histotype will be reviewed, being the histotype where WNT signalling dysregulation is believed 
to play a role in tumourigenesis, rendering it a suitable histotype to study roles of APC2 protein 
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in epithelial ovarian tumourigenesis. A review of published models was performed to choose 
the most suitable OEA model to be used for molecular and phenotypic characterization of 
APC2 (Chapter 6). 
1.4.4.1.Methods used for inducing recombination of targeted genes  
In this section, different methods used for inducing recombination of targeted genes 
while developing OEA models will be reviewed. Most of methods used in this section were 
successfully used in generating other EOC models, meaning that they are not specific to OEA. 
Whenever a method was used successfully to generate EOC models representing different 
histotypes, it will be mentioned as a method of developing an ‘EOC’ model rather than an 
‘OEA’ model. 
 The development of GEMMs for EOC has been hampered due to the lack of 
transcriptional promoters specifically expressing in the OSE, the historically proposed cell of 
origin of EOC, to drive the expression of the cre. The cre recombinase enzyme induces excision 
of the DNA sequence flanked by loxP sites inserted in the gene of interest, causing DNA 
rearrangements resulting in ‘turning off ‘of the required gene or activation of a quiescent 
transgene (activated post-excision of polyadenylation-silencing sequences) (Sauer 1998; 
Bouabe and Okkenhaug 2013). The first trial to develop an EOC transgenic mouse model was 
attempted by Connolly et al. using the Müllerian inhibitory substance type II receptor cre 
(Misr2-cre, also known as the anti-Müllerian hormone receptor 2-cre, Amhr2-cre) to target the 
expression of simian virus SV40 TAg  specifically to the OSE (Connolly et al. 2003). This cre 
is expressed in the OSE in addition to granulosa cells of pre-antral follicles, and in the stroma 
of Müllerian duct-derived organs, such as the oviducts and uterus. In the SV40 TAg model, 
50% of the female mice developed bilateral ovarian carcinomas, which were either poorly 
differentiated or resembling serous carcinomas. 3% of the female mice developed uterine 
leiomyoma, and 3% developed polycystic kidney with neoplastic component (Connolly et al. 
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2003). In 28% of the male mice, testicular cancers were observed. As can be seen from these 
results, the Amhr2-cre expression was not limited to the OSE and its recombination site was 
unpredictable, causing the formation of tumours in other Müllerian duct-derived organs. Even 
the tumours formed in the ovaries were not purely epithelial. The timing of recombination of 
floxed genes is unpredictable, but is thought to be anytime during development and early life, 
in contrast to EOC where the genetic alterations happen during adulthood. 
Because of the complexity in finding a specific promoter for OSE, a different technique 
was developed for targeting the OSE, by making use of its anatomical location (Flesken-Nikitin 
et al. 2003). OSE is a single layer of epithelial cells covering the whole surface of the ovary. 
The mouse ovary differs from the human ovary by being enclosed within a balloon-like 
membrane, the bursa. The proposed technique delivered adenoviral vector-expressing cre 
recombinase (Ad-cre) to the exposed OSE cells via trans-infundibular intrabursal injection, 
thus inducing the recombination of floxed genes exclusively in the OSE. This technique was 
successful and induced the formation of epithelial tumours in the ovary, and has since been 
chosen by many researchers working on developing EOC GEMMs. 
The main advantages of this technique are the ability to control the site of 
recombination, and performing the inductions in adult mice. Some drawbacks are related to the 
technical difficulty of correctly targeting the intra-bursal space and the need to perform a 
surgery, which makes it not a preferred choice for large-scale application. In addition, some 
reviewers questioned the exposure of other cell types to the viral injection, such as the bursal 
membrane and the oviductal epithelium. To avoid later issues, intrabursal injection was 
attempted directly into the bursa and compared to oviductal injection (Tirodkar et al. 2014). 
Both the intrabursal and intraoviductal injection induced recombination of floxed genes in 
ovaries and oviducts respectively, with the formation of tumours. Another concern is whether 
the adenovirus leaks away from its site of injection to outside. Preliminary studies showed that 
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no leakage was observed with an injection volume up to 10 µl (Flesken-Nikitin et al. 2003). 
Most published experiments working with this technique used an injection volume ranging 
from 2-10 µl. 
Recent emerging evidence suggests that the fallopian tube could be an alternative origin 
of EOC. To test this hypothesis in OEA development, progesterone (Pgr) promoter was used 
to drive recombination of floxed Apc in the mouse oviduct (van der Horst et al. 2014). Pgr is 
expressed in Müllerian duct-derived organs, granulosa cells of growing follicles in the ovary, 
but not in the OSE (van der Horst et al. 2014). Driving recombination of floxed Apc in the 
mouse oviduct resulted in OEAs in 28% of the mice, and granulosa cell tumours in 2% of the 
mice. Although successful in testing the hypothesis, this promoter suffers from the limitation 
of being expressed in more than one cell type (stromal and epithelial cells in oviducts, and 
granulosa cells in the ovary), and unpredictable recombination time. 
Another promoter was recently used to initiate OEA from oviducts, the oviductal 
glycoprotein 1 (Ovgp1) promoter (Wu et al. 2016). Ovgp1 is exclusively expressed in the 
oviductal epithelium, but not in the OSE (Wu et al. 2016). Driving recombination of floxed 
Apc and Pten in the mouse oviductal epithelium post-tamoxifen induction of the cre 
recombinase in adult mice resulted in oviductal endometrioid adenocarcinoma-like tumour of 
100 % penetrance, which metastasized to the ovary in 66% of mice 16-33 weeks post-induction 
(Wu et al. 2016). 
Advances made in the last few years in the isolation of OSE could help in identifying 
genes preferentially expressed within it. This question was addressed by comparing the gene 
expression profile of mouse OSE to the remaining ovarian cells, as well as its expression profile 
during different stages of the oestrous cycle (Gava et al. 2008). The results showed that 30% 
of 3075 transcripts studied were more highly expressed in OSE than in the remaining ovary, 
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with only 25% of the identified transcripts corresponding to genes with known functions (Gava 
et al. 2008). However, genes identified with known functions are common genes involved in 
many cellular processes in different organs, and thus could not be used as an OSE-specific 
promoter. Hopefully, with advances in characterizing genes of unknown functions, one or more 
genes might be identified in the future to be exclusively expressed in the OSE, and thus useful 
as an OSE-specific promoter. 
1.4.4.2. Can a single genetic alteration drive OEAs? 
Over the last decade, massive advances were achieved in defining the molecular 
pathogenesis of EOC, including OEA histotype. With many genes being identified as potential 
oncogenes or tumour suppressor genes, attempts were made to elucidate their functions using 
GEMMs. Whether a single genetic alteration is sufficient to initiate OEA formation was 
investigated by many research groups. Discrepancies in their findings are evident and will be 
discussed shortly in this section. 
1.4.4.2.1. WNT signalling  
WNT signalling dysregulation is believed to play a role in the initiation of OEA. In 
human OEA cases, CTNNB1, the gene encoding for the β-catenin protein, is the most 
frequently-reported mutated gene in the pathway, followed by mutations in the APC gene 
(Palacios and Gamallo 1998). A conditional gain-of-function Ctnnb1 mutation mouse model 
was designed such that Amhr2-cre was used to drive the recombination of Ctnnb1 in the OSE, 
resulting in the formation of degradation-resistant functionally active β- catenin (Tanwar et al. 
2011a). Tumour development was observed in 50% of mice aged 8-12 months, and most of the 
tumours were classified as OEAs (Tanwar et al. 2011a). Tanwar et al. proposed that activation 
of WNT signalling is required for OEA development. However, they proposed that the slow 
progression of tumours was caused by an increase in PTEN expression which antagonized the 
Wnt-induced tumour progression (Tanwar et al. 2011a). They proved their hypothesis by 
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combining Pten deletion with Ctnnb1 activation, which resulted in  rapid development of more 
aggressive OEAs (Figure 1.12).  
The APC gene, a negative regulator of canonical WNT signalling, was previously 
shown to be mutated in many human cancers, including EOCs (Wu et al. 2001). Loss-of-
function mutation in the Apc gene, induced by the conditional deletion of exon 14 in the mouse 
OSE, has been studied by two different groups. Wu et al. induced recombination in the OSE 
using the adenovirus-cre and did not observe tumours in mice 12-13 months old; however, they 
reported the development of endometriosis in 18% of these mice (Wu et al. 2011). On the other 
hand, the use of Amhr2-cre to induce recombination of floxed Apc in the OSE resulted the 
development of OEAs in 35% of mice by 11 months of age (Tanwar et al. 2013). Tanwar group 
has also shown that Hoxa10 expression was increased following Apc deletion, and proposed 
this as a mechanism driving differentiation into OEA histotype (Figure 1.12)(Tanwar et al. 
2013). 
 
Figure 1.12: Schematic representation of ovarian endometrioid adenocarcinoma initiation and 
progression in WNT/PI3K dysregulated murine model, as proposed by Tanwar et al. (Tanwar 
et al. 2011a; Tanwar et al. 2013).  
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 It is noteworthy that Tanwar group had previously reported that Amhr2-driven Apc 
deletion caused endometrial adenocarcinomas in the uterus (Tanwar et al. 2011b). Whether 
these cancers are contributing to the phenotype observed in the ovary is not clear. Performing 
hysterectomy in mice early before uterine tumour progression would have helped to clarify this 
ambiguity.  
Another model was developed using a different mutation in the Apc gene; deletion of 
exon 15 (van der Horst et al. 2014). A different promoter was used to drive this mutation; the 
Pgr-cre recombining in the oviductal epithelium. Tubal and ovarian endometrioid tumours 
were observed in 28% of the mice between 20-40 weeks of age. Thus far, this is the only 
reported GEMM for OEAs where endometrioid adenocarcinoma originates from outside the 
ovary (van der Horst et al. 2014). 
1.4.4.2.2. PTEN/PI3K/AKT signalling 
Frequent genetic alterations in PTEN, which codes for PTEN protein, the negative 
regulator of PI3K, have been found in many types of human cancers, including EOCs (Saito et 
al. 2000). Conditional deletion of Pten in the OSE, using Amhr2-cre or adenovirus-cre, did not 
result in any ovarian lesions or tumours in 2 separate studies (Tanwar et al. 2011a; Wu et al. 
2011). However, a third study reported the development of ovarian surface papillary 
hyperplasia and OEAs in 62% and 7.5% (respectively) of 26-week-old Pten-conditionally 
deleted (exon 5) mice using adenovirus-cre (Dinulescu et al. 2005). This could be partly 
explained by differences in the genetic manipulation and location of loxP sites within the Pten 
gene in these different models. 
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1.4.4.3.Multi-mutational tumour models and their application in cancer research 
1.4.4.3.1. Activated KRAS/PTEN-deficient model 
The first OEA transgenic mouse model, developed by conditional expression of 
oncogenic Kras concomitantly with deletion of Pten in the OSE using intrabursal injection of 
adenovirus-cre, resulted in invasive OEAs in all the mice as early as 7 weeks post-induction  
(Dinulescu et al. 2005). Although Kras is not frequently mutated in human OEAs, the tumours 
in this model recapitulated their histological and biological behaviour.  
This model was successfully used to define the PI3K isoform dependency of this subset 
of OEAs (Schmit et al. 2014). Results showed that the developed OEAs depend on p110α 
isoform of PI3K, and that its loss prevents tumour formation. These results suggest the 
usefulness of PI3K (specifically p110α isoform) inhibitors in OEA patients with these genetic 
alterations. This hypothesis was tested using supramolecular nanoparticles to deliver the PI3K 
inhibitor PI103 (Kulkarni et al. 2013). Mice treated following tumour development showed 
significant tumour regression, as assessed by a bioluminescence signal. This was associated 
with a significant decrease of downstream PI3K target genes, such as phospho-mTOR, 
phospho-AKT and phospho-S6 (Kulkarni et al. 2013). Another preclinical study was 
performed using this model, to test a dual PI3K/mTOR inhibitor PF-04691502 (Kinross et al. 
2011). Treatments for 2 or 7 days with PF-04691502 following tumour development caused a 
decrease in p-AKT and p-S6 protein levels post-treatment. However, Kinross group was not 
able to use the model for a larger preclinical testing of the compound, due to inability to follow 
tumour growth by palpation, long latency of tumour development (compared to transplants) 
and difficulty identifying tumours and following their response to therapy, even with 
ultrasound, due to the development of ascites and peritoneal metastases (Kinross et al. 2011). 
An attractive research question emerging from epidemiological studies is the role of 
combined oral contraceptives in decreasing the risk of developing EOC, and the KRAS/PTEN 
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model has been used to research this question (Romero et al. 2009). Treatment with 
norethindrone alone or in combination with ethinyl estadiol was started 3 weeks prior to tumour 
induction and continued thereafter for 8 weeks, which caused a trend of decrease in tumour 
weight with both treatments. The study findings pointed to a decrease in matrix 
metalloproteinase 2 (MMP2) activity, which is known to play important roles in cancer 
initiation and/or progression through remodelling of the extracellular matrix of the tumour, and 
controlling important cellular process such as proliferation, apoptosis and differentiation 
(Romero et al. 2009). However, because treatments were started before tumour formation and 
continued thereafter, it is hard to conclude whether the reduction in tumour weight observed 
happened due to delaying tumour initiation or by slowing tumour progression. 
The model was further developed by conditionally expressing a human MUC1 allele in 
the OSE using the adenovirus-cre injection (Budiu et al. 2013). The new triple 
(MUC1/Kras/Pten) mouse model developed OEAs similar to those previously described in the 
Kras/Pten model, but also developed ascites and loco-regional metastases more frequently. 
This model closely mimics human EOCs, which were previously reported to highly express 
MUC1 regardless of the tumour histotype, and has proven to be useful in preclinical studies of 
EOC using immunotherapeutics targeting MUC1. Administration of MUC1 vaccine loaded 
onto type 1 polarized dendritic cells significantly prolonged survival via downregulation of 
regulatory T cells and upregulation of multiple immune effector genes such as CD80, CD40 
and CD45 (Budiu et al. 2013) . 
1.4.4.3.2. APC/PTEN double knockout model 
Wu et al. were the first to describe an OEA mouse model developed by dysregulation 
of both canonical WNT signalling and PTEN/PI3K signalling (Wu et al. 2007). In their model, 
intrabursal injection of adenovirus-cre was used to induce the recombination of floxed Apc and 
Pten in the OSE cells, causing loss of functional APC and PTEN proteins. This model 
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genetically and histologically resembled a subset of human OEAs with the same genetic 
mutations. However, tumours showed some glandular formation mixed with less differentiated 
mesenchymal cells, unlike the human OEAs, which show more epithelial differentiation. Wu 
group proposed an epithelial to mesenchymal transition (EMT) in these less differentiated areas 
due to dysregulation in WNT signalling, but they did not fully characterize the proposed EMT. 
They concluded that this model could successfully be used to study the biology of low grade 
Type I OEAs (Wu et al. 2007). After a decade, Wu group were able to use an Ovgp1-cre to 
drive recombination of the same genes in the oviducts, and reported the development of 
oviductal endometrioid adenocarcinoma-like tumours which histologically and molecularly 
more closely resembled human OEA compared to the OEAs originating from OSE post-
adenovirus cre induction (Wu et al. 2016). 
Wu et al. continued working with their model to explore OEA biology and in 
translational studies for drug testing and in vivo imaging. They reported that either Pik3ca 
mutation or Trp53 mutation/deletion in the Apc/Pten double knockout mouse caused the 
tumour to be more aggressive, resulting in metastasis even to distant organs, coupled with 
reduced survival (Wu et al. 2013). They concluded that progression from type I to type II OEAs 
requires additional mutations in other genes such as Trp53 or Pik3ca and introduced this as a 
model, which could be used for preclinical testing of therapeutics targeting type II OEAs 
patients (Wu et al. 2013). 
Another study adapted this model to elucidate the effect of additionally deleting Arid1a, 
the gene encoding for the chromatin remodelling complex protein AT-Rich Interaction Domain 
1A, which is frequently mutated in OEAs (Takeda et al. 2016). Deleting Arid1a in the Apc/Pten 
double knockout model resulted in the formation of larger and more epithelial-differentiated 
OEA, which more closely resembled human OEA, but surprisingly prolonged mice survival 
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(Zhai et al. 2016). These findings suggest that ARID1A may contribute to the EMT proposed 
by Wu and colleagues when they first introduced the Apc/Pten double knock out OEA model. 
Two different interventions were carried out using the Apc/Pten double knockout model 
to enable in vivo imaging of tumour progression. The first was performed by incorporating a 
luciferase reporter allele, which is activated after the adenovirus-cre intrabursal injection (Wu 
et al. 2011). The usefulness of this mouse to follow tumour burden and metastasis using 
bioluminescence imaging was proven in mice treated by AKT/mTOR inhibitors (rapamycin, 
perifosine or API-2)(Wu et al. 2011). The second intervention was performed by crossing a 
conditional bioluminescent apoptosis reporter mouse with the Apc/Pten mouse to generate 
Apc/Pten/Apoptosis reporter mouse (Wang et al. 2013). The efficacy of using this mouse to 
follow response to treatment was tested using cisplatin and/or perifosine (AKT pathway 
inhibitor), once tumours of 50 mm3 were formed and detected by magnetic resonance imaging 
(MRI). Mice treated with the combination therapy showed the highest bioluminescence, 
indicating the highest level of apoptosis, which in turn resulted in the greatest reduction in 
tumour burden, as measured by MRI (Wang et al. 2013). 
1.4.4.3.3.  Activated β-catenin/PTEN deficient model 
One more model with dysregulation of canonical WNT and PTEN/PI3K signalling 
pathways was developed by combining PTEN deletion with conditional expression of 
degradation-resistant β-catenin mutant protein, which resulted in the formation of aggressive 
OEAs in all experimental mice as early as 6 weeks of age (Tanwar et al. 2011a).   
1.4.4.3.4. ARID1A/PTEN double knockout model 
ARID1A mutations are often present with mutations in the PTEN/PI3K signalling 
pathway in human endometrioid and clear cell ovarian histotypes (Guan et al. 2014). A double 
knock out Arid1a/Pten ovarian mouse model was generated by driving recombination of floxed 
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Arid1a and Pten in the OSE using adenovirus-cre (Guan et al. 2014). Loss of ARID1A and 
PTEN proteins resulted in the development of either OEAs or undifferentiated carcinomas with 
metastaic potential 6-9 months post-induction (Guan et al. 2014). Shortly after this, another 
mouse model was developed based on the knockout of Arid1a accompanied by Pik3ca 
activating mutation in the OSE (Chandler et al. 2015), where recombination of the floxed genes 
was performed in a similar way. This lead to the development of the first ovarian clear cell 
carcinoma (CCC) GEMM, which was genetically and histopathologically similar to human 
CCC. An autocrine IL-6 signalling was identified to contribute to the pathogenesis of CCC in 
this model by promoting tumour cell growth (Chandler et al. 2015). Chandler et al. proposed 
a model where PI3K acts as an inflammatory ‘insult’ driving the cells to produce IL-6, which 
remains highly sustained due to the absence of its  negative  regulator, ARID1A (Chandler et 
al. 2015). 
1.4.4.4.Limitations of GEMM in OEA modelling 
1.4.4.4.1. Human vs. mouse ovarian anatomy and physiology 
There are some anatomical and functional differences between mouse and human 
ovaries, which should be taken into consideration when interpreting results related to tumour 
initiation, progression, metastasis and response to therapy. Firstly, the mouse ovary is 
surrounded by the ovarian bursa, which potentially could be protecting other organs in the 
peritoneal cavity from invasion and metastasis. In humans, ovarian tumour cells are directly 
shed into the peritoneal cavity, whereas in the mouse case, they are shed into the intrabursal 
space. 
Other major differences between mouse and human ovaries are related to ovulation. 
Human are mono-ovulatory while mice are poly-ovulatory, meaning that more damage is 
potentially caused to the OSE in mice during ovulation as compared to humans. Mice tend to 
retain corpora lutea from previous ovulations, as well as those from the most recent ovulation, 
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inside their ovaries while in humans, only one corpus luteum is formed per ovulation and 
deteriorates by the end of the cycle. The presence of these multiple corpora lutea could 
influence the hormonal status between the 2 species. There is also a great difference in the 
length of the menstruation cycle, with mice showing a very short cycle of 4-5 days, in contrast 
to humans whose cycles are 28 days in length. 
1.4.4.4.2. Phenotypic differences 
Discrepancies in the literature describing phenotypes of mice carrying the same genetic 
modifications, could be attributed to a number of reasons. These may include, first, differences 
in the experimental design, especially for the follow-up period after induction, which could 
account for the failure of some groups to describe phenotypes which have been reported by 
others. A second reason could be differences in the genetic background of the mouse strains 
used by the different groups in their experiments. Differences in the site of the genetic 
modification of the gene itself (loxP sites) could also attribute to the different phenotypes 
observed. 
Another significant variable is the use of different types of cre, especially the use of a 
cre exclusively recombining in the OSE (adenovirus-cre) in contrast to a cre driving 
recombination in OSE cells as well as other cells in the ovary (Amhr2-cre). The effect of 
crosstalk between stromal and epithelial cells has been reported in other cancers, and driving 
recombination in stromal cells as well as OSE/oviductal epithelial cells using the Amhr2-cre 
or Pgr-cre, respectively, could affect ovarian cancer pathogenesis and/or progression. With the 
ability of these cre to induce tumour formation in other organs (e.g. oviducts and uterus), it is 
hard to tell whether tumours formed originate from the ovary or extra-ovarian tumours are 
contributing to the observed phenotypes. Of note is that Amhr2-cre was successful to drive 
tumour formation from a single genetic alteration while the adenovirus-cre failed to do so. 
Thus, comparative studies using these 2 cre types would be useful to show whether stromal 
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interactions are required for the early initiation and/or progression of ovarian tumours arising 
from the OSE.  
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1.5. Modelling ovarian granulosa cell tumour 
As mentioned previously, the prevalence of ovarian GCT is low and its prognosis is 
favourable. However, the main concern about GCT is the risk of relapse years after removal of 
the primary tumour, which requires long term follow up of patients. Unfortunately, GCT 
biology is less well defined compared to epithelial ones. This necessitates the development of 
mouse models, which can be used to study tumour biology and act as preclinical models for 
testing therapeutics.  
1.5.1. GCT transplantation models 
As early as 1946, transplantation models were developed for GCTs (Furth 1946). These 
models were mainly used to define gross pathologies associated with tumour progression, such 
as hypervolemia (Furth and Sobel 1947; Cliffton and Wolstenholme 1949; Furth and Moshman 
1951), hormone production (Van Nie 1957) and vascularity (Waters and Green 1959). Later 
on, they were used to explore the interaction between steroidal hormones and tumour 
progression (Hatanaka et al. 1981). However, the main drawback of these models was the 
transplantation of tumours to sites away from their organ of origin, such as into the spleen, 
under the kidney capsule or into the liver (Lipschutz et al. 1964). Another important drawback 
was the development and progression pattern of GCT, whereby a luteoma is converted to GCT 
(Lipschutz et al. 1967), which is not similar to the natural progression of the disease. 
1.5.2. Chemically-induced GCT 
Carcinogens such as 7,12-DMBA (Jull et al. 1966), 7,8,12-trimethylbenz-[a]anthracene 
(Uematsu and Huggins 1968), and 9,10-DMBA (Krarup 1969) were successfully used to 
induce ovarian GCTs. However, these chemicals are not known to play a role in the etiology 
of the tumour. 
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  The first trial to induce ovarian GCT by hormonal administration was conducted using 
prolonged and continuous administration of progesterone, which led to successful development 
of ovarian GCTs, starting from the periphery of the ovary (Lipschutz et al. 1967). Although 
administration of pregnant mare’s serum gonadotrophin (PMSG) failed to induce ovarian GCT 
in Balb/C mice (Menczer et al. 1977), priming ovaries by PMSG followed by mutagen or 
carcinogen administration, increased the incidence of GCT (Rao 1981).  
1.5.3. Spontaneous ovarian GCT models 
Some mouse strains (e.g. SWXJ-9 and SWR) are known to spontaneously develop GCT 
around puberty (Beamer et al. 1985). SWXJ-9  mice were used to explore the effect of 
hormonal treatment with dehydroepiandrosterone, which appeared to increase the incidence of 
ovarian GCT (Beamer et al. 1988). Using a SWR spontaneous model, it was shown that EGFR 
is upregulated in GCT cells, causing increased proliferation in response to EGF (Tennent et al. 
1989). Xenografting ovaries from these mouse strains under the kidney capsule of immune-
deficient and immune-intact mice revealed comparable tumour incidence, and showed that the 
immune system does not contribute to tumourigenesis (Beamer et al. 1993). However, 
xenografting under the kidney capsule of gonadotrophin-producing or gonadotrophin-deficient 
mice revealed that tumourigenesis is dependent on gonadotrophins, primarily due to 
gonadotrophin-dependent production of androgens (Beamer et al. 1993). 
1.5.4. GEMMs of adult GCT 
Because GCTs are believed to originate from granulosa cells of growing follicles, early 
efforts of modelling were designed to disrupt regulatory pathways known to control granulosa 
cell proliferation and/or differentiation. Later on, oncogenes and tumour suppressors known to 
play a role in tumourigenesis in other tissues were conditionally targeted in the ovarian 
granulosa cells to explore their ability to initiate ovarian GCTs. 
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1.5.4.1. Targeting female hormones or hormone receptors 
The first mouse model developed to test the effect of gonadotrophins on GCT formation 
was a mouse hypersecreting LH from the pituitary gland, leading to infertility, polycystic 
ovaries and ovarian GCT formation in 4-9 months old female mice (Risma et al. 1995).  
Another mouse expressing a constitutively-active mutant luteinizing hormone 
chorionic gonadotrophin receptor (LHCGR) was developed (McGee and Narayan 2013), 
wherein 50% of the female mice developed GCTs by 6 months of age (Hai et al. 2015). 
The ovaries are known to express both estrogen receptors α and β (ERα and ERβ), with 
ERβ being predominantly expressed in granulosa cells (Sar and Welsch 1999). In addition, 
ERβ is exclusively expressed in gonadotrophin-releasing neurons (Hrabovszky et al. 2007). 
ERα, ERβ and double knockout models were developed (Emmen and Korach 2003). Of the 3 
models studied, only ERβ knockout female mice developed ovarian GCTs as early as 15 
months of age, secondary to hormonally-active pituitary tumours (Fan et al. 2010b) 
1.5.4.2. Targeting TGFβ signalling pathway 
Inhibin-α was the first member of the TGFβ family of transcription factors to be 
targeted by constitutive deletion in all the mouse cells of the whole body, which resulted in the 
development of ovarian sex-cord stromal tumours including GCTs (Matzuk et al. 1992). Co-
deletion of the cell cycle inhibitor p27 enhanced tumour progression, leading to earlier 
mortality (Cipriano et al. 2001). With the hypothesis that SMAD3 is required for activin 
signalling, and thus for tumour development and progression in inhibin-α null mice, a double 
knockout model of SMAD3 and inhibin-α was developed (Looyenga and Hammer 2007). 
SMAD3 deletion attenuated GCT formation in 2 months-old ovaries (Looyenga and Hammer 
2007). Later, a similar model was developed, in which inhibin-α and SMAD2 were both 
targeted (Rajanahally et al. 2010). Unlike the SMAD3/inhibin-α double knockout model, these 
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mice developed ovarian GCTs which were comparable to inhibin-α null mice, indicating that 
SMAD2 is not required for ovarian activin-mediated tumourigenesis (Rajanahally et al. 2010). 
With activin-A being the main driver of tumourigenesis in inhibin-α-null mice, counteracting 
activin-A signalling was predicted to decrease tumour development (Gold et al. 2013). To test 
this hypothesis, a mouse overexpressing activin-β C, which antagonizes activin-A, was crossed 
with inhibin-α-null mouse, resulting in at least 50% decrease in GCT development and a 50% 
increase in survival (Gold et al. 2013).  
Single constitutive or conditional deletion of the BMP-signalling SMADs (SMAD1, 
SMAD5 or SMAD8), using Amhr2-cre failed to drive GCT formation in the ovary (Pangas et 
al. 2008). However, conditional deletion of both SMAD1 and SMAD5, or triple deletion of 
SMAD1, SMAD5 and SMAD8 caused the formation of metastatic GCTs with 100% 
penetrance as early as 3 months of age (Pangas et al. 2008). A similar effect was seen with 
conditional deletion of BMP receptors; where a single deletion of either BMPR1A or BMPR1B 
did not cause GCT formation, while knockout of both together resulted in the development of 
ovarian GCTs as early as 8 months of age (Edson et al. 2010). 
A recent ovarian GCT model was developed by conditionally-expressing activated 
transforming growth factor β receptor TGFBR1 in granulosa cells of growing follicles using 
Amhr2-cre or Cyp19-cre (Gao et al. 2016). Activation of TGFBR1 led to the development of 
adult GCTs with 100% penetrance as early as 2 months of age, with tumours phenocopying the 
human adult ovarian GCTs and eventually causing mortality with tumour progression (Gao et 
al. 2016). 
1.5.4.3. Targeting FOX transcription proteins 
As mentioned previously, members of the FOX family of transcription proteins, such 
as FOXO1, FOXO3 and FOXO4, are expressed in the ovary and have been shown to control 
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granulosa cell proliferation and follicular activity (Uhlenhaut and Treier 2011). Conditional 
deletion of FOXO1 and FOXO3 in granulosa cells of pre-antral follicles (using Amhr2-cre) or 
antral follicles (using Cyp19-cre) lead to the development of GCTs in 20% of mice aged to 6-
8 months (Liu et al. 2015). A single-dose treatment with superovulatory gonadotrophins 
increased the incidence of tumour formation, with 62.5% of mice now developing GCTs by 
2.5 months (Liu et al. 2015). The same happened when a triple knockout mouse was developed 
by deleting PTEN, FOXO1 and FOXO3 in granulosa cells of antral follicles, with 60% of mice 
developing GCTs by 2-3 months (Liu et al. 2015) 
1.5.4.4. Targeting paracrine regulators of granulosa cells 
As mentioned previously, ovarian functions are tightly regulated by hormonal, 
paracrine and autocrine signals. PI3K signalling has been identified as a paracrine regulator of 
follicular growth, where the high levels of PI3K in oocytes control growth of somatic follicular 
cells through a bidirectional communication between oocytes and surrounding granulosa cells 
(Liu et al. 2006). A proof-of-concept mouse model was recently published, in which 
conditional activation of PI3K in oocytes using Gdf9-cre, which recombines exclusively in 
germ cells, resulted in GCT development in 100% of mice by 65 days (Kim et al. 2016). 
1.5.4.5. Targeting oncogenes and tumour suppressor genes  
1.5.4.5.1. Simian virus 40 T-antigen 
Simian Virus 40 T-antigen (TAg) is a well-known viral oncogene, and was used in the 
early days to develop an in vivo model of ovarian GCT, although it is not a known clinical 
cause of GCT. This was achieved by directing expression of the oncogene to the ovarian 
granulosa cells using the inhibin-α promoter (Kananen et al. 1995). This mouse model was 
successfully used to test the contribution of gonadotrophins to tumourigenesis, by giving the 
mice a gonadotrophin-releasing hormone antagonist, which resulted in complete or partial 
inhibition of tumour development in 2 different mouse lines (Kananen et al. 1997). When this 
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mouse was crossed with a hypogonadotrophic mouse, double mutant mice did not develop 
GCTs, even after long-term treatment with testosterone (Rilianawati et al. 2000). Mice of the 
original model were treated with a lytic peptide (Hecate) conjugated to chorionic 
gonadotrophin-beta subunit, to target LHCGR-expressing GCT cells (Bodek et al. 2005). This 
treatment resulted in a 36% reduction in ovarian tumour volume due to increased tumour cell 
death (Bodek et al. 2005). Attempting immunotherapy was successful as well, by immunizing 
inhibin α-TAg mice with anti-zona pellucida-3 protein, a protein highly expressed in GCT, 
which stopped tumour formation or delayed tumour progression, depending on the time of 
immunization (Rahman et al. 2012). The results were reproducible when mice were immunized 
with the mouse inhibin-α peptide 215-234 (Altuntas et al. 2012). 
Another promoter was used to drive the expression of TAg to the ovaries, the ovarian-
specific promoter OSP1, which is exclusively expressed in different ovarian lineages (Garson 
et al. 2003). Although 2/3 of the female mice developed ovarian GCTs, the promoter was leaky 
in cells of other tissues, leading to tumour development in many tissues other than the ovary 
(Garson et al. 2003). 
1.5.4.5.2. WNT signalling 
Ovarian GCTs have been shown to express nuclear β-catenin in granulosa cells, 
suggesting that WNT signalling dysregulation may be contributing to tumourigenesis 
(Boerboom et al. 2005). Amhr2-cre was used to develop an ovarian GCT model with 57% 
penetrance, by expressing a mutant gene coding for degradation-resistant β-catenin protein 
(Boerboom et al. 2005). When PTEN loss was combined with degradation-resistant β-catenin 
expression, 100% of mice developed metastatic GCT as early as 6 weeks (Lague et al. 2008), 
similar to the accelerated GCT development seen when degradation-resistant β-catenin 
expression was combined with activated KRAS (Richards et al. 2012). The combined PTEN 
loss/activated β-catenin model was successfully used as a preclinical model in 2 studies, where  
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either treatment with mTOR inhibitor everolimus (Rico et al. 2012), or with the anti-VEGFA 
antibody (Tsoi et al. 2013) resulted in reduced tumour growth and prolonged survival. 
A novel mouse model was developed by expressing activated Rspondin1 (RSPO1), a 
known WNT signalling regulator protein, using steroidogenic factor 1-cre (SF1-cre) (De Cian 
et al. 2016). This cre recombines in the ovaries as well as in the hypothalamus, pituitary glands 
and adrenal glands (Bingham et al. 2006). Conditional activation of RSPO1 caused ovarian 
GCT development in 10% of mice, starting at 12 months of age (De Cian et al. 2016). 
1.5.4.5.3. Fanconi anaemia  
Loss of Fanconi anaemia genes, including Fancf, predisposes to leukaemia and solid 
tumours, including gynaecological tumours, both in anaemic and non-anaemic carriers (Bakker 
et al. 2012). To directly elucidate whether FANCF protein loss contributes to ovarian 
tumourigenesis, a constitutive knockout mouse for Fancf was developed (Bakker et al. 2012). 
In this model, more than 50% of female mice homozygous for Fancf-null allele developed 
ovarian GCTs as early as 390 days of age (Bakker et al. 2012). 
1.5.5. Future directions 
Similar to epithelial ovarian cancer, the last decade has witnessed the development of 
multiple GEMMs for GCTs, which could serve as valuable tools for studying cancer biology 
and as preclinical models. However, one important model which still needs to be developed is 
a mouse which bears a mutation of Foxl2 gene. With recent advances in defining the molecular 
pathology of adult GCT pointing to the FOXL2 mutation as a major contributor in 97% of 
human GCTs (Shah et al. 2009), the pathogenesis of this mutation and its consequences need 
to be studied. With the accumulating evidence from mouse models that FOXL2 protein 
expression is elevated in GCTs (Liu et al. 2015; Gao et al. 2016), it seems crucial to develop a 
  
60 
 
degradation-resistant FOXL2 conditional mutation targeted to the granulosa cells, to see 
whether it contributes to tumourigenesis.  
Acknowledging the efforts done by the Boerboom lab and apart from the efforts done 
using the Simian virus TAg model, GEMMs of ovarian GCT have been rarely used in 
translational medicine; a limitation which needs to be addressed in the near future. With further 
insights being revealed about GCT biology from both human studies and GEMMs, more 
studies should be directed towards testing the efficacy of targeted therapy in tumour eradication 
and prevention of relapse. 
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2. Aims 
APC2 has been shown to negatively regulate WNT signalling in Drosophila and in 
cancer cell lines. However, little is known about APC2 role in regulating WNT signalling in 
an in vivo setting. It is noteworthy that because the highest levels of expression of APC2 protein 
are found in the brain, most in vivo research has been directed towards the brain.  
Shortly after the discovery of APC2, Van Es et al. constructed a constitutive knockout 
Apc2 mouse to study whether APC2 loss contributes to colon cancer, similar to its homologous 
Apc tumour suppressor (Van Es et al. 1999). However, they did not fully publish their results, 
and only reported that mice did not develop colon cancer. This mouse was gifted to the Clarke 
lab, which started to explore roles of APC2 protein on WNT signalling and tumour formation 
in different mammalian tissues. It has been shown that APC2 regulation of WNT signalling is 
tissue-specific, with APC2 regulating WNT signalling in the liver and intestines but not in 
mammary glands (Daly 2013). APC2 roles in homeostasis were tissue-specific as well, with 
only intestinal homeostasis shown to be disrupted following APC2 loss, unlike the mammary 
gland or the liver (Daly 2013). APC2 loss on its own failed to induce tumourigenesis in any of 
these tissues. However, combining both APC2 and APC loss initiated tumour formation in the 
mammary gland (Daly et al. 2016), attenuated APC-driven tumour formation in the liver and 
did not alter APC-driven tumourigenesis in the intestine (Daly 2013). 
It has been observed in the Clarke lab that a subset of aging Apc2-/- mice developed 
ovarian cysts, which were not observed in their control littermates. However, this phenotype 
has not been further characterized. With the accumulating evidence that APC2 is lost in EOC, 
and stemming from the previous characterization performed for APC2 protein in different 
mouse tissues in the Clarke lab, the aims of the work outlined in this thesis were: 
 To investigate whether APC2 loss activates WNT signalling in the ovaries 
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 To characterize the consequences of APC2 loss on ovarian homeostasis and female fertility 
in early adulthood. 
 To follow ovarian tumour formation in aging APC2-deficient mice. 
 To elucidate whether APC2 loss in combination with APC or PTEN loss can initiate 
epithelial tumourigenesis in the ovaries 
 To unravel contributions of APC2 in epithelial ovarian tumourigenesis using an OEA 
GEMM. 
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3. Material and methods 
3.1. Breeding and maintenance of experimental animals 
3.1.1. Animal husbandry 
All mice were bred and maintained according to UK Home Office Regulations. They 
were housed in plastic cages with free access to Harlan standard diet (Special Diets Service, 
UK) and water.  
3.1.2. Breeding 
All mice were maintained on a mixed background. Adult mice over 6 weeks of age with 
known genotypes were bred in trios (one male and 2 females in the same cage). The pups were 
left in the breeding cages with their mothers until they were able to feed independently. Pups 
were weaned when they were 3-4 weeks old (no more than this to avoid female mice getting 
pregnant). At weaning, pups were sexed, ear-tipped for identification and placed in separate 
cages (maximum 5 mice/cage). The ear tips were then processed for genotyping (Section 3.3.1).  
3.2. Transgenic mice  
In this study, 3 different genetic alleles were utilized. Mice with an allele of the 
constitutive knockout of Apc2 (Apc2-) were a kind gift from Prof. Hans Clevers lab (Daly et al. 
2016).  This allele was genetically-engineered to produce a truncated APC2 protein lacking the 
important functional β-catenin and Axin binding domains (Daly 2013). The alleles for 
conditional deletion of Apc (Apcfl) and Pten (Ptenfl) were previously described (Shibata et al. 
1997; Suzuki et al. 2001). They were developed by flanking the desired exons (exons 4 and 5 
in Pten, and exon 14 in Apc) with loxP sites, allowing for the conditional deletion (floxing) of 
the genes using the Cre-recombinase enzyme. Conditional deletion of the floxed genes in the 
OSE was performed by injecting a replication-incompetent adenovirus-expressing cre-
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recombinase under the control of the CMV promoter (Ad-cre) into the ovarian bursa (Section 
3.3.4,(Flesken-Nikitin et al. 2013)).  
3.3. Experimental procedures on mice 
All experimental procedures performed were approved by the UK Home Office under 
project licences 30/2737 and 30/3279 and were performed by UK Home Office personal 
licence holders.  
3.3.1. Ear notching for genotyping  
Mice were genotyped for Apc, Apc2 and Pten alleles using gDNA extracted from ear 
notches used for mouse identification purposes, collected at the time of weaning. A 
regenotyping was performed for all mice at the end of experiments (at time of culling). Primers 
used in genotyping were either provided by collaborators (Apc2 primer sequences from the 
Clevers lab) or established and used in the Clarke lab  (Apc  and Pten  primer sequences, (Daly 
2013). All the primers were synthesised by Sigma (Table 3.1). All the ear notching and 
genotyping were kindly performed by Elaine Taylor and Matthew Zverev. 
3.3.1.1. DNA extraction and purification (Puregene® method) 
The Gentra Puregene® tissue kit (Qiagen) was used for DNA extraction. An ear biopsy 
was placed in a 1.5 ml microcentrifuge tube, containing 250 µl cell lysis buffer (Puregene®, 
USA) and 1.5 µl of Proteinase K (20 mg/ml, Roche, Switzerland), and incubated overnight in 
a shaking incubator at 55ºC. Following this, the protein was precipitated by adding 100 µl of 
protein precipitation solution (Puregene®, USA) and contents mixed by vortexing followed by 
1 hour incubation at 4ºC. The samples were centrifuged at 10 000 rpm for 10 minutes. The 
supernatant was carefully removed, mixed with 100 µl isopropanol, incubated for 1 hour at 4ºC 
and centrifuged at 10 000 rpm for 15 minutes. The supernatant was carefully discarded and the 
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formed pellet containing gDNA was air dried for 1 hour before dissolving in 250 µl of ultrapure 
water (Sigma, USA). The gDNA was stored at 4ºC until further processing. 
Table 3.1: Primer sequences and reaction conditions used in genotyping 
Gene  Primer sequence Taq 
polymerase 
Buffer  PCR cycle 
Apc Forward primer (5’-3’) 
GTTCTGTATCATGGAAAGAT
AGGTGGTC 
 
Reverse primer (5’-3’) 
CACTCAAAACGCTTTTGAGG
GTTGATTC 
Dream Taq® 
(Thermo 
Fisher 
Scientific, 
USA) 
 
 
Green Initial denaturation: 
95ºC X 3 minutes 
followed by 30 cycles 
(95ºC X 30 seconds, 
60ºC X 30 seconds, 
72ºC X 1 minute) and 
a final extension at 
72ºC X 5 minutes. 
Apc2 Forward primer (5’-3’) 
 Wild type primer: 
CTCCAAACACAAGATGATCG 
 Knockout primer: 
AGGTCTGAAGAGGAGTTTAC 
Reverse primer (5’-3’) 
AGCTGTGTCTGATGAGGTG 
Go Taq®  
(Promega, 
USA) 
Clear Initial denaturation: 
95ºC X 3 minutes 
followed by 30 cycles 
(95ºC X 30 seconds, 
60ºC X 30 seconds, 
72ºC X 1 minute) and 
a final extension at 
72ºC X 5 minutes. 
Pten Forward primer (5’-3’) 
CTCCTCTACTCCATTCTTCCC 
 
Reverse primer (5’-3’) 
ACTCCCACCAATGAACAAAC 
Dream Taq® 
(Thermo 
Fisher 
Scientific) 
Green Initial denaturation at 
95ºC X 2.5 minutes 
followed by 30 cycles 
(94ºC X 1 minute, 
54ºC X 1 minute and 
72ºC X 1 minute) and 
a final extension at 
72ºC X 5 minutes. 
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3.3.1.2. PCR amplification 
The PCR reaction was performed in strip-tubes (Grenier Bio-one, Austria) using 2.5 µl 
of the prepared gDNA added to 47.5 µl of master mix consisting of Taq polymerase (Promega, 
USA), polymerase buffer (Promega, USA), specific gene primer mix (Sigma, USA Table 3.1), 
ultrapure water (Sigma, USA), magnesium chloride (Promega, USA) and dNTPs (Bioline, UK) 
(Table 3.2). For each PCR reaction, one sample was prepared with 2.5 µl of ultrapure water 
(Sigma, USA) instead of gDNA to serve as control (negative) reaction. All the strip-tube 
components were mixed, centrifuged for 10 seconds and placed in a thermal cycler according 
to the specific reaction conditions (Table 2.1). 
Table 3.2: Composition of PCR master mix 
Constituent Volume required 
Buffer 10 µl 
Mg (25 mM) 5 µl 
dNTPs 0.4 µl 
Primers (10 µm) 1 µl 
Taq polymerase 0.2 µl 
Ultrapure water 30.9 µl 
 
3.3.1.3. PCR product visualization 
PCR products were visualized by agarose gel electrophoresis. A 1% w/v agarose gel 
was prepared in a conical flask by dissolving 1 gram agarose (Sigma) in 100 ml 1 X Tris Borate 
EDTA (TBE) buffer [Appendix 1]  using a microwave. The dissolved agarose was cooled by 
swirling the bottom of the conical flask under running water.  5 µl of SafeView® nucleic acid 
stain (NBS Biologicals, UK) were added to the gel and mixed well before pouring into the gel 
mould and inserting the comb to create the wells.  After the gel was set, the combs were 
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carefully removed and the gel placed in an electrophoresis tank filled with TBE buffer 
containing 5 µl of SafeView®/100 ml TBE. 5 µl of the PCR products were mixed with 5 µl of 
loading dye [50% glycerol + 50% ultrapure water + 0.1% bromophenol blue (all from Sigma, 
USA)] and loaded into wells alongside 100 bp and 1Kbp DNA ladders (Promega, USA). The 
gel was run at 100V for 40 minutes and DNA bands visualized by UV light using GelDoc XR 
(Bio-Rad, USA). 
3.3.2. Synchronization of oestrous cycle 
Female mice aged 10 weeks, 6, 12 or 18 months, were synchronized for oestrous cycle 
by manually staging the mice using the vaginal cytology method (Byers et al. 2012). Briefly, 
the vagina was flushed with 50 µl of sterile 1X phosphate buffered saline (PBS) solution, pH 
7.4 (Gibco®, Life Technologies, USA) by inserting the plastic tip of micropipette, filled with 
PBS, into the vagina and repipetting for 3-5 times. The vaginal flush contained in the pipette 
tip was placed on a glass slide, air-dried and stained with Haemalum (RA Lamb, ThermoFisher, 
USA) for 1 min. The slide was washed with running water, air-dried and examined under a 
light microscope using 10X objective (Section 3.5.4.1). Mice were manually staged for 5 
consecutive days, and culled when present at the diestrus stage of the oestrous cycle, at which 
point ovaries were dissected and processed. 
3.3.3. Superovulation 
Randomly-cycling female mice aged 10 weeks were superovulated by giving the mice 
a single intraperitoneal injection (using a 1 ml insulin syringe) of 5 I.U. pregnant mare's serum 
gonadotropin (PMSG) [Folligon®, MSD animal health, UK] to induce follicular growth, 
followed by a single intraperitoneal injection of 5 I.U. human chorionic gonadotrophin (HCG) 
[Chorulon®, MSD animal health, UK] 47 hours later to induce ovulation (Luo et al. 2011). 
Mice were either culled 16-17 hours post-HCG injection (for oocyte retrieval, (Zudova et al. 
2004)) or 24 hours post-HCG injection (for collecting ovaries at diestrus stage). 
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3.3.4. Induction of genetic recombination in the OSE 
To induce recombination of floxed genes exclusively in the OSE, virgin female mice at 
9-13 weeks of age were anaesthetized and 2.4x108 plaque forming units (PFU) of Ad-cre were 
injected directly into the ovarian bursa. Both right and left ovaries were injected to reduce the 
number of mice used in the study.  
3.3.4.1. Induction of anaesthesia 
All of the injectable solutions used in this section were prepared aseptically in sterile 
bijou tubes and stored at 4ºC for up to 7 days. The mice were anaesthetised using a ketamine 
and medetomidine combination, as recommended by the named veterinary surgeon for our 
animal facility. Briefly, 150 µl of ketamine hydrochloride (Ketamidor ® 100 mg/ml solution 
for injection, Chanelle, Ireland) and 200 µl of medetomidine (Domitor® solution for injection, 
1 mg/ml, Orion pharma, Finland) were added to 3.65 ml of sterile saline solution [Appendix 
1]. Intraperitoneal injection of 0.2 ml/10 g body weight was used to induce anaesthesia. 
Following the onset of anaesthesia, a single dose of meloxicam was given as an analgesic.  This 
was prepared by diluting 100 µl of meloxicam (Metacam® solution for injection, 2 mg/ml, 
Boehringer Ingelheim, Germany) to a final volume of 2 ml using sterile saline as a diluent. 0.1 
ml/10 g body weight was injected subcutaneously (SC). Before performing the surgery, deep 
anaesthesia was confirmed by checking the loss of pedal reflexes (approximately 20 minutes 
post-anaesthesia). 
3.3.4.2. Intrabursal injection of adenovirus-cre 
All pieces of the surgical equipment were autoclaved prior to surgery, and all solutions 
used were aseptically prepared. The surgery was performed in a class 2 biological safety 
cabinet.  
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3.3.4.2.1. Preparation of Adenovirus-cre 
The Adenovirus-cre (a replication-incompetent adenovirus expressing cre recombinase 
under the control of the CMV promoter, Ad5-CMV-cre) was purchased from Vector 
Development Lab (Houston, USA) with an infectious titre of 2.4×1011 PFU/ml. Once received, 
the virus was divided into 25 µl aliquots in sterile small microcentrifuge tubes in a class 2 
biological safety cabinet, and stored at -80ºC. On the day of the surgery, a 25 µl aliquot of the 
adenovirus-cre was thawed on ice and diluted with 74 µl of sterile 1X PBS (Gibco® Life 
technologies, USA) and 1 µl of sterile Trypan blue dye (Life technologies, USA) to a final 
infectious titre of 2.4×108 PFU/4 µl.  
3.3.4.2.2. Injection of Adenovirus-cre 
After the complete loss of pedal reflexes, the mouse was placed on its ventral surface 
on a piece of paper towel and the fur on its dorsal surface was sprayed with 70% ethanol. Using 
a pair of scissors, a 1 cm transverse incision was made in the skin slightly below the mid-back 
of the mouse (towards the tail) and a small piece of paper towel sprayed with 70% ethanol was 
used to remove any hair surrounding the incision (Figure 3.1). The incision was placed over 
the left ovary and a pair of springbow scissors was used first to cut the fine membrane covering 
the muscles followed by cutting the muscle (a small vertical incision of 3 mm just enough to 
pull the ovary out). The ovary was carefully pulled out of the body cavity by holding the fat 
pad surrounding the ovary with a pair of forceps. The exposed ovary was placed over a small 
piece of paper towel (placed on the right side of the incision) and was kept in position either 
by using a surgical clamp attached to the fat pad or by using a small piece of paper towel over 
the fat pad.  A 25 µl Hamilton syringe with a 32 gauge bevelled needle was used to inject 4 µl 
of the diluted virus slowly into the ovarian bursa, by going through the bursal membrane in the 
small space next to the entrance of the oviduct into the bursa. Following injection, the ovary 
was returned back to inside the body cavity, and the skin incision was placed over the right 
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ovary, for which the same procedure was performed. After both ovaries were injected and 
returned back to their position in the body cavity, the skin incision was closed by wound clips 
using a clip applicator. These clips were removed 7-10 days post-surgery using a clip remover. 
The intrabursal injections were kindly performed by Bridget Allen. 
  
 
Figure 3.1: An outline of the intrabursal injection used for adenovirus-cre delivery. (A) 
Positioning the mouse and the place of incision. (B) Pulling the ovary outside the body from 
the fat pad and placing it on a piece of paper towel prior to injection. (C) Site of adenovirus-
cre (AdCre) injection into the bursa. Adapted from (Wu et al. 2007; Cordero et al. 2010). 
3.3.4.3. Reversing anaesthesia 
 Reversal of anaesthesia was performed at the completion of surgery by SC injection of 
0.1 ml/10 g body weight of atipamezole hydrochloride, prepared by diluting 0.05 ml of 
atipamezole hydrochloride (Antisedan® solution for injection, 5 mg/ml, Orion pharma, 
Finland) in 2.45 ml of sterile saline. During recovery, mice were housed up to 3/cage and placed 
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on a paper towel without bedding (to prevent inhalation of bedding which can cause asphyxia). 
Mice were covered by a paper towel until fully recovered to provide warmth and avoid dryness 
of eyes. The cages were placed on a fluffy wool mat to avoid loss of heat during recovery. 
Animals were closely monitored until fully recovered (at least 2 hours) and kept in the class 2 
biological safety cabinet for 24-48 hours, with free access to food and water. After this period, 
the paper towels were removed and the animals provided with normal bedding, before being 
moved to a negative pressure isolator. Mice were housed in the negative pressure isolator for 
2 weeks before being transferred to conventional housing. 
3.4. Tissue preparation 
3.4.1. Tissue dissection 
Mice were culled by cervical dislocation Schedule 1 method. The mouse ventral surface 
was sprayed with ethanol and an incision made throughout the skin and the abdominal wall to 
open the abdominal cavity. A pair of fine scissors were used to cut through the heart and a 1 
ml syringe shaft was used to collect blood before placing it into a clean microcentrifuge tube. 
A second pair of fine scissors and forceps were used to pull the ovaries out by holding them 
from the fat pad, and both sets of ovary, oviduct and uterine horn were dissected as an 
individual unit. On a piece of paper towel, the extra adipose was removed. One set was kept 
attached together and fixed in 10% neutral buffered formalin (Sigma, USA). For the other set, 
the organs (ovary, oviduct and uterine horn) were seperated, placed individually in clean 
microcentrifuge tube and snap frozen on dry ice (Section 3.4.7). For oocyte retrieval, the 
oviducts were dissected and placed in sterile 1X PBS (Gibco®, Life technologies, USA) until 
further processing (Section 3.4.3). 
For brain dissections, the head was sprayed with 70% ethanol and the skin covering the 
skull completely removed. A pair of scissors was used to cut and remove the parietal and frontal 
parts of the skull without damaging the soft brain tissue. Using a dissecting section lifter, the 
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brain was removed and a small piece placed in a clean microcentrifuge tube and snap frozen 
(Section 3.4.7).  
Other tissues, such as the lungs, liver, kidney, spleen and lymph nodes were all placed 
in one flat-bottomed tube filled with 10% neutral buffered formalin solution (Sigma, USA) to 
fix the tissue before embedding in paraffin. A small piece from the ear was collected and used 
for re-genotyping as mentioned previously (Section 3.3.1). 
3.4.2. Estimating ovarian volume 
A set of calipers was used to measure the length (L), width (W) and height (H) of the 
ovaries, just after dissection and before fixing or snap-freezing. The following ellipsoid volume 
equation was used to estimate the normal ovarian or ovarian tumour volume (Pavlik et al. 
2000): 
𝑂𝑣𝑎𝑟𝑖𝑎𝑛 𝑣𝑜𝑙𝑢𝑚𝑒 =  
4
3
 𝜋 (
𝐿
2
)(
𝑊
2
)(
𝐻
2
) 
3.4.3. Oocyte retrieval 
Each oviduct was placed on a microscope slide and bathed in 40 µl 1X PBS (Gibco®, 
Life technologies, USA). It was held in position by a pair of forceps and a small hole was made 
in the ampulla using a blunt needle. Using forceps or a needle, the oviduct was squeezed in the 
direction of the opening to force the cumulus oophorous complexes (COCs) to move out of the 
oviduct and into the PBS droplet (Figure 3.2). Oocyte retrieval was kindly performed by Elaine 
Taylor. 
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Figure 3.2: Schematic diagram for oocyte retrieval from the oviducts (Center for Animal 
Resources and Development 2016).  
3.4.4. Tissue fixation using formalin 
Tissues were fixed by placing them in flat-bottomed tubes filled with ice-cold 10% 
neutral buffered formalin (Sigma, USA), and incubating overnight at 4ºC. Subsequently, the 
formalin was discarded and the tissue stored in 70% ethanol at 4ºC until paraffin embedding.  
3.4.5. Paraffin embedding of fixed tissue 
Fixed tissues were removed from the 70% ethanol and placed into cassettes (Fisher, 
USA). They were processed using the automatic processor (Leica TP1050, Germany). The 
tissues were dehydrated by placing in increasing concentrations of ethanol [1 hour 70% 
ethanol, 1 hour 95 % ethanol, 2 X 1.5 hours 100% ethanol, 2 hours 100% ethanol]. This was 
followed by 2 X xylene incubation each lasting for 2 hour. The tissues were then transferred to 
liquid paraffin and incubated initially for 1 hour followed by 2 incubations each 2 hours long. 
Following this, the tissues were taken out of the liquid paraffin, placed in paraffin wax and left 
until complete solidification. 
3.4.6. Sectioning of fixed tissue 
The fixed tissues were cut into 5 µm sections using a microtome (Leica RM2135, 
Germany). The sections were placed on poly L-lysine (PLL)-coated glass slides and baked at 
58ºC for 24 hours. 
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When serial sectioning was required, the tissue was cut into 100 sections, each 5 µm 
thick, with 2 sections placed per slide. Every 10th section (5th slide) was stained with H&E and 
used for histologic assessment. Because this resulted in most of the paraffin-embedded tissue 
being sectioned, all the PLL slides were redipped in paraffin wax to preserve antigens from 
being lost during storage (mainly the membranous antigens). 
Paraffin embedding and sectioning of fixed tissue was kindly performed by Derek 
Scarborough. 
3.4.7. Snap-freezing 
Ovaries, oviducts and uterine horns were dissected separately and placed in clean 
microcentrifuge tubes. For brain and spleen, small pieces of the tissue were dissected and 
placed in clean microcentrifuge tubes. Immediately after this, the tubes were either placed on 
dry ice or immersed in liquid nitrogen and transferred to a -80ºC freezer until required.  
3.4.8. Isolation of ovarian surface epithelium (OSE) 
When OSE was needed for in vitro experiments, it was separated from the rest of the ovary 
according to the method of Nikitin et al. with slight modifications (Flesken-Nikitin et al. 2013).  
Individual ovaries were dissected from 10-12 weeks old virgin mice and washed twice with ice 
cold sterile 1X PBS (Gibco®, Life technologies). Each individual ovary was then transferred 
to a capped microcentrifuge tube filled with 200 μl digestion-buffer [prepared as shown in 
Table 3.3 and sterilized by filtration using 40 µl cell strainer (Falcon®, Fisher, USA)], and 
incubated for 60-75 minutes at 37°C in a 5% CO2 incubator with intermittent shaking. The 
complete peeling-off of the epithelial cells was checked under the microscope before removing 
the ovary from the tube. Following this, 1 ml of OSE complete medium (Table 3.3, prepared 
aseptically) was added to the tube and samples centrifuged at 1000 rpm for 5 minutes. The 
supernatant was discarded and the pellet washed with 1 ml of ice-cold sterile 1X PBS. The tube 
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was centrifuged and the pellet was resuspended in 500 µl of OSE complete medium for OSE 
2D cultures (Section 3.9.1).  
Table 3.3: Preparations used in OSE isolation from ovaries 
Preparation name Ingredients  Amount 
required  
Digestion buffer DMEM/F12 medium (Mediatech) 
Collagenase-dispase (Roche) 
Bovine serum albumin (Sigma) 
Dnase I (Sigma) 
1 ml 
4 mg 
30 mg 
1 µl 
OSE complete medium DMEM/F12 medium (Mediatech) 
Fetal bovine serum (Sigma) 
L-glutamine 200 mM (Mediatech) 
ITS liquid media supplement 100X (Sigma) 
Sodium pyruvate 100 mM (Mediatech) 
MEM non-essential amino acids 100X (Mediatech) 
Hydrocortisone (Sigma) 
Epidermal growth factor EGF (Sigma) 
450 ml 
25 ml 
10 ml 
5 ml 
5 ml 
5 ml 
250 mg 
10 mg 
 
3.4.9. Serum collection 
Blood collected at diestrus stage from 10-week-old Apc2+/+ and Apc2-/- mice was placed 
in microcentrifuge tubes and allowed to clot for 90 minutes at room temperatures. Following 
this, samples were centrifuged for 10 minutes at 2000 rpm. Serum was collected and stored in 
microcentrifuge tubes at -80ºC until used for hormone assays. 
3.5. Histological analysis 
3.5.1. Dewaxing and hydrating PLLs 
Prior to IHC staining, PLLs were placed in a plastic slide staining rack. Dewaxing of 
paraffin-embedded 5 µm tissue sections was performed by dipping the PLLs 2 X 5 minutes in 
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xylene solution, until complete removal of the paraffin wax. Slides which had been redipped 
in paraffin wax were incubated overnight in Histoclear (National Diagnostics, USA) bath for 
complete removal of the thick paraffin layer before performing the dewaxing steps described 
above. Following this, hydration was performed by dipping the sections in decreasing 
concentration of ethanol (2 X 100% ethanol, 1 X 95% ethanol, 1 X 70% ethanol, for 3 minutes 
each). The hydrated PLLs were then transferred to distilled water until further processing. 
3.5.2. Haematoxylin and eosin (H&E) staining 
Fully hydrated PLLs were stained with H&E to enable the histologic assessment of 
tissues. The hydrated PLLs were immersed in Mayer’s Haemalum (RA Lamb, ThermoFisher, 
USA) stain for 1 minute, washed in running water for 5 minutes and dipped in Eosin (RA 
Lamb, ThermoFisher, USA) stain for 1 minute. Following a further wash under running tap 
water for 5 minutes, sections were dehydrated and mounted (Section 3.5.3.8). H&E staining 
was kindly performed by Derek Scarborough. 
3.5.3. Immunohistochemistry  
Immunohistochemistry was used to assess the expression and localization of proteins 
of interest in the ovarian sections (Table 3.4). PLLs were first dewaxed and hydrated (Section 
3.5.1) before processing as described below. A negative control (lacking primary antibody) 
was included each time an immunostain was performed, to support the validity of the staining. 
Oviducts and uteri present on slides served as positive controls for most of the proteins 
assessed. 
3.5.3.1. Antigen retrieval 
Antigen retrieval was performed by boiling hydrated PLLs in citrate buffer [Appendix 
1] to unmask the antigens from protein crosslinking that occurs during fixation. Briefly, 800 
ml of citrate buffer was placed in a pressure cooker and preheated in a microwave oven for 5 
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minutes at 900 W. The slides were placed in the preheated citrate buffer in the pressure cooker 
and heated at 900 W for 5 minutes (until the pressure valve rises). This was followed by heating 
for a further 15 minutes at 300 W. After the pressure was released from the pressure cooker, 
the lid was removed and the slides left to cool down to room temperature in the solution. 
Following this, the slides were removed and washed twice with distilled water for 5 minutes 
with continuous agitation. 
3.5.3.2. Blocking endogenous peroxidase activity 
As horseradish peroxidase (HRP) enzyme catalyses the final reaction required for 
antibody visualization later in the procedure (Section 3.5.3.7), endogenous peroxidase activity 
was blocked to avoid interference and prevent false positive results. This was performed by 
incubating the slides for 30 minutes in 1.5% hydrogen peroxide (Sigma, USA) with shaking 
on a rocker. The slides were then washed 2 X 5 minutes with  distilled water, followed by 1 X 
5 minutes TBST buffer [Appendix 1] with continuous shaking. 
3.5.3.3. Blocking of non-specific antibody binding 
Blocking of non-specific antibody binding was performed by incubating the slides in 
10% serum (in TBST) from the species that the secondary antibody was raised in, for 60 
minutes at room temperature in a humidified chamber (Table 3.4). When using a mouse 
primary antibody, the mouse on mouse (M.O.M) Ig blocking reagent of the M.O.M kit (Vector 
Labs, USA) was used instead (prepared by diluting 9 µl of the reagent with 250 µl TBST).  A 
wax pen (ImmEdge hydrophobic barrier pen, Vectorlabs, USA) was used to draw wells 
surrounding the tissue to be stained and 70 µl of the diluted blocking reagent or serum was 
applied to each section.  
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3.5.3.4. Application of primary antibody 
Antibodies against proteins of interest were diluted in 10% blocking serum (in TBST) 
to an appropriate concentration (Table 3.4). The blocking serum was tipped off slides and 80 
µl of the primary antibody solution applied to each tissue section and incubated in a humidified 
chamber for 1 hour at room temperature or overnight at 4ºC. A piece of parafilm was placed 
on each slide to minimize evaporation. 
3.5.3.5. Application of secondary antibody 
Slides were washed 3 X 5 minutes with TBST. Before incubation with a secondary 
antibody against the host species in which the primary antibody was raised. Either 1:200 [in 
10% blocking serum] biotinylated secondary antibody (Vector labs, USA) or undiluted HRP-
conjugated (Dako Envision plus kit, Agilent, USA) secondary antibody was utilized (Table 
2.4). When using M.O.M kit, 1:250 MOM biotinylated anti-mouse Ig reagent [in M.O.M 
diluent prepared by adding 600 µl of protein concentrate stock solution to 7.5 ml of TBST] 80 
µl was applied to each tissue section and incubated for 60 minutes at room temperature in a 
humidified chamber. 
3.5.3.6. Signal amplification 
A signal amplification step was required when a biotinylated secondary antibody was 
used. This was carried out using the VECTASTAIN ABC kit (Vector labs, USA), which 
enables the binding of HRP to the biotin of the secondary antibody. The ABC working solution 
was prepared 30 minutes prior to use (1 drop of reagent A added to 2.5 ml of TBST, followed 
by 1 drop of reagent B) and incubated at room temperature. Following the secondary antibody 
incubation, the slides were washed 3 X 5 minutes with TBST with agitation. 80 µl of ABC 
working solution was applied to the sections and incubated in the humidified chamber for 30 
minutes at room temperature. 
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3.5.3.7. Visualization of antibody binding 
Diaminobenzidine (DAB) reagent (Dako, Agilent, USA) is utilized as a substrate for 
the HRP enzyme conjugated to the secondary antibody. DAB is oxidized by HRP to give a 
brown colour at the site of the antibody binding. Following the secondary antibody step (and 
signal amplification step if required), the slides were washed 3 X 5 minutes with TBST 
solution. 80 µl of DAB working solution (prepared by adding 1 drop of the DAB chromogen 
to 1 ml of DAB substrate buffer) were applied for 5-10 minutes. After the development of 
brown colour, the DAB reagent was tipped off. Slides were washed 2 X 5 minutes in TBST 
before performing a final wash for 5 minutes in distilled water. Slides were then placed in a 
bath of Mayer’s Haemalum (RA Lamb, USA) stain for 1 minute and subsequently washed 
under running water until complete removal of excess Haemalum (5 minutes). 
3.5.3.8. Dehydration and mounting of slides 
The slides were removed from water and placed in increasing concentration of ethanol 
to dehydrate the slides (1 x 3 minutes in 70% ethanol, 1 x 3 minutes in 95% ethanol, 3 x 3 
minutes in 100% ethanol). This was followed by 2 x 5 minutes incubation in xylene. Slides 
were then mounted using DPX mounting medium (RA Lamb, USA) and 40 mm coverslip were 
applied, avoiding air bubble formation. Slides were left to dry in the fume hood overnight.    
Table 3.4: Antibodies and conditions required for immunohistochemistry staining 
 Primary 
antibody 
IgG source  Dilution used Blocking 
serum 
Secondary antibody 
and dilution used 
APC2 
Abcam  
113370 
Rabbit polyclonal 1/400 10% goat 
serum 
Biotinylated Goat Anti-
Rabbit 
Immunoglobulins 
APC2 
Santa cruz 
12425 
Goat polyclonal 1/400 10% rabbit 
serum 
Biotinylated rabbit anti-
goat immunoglobulin  
Ki67 
Abcam 
Ab1667 
Rabbit polyclonal  1/75 10% goat 
serum 
Biotinylated goat anti-
rabbit immunoglobulins  
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Active caspase-3 
Cell signalling 
9661 
Rabbit polyclonal  1/200 10% goat 
serum 
Biotinylated Goat Anti-
Rabbit 
Immunoglobulins 
CD34 
Abcam 
Ab81289 
Rabbit polyclonal 1/150 10% goat 
serum 
Biotinylated Goat Anti-
Rabbit 
Immunoglobulins  
E-cadherin 
BD Transduction 
610182 
Mouse 
monoclonal  
1/200 MOM 
blocking 
reagent 
EnVision+ System- 
HRP  
Labelled anti-mouse 
Vimentin  
Santa cruz  
SC-7557 
Goat polyclonal 1/300 10% rabbit 
serum 
Biotinylated rabbit anti-
goat immunoglobulin  
Cytokeratin 18 
multiepitope 
cocktail 
Progen  
651134 
Mouse 
monoclonal  
1/5 MOM 
blocking 
reagent 
MOM biotinylated anti-
mouse Ig reagent 
Β-catenin 
Pharmingen  
562505 
Mouse 1/200 10% rabbit 
serum 
EnVision+ System- 
HRP  
Labelled Polymer  
Anti-mouse 
PTEN 
Cell signalling  
9559 
Rabbit 
monoclonal 
1/200 10% goat 
serum 
Biotinylated Goat Anti-
Rabbit Immunoglobulin 
(1/200) 
p-AKT (Ser 473 
D9E) 
Cell signalling 
4060S 
Rabbit 
Monoclonal 
1/75 10% goat 
serum 
Biotinylated Goat Anti-
Rabbit Immunoglobulin 
(1/200) 
p-FOXO1/3/4 
Cell signalling 
2599 
Rabbit 
monoclonal 
1/40 10% goat 
serum 
Biotinylated Goat Anti-
Rabbit Immunoglobulin 
(1/200) 
FOXL2 
Abcam 
Ab5096 
Goat polyclonal 1/750 10% rabbit 
serum 
Biotinylated rabbit anti-
goat immunoglobulin 
(1/200) 
ERα 
 
Mouse 1/500 MOM 
blocking 
reagent 
MOM biotinylated anti-
mouse Ig reagent 
(1/250) 
FOXO1 
Cell signalling 
14952 
Mouse 1/500 10% goat 
serum 
EnVision+ System- 
HRP  
Labelled anti-mouse 
Inhibin α (T-17) 
Santa cruz 
22048 
Goat polyclonal 1/20 10% rabbit 
serum 
Biotinylated rabbit anti-
goat immunoglobulin 
(1/200) 
p44/42 MAPK 
(Erk1/2) (137F5) 
Cell signalling 
4695S 
Rabbit 1/100 10% goat 
serum 
Biotinylated Goat Anti-
Rabbit Immunoglobulin 
(1/200) 
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3.5.4. Image acquisition and analysis 
Stained sections were examined with an Olympus BX43 light microscope 
Photomicrographs were taken by 5 Megapixel HD Microscope Camera (Leica MC170 HD, 
Germany) or using the ZEISS Axio Scan Z1 (Zeiss, Germany). The 4X magnification lens was 
used for counting ovarian follicles, corpora lutea and cysts. The 10X magnification was used 
for the vaginal smear examination for oestrous cycle staging. The 20X and 40X magnification 
was used for detailed H&E or immunohistochemistry ovarian tissue/tumour examination.  
3.5.4.1. Cytological assessment of vaginal smear  
The cytological evaluation of oestrous cycle stage was performed as previously 
described by McLean et al. (McLean et al. 2012). The three cell types identified in vaginal 
smears and used for staging are nucleated epithelium (NE), cornified epithelium (CE) and 
leucocytes (L). In the proestrus stage, the NE predominates. In the estrus stage, the CE 
predominates, with cells often aggregated in clusters. In the metestrus stage, the CE are still 
present but with less clustering and leucocytes are also observed. In the diestrus stage, 
leucocytes predominate, and occasional NE and CE are present (Figure 3.3). 
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Figure 3.3: Cytological assessment of vaginal smears to identify oestrous stage. Red 
arrowheads indicates the three main cell types detected in vaginal smear samples: nucleated 
epithelial cells (NE), cornified squamous epithelial cells (CE), and leukocytes (L). Vaginal 
smear of mouse at (a) Proestrus stage showing the dominance of nucleated epithelial cells, (b) 
Estrus stage when the cornified epithelial cells predominate, (c) Metestrus stage showing 
cornified epithelial cells and leucocytes, and (d) Diestrus stage showing the presence of all 
three cell types. Scale bar 100 µm. 
3.5.4.2. Characterization of cumulus oophorous complexes retrieved from oviducts 
After releasing COCs from the oviducts (Section 3.4.3) under a dissection microscope 
using 2X magnification, the number of COCs released from each oviduct was counted. They 
were examined under a bright field microscope to assess their morphology, by counting the 
number of layers of cumulus cells surrounding the oocyte. Following this, 40 µl of 4 mg/ml 
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collagenase/dispase (Roche, Switzerland) dissolved in DMEM/F12 medium (Mediatech, USA) 
were applied to the PBS drop to free oocytes from surrounding cumulus cells. Gentle pipetting 
was performed and the solution left for 10 minutes to complete the digestion. Oocytes were 
examined under the microscope to determine their integrity, by recording cytoplasmic 
fragmentation, surface granulation and/or blebbing and smoothness of oocyte edge (Kiyosu et 
al. 2012) and to measure oocyte diameter (Brown et al. 2010). A minimum of 8 diameters were 
measured in order to determine the mean oocyte diameter. 
3.5.4.3. Histological characterization of the ovary 
Formalin-fixed paraffin-embedded ovaries were serially sectioned into 100 sections, 
each of 5 µm thickness, with each 10th section stained with H&E. Growing follicles were 
counted every 10th section when the nucleus of the oocyte was present. Decisions about 
basophilic intra-ovarian structures without a clear oocyte in the section (i.e. whether growing 
follicle or cyst) were made by examining the previous and following 10th stained sections. The 
total number of structures throughout the 10 counted sections was used as an estimate for the 
number in the whole ovary. The identification of the range of structures and abnormalities 
listed below was done according to the published INHAND project (International 
Harmonization of Nomenclature and Diagnostic Criteria for Lesions in Rats and Mice) (Dixon 
et al. 2014). 
3.5.4.3.1. Quantifying follicles 
All growing follicles with intact oocytes were counted and classified into primary 
follicles (oocyte surrounded by one layer of cuboidal granulosa cells); secondary follicles 
(oocyte surrounded by two or more layers of cuboidal granulosa cells and devoid of antral 
space), antral follicles (oocyte surrounded by multiple layers of cuboidal granulosa cells, with 
the presence of an antral space) and pre-ovulatory follicles (oocyte surrounded by multiple 
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layers of cuboidal granulosa cells, with the presence of an antral space and cumulus oophorous 
that forms a stalk into the antral cavity) (Figure 3.4; (Balla et al. 2003)). Atretic follicles were 
identified by the presence of pyknotic bodies in the granulosa cells and/or oocyte degeneration, 
and counted separately (Visser et al. 2007). 
 
 
Figure 3.4: Photomicrographs of the follicles (black letters) quantified in serial sections. 
Primary follicles (1ry), secondary follicles (2ry), antral follicles (AF), pre-ovulatory follicle 
(POV). Atretic follicles were classified as small atretic follicles (SAF) and large atretic follicles 
(LAF). Different elements of the follicles are labelled using red letters. O:oocyte. GC: 
granulosa cells. COC: cumulus oophorus comples. AS: antral space/antrum. DO: degenerating 
oocytes. P: pyknotic body (Pyknosis). Scale bars all 100 µm except lower left panel (scale bar 
200 µm). 
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3.5.4.3.2. Quantifying corpora lutea 
All corpora lutea (CL) were counted, whether they were an eosinophilic CL (mature, 
present near to the surface or towards the centre, representing newly formed, recent or old CL) 
or a basophilic CL (recent, present close to the ovarian surface, resulting from the most recent 
ovulation, Figure 3.5). 
 
Figure 3.5: Corpora lutea in ovarian sections. ECL: eosinophilic corpus luteum. BCL: 
basophilic corpus luteum. Scale bar 500 µm. 
3.5.4.3.3. OSE irregularities 
 A range of OSE irregularities was observed in induced ovaries and counted whenever 
identified. The presence of papillary-like epithelial structures projecting to the outside were 
identified as ‘papillary epithelium’. Presence of more than one layer of epithelial cells was 
identified as ‘multi-layering’. A deep groove inside the ovarian tissue formed of epithelial cells 
was identified as ‘OSE invagination’. Bulging of the normal contour of the ovary was identified 
as ‘ovarian outgrowth’ (Figure 2.6).  
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Figure 3.6: Photomicrographs of OSE irregularities analysed, representing papillary epithelium 
(PE), multi-layering (ML), ovarian outgrowth (OG) and invaginations in the OSE (INV). Other 
abnormalities inside the ovaries include follicular cysts (FC) and pigmentation (P). Scale bar 
100 µm. 
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3.5.4.3.4. Abnormal structures inside the ovary 
Decisions about cysts were only made after examining the serial sections to ensure that 
none of them contained an oocyte in another section (Figure 3.7). Any structure present inside 
the ovary, of the same size or bigger than a normal corpus luteum, having one or more 
granulosa cell layers without an oocyte and with a large empty space was identified as a 
‘follicular cyst’. Any cystic structure filled with blood was identified as ‘blood cyst’. When the 
cyst was lined with epithelial cells (confirmed by E-cadherin immunostaining), it was identified 
as an ‘epithelial cyst’.  
 
 
Figure 3.7: Photomicrographs of cysts or abnormal follicles found inside the ovary, 
representing blood cysts (BC), folliclular cysts (FC), and epithelial cysts (EC) lined with 
columnar epithelium (Col). Scale bar 100 µm. 
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3.6. Quantitative Reverse-Transcription Polymerase Chain Reaction (qRT-PCR) 
qRT-PCR was used to analyze the relative expression levels of genes present in ovarian 
tissue or ovarian tumours. RNA was extracted from the whole ovaries or a piece of the tumour. 
A reverse transcription step was performed to synthesize cDNA from the isolated RNA prior 
to performing the PCR amplification. A minimum of three mice per cohort was assessed, unless 
it was only one tumour per cohort when 2 different samples of the same tumour were processed 
separately. 
3.6.1. RNA extraction 
Total RNA was extracted from individual ovaries or tumours using RNeasy plus mini 
extraction kit (Qiagen, Germany) in accordance with the manufacturer’s instructions. Briefly, 
the whole ovary or a tumour piece weighing 10 mg, was homogenized in 350 µl RLT buffer 
using a hand-held tissue grinder and disposable plastic pestles (FisherBrand® disposable pestle 
system, ThermoFisher, USA).  A series of columns and reagents were used to extract the RNA 
according to the manufacturer instructions (Figure 3.8). The total RNA extracted from one 
whole ovary was dissolved in 50 µl of ultrapure water (Sigma, USA). The RNA quantity and 
quality were measured using a NanoDrop 2000® (Thermo Scientific, USA). The extracted 
RNA was kept at -80ºC until further processing for cDNA synthesis. 
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Figure 3.8: Workflow of RNeasy plus mini extraction kit. Picture adapted from RNeasy plus 
mini handbook available at 
https://www.qiagen.com/kr/resources/resourcedetail?id=c8cdc6bf-5bbf-4e3b-a0f4-
476da9215012&lang=en 
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3.6.2. Reverse transcription 
A volume equivalent to 1 µg of RNA was used for genomic DNA (gDNA) removal 
followed by cDNA synthesis by reverse transcription, using QuantiTect reverse transcription 
kit (Qiagen, Germany). Briefly, template RNA was placed in one well of a strip tube, 2 µl of 
7X gDNA wipeout buffer were subsequently added and the volume adjusted to 14 µl using 
ultrapure water (Sigma, USA). The strip tube was then incubated at 42ºC for 2 minutes to 
remove gDNA. Following this, reverse transcription was performed by adding 6 µl of reverse 
transcription master mix [consisting of 1 µl reverse transcriptase, 4 µl 5X RT buffer and 1 µl 
RT primer mix] to each well and incubated at 42ºC for 15 minutes, followed by a 3 minutes 
incubation at 95ºC to inactivate the transcriptase. The synthesized cDNA (20 µL) was stored 
at -20ºC or directly used as a template for polymerase chain reaction (PCR). 
3.6.3. Quantitative polymerase chain reaction (qPCR) 
qPCR reactions were performed in triplicates in 384-well reaction plates (Applied 
Biosystems). To normalize the expression of genes of interest, β-actin was used as an 
endogenous housekeeping control gene.  In order to compare mRNA expression levels, each 
cDNA sample was amplified using primer pairs (SYBR® Green analysis) or predesigned 
probes (TaqMan® analysis) of genes of interest as well as β-actin. A "no template control" that 
contained water was included in each plate.  
3.6.3.1. SYBR Green gene expression analysis preparation 
All primers used were designed using Primer BLAST (available at 
http://www.ncbi.nlm.nih.gov/tools/primer-blast) and synthesized by Sigma (Table 3.5). Each 
reaction mixture contained 0.5 µl cDNA, 0.25 µl forward primer (10mM), 0.25 µl reverse 
primer (10mM), 5 µl PowerUp™ SYBR™ green master mix (Applied Biosystems, USA) and 
4 µl ultrapure water (Sigma, USA) to a final volume of 10 µl. The plate was sealed and 
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centrifuged for 1 minute at 10 000 rpm. The plates were either amplified on the PCR machine 
on the same day of preparation or stored at 4ºC and amplified the following day. 
 Real-time RT-PCR was performed using QuantStudio™ 7 Flex Real-Time PCR 
System (ThermoFisher, USA) according to the manufacturer’s instructions. After an initial 
hold stage (2 minutes at 20ºC), followed by an initial denaturation at 95ºC for 10 minutes, 
amplification was performed for 40 cycles, each of 15 seconds denaturation at 95ºC followed 
by 60 seconds of annealing and extension at 60ºC. A final melt curve stage was performed (15 
seconds at 95ºC followed by 1 minute at 60ºC and 15 seconds at 95ºC).  
Table 3.5: List of genes and primers used in SYBR Green gene expression analysis 
Gene  Forward primer sequence (5'-3') Reverse primer sequence (5'-3') 
Actb (actin b) GCT ACA GCT TCA CCA CCA 
CA 
TCT CCA GGG AGG AAG 
AGG 
Apc2 exon 13 beginning CTC TGT GGA ACC TGT CAG 
CA 
AAC CCA GTG CAC CAT 
CTA CC 
Apc2 exon 13 end GGA ACT CCC TGG CAG TCA 
TC 
TAG TCC TCC CGT GTG GCA 
AT 
Apc2 exon 14 GGA GGA TGC AAC ACC 
ATC CA 
ACG GAA CTA CAA CGG 
CTC AG 
Results of Apc2 expression analysis using SYBR Green gene expression are presented 
in Appendix 2. 
3.6.3.2. TaqMan gene expression analysis 
All primer/probe sets used were pre-designed and purchased from ThermoFisher 
Scientific, USA. They were selected using Taqman® gene expression assay search tool by 
searching for mouse gene expression assay and choosing the primer/probe set with the best 
coverage (Table 3.6). Each reaction mixture contained 0.5 µl cDNA, 0.5 µl TaqMan® assay 
(primer/probe set), 5 µl TaqMan® universal master mix II with UNG (Applied Biosystems, 
USA) and 4 µl ultrapure water (Sigma, USA) to a final volume of 10 µl. The plate was sealed 
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and centrifuged for 1 minute at 10 000 rpm. The reactions were either amplified on the PCR 
machine on the same day of preparation or stored at 4ºC and amplified the following day. 
Table 3.6: List of TaqMan® assays used in gene expression analysis. 
Taqman® 
Gene 
Expression 
Assay  
Assay ID  Taqman® 
Gene 
Expression 
Assay  
Assay ID 
Actb Mm00607939_s1 Esr1 Mm00433149_m1 
Apc Mm00545877_m1 Esr2 Mm00599819_m1 
Apc2 Mm00478649_m1 Fasl Mm00438864_m1 
Ar Mm00442688_m1 Fgf1 Mm00438906_m1 
Areg Mm00437583_m1 Foxl2 Mm00843544_s1 
Axin2 Mm00443610_m1   Foxo1 Mm00490671_m1 
Bcl2l11 Mm00437796_m1 Foxo3 Mm01185722_m1 
Bcl6 Mm00477633_m1 Fshr Mm00442819_m1 
Cd44 Mm01277163_m1 Gdf9 Mm00433565_m1 
Cdh1 Mm01247357_m1 Kitlg Mm00442972_m1 
Cdkn1b Mm00438168_m1 Lef1 Mm00550265_m1   
Ctnnb1 Mm00483039_m1 Lgr5 Mm00438890_m1 
Cyp11a1 Mm00490735_m1 Lhcgr Mm00442931_m1 
Cyp17a1 Mm00484040_m1 Pgr Mm00435625_m1 
Cyp19a1 Mm00484049_m1 Pten Mm00477210_m1 
Egf Mm00438696_m1 Tnfsf10 Mm01283606_m1 
Egfr Mm00433023_m1 Vegfa Mm01281448_g1 
Ereg Mm00514794_m1 Wif1 Mm00442355_m1 
Real-time RT-PCR was performed using QuantStudio™ 7 Flex Real-Time PCR 
System (ThermoFisher, USA) according to the manufacturer’s instructions. After an initial 
hold stage (2 minutes at 20ºC followed by an initial denaturation at 95ºC for 10 minutes), 
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amplification was performed (PCR stage) for 40 cycles of 15 seconds denaturation at 95ºC 
followed by 60 seconds of annealing and extension at 60ºC.  
3.6.4. Gene expression analysis  
Gene expression analysis was performed using QuantStudioTM Real-Time PCR 
software version 1.3 (available at https://www.thermofisher.com/uk/en/home/technical-
resources/software-downloads/quantstudio-flex-real-time-pcr-system.html), utilizing the 2(-
Delta Delta C(T)) method to calculate relative gene expression levels (Livak and Schmittgen 
2001). Melt curves for each reaction were checked to confirm the presence of one peak only 
and to avoid potential interference due to primer-dimer formation (for SYBR gene expression). 
A threshold was set in the exponential linear range on the amplification curve. A cycle 
threshold (CT) was defined as the number of thermocycles required by each well reaction to 
reach the threshold. The 3 readings of the triplicates were used in the analysis, provided that 
they did not differ by more than 1 CT value. Any reaction with more than one peak on the 
melting curve or differing by more than 1 CT value was excluded from the analysis. The sample 
CT value was calculated as the average value of the triplicates (or valid results) for each gene 
of interest. The readings of each sample were normalized by subtracting the average CT value 
of β-actin from the average CT value of the gene of interest to calculate ΔCT value. The ΔΔCT 
values were calculated using the control cohort (Apc2+/+ group) as the calibrator, by subtracting 
the average ΔCT value of the control cohort from the average ΔCT value of the test cohort. The 
relative mRNA expression level was calculated using the formula:  
𝑅𝑒𝑙𝑎𝑡𝑖𝑣𝑒 𝑚𝑅𝑁𝐴 𝑒𝑥𝑝𝑟𝑒𝑠𝑠𝑖𝑜𝑛 𝑙𝑒𝑣𝑒𝑙 = 2−∆∆𝐶𝑇 
Relative expression levels (RQ), minimum (RQ Min) and maximum (RQ Max) values 
were extracted from the QuantStudio™ software output after performing the analysis. These 
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values were used to plot the graphs, and statistical significance was estimated using the overlap 
rule for 95% confidence interval bars (Cumming et al. 2007) for small biological groups (n=3). 
3.7. Western blotting 
 3.7.1. Preparation of protein extract 
Cryogenic grinding was used to mechanically disrupt tissue and produce the desired 
lysate. Frozen whole ovaries or small pieces of brain (up to 20 mg) were ground under liquid 
nitrogen using a mortar and pestle until the tissue was fully powdered. It was collected in a 1.5 
ml microcentrifuge tube and 100 µl of lysis buffer [preheated at 95ºC for 2 minutes on a heat 
block, supplemented with protease inhibitors] were added to the tube (Table 3.7). The contents 
were mixed by vortexing for 1 minute and placed on a heat block for 3 minutes at 95ºC. This 
vortex-heat cycle was repeated 3 times and cell lysate centrifuged at 13 000 rpm for 5 minutes 
at room temperature. The supernatant was aliquoted in clean microcentrifuge tubes and stored 
at -80ºC until further processing. 
Table 3.7: Lysis buffer supplemented with protease inhibitors 
Constituent  Preparation  Amount used in 
lysis buffer 
50 mM Tris buffer pH 
7.4+2% SDS 
0.71 g of Tris (Fisher Bioreagents, 
USA) dissolved in 100 ml of ultrapure 
water (Sigma, USA), pH adjusted to 
7.4 using concentrated hydrochloric 
acid (Sigma, USA). 2.35 g of sodium 
dodecyl sulphate SDS (Sigma, USA) 
were then added to the solution (stored 
at room temperature) 
850 µl (kept at 
room temperature 
to avoid SDS 
precipitation) 
Protease inhibitor 
(complete mini EDTA-free 
protease inhibitor cocktail 
tablet, Roche, Switzerland) 
One tablet was dissolved in 1.5 ml of 
ultrapure water (Sigma, USA) and 
stored in aliquots of 150 µl at -20ºC 
150 µl (added just 
before use of lysis 
buffer) 
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 3.7.2. Protein quantification 
Protein quantification was determined colorimetrically using the bicinchoninic acid 
(BCA) reaction (Smith et al. 1985). This method combines the Biuret reaction (reduction of 
divalent copper ions to monovalent copper ions by protein in alkaline medium) with the 
colorimetric determination of the monovalent copper ions produced, using BCA. One copper 
monovalent ion chelates with 2 BCA molecules forming a purple complex with a strong 
absorbance at 562 nm. The number of copper ions present is directly proportional to the protein 
concentration of the samples, thus allowing it to be determined colorimetrically (Figure 3.9). 
 
Figure 3.9: Schematic representation of chemical reactions in the BCA assay of protein 
determination. Figure taken from Biotek website and available at 
http://www.biotek.com/resources/articles/in-situ-micro-volume-bicinchoninic-acid-protein-
assay.html 
The concentration of protein in the lysate was determined using the Pierce BCA protein 
assay kit (ThermoFisher Scientific, USA). The working reagent (WR) was prepared by adding 
5 ml of reagent A to 0.1 ml of reagent B. Protein standards were prepared by dissolving stock 
bovine serum albumin (BSA) in the lysis buffer used and diluting to yield 8 different 
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concentrations (25, 125, 250, 500, 750, 1000, 1500 and 2000 µg/ml). In a microplate well, 10 
µl of the prepared protein lysate or standard dilution were added to 200 µl of WR (assayed in 
duplicates). The contents were mixed on a plate shaker for 30 seconds after which the plate 
was covered and incubated at 37ºC for 30 minutes. The plate was left to cool to room 
temperature and the absorbance of the colour formed was measured colorimetrically using a 
CLARIOstar® monochromator microplate reader (BMG Labtech, Germany) set at 562 nm. 
Absorbances of the different concentrations of BSA were used to construct a calibration curve, 
and the protein concentration of samples calculated using this calibration curve.  
 3.7.3. PAGE gel preparation 
Gels used were hand-cast in house. Gel cassettes were set up in Mini-PROTEAN® tetra 
hand casting system (BioRad, USA) with a 10 well comb. The short plate and spacer plate of 
the cast were cleaned thoroughly with detergents, rinsed with ultrapure water (Sigma, USA) 
followed by 70% ethanol and dried with paper towel. The assembled plate was then placed in 
the frame of the casting stand (on a rubber gasket) and clamps closed. Leakage was tested after 
the assembly by using ultrapure water (Sigma, USA), which was subsequently poured off. The 
running gel (6% acrylamide) and the stacking gel (3% acrylamide) were both prepared in sterile 
falcon tubes (recipes in Table 3.8), but without adding TEMED (ThermoFisher Scientific, 
USA). Once ready, TEMED was added to the running gel and mixed by inversion. Quickly, a 
micropipette set at 1000 µl was used to pour the gel between the plates to 2 cm below the top 
of the short plate.   2 ml of ultrapure water  (Sigma, USA) were then added on top of the gel to 
avoid formation of air bubble and to ensure the gel surface is flat. Once the gel was set (after 
15 or 20 minutes), the water was poured off, TEMED was added to the stacking gel which was 
mixed and poured on top the running gel. A 1.5mm 10 well comb was inserted into the stacking 
gel and left to set. Once set, the plates were removed from the casting apparatus. The gel was 
either used on the same day or stored in the fridge for up to 4 days, after wrapping the plates in 
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paper towels and generously spraying them with ultrapure water (Sigma, USA) to avoid 
dryness. For use, the gel was placed in a Mini-PROTEAN® tetra vertical electrophoresis cell 
(BioRad, USA) and the tank filled with 1X running buffer (Table 3.8). The comb was removed 
and the wells washed with the running buffer using a 100 µl micropipette (to remove any debris 
from the wells). The wells were then thoroughly checked and any air bubbles removed.   
Table 3.8: Recipes of gels and running buffer used for protein separation 
Preparation name Ingredients  Amount required 
(added in the same 
order written) 
Running/separating 
gel  
(6% acrylamide) 
Ultrapure water (Sigma, USA) 
Tris (Fisher Bioreagent, USA) 1.5M pH 
8.8 
30% Acrylamide (Sigma, USA) 
10% SDS (Sigma, USA) 
25% Ammonium persulfate (Sigma, 
USA) 
Temed (Sigma, USA) 
4 ml 
1.875 ml 
 
1.5 ml (toxic) 
75 µl 
50 µl 
 
10 µl 
Stacking gel  
(3% acrylamide) 
Ultrapure water (Sigma) 
Tris (Fisher Bioreagent, USA) 0.625M 
pH 6.8 
30% Acrylamide (Sigma, USA) 
10% SDS (Sigma, USA) 
25% Ammonium persulfate (Sigma, 
USA) 
Temed (Sigma, USA) 
2.525 ml 
0.625 ml 
 
0.525 ml 
37.5 µl 
75 µl 
 
7.5 µl 
Running buffer 
(1X) 
Tris base (Fisher Bioreagent, USA) 
Glycine (Sigma, USA) 
10% SDS (Sigma, USA) 
Ultrapure water (Sigma, USA) 
3.02 grams 
18.8 grams 
10 ml         
Up to 1000 ml 
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 3.7.4. Loading protein samples and running the gel (SDS-Page) 
Prior to loading onto the gel, frozen protein aliquots were defrosted on ice. A volume 
equivalent to 50 µg protein was pipetted into a clean microcentrifuge tube, 5 µl of 4X Laemmli 
buffer (Sigma, USA) was added and ultrapure water (Sigma, USA) used to adjust the final 
volume to 20 µl. The protein sample was then denatured by placing on a heat block at 95ºC for 
10 minutes. After heating, the samples were quenched on ice, briefly centrifuged and loaded 
into the wells of the gel. The PageRuler™ Plus pre-stained protein ladder (ThermoFisher 
Scientific, USA), with proteins ranging from 10 to 250 kDa was used as a protein marker. This 
was performed by mixing 5 µl of the PageRuler™ with 15 µl of 1X  Leammli buffer (Sigma, 
USA) and loading in one well of the gel. The gel was then run at 125V for 75 minutes. The gel 
was removed from the electrophoresis cell, the plates were separated and the stacking gel was 
cut away and discarded. The gel was then carefully peeled off the plate and soaked in a box 
filled with transfer buffer (Table 3.9) until ready to be transferred. 
Table 3.9: Recipe of transfer buffer 
Ingredients Amount required 
Tris base (Fisher BioReagent, USA) 
Glycine (Sigma, USA) 
Methanol (Sigma, USA) 
Ultrapure water (Sigma, USA) 
2.9 grams 
14.5 grams 
200 ml 
Up to 1000 ml 
 
3.7.5. Protein transfer (Electrophoretic blotting) 
The wet transfer method was used for protein transfer. Mini Trans-Blot® cell (BioRad, 
USA) and polyvinylidene difluoride membrane PVDF (BioRad, USA) were used. Because 
PVDF is highly hydrophobic, it was activated by soaking in methanol (Sigma, USA) for 2 
minutes. It was then rinsed with ultrapure water (Sigma, USA) at least 3 times until it could be 
submerged into water and then soaked in the transfer buffer until used. The transfer stack was 
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then built in a mini gel holder cassette, where the gel and the PVDF membrane were 
sandwiched between sponges and filter papers (Whatman, UK) which had been pre-soaked in 
transfer buffer (Figure 3.10). The Mini Trans-Blot® cell was then filled with a pre-chilled 
transfer buffer and the transfer stack was placed in the central core. The cooling unit was placed 
in the cell and the transfer performed at 120V for 75 minutes at 4ºC (cold room). After transfer, 
the PVDF membrane was carefully removed and washed with ultrapure water (Sigma, USA) 
for 5 minutes. Ponceau S® (Sigma, USA) was applied to the membrane for 1 minute for rapid 
visualization of separated protein bands. The membrane was washed with ultrapure water 
(Sigma, USA) for 5 minutes on a lab rocker to remove the red Ponceau stain. A final wash with 
1X TBST buffer was performed before further processing. 
 
Figure 3.10: Assembly of the transfer stack used in electrophoretic blotting (Taken from 
Abcam Western blot protocol, http://www.abcam.com/protocols/general-western-blot-
protocol) 
 3.7.6. Antibody probing of the PVDF membrane 
To prevent non-specific background protein binding, the PVDF was blocked with 5% 
bovine serum albumin (BSA) solution [prepared by dissolving 0.5 g of BSA (Sigma) in 10 ml 
of TBST buffer] for 1 hour with shaking on a rocker at room temperature. The membrane was 
washed with 1X TBST for 5 minutes. The diluted APC2 primary antibody [Abcam ab113370, 
1:1300, using 1% BSA/TBST as diluent] was applied and incubated overnight at 4ºC with 
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continuous agitation, such that the membrane was fully immersed all the time. This was 
followed by washing the PVDF membrane 1X15 minutes, 2X5 minutes with TBST at room 
temperature with continuous shaking. The horseradish peroxidase (HRP)-conjugated goat anti-
rabbit secondary antibody [1:5000 in TBST, Vector Labs, UK] was applied to the PVDF 
membrane for 1 hour at room temperature with continuous shaking, followed by washing 1X15 
minutes, 2X5 minutes with TBST prior to signal detection. 
 3.7.7. Signal detection 
Luminata Forte Western HRP substrate (Merck Millipore, USA) was used as the 
chemiluminescent HRP detection reagent. The membrane was incubated with 1 ml of the 
Luminata reagent for 1 minute at room temperature and excess reagent discarded. The 
membrane was placed inside the GelDoc XR (Bio Rad, USA) chamber and Image Lab software 
was used for image acquisition using signal accumulation mode, to allow for a cumulative 
sequence of exposures. The settings were adjusted to get the first image after 5 seconds, 
followed by one image every 20 seconds up to 5 minutes.  
3.7.8. Confirming equal protein loading (GAPDH re-probing) 
In order to ensure that differences in APC2 protein expression were not due to unequal 
loading of protein samples, membranes were re-probed with an antibody to the house-keeping 
protein GAPDH. Following APC2 protein signal detection, the membrane was washed 3X5 
minutes with TBST to remove residual Luminata reagent. The diluted GAPDH primary 
antibody (Millipore MAB374, 1:2000) was applied overnight at 4ºC. This was followed by 
washing the membrane 3X5 minutes with TBST, applying the diluted secondary antibody (anti 
mouse IgG, Sigma A4416, 1:5000) for 1 hour at room temperature and performing signal 
detection as described above (Section 3.7.7). 
Results of Western blotting for APC2 protein are presented in Appendix 2. 
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3.8. Apc2 mutant allele (Apc2-) DNA sequencing 
3.8.1. PCR amplification 
DNA extraction and PCR product visualization were done by methods described in 
Section 3.3.1. PCR reaction was performed using 170 ng of prepared DNA. An equivalent 
volume of DNA template was added to a strip-tube well containing 25 µl GoTaq long PCR 
master mix (Promega, USA), 5µl of the forward primer (10 µmol), 5µl of the reverse primer 
(10 µmol) and ultrapure water (Sigma, USA) up to a final volume of 50 µl. The components 
were mixed, centrifuged for 10 seconds and placed in a thermal cycler. Samples were subjected 
to 2 minutes initial denaturation at 95ºC followed by 34 cycles of 30 seconds denaturation at 
94ºC and 6 minutes annealing and extension at 65ºC.  A final extension was done at 72ºC for 
10 minutes. The primers used for amplification were either the previously described Apc2 
primers used in genotyping (primer pair 1, Table 3.10), or a forward primer designed using 
Primer BLAST (available at http://www.ncbi.nlm.nih.gov/tools/primer-blast) to amplify DNA 
starting from exon 13, with the same reverse primer of primer pair 1 (primer pair 2, Table 3.10). 
All primers were synthesized by Sigma  
 
Table 3.10: Primers used for genomic DNA amplification and sequencing of Apc2- allele  
 Forward primer sequence (5'-3') Reverse primer sequence (5'-3') 
Primer pair 1 
(Clevers’ primers) 
Apc2+ primer: 
CTCCAAACACAAGATGATCG 
 
AGCTGTGTCTGATGAGGTG 
Apc2- primer: 
AGGTCTGAAGAGGAGTTTAC 
Primer pair 2 CTCTGTGGAACCTGTCAGCA AGCTGTGTCTGATGAGGTG 
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3.8.2. PCR product cleaning 
PCR products (amplified by primer pair 1, Table 3.10) were cleaned prior to sending 
for sequencing. Briefly, 40 µl of PCR products were added to 4 µl of 3M sodium acetate 
(Sigma, USA) and 80 µl of 100% ethanol (Sigma, USA) in a 1.5ml microcentrifuge tube. The 
tube was placed at -20ºC for 1 hour to precipitate DNA, and centrifuged at 13 000 rpm for 10 
minutes. The supernatant was discarded and the pellet washed with 70% ethanol and 
centrifuged again. After discarding the ethanol, the DNA was left to air-dry for 1 hour. It was 
dissolved in 20 µl ultrapure water (Sigma, USA) and incubated on a hot plate at 55ºC for 1 
hour with occasional vortexing. The concentration of DNA was measured using the 
NanoDrop® and the DNA stored at 4ºC until further processing. PCR product, amplified using 
primer pair 2 (Table 3.10) was sent for a walking primer sequencing project without performing 
this cleaning step. 
3.8.3. Sequencing 
The amplified PCR product (using primer pair 1, Table 3.10) together with the primers 
used for DNA amplification were sent to and sequenced by Eurofins Genomics DNA 
automated Sanger sequencing service. Following this, a walking primer sequencing project was 
performed on DNA amplified using primer pair 2 (Table 3.10) by Eurofins Genomics to 
unravel the full sequence of Apc2- allele. 
Results of Apc2- walking primer sequencing project are presented in Appendix 3. 
3.9. In vitro characterization of OSE 
3.9.1. OSE 2D culturing 
Wells were gelatinized by incubating 500 µl of 0.1% sterile gelatine solution [Appendix 
1] per well for 30 minutes. Following this, gelatine solution was aspirated and wells washed 
with 500 µl sterile 1X PBS (Gibco, Life technologies, USA). A second aliquot of PBS was 
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placed in individual wells (to prevent gelatine cracking) and discarded just before seeding the 
cells. 
Isolated OSE cells from a single ovary were resuspended in 500 µl OSE complete 
medium (Section 3.4.7), seeded onto one gelatinized well of a 24 well plate and incubated at 
37ºC and 5% CO2 (Flesken-Nikitin et al. 2013). 
3.9.2. Passaging OSE cells 
When cultured cells reached 80-90% confluency (3-5 days post-seeding), the media 
was aspirated, each well washed twice with 500 µl of PBS, and 400 µl of 0.25% trypsin 
(Mediatech, Germany) was added to each well and incubated for 10 minutes with occasional 
tapping. At the end of the incubation, the trypsin digestion was stopped by adding an equivalent 
amount of OSE complete medium, and cells were collected by centrifugation. Cells were 
washed by resuspending in 1000 µl of sterile 1X PBS (Gibco, Life Technologies, USA) and 
re-centrifuged. Following this, they were resuspended in 1500 µl OSE complete medium and 
seeded onto three gelatinized wells of a 24 well plate at 37ºC and 5% CO2.  
3.9.3. Quantifying viable cells 
Viable cells were quantified based on the amount of ATP present using the Cell Titer-
Glo 2 assay (Promega, USA) according to the manufacturer instructions. Briefly, passaged 
cells were resuspended in 1000 µl OSE complete medium and cell counts were determined 
using a haemocytometer. Subsequently, cells were diluted to a final concentration of 50 cells/µl 
using OSE complete medium and 100 µl of the diluted cell suspension were seeded on to one 
gelatinized well of a 96 opaque-walled well plate and incubated at 37ºC and 5% CO2 for 72 
hours. The plate was equilibrated to room temperature for 30 minutes before adding 100 µl of 
the Cell Titer-Glo 2 reagent. The cells were then shaken for 2 minutes on an orbital shaker and 
incubated for 10 minutes to stabilize the luminescent signal before measuring the luminescence 
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formed using CLARIOStar monochromator microplate reader (BMG LabTech, Germany) with 
an integration time of 1 second/well. 
3.9.4. Sphere formation assay 
The sphere-forming ability of OSE cells in suspension was assessed based on a 
previously-published method  (Flesken-Nikitin et al. 2013). Briefly, 1000 OSE cells were 
suspended in 200 µl OSE sphere formation medium [DMEM/F12 (Ham's) medium 
(Mediatech, Germany) supplemented with 2.4% methyl cellulose (Sigma, USA), 0.4% Bovine 
serum albumin (Sigma, USA), 4 mM L-glutamine (Mediatech, Germany), 1 mM sodium 
pyruvate (Mediatech, Germany), 10 ng/ml epidermal growth factor (Sigma, USA), 500 ng/ml 
hydrocortisone (Sigma, USA), 5 μg/ml insulin (Sigma, USA), 5 μg/ml transferrin (Sigma, 
USA), 5 ng/ml sodium selenite (Sigma, USA), 0.1 mM MEM non-essential amino acids 
(Mediatech, Germanay), 10 ng/ml fibroblast growth factor basic (Sigma, USA), 10 ng/ml 
leukaemia inhibitory factor (Millipore, USA)] per  well of a 96-well ultra-low attachment plate 
(Corning NY, USA) for 14 days. 100 µl of OSE formation medium were added to the well 7 
days post-seeding. The number of spheres formed whose diameter was greater than 50 µm were 
counted under the microscope every 3 days. 
3.9.5. Migration assay 
Migration of OSE cells was evaluated using the scratch assay developed by Liang et al. 
(Liang et al. 2007). Briefly, OSE cells were grown on one gelatinized well of a 24-well plate 
supplemented with 500 µl OSE complete medium (Section 3.9.1) until 80% confluency and 
then a scratch was done using a sterile 200 µl micropipette tip. Subsequently, cells were washed 
with sterile 1X PBS (Gibco, Life Technologies, USA) to remove any debris, supplemented 
with 500 µl OSE complete medium and incubated at 37ºC and 5% CO2 for 24 hours. Images 
were captured at 0 and 24 hours following the scratch for the same field, identified by a marker 
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reference point drawn close to the scratch but not within it. Quantitative analysis of the captured 
images was performed by measuring the distance in µm between the 2 sides of the scratch 
using ImageJ software. At least 10 distances were measured for each image. Distance migrated 
was calculated using the following formula 
Distance migrated = (Average scratch width at zero time) – (Average scratch width 24 
hours post scratch) 
3.10. RNA sequencing analysis 
RNA sequencing was performed for the ovarian tumours formed 8-weeks post 
adenovirus-cre injection from the 2 experimental cohorts Pten-/-Apc-/-Apc+/+ and Pten-/-Apc-/-
Apc2-/-. RNA was extracted from whole tumour-bearing ovaries and sent to Wales Gene Park, 
where the analysis was performed. 
3.10.1. RNA-Seq sample preparation and sequencing  
Total RNA quality and quantity was assessed using Agilent 2100 Bioanalyser and a 
RNA Nano 6000 kit (Agilent Technologies, USA). 100-900 ng of Total RNA with a RNA 
integrity number (RIN) >8 was depleted of ribosomal RNA and the sequencing libraries were 
prepared using the Illumina® TruSeq® Stranded Total RNA with Ribo-Zero Gold™ kit 
(Illumina Inc., USA). The steps included rRNA depletion and clean up, RNA fragmentation, 
1st strand cDNA synthesis, 2nd strand cDNA synthesis, adenylation of 3’ ends, adapter ligation, 
PCR amplification (12-cycles) and validation. The manufacturer’s instructions were followed 
except for the clean up after the ribozero depletion step where Ampure® XP beads (Beckman 
Coulter, USA) and 80% Ethanol were used. The libraries were validated using the Agilent 2100 
Bioanalyser and a high-sensitivity kit (Agilent Technologies, USA) to ascertain the insert size, 
and the Qubit® (Life Technologies, USA) was used to perform the fluorometric quantitation. 
Following validation, the libraries were normalized to 4 nM, pooled together and clustered on 
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the cBot™2 following the manufacturer’s recommendations. The pool was then sequenced 
using a 75-base paired-end (2x75bp PE) dual index read format on the Illumina® HiSeq2500 
in high-output mode according to the manufacturer’s instructions. Each sample was run in one 
sequencing lane. This work was kindly performed by Sarah Edkins and her team in Wales Gene 
Park. 
3.10.2. Data quality control 
All the quality control for the RNA seq data was kindly performed by Dr. Anna Evans, 
Wales Gene Park. Each sequencing lane was represented by two fastq files, which represented 
the paired-end reads generated within that lane. The fastq files were labelled R1 and R2 and 
represented the forward and reverse tags within the paired-end read, respectively. Trimming to 
remove adapter sequences and poor quality ends of reads was performed by Trim Galore (a 
wrapper to cutadapt). Trimming was performed using default parameters in paired-end mode. 
Trimmed reads were aligned to the mouse Mm10 genome using TopHat, a fast splice junction 
mapper for RNA-Seq reads. Tophat aligned reading using the Bowtie mapper before analyzing 
the results to identify splice junctions between exons. The RPKM (reads per kilobase million) 
scores for both (i) exons and (ii) transcripts were calculated using a Wales Gene Park in-house 
software for all six samples. 
To define the exon and transcript locations used in the analysis, the RefSeq gene model 
RefGene, as provided by the UCSC mouse reference Mm10 website 
(http://hgdownload.cse.ucsc.edu/goldenPath/mm10/database/) was used. 
In counting reads, at least 20 bases of a read had to map to the exon for that read to be 
counted. In addition, reads had to have the same orientation. Mapping quality and read 
duplication were ignored due to limited data. 
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3.10.3. Differential gene expression testing 
Differentially-expressed genes were identified using an DEseq2 analysis (Love, 2014) 
on normalized count data. The analysis was modelled using the null hypothesis that no 
transcript is affected by Apc2 deletion. The resultant p-values were corrected for multiple 
testing and false discovery issues using the FDR method (Benjamini & Hochberg, 1995). 
Outputs generated were matrix of normalized counts for each transcript, p-values, corrected p-
values and fold-change calculations. All these data were kindly produced by Dr. Anna Evans. 
3.10.4. Generating heatmaps 
The Wales Gene Park in house software was used to generate heatmaps for the genes 
with FDR values<0.05. Data were log2 transformed and median centered before hierarchical 
clustering (using average linkage and Pearson's correlation as the similarity metric) to group 
similar data together and reveal any patterns within the dataset. 
3.10.5. Generating protein-protein interaction networks 
Protein symbols for upregulated or downregulated genes with FDR values<0.05 were 
pasted in the multiple protein search box of STRING v.10.5 online tool (available at 
https://string-db.org/cgi) and Mus musculus was selected as the organism of choice (Szklarczyk 
et al. 2015). The settings were adjusted to select for interactions extracted from curated 
experiments or databases only, and protein interaction networks were generated. Following 
this, protein interactions of both upregulated and downregulated lists were exported in a tabular 
form, a SIF file was generated (4 columns representing node1, interaction, node2, combined 
score), and imported as a network in Cytoscape 3.4.0. software (available to download at 
http://www.cytoscape.org/download.php)(Su et al. 2014). A protein interaction network for all 
interacting protein of differentially-expressed genes with FDR<0.05 was generated, and the 
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style was adjusted so that yellow circles denote upregulated genes, blue circles denote 
downregulated genes and edges in the form of arrows pointing from source to target.  
3.10.6. Pathway analysis 
Pathway analysis for upregulated or downregulated genes with FDR<0.01 was 
performed using DAVID bioinformatics resources 6.8 (available at https://david.ncifcrf.gov/) 
(Huang da et al. 2009). Briefly, gene accession codes were pasted to generate a gene list and 
and genebank accession was selected as the identifier. Following this, pathway analysis was 
performed by selecting functional annotation chart option using Goterm BP Direct gene 
ontology database. Biological functions of most differentially regulated genes were performed 
using DAVID bioinformatics resources 6.8, by selecting functional annotation table option 
using SP Comment Type functional category database. 
3.11. Data processing and statistical analysis 
A minimum of 3 animals were analysed per experimental cohort. All statistical analyses 
were performed by using IBM SPSS version 20 (SPSS Inc, Chicago, IL, USA). Descriptive 
statistics were calculated. Values are presented as mean ± standard error, except for qRT-PCR 
data which are presented as mean±95% confidence interval. 
When 2 experimental cohorts were compared, significance testing was performed using 
unpaired 2-tailed Student's t-test, along with Levene’s test for equality of variance. When more 
than 2 experimental cohorts were compared, ANOVA (analysis of variance) test was used to 
test whether their means were significantly different. When the F-statistic value was 
significant, a post-hoc analysis was done to test for significant differences between every 2 
cohorts within the cohorts tested in the ANOVA. Levene’s test for equality of variances was 
run first. When variances of groups were homogeneous, post-hoc analysis was performed using 
least significant difference (LSD) test. When variances of tested groups were not 
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homogeneous, post-hoc analysis was performed using Games-Howell test. A p-value < 0.05 
was considered statistically significant. 
Means and standard errors calculated by SPSS were imported to Excel. All the graphs 
presented were prepared by Excel 2013 software package. 
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4. Roles of APC2 protein in ovarian homeostasis 
4.1. Introduction 
The role of APC2 protein in ovarian WNT signalling was not studied before. For the 
first time, this question is addressed here. In addition, roles of APC2 protein in ovarian 
homeostasis and female fertility are being characterized, using a constitutive Apc2-/- 
genetically-engineered mouse model (GEMM).  
4.1.1. Regulation of ovarian homeostasis 
The ovary is the female reproductive organ responsible for production of oocytes 
through the processes of folliculogenesis and ovulation. In addition, it is an endocrine organ 
producing the female hormones estradiol and progesterone (Adhikari and Liu 2013). 
 In adult mammals, the ovarian cycle starts with recruitment of a subset of quiescent 
primordial follicles to undergo folliculogenesis (Diagram 4.1). First, primary follicles are 
formed. This non-gonadotrophin dependent recruitment is primarily activated by oocyte 
PI3K/AKT signalling while being inhibited by estradiol, AMH, PTEN and FOXO3 
(McLaughlin and McIver 2009). Follicles continue to grow to form secondary or pre-antral 
follicles. Although the growth at this stage is gonadotrophin-independent, it is responsive to 
FSH, activated by insulin-like growth factor 1 (IGF1) (Shiomi-Sugaya et al. 2015) and 
members of TGFβ superfamily secreted by either the oocyte or granulosa cells (such as activin 
and BMP), and inhibited by AMH (Dunlop and Anderson 2014). The continued growth of 
follicles beyond this stage, from antral stage onwards, is gonadotrophin-dependent and relies 
on estradiol. Selection of dominant follicles, which reach the pre-ovulatory stage, happens 
when FSH levels drop as a result of increased estradiol concentration. Only the follicles that 
can continue to grow under low FSH/increasing LH levels are able to survive, and grow to pre-
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ovulatory follicles. However, the majority of antral follicles cannot thrive under these 
conditions and undergo atresia via apoptosis (Ginther et al. 2001). 
Ovulation of the oocyte from the pre-ovulatory follicle is under the control of LH. An 
LH surge happens before ovulation, and binding of LH to its receptor initiates a cascade of 
signalling events, mediated by EGF family members, to cause terminal differentiation of 
granulosa cells, release of the oocyte and conversion of the remaining follicle cells to the corpus 
luteum (Stocco et al. 2007). The corpora lutea are the sites of synthesis of progesterone, which 
is required to maintain pregnancy in the first few days post-fertilization. 
 
Diagram 4.1 Factors controlling folliculogenesis, adapted from Sanchez and Smitz (Sánchez 
and Smitz 2012; Chang et al. 2017). The blue lines indicate factors secreted by theca cells, 
purple lines indicate factors secreted by granulosa cells, magenta lines indicate factors 
secreted by oocytes, and green colours are factors secreted by both oocyte and granulosa cells. 
* denotes transcription factors.    
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4.1.2. Roles of canonical WNT signalling in ovarian homeostasis 
Canonical WNT signalling has been shown to be detrimental for female sex 
differentiation during embryogenesis (Biason-Lauber and Chaboissier 2015). Wnt4 levels 
increase in the mouse ovary as early as 11.5 days post conception, followed by upregulation of 
the canonical WNT activator Rspo1 (Rspondin1), and downstream targets Axin2 and Lef1 one 
day later (Chassot et al. 2008). GEMMs studying roles of Rspo1, Wnt4 and Ctnnb1 (gene 
encoding for β-catenin) in sex determination have illustrated a female-to-male sex reversal after 
deletion of these factors in XX gonadal cells (Ottolenghi et al. 2007; Tomizuka et al. 2008). 
The reverse was also true; a male-to-female sex reversal was observed after expressing these 
factors in XY gonadal cells (Maatouk et al. 2008; Jameson et al. 2012). Advances in molecular 
diagnosis of sex reversal in humans pointed to these WNTt members as main players of female 
sex determination. WNT4 (Domenice et al. 2004) or RSPO1 (Tomaselli et al. 2008) inactivating 
mutations have been reported in XX hermaphrodite cases. Thus, data from human and mouse 
models support the importance of canonical WNT signalling in female sex determination. 
Roles of canonical WNT signalling in adult ovarian homeostasis are not as well 
characterized. It was first thought that active canonical WNT signalling was important for 
ovarian folliculogenesis, ovulation and corpus luteum formation. This hypothesis relied on the 
presence of different Wnt members and Frizzled receptors in the cells of different ovarian 
compartments (Hernandez Gifford 2015). In vitro studies, using granulosa cell cultures, 
reflected an increase in β-catenin levels post-gonadotrophin treatment (Law et al. 2013), and 
pointed to β-catenin roles in inducing aromatase activity and estradiol production in response 
to FSH (Parakh et al. 2006). However, studies utilizing GEMMs did not confirm this 
hypothesis. When Ctnnb1 was conditionally deleted in murine granulosa cells of pre-antral 
follicles, using the Amhr2-cre, folliculogenesis and ovulation were normal (Hernandez Gifford 
et al. 2009). However, due to the nature of Amhr2-cre, the recombination of Ctnnb1 in oviducts 
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and uteri resulted in abnormalities in their formation, causing lack of implantation sites and 
rendering these mice infertile (Hernandez Gifford et al. 2009). Despite these abnormalities, 
ovaries were completely functional. This finding was reproduced when Ctnnb1 was 
conditionally-deleted in granulosa cells of antral follicles (Fan et al. 2010a), using an 
aromatase-cre which drives recombination exclusively in these cells. These mice were 
completely fertile and delivered comparable number of pups to their control (Fan et al. 2010a). 
Conditional deletion of Wnt4 (Boyer et al. 2010), or constitutive deletion of  Fzd4 (Hsieh et al. 
2005) in mice caused subfertility and complete infertility, respectively. However, in these 
models, WNT signalling activity was not measured and it is unclear whether the reported 
phenotypes are caused by impaired canonical WNT signalling or by other mechanisms. This 
was evident when FZD1 was constitutively deleted in mice. The female mice were fertile apart 
from 17.6% of mice which were completely infertile due to early follicle depletion (Lapointe 
et al. 2012). In these mice, despite FZD1 deletion, total activated catenin levels in ovaries were 
not changed when compared to the control (Lapointe et al. 2012). Collectively, data from 
GEMMs indicate that active canonical WNT signalling is not essential for adult ovarian 
folliculogenesis and fertility. 
However, GEMMs provided some evidence that over-activation of canonical WNT 
signalling has deleterious effects on ovarian homeostasis. Over-expression of Rspo1 (De Cian 
et al. 2016), deletion of Wnt5a (antagonist of canonical WNT signalling; (Abedini et al. 2016)), 
or expression of dominant stable β-catenin (Boerboom et al. 2005; Fan et al. 2010a) all 
upregulated ovarian WNT signalling and caused ovarian subfertility of different phenotypes. 
Inhibitory effects of over-activated WNT signalling on follicular growth were also tested in 
vitro. Follicle cultures were used to test this hypothesis by characterizing the effects of 
canonical WNT signalling activators (Lithium chloride or WNT3a) and WNT inhibitor (IWR1) 
on the growth of mouse secondary follicles (Li et al. 2014). Treatments with WNT activators 
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impaired follicular growth, estradiol synthesis and increased apoptosis while the WNT 
inhibitor caused the reverse and increased follicular growth (Li et al. 2014). These findings 
were reproduced when cultured rat granulosa cells were treated with WNT3a; inhibition of 
steroidogenesis was reported (Stapp et al. 2014). Taken together, these findings indicate the 
importance of repressing canonical WNT signalling in growing follicles as early as the pre-
antral stage. 
4.1.3. Roles of APC2 in canonical WNT signalling 
When APC2 (APCL or E-APC) was first discovered, it was described as a homologue 
of the tumour suppressor protein APC (Hamada et al. 1999; Van Es et al. 1999). Structurally, 
APC2 possesses Axin1 and β-catenin binding sites, which enables it to destabilize β-catenin 
targeting it for degradation and thus suppressing its transcriptional activity (Hamada et al. 
1999; Van Es et al. 1999). This finding was true both in Drosophila and in cell lines of intestinal 
tumours (Hamada et al. 1999; Van Es et al. 1999). However, in an in vivo mammalian setting, 
the situation is different. The Clarke lab using a constitutive Apc2-/- mouse, kindly gifted by 
Prof. Hans Clevers, reported that the extent and effects of WNT signalling activation caused 
by APC2 loss are tissue specific. APC2 loss caused WNT signalling activation in the small 
intestine and liver, but not in the mammary glands (Daly 2013). Phenotypic changes post-APC2 
loss were only observed in the small intestine (Daly 2013). 
4.1.4. Aims, hypothesis and highlights 
It had been previously observed in the Clarke group that a subset of ovaries of aging 
Apc2-/- mice were abnormal and developed fluid-filled cysts, which were suspected to be 
epithelial. Stemming from this observation and based on tissue specificity of APC2 functions 
previously characterized (Daly 2013), we aimed to characterize the effect of deleting APC2 on 
ovarian homeostasis during early adulthood (in 10-week-old mice). Our objectives were: 
1- To explore whether APC2 loss results in WNT signalling activation in the ovaries. 
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2- To characterize the ovarian phenotype caused by APC2 loss, with special attention 
to folliculogenesis, ovulation, corpus luteum formation and fertility. 
3- To define the possible molecular mechanisms of the observed phenotype. 
We hypothesized that APC2 loss in the ovary activates WNT signalling, causing 
subfertility due to defects in folliculogenesis and/or ovulation/corpus luteum formation. For 
the first time, roles of APC2 in ovarian homeostasis are characterized. Study findings highlight 
the importance of functional APC2 for ovarian folliculogenesis and fertility. WNT signalling 
was activated post-APC2 deletion in ovaries, and this is proposed as one of the mechanisms 
causing the subfertility observed in Apc2-/- mice. The subfertility observed is of ovarian origin, 
and caused by reduced ovulation due to aberrant folliculogenesis. Possible mechanisms include 
(1) defects in response to gonadotrophin caused by over-expression of Lhcgr, (2) increased 
granulosa cell apoptosis due to upregulation of Foxo1 as a result of suppression of PI3K/AKT 
signalling, (3) defective follicular steroidogenesis, and (4) impaired follicular vascularization.  
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4.2. Results 
4.2.1. APC2 loss in the ovaries activates canonical WNT signalling 
In order to determine whether APC2 loss altered canonical WNT signalling in the 
ovary, expression levels of a subset of Wnt-target genes were quantified. Total RNA was 
extracted from whole ovaries, collected at diestrus stage from 10-week-old virgin Apc2+/+ and 
Apc2-/- mice. Gene expression levels were compared using quantitative RT-PCR. Results 
revealed significant increases in the expression levels of Apc, Axin2, Ctnnb1, Fgf1, and Lgr5 
in Apc2-/- compared to Apc2+/+ ovaries (Figure 4.1). However, the expression levels of Cd44, 
Lef1 and Wif1 were not significantly changed (Figure 4.1). 
 
Figure 4.1:  APC2 loss causes activation of canonical WNT signalling in the ovary. Expression 
levels of a subset of Wnt-target genes were compared between Apc2+/+ and Apc2-/- ovarian 
extracts using qRT-PCR and normalized to Actb expression. Expression levels of five out of 
eight genes analysed were significantly elevated. Data are shown as mean±95% confidence 
intervals of relative mRNA expression levels, n=3-4. Statistical significance was determined 
according to Cumming et al. (Cumming et al. 2007). * denotes significance from Apc2+/+ at 
p<0.05.  
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In order to determine the subcellular localization of β-catenin protein in different 
ovarian compartments, immunohistochemistry (IHC) was performed on ovaries collected from 
10-week-old Apc2+/+ and Apc2-/- female mice at diestrus stage. Microscopic examination of 
stained sections showed that β-catenin was differentially expressed in all ovarian 
compartments, but the expression pattern was comparable in Apc2+/+ (Figure 4.2a-g) and    
Apc2-/- (Figure 4.2h-n) ovaries. In the ovarian surface epithelium, β-catenin was mainly 
membranous and cytoplasmic (Figure 4.2a,c,h). Granulosa cells of growing follicles showed 
strong membranous, cytoplasmic and nuclear expression of β-catenin, with the strongest 
expression observed in the primary, secondary and small antral follicles (Figure 4.2a-c,h,i). 
The nuclear expression was not frequently observed in granulosa cells of large antral (Figure 
4.2d,j) and pre-ovulatory follicles (Figure 4.2e,k). The expression levels of β-catenin were 
weaker in atretic follicles, showing strong membranous but weak cytoplasmic staining in the 
granulosa cells (Figure 4.2d,g,h,i,k-n), with higher expression observed in atretic follicles from 
Apc2-/- ovaries (Figure 4.2n) as compared to Apc2+/+ ovaries (Figure 4.2g). Theca cells mainly 
showed membranous and cytoplasmic β-catenin expression. In corpora lutea, β-catenin 
expression was mainly membranous, with occasional cytoplasmic staining (Figure 
4.2a,d,f,l,m).  
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Figure 4.2: Immunohistochemical localization of β-catenin protein in ovaries of (a-g) Apc2+/+ and (h-n) 
Apc2-/- 10-week-old female mice. OSE: ovarian surface epithelium. 1ry: primary follicle. 2ry: secondary 
follicle. SA: small (early) antral follicle. LA: large antral follicle. PO: pre-ovulatory follicle. Cl: corpus 
luteum. AF: atretic follicles. Scale bars: 100 µm, except (f, l) scale bars: 200 µm. Insets shows granulosa 
cells of growing follicles at 4X original magnification  
 
4.2.2. Constitutive loss of APC2 protein induces subfertility in female mice 
In order to evaluate effects of APC2 loss on normal ovarian homeostasis, fertility was 
first assessed in Apc2+/- and Apc2-/-, as compared to Apc2+/+ mice, by retrospective analysis of 
matings set for breeding. Only mice fulfilling the following criteria were included in the 
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analysis; 7-11 week-old female mice of the experimental genotypes housed with 7-9 week-old 
males of the corresponding genotype housed as trios (2 females and 1 male) for 3 months. 4 
matings were analysed for each genotype.  Litter sizes at the time of weaning, 3-4 weeks after 
birth, were used in the analysis. 
Although partial loss of APC2 protein in the Apc2+/- mice did not affect the length of 
time between mating and producing the first litter, as compared to Apc2+/+ mice (21.25±0.48 
days vs. 20.75±0.92 days, mean ± S.E, Figure 4.3a), a reduction in mean cumulative number 
of weaned pups was observed (18.5±1.32 vs. 31.75±5.68, mean ± S.E., Figure 4.3c). This was 
coupled with a non-significant decrease in the gestation frequency in the Apc2+/- vs. Apc2+/+ 
mice (3±0.41 vs. 3.75±0.14, mean ± S.E., Figure 4.3b). However, the complete loss of APC2 
protein in Apc2-/- mice markedly impaired fertility in 3 of the cages analysed; as reflected by 
the significant increase in time to first litter (32.38±5 days, p<0.05, Figure 4.3a), the significant 
decrease in gestation frequency (2.13±0.77 rounds, p<0.05, Figure 4.3b) and the reduction in 
mean cumulative numbers of weaned pups (13.5±4.9, p<0.05, Figure 4.3c). Mice in one     
Apc2-/- breeding cage were completely infertile and did not show any signs of pregnancy 
throughout the length of the study. 
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Figure 4.3: APC2 loss causes subfertility in adult mice. (a) Mating efficiency of the different 
Apc2 experimental genotypes as a function of time recorded in days between pairing the mice 
and delivering the first litter. One Apc2+/+, Apc2+/- or Apc2-/- male was crossed with 2 Apc2+/+, 
2 Apc2+/- or 2 Apc2-/- female mice respectively. (b) Breeding efficiency as reflected by number 
of gestations occurring in 3 months period. Data are shown as mean ± S.E. (c) Cumulative 
number of pups weaned in 3 months’ time. n=4. Statistical significance between groups was 
determined using ANOVA test followed by Games-Howell post hoc analysis (variances of 
experimental groups were not homogeneous, tested by Levene’s test). * denotes significance 
from Apc2+/+ at p<0.05. 
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Histological analysis of ovaries, oviducts and uteri of 10-week-old virgin Apc2+/+ and 
Apc2-/- mice were performed to assess the etiological causes of subfertility in Apc2-/- mice. For 
this purpose, fixed ovaries, oviducts and uteri were serially sectioned into 100 sections 5 µm 
apart, and every 10th section was stained by H&E and analysed. No gross morphological 
differences were observed in the oviducts and uteri of Apc2+/+ and Apc2-/- mice (results not 
shown). In addition, no problems were reported during labour in all the experimental groups, 
suggesting that uterine problems are not contributing to the observed subfertility phenotype in 
APC2-deficient mice. Volume of ovaries of Apc2+/+ and  Apc2-/- mice were not different (Figure 
4.4a), although a significant decrease in body weight was recorded in Apc2-/- mice as compared 
to Apc2+/+ mice (16.88±0.43 vs. 21.5±0.61, p<0.05, Figure 4.4b).  
     
Figure 4.4: Ovarian sizes are not changed post-APC2 deletion. (a) Volume of Apc2+/+ and  
Apc2-/- ovaries collected at diestrus stage. (b) Body weights of Apc2+/+ and Apc2-/- female mice. 
n=4. Data are represented as mean±S.E. Statistical significance was determined by t-test. * 
denotes significance from Apc2+/+ at p<0.05.  
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Morphometric analysis revealed a significant decrease in the number of corpora lutea 
formed in Apc2-/- vs. Apc2+/+ ovaries (2.5±0.5 vs. 5±1.08, p<0.05, Figure 4.5a and Figure 
4.6a,b). However, there was a non-significant increase in the total number of growing follicles 
in Apc2-/- vs. Apc2+/+ ovaries (81.5±12.67 vs. 66.25±7.19 in Apc2+/+ ovaries, Figure 4.5b and 
Figure 4.6a,b). Gene expression analysis was performed on RNA extracted from Apc2+/+ and 
Apc2-/- ovaries for the germ cell marker Gdf9, to confirm growing follicles count results (Figure 
4.5c).  A non-significant increase in Gdf9 expression levels was observed in Apc2-/- vs. Apc2+/+ 
ovaries (Figure 4.5c). Collectively, these findings suggested that the subfertility observed in 
APC2-deficient mice is of ovarian origin and is caused by reduced ovulation. 
    
Figure 4.5: Subfertility in 10-week-old Apc2-/- mice is caused by reduced ovulation. Total 
number of (a) corpora lutea, and (b) healthy growing follicles, counted across 100 serial 
sections of ovaries collected at diestrus stage. (c) Expression levels of Gdf9 gene in Apc2+/+ 
and Apc2-/- ovaries. n=4. Data are represented as mean±S.E., except the gene expression levels 
which are expressed as mean±95% confidence interval. Statistical significance was determined 
by t-test. * denotes significance from Apc2+/+ at p<0.05.  
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Figure 4.6: Reduced corpus luteum formation in Apc2-/- mice. Representative photomicrograph 
of (a) Apc2+/+ and (b) Apc2-/- ovaries, showing a trend of increase in growing follicles (red 
arrows) and a significant decrease in corpora lutea (black arrows) in Apc2-/- compared to 
Apc2+/+ ovarian section. scale bar 500 µm. n=4.  
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4.2.3. Subfertility of constitutive APC2-deficient female mice is not caused by 
extra-ovarian defects 
As APC2 loss is constitutive in all mouse organs, the genotype dose-dependent 
subfertility observed in APC2-deficient mice could be due to defects in extra-ovarian 
regulation of ovarian functions, triggered by hypothalamic/pituitary endocrine signals. To test 
this hypothesis, the following experiments were conducted. 
First, serum samples were collected from 10-week-old virgin Apc2+/+ and Apc2-/- female 
mice at diestrus stage, and levels of follicle stimulating hormone (FSH) and luteinizing 
hormones (LH) were measured using ELISA kits. No significant differences were observed in 
serum levels of either hormones (Figure 4.7). 
                
Figure 4.7: Constitutive loss of APC2 has no effect on fertility hormones produced by pituitary 
gland. Serum levels of (a) FSH and (b) LH measured by ELISA kits. n=4-6. Data represented 
as mean±S.E. 
A second experiment performed to confirm the ovarian origin of the observed 
subfertility was the administration of exogenous gonadotrophins, following the superovulation 
protocol (Section 3.3.3), performed on 10-week-old virgin mice from the three experimental 
genotypes. Mice were euthanized 16-17 hours post-HCG injection, and oviducts were 
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dissected. Cumulus oocyte complexes (COCs) were collected from the ampulla in 40 µl PBS 
and counted. Morphology of ovulated COCs was assessed to determine their integrity. All 
ovulated oocytes were surrounded by cumulus cells of comparable thickness, irrespective of 
the genotype (Figure 4.8). Quantitative analysis of retrieved COCs showed a gene dose-
dependent decrease in the number of COCs retrieved from the oviducts of  Apc2+/- and Apc2-/- 
mice as compared to Apc2+/+ mice (3.33±0.95 and 2.25±1.24 vs. 6.83±1.39 respectively, Figure 
4.9a). Morphometric analysis of ovulated oocytes, after treating the COCs with 
collagenase/dispase to remove the cumulus cells, revealed that they were healthy with no signs 
of fragmentation, and of comparable sizes (Figure 4.8,4.9b). Collectively, these results 
indicated that the main defect occurring in APC2-deficient mice is a reduction in number of 
ovulated oocytes while maintaining a normal COCs morphology. 
 
Figure 4.8: Characterizing oocytes ovulated after exogenous gonadotrophin administration.   
(a) Representative photomicrographs of retrieved COCs showing the presence of oocytes 
(black arrows) surrounded by cumulus cells (red arrows) in the upper panel. Scale bar 200 µm. 
In the lower panel, higher magnification was used to examine oocytes after freeing them from 
cumulus cells, 10 minutes post-collagenase/dispase treatment. Scale bar 50 µm. 
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 Figure 4.9: APC2-deficiency caused a reduction in ovulated healthy oocytes post- 
gonadotrophin administration. (a) APC2-deficiency caused a gene dose-dependent decrease in 
the number of ovulated COCs retrieved from the oviducts post-superovulation. (b) Average 
oocyte diameter was not different among the experimental groups. n=3-5. Statistical 
significance between groups was determined using ANOVA test followed by LSD post hoc 
analysis (variances of experiment groups were homogeneous tested by Levene’s test).                   
* denotes significance from Apc2+/+ at p<0.05. 
Histologic analysis of ovaries dissected from superovulated Apc2+/+ and Apc2-/- mice, 
24 hours post-HCG administration, was conducted to test whether exogenous gonadotrophin 
administration could normalize the number of corpora lutea formed. Results showed that 
external gonadotrophin administration could not rescue the previously described ovarian 
phenotype in APC2-deficient female mice (Figure 4.5 and 4.6). Similar to the non-
superovulated ovaries, a significant decrease in the number of corpora lutea was observed in 
superovulated Apc2-/- ovaries as compared to Apc2+/+ ovaries (4.8±0.97 vs. 8.6±1.03, p<0.05, 
Figure 4.10a and 4.11a,b). This was associated with a non-significant increase in healthy 
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growing follicles in Apc2-/- ovaries in contrast to Apc2+/+ ovaries (69.2±6.96 vs. 52.4±5.73, 
Figure 4.10b and 4.11a,b). Taken together, the results from these investigations in which mice 
were exogenously-administered gonadotrophins, suggest that the subfertility phenotype is not 
due to extra-ovarian defects in pituitary gonadotrophin secretion, but rather due to intra-ovarian 
defects in response to gonadotrophins.  
         
Figure 4.10: External gonadotrophin administration could not rescue reduced ovulation in   
Apc2-/- ovaries. Total number of (a) corpora lutea, and (b) healthy follicles counted across 100 
serial sections of superovulated stage-matched ovaries. n=5. Data are represented as mean±S.E. 
Statistical significance was determined by t-test. * denotes significance from Apc2+/+ at p<0.05. 
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 Figure 4.11: Decreased corpus luteum formation in Apc2-/- ovaries collected post-
gonadotrophin administration. Representative photomicrograph of (a) Apc2+/+, and (b) Apc2-/- 
superovulated ovarian section, showing a trend of increase in growing follicles (red arrows), 
and a significant decrease in corpora lutea (black arrows) in Apc2-/- compared to Apc2+/+ 
ovarian section. scale bar 500 µm. n=5.  
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4.2.4. Reduced ovulation of Apc2-/- mice is not caused by defects in terminal 
granulosa cell differentiation or ovulation process 
In order to identify the cause of reduced ovulation observed in Apc2-/- female mice, two 
different hypotheses were tested. The first was that APC2 loss causes defects in the terminal 
differentiation of granulosa cells and oocyte ovulation in response to LH surge. The second 
hypothesis was that APC2 loss impairs follicular growth leading to a decrease in the number 
of follicles reaching the pre-ovulatory stage (Section 4.2.5). 
To test the first hypothesis, serial-sectioned ovaries were examined to identify pre-
ovulatory follicles and corpora lutea. As all the ovaries were collected at the diestrus stage of 
the oestrous cycle, a post-ovulatory stage distant from ovulation, only few follicles were 
present in late antral to pre-ovulatory stage. Microscopic examination of these follicles did not 
reveal any morphological differences between Apc2+/+ and Apc2-/- follicles (Figure 4.12a,b). 
Follicles from both genotypes contained an oocyte of comparable size, surrounded by layers of 
granulosa cells forming COC. COC expansion was not evident at this stage in any of the 
follicles examined from both genotypes. However, the main observation was that follicles 
examined at that stage in Apc2-/- ovaries were smaller and fewer as compared to Apc2+/+ ovaries 
(Section 4.2.5). 
EGF and EGF receptor (EGFR) ligands, Amphiregulin (AREG) and Epiregulin 
(EREG), are involved in COC expansion in response to LH surge (Park et al. 2004). In order 
to investigate whether defects in ovulation are contributing to the subfertility observed in   
Apc2-/- female mice, gene expression analysis of Egf, Areg, Ereg and Egfr were performed by 
qRT-PCR. A significant increase in Egf expression levels was observed in Apc2-/- ovaries as 
compared to Apc2+/+ (Figure 4.12c). No significant differences were observed in the expression 
levels of the other genes tested between the two studied genotypes (Figure 4.12c). 
 
  
130 
 
 
 
Figure 4.12: APC2-deficiency does not impair the ovulation process. Representative 
photomicrograph of follicles approaching the pre-ovulatory stage in (a) Apc2+/+ and                    
(b) Apc2-/- ovarian sections. Scale bar 100 µm. (c) Gene expression levels of a subset of Egf 
ligands and receptor, known to regulate COC expansion. Expression levels were compared 
between Apc2+/+ and Apc2-/- ovarian extracts using qRT-PCR and normalized to Actb 
expression. Data are shown as mean±95% confidence intervals. n=4. Statistical significance 
was determined according to Cumming et al. (Cumming et al. 2007). * denotes significance 
from Apc2+/+ at p<0.05. 
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Morphometric analysis of corpora lutea did not reveal any histologic differences 
between Apc2+/+ and Apc2-/- ovaries (Figure 4.13a,b). Apart from the significant decrease in 
the number of corpora lutea observed in Apc2-/- ovaries (Figure 4.5a), the size of formed 
corpora lutea were comparable in Apc2+/+ and Apc2-/- ovaries (667.1±8.7 µm vs. 693.7±51 µm, 
Figure 4.13c). In addition, they were equally healthy as reflected by comparable 
neovascularization capacity (CD34 immunostaining, Figure 4.13d,e). Proliferation (Ki67 
immunostaining, Figure 4.14a-c) and apoptosis frequency (cleaved caspase 3 immunostaining, 
Figure 4.14d,e) were assessed in corpora lutea of both genotypes, by counting positively-
staining cells and normalizing to corpus luteum area,  and were not different. Overall, therefore, 
it is unlikely that defects in ovulation process and granulosa cells terminal differentiation are 
contributing to the observed phenotype. 
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Figure 4.13: Characterizing effects of APC2 deletion on corpora lutea. Representative 
photomicrographs of corpus luteum in (a) Apc2+/+, and (b) Apc2-/- ovarian sections. (c) 
Histogram showing comparable corpora lutea size in the two genotypes. Representative 
photomicrographs of CD34 immunostaining in corpora lutea of (d) Apc2+/+ and (e) Apc2-/- 
ovarian sections. n=4. Data are represented as mean±S.E. Scale bars 200 µm. 
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Figure 4.14: Characterizing effects of APC2 deletion on proliferation and apoptosis of corpora 
lutea. (a) Histogram reflecting equivalent positive Ki67 cell counts in the two genotypes. 
Representative photomicrographs of Ki67-positive cells (black arrows) in (b) Apc2+/+, and (c) 
Apc2-/- corpora lutea. Cleaved caspase 3 positive cells (red arrows in atretic follicles) were 
absent in corpora lutea of (d) Apc2+/+, and (e) Apc2-/- ovarian sections. n=4. Data are 
represented as mean±S.E. Scale bars 200 µm.  
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4.2.5. Reduced ovulation of Apc2-/- mice is caused by defects in follicular growth 
Morphometric analysis was performed on the serial-sectioned Apc2+/+ and Apc2-/- 
ovaries, collected at the diestrus stage, to evaluate whether the reduced ovulation rate observed 
in Apc2-/- mice is caused by a reduction in number of follicles ready to ovulate. As previously 
mentioned, there was a non-significant increase in the total number of healthy growing follicles 
in  Apc2-/- ovaries (Figure 4.5b). When follicle counts were analysed per follicular stage, a non-
significant increase was found in the number of primary and antral follicles in Apc2-/- ovaries 
(34.5±5.6 and 25.75±4.4 vs. 26.25±4.21 and 18.25±2.17 respectively, Figure 4.15a). However, 
it was observed that most of the antral follicles were small. A non-significant decrease in the 
number of pre-ovulatory follicles was observed in Apc2-/- ovaries (0.75±0.25 vs. 1.5±0.87, 
Figure 4.15a). 
A size distribution analysis for all the healthy antral and pre-ovulatory follicles was 
performed, and represented as a percentage of total number of antral and pre-ovulatory follicles 
per serial-sectioned ovary. A significant increase was observed in the percentage of small 
follicles, having a diameter less than 200 µm, in Apc2-/- ovaries (56.29±4.9 vs. 32.8±5.7, 
p<0.05, Figure 4.15b). However, a significant decrease was observed in the percentage of 
follicles with diameter bigger than 300 µm in Apc2-/- (16.15±2.1 vs. 32.04±5.3, p<0.05, Figure 
4.15b). The reduction in size of follicles was evident in the larger follicles, with no single 
follicle observed greater than 450 µm in Apc2-/-ovaries, in contrast to 6 follicles observed in 
the all the ovaries of the Apc2+/+ cohort. 
An analysis of atretic follicles was performed to determine whether the reduction in 
number of follicles bigger than 300 µm is due to increased atresia. There was not a significant 
change in the total number of atretic follicles between Apc2+/+ and Apc2-/- ovaries (195±24.5 
vs. 203.5±23.8, Figure 4.16a). Most of the follicles counted were small atretic follicles present 
in the ovarian medulla (Figure 4.16b,c). Counting atretic follicles present in the antral and pre-
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ovulatory stages did not reveal a significant difference between Apc2+/+ and Apc2-/- ovaries 
(23±5.6 vs. 22.5±4.6, Figure 4.16a). However measuring the size of atretic antral and pre-
ovulatory follicles revealed a non-significant increase in the percentage of atretic follicles 
whose diameter is bigger than 300 µm in Apc2-/- ovaries (34.7±7.74 vs. 27.1±7.1 in Apc2+/+ 
ovaries, Figure 4.16d). All the aforementioned results suggest that the main defect in Apc2-/- 
ovaries is the reduced ability of healthy follicles to grow beyond a certain size (300 µm), 
limiting the availability of follicles reaching the pre-ovulatory stage. 
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Figure 4.15: APC2-deficiency impairs follicular growth in the ovary. (a) Histogram showing 
total number of primary (1ry), secondary (2ry), antral and pre-ovulatory follicles in Apc2+/+ and 
Apc2-/- ovarian sections. (b) Size distribution of healthy antral and pre-ovulatory follicles. n=4. 
Data are represented as mean±S.E. Statistical significance was determined by t-test. * denotes 
significance from Apc2+/+ at p<0.05. 
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Figure 4.16: Analysis of atretic follicles in the ovaries collected from Apc2+/+ and Apc2-/- mice.  
(a) Histogram of atretic follicle counts in ovaries of Apc2+/+ and Apc2-/- mice. Representative 
photomicrographs of (b) Apc2+/+ and (c) Apc2-/- ovarian sections, showing that most of the 
atretic follicles (arrows) are small, and present in the ovarian medulla. Insets shows 5X original 
magnification of small atretic follicles (arrows). (d) Size distribution of atretic antral and pre-
ovulatory follicles. n=4. Data are represented as mean±S.E. Statistical significance was 
determined by t-test. * denotes significance from Apc2+/+ at p<0.05. Scale bars 500 µm.  
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4.2.6. Impaired follicular growth in Apc2-/- ovaries is due to increased apoptosis 
The impaired follicular growth observed in Apc2-/- ovaries could be either due to 
reduced proliferation or increased apoptosis. In order to unravel which of these mechanisms is 
causing the observed defects in folliculogenesis, immunohistochemistry for markers of 
proliferation (Ki67 antigen) and apoptosis (cleaved caspase 3 protein) were used. Follicular 
cells positively-stained were quantified and normalized to the follicle area. A non-significant 
increase in the number of granulosa cells with nuclear staining for Ki67 was observed in     
Apc2-/- follicles, as compared to Apc2+/+ follicles (30.85±3.6 vs. 23.27±4.5, Figure 4.17a,b). 
There was no significant difference in the number of theca cells staining positively for Ki67 
between Apc2+/+ and Apc2-/- follicles (12±0.62 vs. 11.8±0.6, Figure 4.17a). In contrast, a 
significant increase in granulosa cells positively staining for cleaved caspase 3 was observed 
in Apc2-/- follicles compared to Apc2+/+ follicles (14.22±1.3 vs. 6.04±1.01, p<0.05, Figure 
4.17c,d). 
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Figure 4.17: Restricted follicular growth in Apc2-/- ovaries is caused by increased granulosa cells 
apoptosis. (a) Histogram showing comparable proliferation of Apc2+/+ and Apc2-/- follicular cells. 
(b) Representative photomicrographs of Ki67 immunostaining in Apc2+/+ and Apc2-/- ovarian 
follicles. (c) Histogram showing more than a 2-fold increase of apoptosis in granulosa cells of 
Apc2-/- follicles. (d) Representative photomicrographs for cleaved caspase 3 immunostaining. 
n=4. Data are represented as mean±S.E. Statistical significance was determined by t-test.                 
* denotes significance from Apc2+/+ at p<0.05. Scale bars 100 µm.  
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Members of FOX family of transcription factors are well-known regulators of 
apoptosis. Previous studies have shown that overexpression of FOXO1, FOXO3 or FOXL2 
induces granulosa cell apoptosis (Kim et al. 2011; Matsuda et al. 2011; Shen et al. 2012). A 
gene expression analysis was performed for these Fox member genes on RNA extracted from 
Apc2+/+ and Apc2-/- whole ovaries. A significant increase was observed only in Foxo1 
expression levels in Apc2-/- vs. Apc2+/+ ovaries (Figure 4.18a).  
The expression levels of a panel of FOXO target genes involved in cell cycle regulation 
and apoptosis were investigated. Of the studied genes, Bcl6 and Cdkn1b were significantly 
upregulated in Apc2-/- as compared to Apc2+/+ ovaries, while Bcl2l1, Fasl and Tnfsf10 
expression levels were not significantly changed (Figure 4.18d). 
PTEN/PI3K/AKT signalling is the most studied regulator of FOXO transcriptional 
activity and post-translational modification (Tzivion et al. 2011). On activation of AKT, FOXO 
proteins are inactivated by being phosphorylated and translocated out of the nucleus to the 
cytoplasm. Immunohistochemistry was performed to determine the level and localization of 
PTEN, p-AKT and p-FOXO 1,3,4 in Apc2+/+ and Apc2-/- follicles. PTEN expression was 
stronger in theca cells and granulosa cells of Apc2-/- follicles (Figure 4.19a). This was 
associated with a non-significant increase in Pten gene expression levels in Apc2-/- ovaries 
(Figure 4.19a). However, p-AKT immunostaining was weaker in granulosa cell of Apc2-/- 
follicles (Figure 4.19b). Consequently, the expression of p-FOXO1,3,4 was very weak in the 
granulosa cells of Apc2-/- ovarian follicles (Figure 4.19c). In summary, the previous results 
showed that the increased apoptosis seen in Apc2-/- follicles is associated with upregulation of 
Foxo1 and its downstream effector genes, which may be secondary to decreased activation of 
PI3K/p-AKT signalling as a result of PTEN upregulation. 
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Figure 4.18: Increased apoptosis in Apc2-/- ovaries is driven by upregulation of Foxo1 and 
downstream targets. Relative expression levels of a panel of (a) Fox transcription factors, and (b) 
FOX downstream target genes performed on RNA extracted from Apc2+/+ and Apc2-/- 10-week-
old ovaries, normalized to Actb expression. n=3-4. Data are represented as mean±95% 
confidence interval. Statistical significance was determined using Cumming et al. (Cumming et 
al. 2007) method for qRT-PCR data. * denotes significance from Apc2+/+ at p<0.05. 
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Figure 4.19: Characterizing PTEN/PI3K/AKT signalling in Apc2-/- ovaries. Representative 
photomicrographs of (a) PTEN (together with Pten gene expression levels), (b) p-AKT (ser-473), 
and (c) p-FOXO1,3,4 immunostaining in Apc2+/+ and Apc2-/- ovarian follicles.  n=4. Data are 
represented as mean±95% confidence interval. Scale bars 200 µm. Insets show 2X original 
magnification. 
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4.2.7. Defects in response to gonadotrophin is caused by upregulation of Lhcgr 
As noted in section 4.2.3., the results of exogenous gonadotrophin administration 
suggested that the subfertility observed in Apc2-/- female mice is due to intra-ovarian defects in 
response to gonadotrophin. To explore this, a gene expression analysis of ovarian 
gonadotrophin receptors, Fshr (follicle stimulating hormone receptor) and Lhcgr (Leutinizing 
hormone chorionic gonadotrophin receptor) was performed, together with the steroid hormone 
receptors Pgr (progesterone receptor), Esr1(estrogen receptor α), Esr2 (estrogen receptor β) 
and Ar (androgen receptor). There were no significant differences in the expression levels of 
any of the receptors apart from the Lhcgr, which was more than 3 times increased in the        
Apc2-/- ovaries as compared to Apc2+/+ ovaries (Figure 4.20).  
 
Figure 4.20: Gene expression levels of hormone receptors performed by qRT-PCR on RNA 
extracted from whole ovaries of Apc2+/+ and Apc2-/- 10-week-old female mice. Relative 
expression levels are normalized to Actb expression. n=3-4. Data are represented as 
mean±95% confidence interval. Statistical significance was determined according to Cumming et 
al. (Cumming et al. 2007). * denotes significance from Apc2+/+ at p<0.05.  
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4.2.8. APC2 deletion impairs follicle steroidogenesis and vascularization 
It has been previously reported that activation of canonical WNT signalling inhibits 
follicular growth by impairing follicle steroidogenesis in addition to increasing granulosa cell 
apoptosis (Li et al. 2014). To investigate whether WNT signalling activation (as a result of 
APC2 deletion) impairs follicle steroidogenesis, expression levels of genes involved in 
estradiol synthesis were performed. Expression levels of Cyp11a1 (gene coding for cholesterol 
side chain cleavage enzyme) were comparable in Apc2+/+ and Apc2-/- ovarian extracts (Figure 
4.21a). However, the expression levels of Cyp17a1 (coding for steroid 17-α-hydroxylase/17,20 
lyase), and Cyp19a1 (coding for aromatase) were significantly reduced in Apc2-/- as compared 
to Apc2+/+ ovaries (p<0.05, Figure 4.21a).  
The vascular network surrounding the growing follicles is essential for follicular 
development, by delivering nutrients and oxygen. Disruption of angiogenesis has been 
previously described to impair follicular growth (Robinson et al. 2009). In order to find out 
whether defects in follicular vascularization contribute to the subfertility phenotype in Apc2-/- 
ovaries, expression levels of Vegfa gene and immunostaining for CD34 protein were 
performed. Vegfa expression was significantly decreased in Apc2-/- ovaries as compared to 
Apc2+/+ (Figure 4.21b). However, it should be taken into consideration that the reduction of 
Vegfa expression levels is-in part- attributable to the reduction in the number of corpora lutea 
formed in Apc2-/- ovaries. CD34 immunostaining enabled the visualization of follicular 
vascularization. In Apc2+/+ ovaries, the late antral to pre-ovulatory follicles were surrounded 
by 2 continuous layers of endothelial cells (Figure 4.21c). In Apc2-/- ovaries, however, the 
endothelial cells surrounding the follicles were discontinuous, reflecting a degree of 
impairment of follicular vascularization (Figure 4.21c) 
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Figure 4.21: APC2 deletion impairs follicle steroidogenesis and vascularization. Gene 
expression levels of (a) steroidogenic enzymes, and (b) Vegfa performed by qRT-PCR on RNA 
extracted from whole ovaries of 10-week-old Apc2+/+ and Apc2-/- female mice. Relative 
expression levels are normalized to Actb expression. (c) CD34 immunostaining of follicles. 
n=3-4. Data are represented as mean±95% confidence interval. Statistical significance was 
determined according to Cumming et al. (Cumming et al. 2007). * denotes significance from 
Apc2+/+ at p<0.05. Scale bars 100 µm. Insets show 2X original magnification. 
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4.3. Discussion 
4.3.1. APC2 deletion in the ovary activates WNT signalling 
APC deletion is known to activate WNT signalling in some tissues such as the intestine 
(Sansom et al. 2004) and the uterus (Tanwar et al. 2011b), but not in the mammary gland (Daly 
et al. 2016). Deleting APC exclusively in the OSE and in ovarian granulosa cells was shown 
to activate WNT signalling in the ovary (Tanwar et al. 2013).  However, when it comes to its 
homologous protein, APC2, the question is more challenging. Although APC2 has been 
previously shown to downregulate β-catenin in a range of colorectal cancer cell lines (Van Es 
et al. 1999; Schneikert et al. 2013), limited data from in vivo studies has supported this finding. 
This could be partly due to the nature of the in vivo studies conducted with Apc2 knockout 
mouse, which were mostly exploring non-WNT functions of APC2 in the brain and nervous 
system (Shintani et al. 2012; Almuriekhi et al. 2015). Even when studies were directed towards 
investigating APC2 functions in WNT signalling, deletion of APC2 on its own was not enough 
to activate WNT signalling in mouse mammary glands (Daly et al. 2016). On the contrary, 
APC2 deletion activated WNT signalling in the small intestine and the liver (Daly 2013).  It 
was thus crucial to unravel the effect of APC2 deletion on WNT signalling in the ovary. 
Loss of Axin1 and β-catenin-binding domains of APC2 protein in the Apc2-/- mouse 
(Appendix 3) caused the activation of canonical WNT signalling in the ovary, as reflected by 
the upregulation of Ctnnb1 and its downstream target genes Axin2 and Fgf1 (Figure 4.1). 
Expression levels of this subset of β-catenin target genes were evaluated because of their 
relevance to the ovarian tissue. Axin2 is believed to be a downstream target of WNT/β-
catenin/TCF, which functions to regulate the activated WNT signalling through negative 
feedback loops (Jho et al. 2002). Axin2 mRNA expression levels (Li et al. 2014) as well as 
reporter mice (De Cian et al. 2016) have been used extensively as surrogates of WNT signalling 
activation in the ovary. Fgf1, known to be overexpressed in epithelial ovarian cancer (Zaid et 
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al. 2011; Smith et al. 2012), has been shown to be a downstream target of Wnt/β-catenin/Tcf 
signalling in the ovary (King et al. 2015). The observed overexpression of Apc could be 
interpreted in terms of functional redundancy between APC and APC2 previously reported in 
some tissues, where the presence of only one of the 2 APC proteins is sufficient to prevent 
WNT signalling perturbation and phenotypic changes (Ahmed et al. 2002; Daly et al. 2016). 
In the current study, it could be regarded as a compensatory mechanism to regulate the activated 
pathway. However, at that stage, WNT signalling was not inhibited as reflected by the 
expression levels of Wif1. 
 
4.3.2. APC2 deletion caused subfertility in adult mice 
Genetically-engineered mouse models GEMMs provide a valuable tool to dissect 
functions of canonical WNT signalling in the ovary. Previous attempts to characterize roles of 
canonical WNT signalling on adult ovarian homeostasis have mainly relied on mutations in 
genes coding for Wnt secreted glycoproteins (Boyer et al. 2010; Abedini et al. 2016), positive 
modulator secreted proteins (De Cian et al. 2016), frizzled receptors (Hsieh et al. 2005; 
Lapointe et al. 2012), and  β-catenin (Boerboom et al. 2005; Boerboom et al. 2006; Hernandez 
Gifford et al. 2009; Fan et al. 2010a). However, equivalent functional studies targeting negative 
regulators of the pathway are lacking, apart from one study performed on APC (Tanwar et al. 
2013). It was thus important to characterize the role of APC2 in adult ovaries and to investigate 
whether these roles could be related to its canonical WNT-regulatory functions. 
Using GEMMs, it is clear that tight regulation of WNT signalling is important for adult 
ovarian functions. Surprisingly, complete silencing of the pathway through deleting its main 
transducer β-catenin has no effect on adult ovarian functions (Hernandez Gifford et al. 2009; 
Fan et al. 2010a). However, it is apparent that over-activation of canonical WNT signalling has 
deleterious effects on follicle growth (Boerboom et al. 2005; Abedini et al. 2016), ovulation 
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process and luteinisation (Fan et al. 2010a; De Cian et al. 2016). The discrepancies in the 
phenotype of ovarian subfertility seen in the published mouse models could be, in part, related 
to the follicular stage when WNT signalling is activated. When this happens early in 
folliculogenesis, at the secondary follicle stage onward, the subfertility is caused by defects in 
follicular growth (Boerboom et al. 2005; Abedini et al. 2016). However, when the activation 
happens at later stages of folliculogenesis, from the antral follicle stage onward, the subfertility 
is caused by defects in ovulation process and/or corpus luteum formation (Fan et al. 2010a; De 
Cian et al. 2016). Evidence from both GEMMs and in vitro studies supports this hypothesis. 
Using different cre transgenes, which drives recombination of floxed genes at specific 
cells/follicular stages in GEMMs, has helped in defining roles of WNT signalling in 
folliculogenesis. For instance, Amhr2-cre drives the recombination of floxed genes in the OSE 
and in granulosa cells of growing follicles starting from pre-antral stages (Baarends et al. 1995; 
Fan et al. 2009) . However, Cyp19-cre drives the recombination of floxed genes specifically 
in granulosa cells of antral and pre-ovulatory follicles (Fan et al. 2008), where Cyp19a starts 
to be expressed. SF1-cre (steroidogenic factor 1) targets different cells; it recombines the 
floxed genes mainly in theca cells of growing follicles and corpora luteal cells (Bingham et al. 
2006).  
In vitro culture of follicles collected at different stages has proven to be another 
valuable tool, as it can be used to unravel roles of WNT signalling activation on 
folliculogenesis. Using secondary follicles isolated from mouse ovaries and treating them in 
culture with WNT activators (Wnt3a or LiCl) or inhibitors (IWR-1), Li group showed that 
activation of WNT signalling in this early stage of folliculogenesis impairs follicular growth 
(Li et al. 2014). Using COC isolated from pre-ovulatory follicles of mice with either gain- or 
loss-of-function mutations in the Ctnnb1 gene, Fan group demonstrated that at this late 
follicular stage, WNT signalling activation impairs COC expansion (Fan et al. 2010a). 
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When using constitutive knockout mouse models, such as the APC2 model used in this 
study, it is important to know at which stage of folliculogenesis APC2 is expressed. However, 
such information is lacking in the literature. In this study, attempts were performed to visualize 
APC2 protein expression in different stages of folliculogenesis by immunohistochemistry 
(Appendix 2). However, we could not source an antibody which can differentially stain Apc2+/+ 
and Apc2-/- ovaries, after the discontinuation of the Zymed c-terminal antibody previously used 
by Dr. Carl Daly (Daly 2013; Daly et al. 2016), a limitation which necessitated a detailed 
investigation of all the possible outcomes of WNT signalling activation at the different stages 
of folliculogenesis. 
Activation of canonical WNT signalling, driven by APC2 loss, in this study caused 
subfertility; as reflected by 33% and 57% reductions in gestation frequency and litter size 
respectively (Figure 4.3). Various degrees of subfertility have been previously reported with 
other GEMMs after WNT signalling activation. For example, expression of degradation- 
resistant β-catenin caused a severe reduction of litter size (ranging from 60-95%) as reported 
by 2 different groups (Boerboom et al. 2005; Fan et al. 2010a). Litter size was reduced by 52% 
after deleting WNT5a, which caused activation of canonical WNT signalling (Abedini et al. 
2016). In accordance with these findings, amplification of R-spondin1 was reported to cause 
83% reduction in litter size (De Cian et al. 2016). One of the limitations in the current study 
was crossing different Apc2 female genotypes with the corresponding male genotype, rather 
than crossing them all with Apc2+/+ males. In order to confirm that the subfertility observed 
here is caused by defects in female fertility, retrieval of oocytes from oviducts of female mice 
after exogenous gonadotrophin administration was performed. Results from this experiment 
reflected a genotype-dependent decrease in the number of ovulated oocytes, which mirrored 
the decrease in number of pups recorded in the mating and breeding experiments (Figure 4.9). 
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However, a possible contribution of male APC2-deficient mice cannot be excluded, and need 
to be considered in future research. 
The subfertility reported in the current study is due to restricted follicular growth 
leading to a decrease in the number of ovulated oocytes and corpora lutea formed post-
ovulation (Figure 4.5-4.6, 4.15). This is similar to the phenotype reported by Abedini et al. 
after conditional deletion of Wnt5a in the granulosa cells of pre-antral follicles using Amhr2-
cre (Abedini et al. 2016). Alhough WNT5a is a known activator of non-canonical WNT 
signalling (Oishi et al. 2003), it has been shown to inhibit canonical WNT signalling in some 
contexts (Pourreyron et al. 2012; Kwack et al. 2013). Abedini et al. reported that subfertility 
was caused by WNT signalling activation (Abedini et al. 2016). The phenotype reported here 
due to APC2 loss in the ovaries is in accordance with a previous subfertility phenotype, caused 
by expression of degradation-resistant β-catenin in granulosa cells of pre-antral follicles 
(Boerboom et al. 2005). However, the phenotype reported here is different from that reported 
after deleting Apc in the ovaries using Amhr2-cre (Tanwar et al. 2013). Alhough WNT 
signalling was activated post-APC loss, ovarian functions were normal in early adulthood 
without any reported effects on folliculogenesis or ovulation (Tanwar et al. 2013). Whether 
functional compensation between APC and APC2 were sufficient to protect against 
progressing to subfertility in this model remains unanswered. Contradicting this, an ovarian 
phenotype characterized by increased atretic follicles and elongated oestrous cycle (You et al. 
2006), or absence of pre-ovulatory follicles and corpora lutea (Bennett et al. 2001), was 
described in the ApcMin/+ mouse (a mouse with germline heterozygous mutation in Apc gene). 
However, fertility of female ApcMin/+ mouse has not been characterized. 
In the current study, WNT signalling activation secondary to APC2 deletion did not 
affect ovulation process and luteinisation (Figure 4.12-4.14). This was evident through 
histological examination of pre-ovulatory follicles and corpora lutea, as well as performing 
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functional analyses. In order to correctly analyse the histologic and molecular changes in a 
continuously cycling organ such as the ovary, it is important to collect all samples at a specific 
stage. This will exclude the variation happening in different stages of the oestrous cycle from 
the analysis. However, one of the limitations of the current study was choosing the diestrus 
stage to perform the analysis.  
The diestrus stage was selected because the initial aim of the study was to characterize 
roles of APC2 on OSE homeostasis. Choosing the diestrus stage should help in evaluating this, 
as it is a post-ovulatory stage, rendering it suitable for studying whether APC2 is important for 
repairing the tear happening in OSE during ovulation. However, the choice of this stage limited 
the number of pre-ovulatory follicles available for histological examination. Using estrus stage 
ovaries would have aided in studying pre-ovulatory follicles in more details. In an attempt to 
overcome this limitation, COCs were collected from oviducts post-gonadotrophin 
administration, and their morphology were evaluated. Results from this experiment 
demonstrated that the morphology of ovulated COCs from Apc2-/- were comparable to those 
from Apc2+/+ (Figure 4.8). These results, in addition to functional analysis of the signalling 
pathways controlling ovulation process and analysis of corpora lutea (Figure 4.12-4.14), 
confirmed that APC2-deficiency did not affect the ovulation process or terminal differentiation 
of granulosa cells prior to corpora lutea formation. Although it has been previously reported 
that mutation of E-APC (Drosophila APC2) mislocalized oocytes in mutant egg chambers 
(Hamada and Bienz 2002), this was not evident in the current study for both oocytes 
investigated in ovarian sections or ovulated oocytes. 
Based on the results of this study, and previously published results from GEMMs, it 
can be concluded that APC2 is present in the ovarian follicles as early as the pre-antral stage 
and that APC2 presence suppresses canonical WNT signalling. The presence of APC2 is 
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essential for follicular growth and maturation, and its loss represses follicular growth leading 
to reduced ovulation and corpus luteum formation. 
4.3.3. Subfertility caused by APC2-deficiency is due to ovarian defects 
As mentioned previously, the APC2-deficient mouse used in the current study is a 
constitutive knock out mouse, meaning that APC2 is lost in all mouse tissues. In addition to 
the autocrine and paracrine control of ovarian functions originating from the ovary, exogenous 
control through the hypothalamic and pituitary hormones are required for triggering 
folliculogenesis and ovulation (Plant 2015). Given that APC2 expression is enriched in the 
hypothalamus and pituitary glands, and that APC2 has a low expression in the ovary (The 
GTEx Consortium 2013), the subfertility observed in APC2-deficient mice could be caused by 
extra-ovarian defects in gonadotrophin synthesis/release rather than intra-ovarian defects. To 
test this hypothesis, we first measured levels of FSH and LH in serum collected from Apc2+/+ 
and Apc2-/- female mice (Figure 4.7). Results revealed comparable levels of these hormones in 
both genotypes studied. Our findings for FSH serum levels agreed with the finding of 
unchanged FSH levels in subfertile female mice with activated canonical WNT signalling as a 
result of Wnt5a deletion (Abedini et al. 2016).  
Unfortunately, performing FSH and LH hormonal assays in the diestrus stage does not 
correlate with their peak levels (during proestrus and estrus respectively), making it impossible 
to address whether peak concentrations were affected. It is evident from published work that 
even minimal decreases in FSH peak concentration affect the number of antral follicles 
reaching the pre-ovulatory stage, and increase the number of atretic follicles (Macklon and 
Fauser 2001). Due to uncertainties related to determination of serum FSH levels at diestrus, we 
aimed to confirm our findings using an alternative approach. APC2-deficient mice were 
administered exogenous gonadotrophin and compared to control APC2-intact mice treated 
similarly. Results revealed that the ovarian phenotype of APC2-deficient mice, characterized 
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by 50% reduction in number of corpora lutea, was not reversed after gonadotrophin 
administration, confirming an intra-ovarian origin for the observed phenotype (Figure 4.10-
4.11). These findings are in accordance with previous results, which demonstrated the inability 
of exogenous gonadotrophin administration to rescue subfertility phenotype driven by WNT 
signalling activation, resulting from the expression of degradation-resistant β-catenin 
(Boerboom et al. 2005). 
Reproducing results after exogenous gonadotrophin administration suggests intra-
ovarian defects in response to gonadotrophin. Gonadotrophins (FSH and LH) transduce their 
signal to the ovary via binding with their receptors to initiate a signalling cascade (Fowler and 
Huhtaniemi 2002). Thus, a dysregulation in the expression of FSHR or LHCGR could be 
responsible for the subfertility phenotype. To test this hypothesis, gene expression analyses of 
Fshr and Lhcgr were performed (Figure 4.20). Results showed a 3.5 fold increase in Lhcgr 
expression levels in APC2-deficient mice. Although the molecular mechanism of subfertility 
induced by increased expression of Lhcgr is not yet understood, a recent study using a mouse 
model with a gain-of-function mutation in Lhcgr proved that overexpression of this receptor 
causes infertility in female mice (Hai et al. 2015). These mice were completely infertile, and 
histologic analysis of ovaries revealed failure of follicles to progress beyond the pre-antral 
stage (Hai et al. 2015). Whether this is resulting from disrupted expression of Lhcgr in certain 
follicular stages or to higher expression levels, or both, remains unanswered. Differences in the 
degree of infertility between this model and the APC2-deficient mouse model could be caused 
by differences in the intensity of overexpression of Lhcgr in the two models. 
The upregulation of Lhcgr in APC2-deficient mice is caused by activation of canonical 
WNT signalling. This is evident from the work of Law et al. which revealed a 3.5 fold increase 
in Lhcgr expression levels in granulosa cells transduced with constitutively active β-catenin,  
in the presence of FSH (Law et al. 2013). Law group demonstrated that β-catenin 
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phosphorylated at Ser 552 and 675 binds to and activates TCF3 transcriptional activity, which 
binds to the Lhcgr promoter (Law et al. 2013). In addition, phospho-β-catenin binds to SF1 to 
facilitate its placement on Lhcgr promoter (Law et al. 2013). Both of these β-catenin-driven 
functions activate the transcription of Lhcgr gene, increasing its expression (Law et al. 2013). 
In published GEMMs of canonical WNT-driven subfertility, upregulation of Lhcgr 
expression has not been previously proposed as a molecular mechanism of subfertility. Some 
of the published models quantified Lhcgr expression, but discrepancy in their results is evident. 
For example, Abedini et al. found a 2 fold increase in Lhcgr gene expression (Abedini et al. 
2016), while De Cian et al. reported a decrease in Lhcgr expression (De Cian et al. 2016). This 
could be interpreted by differences in the follicular stage when canonical WNT signalling was 
activated, as well as to the phenotype produced. As mentioned previously, the subfertility 
phenotype reported by Abedini et al. is caused by defects in follicular development (Abedini 
et al. 2016), similar to subfertility phenotype developing in the current study, while the 
subfertility in De Cian et al. model is caused by defects in the ovulation process (De Cian et 
al. 2016). 
4.3.4. Defective follicular growth is caused by increased apoptosis resulting from 
FOXO1 upregulation 
Results of the current study revealed equivalent number of follicles in Apc2+/+ and  
Apc2-/- mice (Figure 4.5). However, antral follicles from Apc2-/- ovaries were significantly 
smaller, failing to grow beyond a certain size (Figure 4.15). This was caused by increased 
apoptosis of granulosa cells, secondary to the increase of Foxo1 expression levels (Figure 4.17-
4.18). 
It was previously mentioned that WNT signalling activation in early stages of follicular 
development, in the pre-antral follicles, restricts follicular growth (Li et al. 2014; Abedini et 
al. 2016). Previous studies have shown that this is mainly due to increased apoptosis of 
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granulosa cells; reflected by increases in active caspase 3 expression (Abedini et al. 2016) or 
by using TUNEL assay (Li et al. 2014). However, WNT signalling activation later in 
folliculogenesis, in the antral follicles, reduced apoptosis and increased proliferation of 
granulosa cells (Fan et al. 2010a). The FOXO family members, FOXO1 and to a lesser extent 
FOXO3, appear to be main regulators of apoptosis in granulosa cells of ovarian follicles 
(Kajihara et al. 2009; Shen et al. 2012; Liu et al. 2013; Shen et al. 2014). However, they were 
not fully explored in the published GEMMs of ovarian subfertility. In addition, GEMMs 
studying the effects of overexpressing these factors on follicular growth are lacking. 
In the current study, Foxo1 expression levels increased by 25% in Apc2-/- ovaries 
(Figure 4.18). Similar to this finding, Foxo1 expression was increased after treating cultured 
pre-antral granulosa cells with WNT3a (Stapp et al. 2014). Granulosa cell apoptosis of 
secondary follicle cultures treated with WNT activators was caused by the nuclear 
accumulation of another FOX member, the active FOXO3, secondary to inhibition of FOXO3 
phosphorylation (Li et al. 2014). When apoptosis was markedly reduced in granulosa cells of 
antral follicles isolated from degradation-resistant β-catenin GEMM, this was accompanied by 
decreases in FOXO1 mRNA and protein experssion (Fan et al. 2010a). 
FOXO1 induces apoptosis via regulating the intrinsic mitochondrial apoptotic pathway 
and/or the extrinsic apoptotic pathway (Zhang et al. 2011b). In the current study, the extrinsic 
pathway was not affected, as reflected by the expression levels of genes coding for FASL and 
TRAIL (Figure 4.18). However, the expression level of the gene encoding for the cell cycle 
regulator p27 was upregulated. 
Apart from FOXO1 functions in apoptosis, it has been shown to function as a repressor 
of Lhcgr expression (Law et al. 2013). Choromatin immunoprecipitation analysis revealed that 
FOXO1 protein is localized to the Lhcgr promoter and functions to repress Lhcgr expression, 
necissating FOXO1 phosphorylation upon FSH stimulation to relieve that repression (Law et 
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al. 2013). A recent RNA deep sequencing study has shown that FOXO1 regulates the 
expression of most FSH-responsive genes in rat granulosa cells (Herndon et al. 2016). Whether 
the increase of Foxo1 expression observed in the current study is a direct consequence of 
canonical WNT signalling activation, or a negative feedback mechanism to repress the 
upregulated Lhcgr remains unclear. 
FOXO1 activity is tightly regulated by PTEN/PI3K/AKT signalling (Zhang et al. 
2011b). Activation of PI3K signalling phosphorylates FOXO1 which is translocated out of the 
nucleus and becomes inactivated. In the current study, PI3K/AKT signalling was suppressed 
in Apc2-/- antral follicles, as a result of increased PTEN expression (Figure 4.19). The cross 
talk between canonical WNT signalling and PTEN/PI3K/AKT signalling is well established. 
For example, it has been shown that activation of canonical WNT signalling alone causes 
delayed tumour formation in the ovary due to over expression of PTEN (Boerboom et al. 2005; 
Tanwar et al. 2013). However, when PTEN was deleted, tumour formation was accelarated  
(Wu et al. 2007; Lague et al. 2008; Richards et al. 2012). Few studies have explored 
PTEN/FOXO1 activation in the context of WNT signalling activation as a possible molecular 
mechanism of subfertility in canonical WNT signalling GEMMs. One exception is the work 
done by Abedini et al. who addressed Pten expression in their study and their findings 
confirmed the upregulation of Pten in their subfertility model caused by WNT signalling 
activation post-Wnt5a deletion (Abedini et al. 2016). 
4.3.5. Defective steroidogenesis in Apc2-/- follicles 
The ovary is responsible for the production of female sex hormones estradiol and 
progesterone, in addition to its ovulatory function (Jamnongjit and Hammes 2006). 
Progesterone is produced by luteal cells of corpora lutea formed post-ovulation. However, 
estradiol production in the antral follicles happens in 2 stages; the first stage occurs in theca 
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cells producing androgens, while the second stage happens in granulosa cells to produce 
estradiol (Jamnongjit and Hammes 2006).  
In the current study, measuring serum levels of estradiol and progesterone were 
attempted (results not shown). However, as serum samples were hemolyzed, results were not 
considered reliable. Instead, quantifying expression levels of enzymes catalyzing the rate 
limiting steps of steroid synthesis was performed (Figure 4.21). Cyp11a1 gene encodes for the 
enzyme cholesterol side chain cleavage (P450scc) which catalyzes the first reaction of steroid 
synthesis in all mammalian tissues (Miller and Bose 2011). In the current study, Cyp11a1 
expression was not changed after APC2 loss. This indicates that the ability of theca cells, 
granulosa cells and luteal cells to produce progesterone from cholesterol was not affected. This 
finding is similar to the findings of Abedini et al. who reproted that ovarian Cyp11a1 
expression levels were not changed after WNT signalling activation (Abedini et al. 2016). 
However, this finding was different from other studies which showed a  decrease in Cyp11a1 
expression after activation of WNT signalling (Li et al. 2014; Stapp et al. 2014; De Cian et al. 
2016). These discrepancies could be -in part- caused by differences in the models used in these 
studies. In three of them, gene expression levels were performed using cultured granulosa cells 
(Li et al. 2014; Stapp et al. 2014; Abedini et al. 2016). Only in the study (De Cian et al. 2016), 
Cyp11a1 expression level was performed on whole ovaries. However, these ovaries were 
isolated from immature superovulated female mice. 
Cyp17a1 encodes the enzyme 17alpha-hydroxylase/c17,20 lyase (P450c17), which is 
exclusively present in theca cells of growing follicles in the adult ovary (Zhang et al. 2001). 
This enzyme catalyses the conversion of progesterone into androgens (Jamnongjit and Hammes 
2006). Cyp19a1 encodes for the aromatase enzyme, which is exclusively present in granulosa 
cells of the growing follicle catalysing the conversion of androgens into estradiol (Jamnongjit 
and Hammes 2006). In the current study, a trend of increase in the number of antral follicles 
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was observed in ovaries of Apc2-/- mice. However, the expression levels of Cyp17a1 and 
Cyp19a1 were markedly reduced in Apc2-/- ovaries. This may indicate a defective 
differentiation of antral follicular cells, which impaired their steroidogenic functions. This 
defect happened in both theca cells and granulosa cells of antral and pre-ovulatory follicles. 
In a model with perturbation of more than one signalling pathway, like the current 
study, it is difficult to dissect the cause of the observed phenotypes. For instance, canonical 
WNT signalling was reported to inhibit steroidogenesis via repressing Cyp19a1 in cultured rat 
granulosa cells (Li et al. 2014; Stapp et al. 2014). Additionally, FOXO1 has been recently 
shown to repress FSH-responsive genes including Cyp19a1 (Herndon et al. 2016). On the other 
hand, over expression of LHCGR caused a decrease in Cyp17a1 expression in 6-week-old adult 
mice while not affecting Cyp19a1 expression (Hai et al. 2015). Thus, it is the combination of, 
and interplay between, these different signalling pathways that ultimately shapes the observed 
phenotype, and it is perhaps naive to try and identify an individual factor as causative. 
4.3.6. APC2 is essential for normal follicular vascularity 
Angiogenesis plays important roles in normal ovarian homeostasis. Being a 
continuously cycling organ, good vascularity is required during follicle growth, ovulation and 
corpus luteum formation (Robinson et al. 2009). This vascular network surrounding the 
follicles and ramifying through the corpora lutea supplies the growing follicles and newly 
formed corpora lutea with nutrients, oxygen and hormones essential for their maturation 
(Robinson et al. 2009). In the current study, the effect of deleting APC2 on angiogenesis was 
investigated by visualizing new blood vessel formation using the endothelial marker CD34 
(Figure 4.21). Results revealed intact vascularization of corpora lutea but reduced vascularity 
surrounding the growing follicles. This reduced vessel formation around follicles may be one 
of the mechanisms causing the restricted follicular growth and subfertility described here. 
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Little attention has been given to the degree of vascularity in previous studies exploring 
effects of canonical WNT signalling on ovarian homeostasis. Generally, effects of canonical 
WNT signalling on embryonic vasculature morphogenesis is well established, with canonical 
WNT signalling being activated in early angiogenesis (Corada et al. 2010). Work done with 
GEMMs showed that canonical WNT signalling should be tightly regulated in endothelial cells, 
with both loss-of-function (Cattelino et al. 2003) or gain-of-function (Corada et al. 2010) 
mutations of β-catenin impairing normal vascularization. Activation of canonical WNT 
signalling in adult angiogenesis was described in pathological conditions such as tumour 
formation (Boerboom et al. 2005). Other than this, canonical WNT signalling does not appear 
to be activated in resting adult vasculature (Dejana 2010).  
Interaction between β-catenin and FOXO1 has been previously described (Taddei et al. 
2008) to affect tight junctions in endothelial cells disrupting angiogenesis. FOXO1 represses 
Claudin 5, an endothelial specific junctional protein. This repression is intensified by β-catenin, 
by increasing FOXO1 transcriptional activity (Taddei et al. 2008). Bearing in mind the increase 
in expression levels of Ctnnb1 and Foxo1 in the current study, a similar synergistic effect could 
be the cause of reduced vascularity observed in the current study. 
Vascular endothelial growth factors (VEGFs) are a group of cytokines, which are 
essential for neovascularization in many body organs including the ovary (Robinson et al. 
2009). VEGFA is expressed in granulosa cells and theca cells of antral and pre-ovulatory, and 
in luteal cells of corpora lutea (Sargent et al. 2015). Using GEMMS, it has been reported that 
deleting Vegfa in granulosa cells of ovarian mice, as early as the secondary follicle stage using 
Amhr2-cre, caused subfertility due to restricted follicular growth resulting from increased 
apoptosis (Sargent et al. 2015). In the current study, a significant decrease in the expression of 
Vegfa was observed in Apc2-/- ovaries, which might have contributed to the subfertility 
phenotype reported, in a manner similar to the previous study (Sargent et al. 2015). Bearing in 
  
160 
 
mind that the qRT-PCR was done on whole ovaries, this reduction in Vegfa expression could 
also mirror the reduction in the number of corpora lutea observed in Apc2-/- ovaries.  
4.3.7. Conclusion and future work 
For the first time, the pleiotropic roles of APC2 protein in ovarian homeostasis have 
been unravelled; with the overall finding that loss of APC2 causes subfertility with 100% 
penetrance. Loss of APC2 activated canonical WNT signalling in the ovary. The subfertility 
phenotype described here is due to restricted follicular growth resulting from increased 
apoptosis. This phenotype has previously been described when canonical WNT signalling was 
activated in early stages of follicular development. Thus, we propose that APC2 protein is 
present in growing follicles as early as the secondary stages, and that its presence is pivotal for 
suppressing canonical WNT activity to enable follicular maturation. 
The molecular mechanisms causing this subfertility are diverse and may be linked to 
canonical WNT signalling activation on its own, or to its interactions with FOXO1 signalling. 
One of the molecular mechanisms revealed by the current study is the defect in response to 
gonadotrophins, and for the first time it is described here to be caused by upregulation of Lhcgr 
expression. A second mechanism is the upregulation of PTEN and its inhibitory effect on 
PI3K/AKT signalling, coupled with the upregulation of Foxo1 expression. The upregulated 
Ctnnb1/Foxo1 expression caused a decrease in aromatase expression and repressed the vascular 
network surrounding antral/pre-ovulatory follicles, which contributed to the restriction of 
follicular growth observed. 
One limitation of the current study is performing the functional characterization on 
small groups (n=4). Increasing replicates in the groups used in the current study might help to 
confirm whether the non-significant changes (increases or decreases) observed are true changes 
which might be contributing to the reported subfertility phenotype. This might impact on the 
strength of conclusions which could be drawn from some of the datasets. 
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To better elucidate the effect of APC2 deletion on various ovarian compartments, 
inducible knockout systems can be used instead of the constitutive mouse used in the current 
study. Selectively knocking down APC2 in theca cells, granulosa cells of pre-antral and/or 
antral follicles as well as in luteal cells will give a clear evidence about APC2 localization and 
functions in these different cells.  
Another question which still remains unanswered is whether a degree of 
redundancy/compensation is present between APC and APC2 in the ovary. Findings of the 
current study clearly show that APC2 is required for normal ovarian functioning, and that its 
loss has detrimental effects even in the presence of intact APC. Whether the same is true with 
APC is not clear. Based on Tanwar et al. work (Tanwar et al. 2013), it seems that the presence 
of intact APC2 in granulosa cells of pre-antral follicles could guard against any deleterious 
effects on ovarian fertility caused by APC deficiency. Whether this would be true if APC is 
deleted in other cells/stages is not yet characterized. One of the interesting questions would be 
to investigate the effect of deleting both genes together in cells of growing follicles at different 
stages. Based on the previous work done in the Clarke lab (Daly 2013), the outcome would be 
difficult to predict. When both APC and APC2 were deleted in the mammary gland, tissue 
homeostasis was disrupted (Daly et al. 2016). However, deleting APC2 in the liver of 
hypomorph Apcfl/fl mouse rescued liver homeostasis and attenuated tumour formation post-
APC reduction (Daly 2013). 
More experiments need to be directed to investigate whether the molecular mechanisms 
described in the current studyare common between activated canonical WNT subfertility 
models. Defining these molecular mechanisms and relating them to activated canonical WNT 
signalling may direct the use of WNT inhibitors in the treatment of infertility. It is also crucial 
to investigate whether WNT signalling is misregulated in infertile women and whether this is 
general or related to specific diseases e.g. endometriosis (Sanchez et al. 2014).  
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5. Characterizing APC2-deficiency in ovaries of aging mice 
5.1. Introduction 
5.1.1. Granulosa cell tumours (GCTs) 
Ovarian tumours are classified into epithelial ovarian cancers (90%), sex cord-stromal 
tumours (7%) and germ cell tumours (3%). Granulosa cell tumours (GCTs) are the most 
prevalent sex cord-stromal tumours, accounting for 5% of ovarian cancer cases diagnosed 
(Colombo et al. 2009). They originate from granulosa cells of ovarian follicles and are 
classified into 2 types; adult GCTs which represent more than 90% of the cases diagnosed, 
with the remaining classified as juvenile GCTs (Sekkate et al. 2013). The gold standard 
treatment for GCT is complete surgical debulking followed by chemotherapy (Khosla et al. 
2014). Generally, GCTs have a good prognosis, with the majority of patients being diagnosed 
in early stages (Khosla et al. 2014). However, tumours can recur very late after resection of the 
primary tumour; the latest recurrence reported was 40 years after initial tumour removal (East 
et al. 2005). This highlights the need for a life-long follow up of GCT cases to avoid 
complications. 
5.1.2. WNT signalling in adult GCTs 
Historically, most of the research directed towards identifying the molecular 
mechanisms behind GCT development studied signalling pathways controlling normal 
granulosa cell proliferation, focusing on those regulated by FSH (Jamieson and Fuller 2012). 
This was followed by characterizing roles of oncogenes or tumour suppressor genes known to 
have roles in carcinogenesis (Jamieson and Fuller 2012). During the last decade, a somatic 
missense mutation in the FOXL2 gene (c.402C→G; p.C134W) was detected in 97% of adult 
GCTs, and was suggested to be oncogenic (Shah et al. 2009).  
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Boerboom et al. were the first group to investigate roles of WNT signalling in GCTs 
(Boerboom et al. 2005). Performing immunohistochemistry for β-catenin on equine and human 
ovarian GCT samples, their results reflected the presence of nuclear β-catenin in 77.8% and 
16.7% of equine and human GCT samples analysed, respectively (Boerboom et al. 2005). 
Based on the hypothesis that over-activated WNT signalling can cause adult GCT formation, 
Boerboom et al. generated a GEMM expressing a degradation-resistant β-catenin in granulosa 
cells of growing follicles and OSE using Amhr2-cre, which caused 57% of mice to develop 
GCTs by 7.5 months of age (Boerboom et al. 2005). Tumour formation in this model was 
accelerated after Pten loss or Kras activation (Lague et al. 2008; Richards et al. 2012). 
Activation of WNT signalling in another GEMM, by introducing a gain-of-function mutation 
of R-spondin1, caused the formation of adult GCTs in 15.8% of mice aging 12-18 months (De 
Cian et al. 2016). Taken together, these data suggest that WNT signalling upregulation plays a 
role in GCT pathogenesis. However, additional aberration in other signalling pathways is 
required to decrease latency/increase progression (Lague et al. 2008; Richards et al. 2012). 
More recent studies of human GCTs have supported the hypothesis that WNT 
signalling contributes to the pathogenesis of ovarian GCT. Kilnozo et al. reported the increase 
in gene expression and protein levels of β-catenin and LEF1 in human ovarian GCTs (Kilonzo 
et al. 2015). Another study showed the presence of β-catenin immunostaining (membranous 
and/or cytoplasmic) in all stage I adult GCT samples analysed (Stewart et al. 2013). However, 
β-catenin staining negatively correlated with risk of recurrence (Stewart et al. 2013). A recent 
molecular study conducted on 30 human ovarian GCTs showed epigenetic silencing of DKK3, 
reflected by an 80% increase in hypermethylation of the gene promoter (Xu et al. 2016). DKK3 
encodes for Dickkopf (DKK) protein, which antagonizes canonical Wnt/β-catenin signalling 
(Niehrs 2006), implying a need for WNT signalling activation for GCT development. 
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5.1.3. Aims, hypothesis and highlights. 
The aim of the current study was to characterize effects of constitutive APC2 loss in 
ovaries of aging mice, with special attention to cyst formation and tumour development. To 
achieve this, ovaries from APC2-deficient and intact mice (on the background of hypomorph 
Apcfl allele) were collected at different time points up to a maximum of 18 months. Based on 
previously published work (Boerboom et al. 2005; De Cian et al. 2016), we hypothesized that 
the activation of canonical WNT signalling observed in the 10-week-old ovaries of our APC2-
deficient mice (Chapter 4) would drive ovarian GCT formation in a subset of aging mice.   
For the first time, it is reported herein that APC2-deficiency increases the risk of ovarian 
GCT development in aging mice. Previous observations in the Clarke lab noted frequent fluid-
filled cyst formation in aging Apc2-/- mice. Here, only one 18-month-old Apc2+/- mouse 
developed a fluid-filled cyst (3.45%).  However, at least 20.7% of APC2-deficient mice 
developed ovarian GCTs as early as 12 months, compared to just 6.25% seen in one 18-month-
old Apc2+/+ mouse. Canonical WNT signalling was highly activated in APC2-deficient GCTs. 
This was associated with a very high expression of PTEN protein. The APC2-deficient GCTs 
recapitulate the histologic pattern and molecular signature of human adult GCTs. 
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5.2. Results 
5.2.1. APC2-deficient aging mice develop ovarian GCTs 
To investigate whether APC2-deficiency promotes cyst and/or tumour formation in 
aging mice, ovaries were collected from Apc2+/+, Apc2+/- and Apc2-/- female mice as early as 6 
months of age. Unlike the mice analysed at 10-week time point (Chapter 4), all mice left to age 
were on a non-induced Apcfl/fl background. No tumours were detected in any of these cohorts 
at the 6-month time point. However, microscopic examination of serial-sectioned Apc2+/+ and 
Apc2-/- ovaries revealed the presence of a range of cysts (Table 5.1 and Figure 5.1). Apc2+/+ 
mice developed haemorrhagic corpus luteum cysts (40%, Figure 5.1a), and blood cysts (40%, 
Figure 5.1b). Apc2-/- mice did not display these types of cysts. Instead, Apc2-/- developed 
follicular cysts (40%, Figure 5.1c,d), and epithelial cysts (20%, Figure 5.1c,d). However, this 
differential pattern of cyst formation was not significant when tested with Chi-square test of 
independence. 
Table 5.1: Frequency of cysts formed in 6 months old Apc2+/+ and Apc2-/- ovaries. 
Cyst formed 
\Genotype 
Corpus 
luteum cysts 
Blood cysts Follicular 
cysts 
Epithelial 
cysts 
Apc2+/+ 2/5 (40%) 2/5 (40%) 0/5 (0%) 0/5 (0%) 
Apc2-/- 0/5 (0%) 0/5 (0%) 2/5 (40%) 1/5 (20%) 
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Figure 5.1: Ovarian cysts formed in 6-month-old Apc2+/+ and Apc2-/- mice. Representative 
photomicrographs of (a) haemorrhagic corpus luteum cyst (CLC), (b) blood cyst (BC), (c) 
follicular cysts (FC) and epithelial cysts (EC). (d) 2.5X higher magnification of the inset in (c). 
n=5. Scale bars 200 µm, except (c) 500 µm. 
A subset of Apc2+/- and Apc2-/- mice, accounting for at least 20.7% of the mice (6/29 
mouse from both Apc2+/- and Apc2-/- cohorts at the 12 and 18 month time points), had developed 
ovarian adult granulosa cell tumours GCTs as early as 12 months of age (Table 5.2). All the 
mice developed unilateral tumours, apart from one 12-month-old Apc2-/- mouse, which 
developed bilateral tumours. Out of a cohort of nine Apc2-/- mice allocated to age to 18 months, 
only five survived to reach the endpoint. The other four succumbed earlier due to unknown 
causes, although a unilateral ovarian tumour was detected within one animal dissected at 17 
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months. Another animal was dissected post-mortem at the age of 12.5 month, but no ovarian 
tumours were detected. The remaining 2 mice died earlier (before 12 month) and were not 
dissected. 
Table 5.2: Frequency of GCT formation in 12 and 18-month-old Apc2 experimental genotypes. 
Ovarian lesion 
\Genotype 
Ovarian cysts Ovarian granulosa 
cell tumour 
12-month-old Apc2+/+ 0/10 0/10 
12-month-old Apc2+/- 0/4 0/4 
12-month-old Apc2-/- 0/10  2/10 (20%) 
(one mouse developed 
bilateral tumours) 
18-month-old Apc2+/+ 0/9 1/9 (11.1%) 
18-month-old Apc2+/- 1/9 (11.1%) 3/9 (33.3%) 
18-month-old Apc2-/- 0/6 1/6 (16.67%) 
 
Tumours ranged in size from small microscopic in situ tumours to large macroscopic 
tumours (Figure 5.2a-e). Morphologically, they recapitulated human ovarian adult GCTs and 
showed a range of different histologic patterns (Figure 5.2f-l). The tumour cells were highly 
anaplastic (Figure 5.2m), and mitotic figures were evident (Figure 5.2n). Call-Exner bodies 
(formed of follicle remnants, Figure5.2j,o) and coffee-bean-shaped nuclei (Figure 5.2o), 
characteristic of adult GCTs, were occasionally present. Only one 18-month-old Apc2+/- mouse 
developed a large fluid-filled ovarian cyst (Table 5.2 and Figure 5.3a). Microscopic 
examination revealed it to be epithelial in nature (Figure 5.3b,c). This cyst is similar to the ones 
previously observed in the Clarke lab in Apc2-/- mice as early as 500 days old (Figure 5.3d,e). 
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Due to the limited tumour material collected in the time available for the study, further 
histologic analysis were performed on one 12-month-Apc2-/- tumour and three 18-month 
Apc2+/- tumours.  Only one tumour from both cohorts was used for gene expression analysis. 
Although results were reproducible and trends of increase/decrease were clear, more samples 
will need to be gathered in order to test for the significance of variations observed. 
Figure 5.2 (on the following page): Aging APC2-deficient mice develop adult GCTs. These 
tumours ranged in size from (a) small in situ tumours (arrow) to (b) small tumours of normal 
ovarian size, (c,d) small but macroscopically visible tumours or (E) large macroscopic tumour 
(arrow). The tumours displayed varying histologic patterns such as (F) follicular, (G) nodular 
(arrows), (H) insular, (I) luteinized (arrow: leutinized area shown at 4X original magnification 
in the inset, L:leutinized, NL: non-leutinized), (J) diffuse (arrow: Call-Exner body), and (K) 
cystic patterns. The tumours were (L) highly vascularized, (M) anaplastic, (N) mitotic (black 
arrow), and showed (O) Call-Exner body (black arrow) and coffee-bean nuclei (yellow arrow). 
Scale bars a-d: 500 µm, f-l: 100 µm, m-n: 50 µm, o: 20 µm. 
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Figure 5.3: Cyst formation in an 18-month-old Apc2+/- mouse. Photograph of (a) the 
macroscopic cyst. (b) Photomicrograph of the cyst. Scale bar 500 µm. (c) 2.5X higher 
magnification of the inset in (b) (arrows point to epithelial lining of the cyst). Scale bar 200 
µm. n=1. (d,e) Representative photographs of cyst developing in Apc2-/- ovaries, previously 
reported in the Clarke group (photos d,e were kindly provided by Dr. Carl Daly). 
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5.2.2. Activation of canonical WNT signalling drives tumourigenesis in APC2-
deficient mice 
In order to elucidate whether GCT formation observed in APC2-deficient mice is 
associated with WNT signalling upregulation, β-catenin IHC was performed on 3 tumours from 
the 18-month-old Apc2+/- cohort (Figure 5.4a), and one tumour from 12-month-old Apc2-/- 
cohort (Figure 5.4b). In all the stained sections, tumour areas (Figure 5.4 black arrows) strongly 
expressed β-catenin, in contrast to the weak expression encountered in the non-tumour areas 
(Figure 5.4 red arrows) of the ovary. This high expression was mostly cytoplasmic with 
frequent nuclear staining. 
 
Figure 5.4: Expression of β-catenin protein in APC2-deficient GCTs. Representative 
photomicrographs of β-catenin immunohistochemistry in (a) 18-month-old Apc2+/- (n=3), and 
(b) 12-month-old Apc2-/- ovaries (n=1). Scale bar 500 µm. black arrow: GCT, red arrow: corpus 
luteum. Insets show GCTs at 5X original magnification. 
In addition, gene expression analysis of a subset of Wnt-target genes was performed on 
one 12-month-old Apc2-/- ovarian tumour and one 18-month-old Apc2+/- tumour, using 
quantitative RT-PCR. For each tumour, RNA was extracted from two independent areas of the 
tumour and subsequently processed both to allow for tumour heterogeneity and to enable 
technical replicates to partly compensate for the lack of biological replicates. Gene expression 
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levels of samples from each tumour were compared to the expression levels of three age-
matched Apc2+/+ ovaries. A gene-dose-dependent increase in expression levels was observed 
for the Wnt-negative regulators Wif1 (Figure 5.5a) and Axin2 (Figure 5.5b), which were highly 
expressed in the tumours. Apc (Figure 5.5c) and Fgf1 (Figure 5.5d) expression levels were only 
increased in Apc2-/- tumour samples. Whether this increase in Apc and Fgf1 expression levels 
was time-dependent or gene dose-dependent could not be further analysed due to the limited 
tumour samples present. 
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Figure 5.5: Gene expression levels of Wnt-target genes in APC2-deficient GCTs. Expression 
levels in APC2-deficient tumours (T) were compared to age-matched Apc2+/+ ovaries using 
qRT-PCR and normalized to Actb expression. Expression levels of negative regulators of WNT 
signalling (a) Wif1 and (b) Axin2 were highly elevated in both tumours. However, expression 
levels of (c) Apc and (d) Fgf1 were only increased in the 12-month Apc2-/- tumour. n=3 for 12-
months and 18-months Apc2+/+ groups. n=1 for 12-months Apc2-/- and 18-months Apc2+/- 
tumours, hence statistical analysis not appropriate (results display 2 independent samples from 
the same tumour). T:tumour.  
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5.2.3. APC2-deficient tumours are highly proliferative and vascularized 
Sustained proliferation is one of the hallmarks of tumour formation (Hanahan and 
Weinberg 2011). In order to investigate whether this is the case in APC2-deficient GCTs, Ki67 
immunohistochemistry was performed on 3 tumours from the 18-month-old Apc2+/- cohort 
(Figure 5.6a), and one tumour from 12-month-old Apc2-/- cohort (Figure 5.6b). All tumour 
areas showed frequent nuclear Ki67 staining, reflecting high proliferative activity. 
 
Figure 5.6: APC2-deficient GCTs are highly proliferative. Representative photomicrographs 
of (a) 18-month-old Apc2+/- tumour (n=3) and (b) 12-month-old Apc2-/- tumour (n=1). Scale 
bar 500 µm. Insets show GCTs at 5X original magnification. 
Another hallmark of tumour progression is neovascularization (angiogenesis) in order 
to provide tumour cells with nutrients and oxygen required for growth (Hanahan and Weinberg 
2011). Neovascularization was evaluated by CD34 immunostaining (Figure 5.7a,b) and Vegfa 
expression analysis using quantitative RT-PCR (Figure 5.7c). Immunohistochemical staining 
for CD34 protein revealed high vascularity of all the tumours analysed (Figure 5.7 a,b). Vegfa 
expression levels were elevated in both tumours (Figure 5.7c). However, it was further elevated 
in the 18-month Apc2+/- tumour, which was highly vascular macroscopically (Figure 5.2e) and 
microscopically (Figure 5.2l).  Whether this increase in Vegfa expression level was time-
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dependent, gene dose-dependent or morphology/size-dependent could not be further analysed 
due to the limited tumour samples present. 
 
   
Figure 5.7: Neovascularization in APC2-deficient mice. Representative photomicrographs of 
CD34 IHC in (a) 18-month-old Apc2+/- (n=3), and (b) 12-month-old Apc2-/- (n=1) sections. 
Scale bar 500 µm. Insets show GCTs at 5X original magnification. (c) Gene expression analysis 
of Vegfa in APC2-deficient tumours (T) were performed and compared to age-matched Apc2+/+ 
ovaries using qRT-PCR and normalized to Actb expression. n=3 for 12-months and 18-months 
Apc2+/+ groups. n=1 for 12-months Apc2-/- and 18 months Apc2+/- tumours (results display 2 
independent samples of the same tumour).  
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5.2.3. APC2-deficient tumour cells resist apoptosis 
Resistance to cell death is an important feature of  tumourigenesis (Hanahan and 
Weinberg 2011). Immunohistochemistry for the apoptotic protein cleaved caspase 3 was 
performed on APC2-deficient tumours. Apoptosis was rarely seen in APC2-deficient tumours 
(less than 0.5%), as reflected by absence of nuclear cleaved caspase 3 in most of tumour cells, 
in contrast to cells in non-tumour areas of the ovary (Figure 5.8). 
 
 
Figure 5.8: Absence of apoptosis in APC2-deficient GCTs. Representative photomicrographs 
of cleaved caspase 3 immunohistochemistry in (a) 18-month-old Apc2+/- (n=3), and (b) 12-
month-old Apc2-/- (n=1) sections. Scale bar 500 µm. Insets show 5X original magnification. 
Black arrows denote positively-stained atretic follicle. T: tumour. AF: atretic follicle. 
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As previously mentioned in section 4.2.6, impaired follicular growth in Apc2-/- ovaries 
was caused by increased apoptosis resulting from increased Foxo1 expression. However, in 
APC2-deficient GCTs, apoptosis was absent (Figure 5.8). It was thus crucial to determine 
Foxo1 expression levels. IHC for FOXO1 protein showed that nuclear staining was not 
frequent in tumour cells, as compared to granulosa cells of growing follicles, which showed 
intense nuclear staining (Figure 5.9a,b). Gene expression analysis of Foxo1 was performed on 
one 12-month-old Apc2-/- GCT and one 18-month-old Apc2+/- GCT. Results showed a 
downregulation of Foxo1 expression in both tumours analysed (Figure 5.9c).  
Kit ligand Kitlg, a pleiotropic factor expressed mainly in granulosa cells, has been 
shown to play anti-apoptotic roles in the ovary (Abdi et al. 2015). In the current study, 
expression levels of Kitlg were increased in both tumours analysed (Figure 5.9d). 
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Figure 5.9: Absence of apoptosis observed in APC2-deficient GCTs is associated with 
downregulation of Foxo1 and upregulation of Kitlg. Representative photomicrographs of 
FOXO1 immunohistochemistry in (a) 18-month-old Apc2+/- (n=3), and (b) 12-month-old    
Apc2-/- (n=1) sections. Scale bar 500 µm. Insets show GCTs at 5X original magnification. 
Arrows denote positive nuclear staining in growing follicles. Gene expression analysis of (c) 
Foxo1, and (d) Kitlg in APC2-deficient tumours (T) were performed and compared to age-
matched Apc2+/+ ovaries using qRT-PCR and normalized to Actb expression. n=3 for 12-
months and 18-months Apc2+/+ groups. n=1 for 12-months Apc2-/- and 18 months Apc2+/- 
tumours (results display 2 independent samples of the same tumour). T:tumour.  
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5.2.4. APC2-deficient GCTs recapitulate molecular signature of human adult 
GCTs 
In the last decade, much attention has been given to the role of FOXL2 in adult GCT 
pathogenesis. It became clear that 97% of adult GCTs carry a somatic missense mutation in the 
FOXL2 gene (genomic 402C→G; protein C134W) (Shah et al. 2009). Several studies have 
shown an increase in FOXL2 protein expression in GCTs in human and animal models 
(D'Angelo et al. 2011; Liu et al. 2015; Gao et al. 2016). In order to investigate whether this is 
the case in our model, FOXL2 protein and gene expression analysis were performed by 
immunohistochemistry and quantitative RT-PCR, respectively. Both the protein (Figure 
5.10a,b) and gene expression levels (Figure 5.10c) were elevated in APC2-deficient GCTs. 
Human adult GCTs of the ovary are characterized by frequent focal 
immunohistochemical staining for estrogen receptor alpha ERα (Farinola et al. 2007). In order 
to test whether GCTs developing in APC2-deficient mice retain this feature, 
immunohistochemical staining for ERα was performed. Frequent nuclear ERα staining was 
evident in all tumours (Figure 5.11a,b). However, the staining in the 12-month-old Apc2-/- 
tumour (Figure 5.11a) was more frequent and more focal as compared to the staining in the 18-
month-old Apc2+/- tumour (Figure 5.11b). The pattern seen in the immunohistochemical 
staining correlated with the expression levels of Esr1 gene (Figure 5.11c), being more 
expressed in Apc2-/- tumour as compared to Apc2+/- tumour. Whether this increase is gene-dose 
dependent or age-dependent could not be further analysed due to limited tumour samples 
available. 
Although estrogen receptor β (ERβ) is known to be highly expressed in ovarian GCTs, 
poor prognosis is associated with loss of expression of the protein (Staibano et al. 2003). In 
order to identify the status of expression of ERβ in the current study, quantitative RT-PCR was 
used to determine the gene expression levels of Esr2, the gene coding for ERβ protein. Esr2 
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was decreased in both the 12-month-Apc2-/- and the 18-month-Apc2+/- tumour (Figure 5.11d), 
however the expression was more variable in the 12-month-Apc2-/- tumour.  
Inhibin is a secreted glycoprotein formed of 2 subunits (alpha and beta), belongs to the 
TGFβ family of growth factors, and is known to inhibit FSH secretion from the pituitary glands 
(Yamashita et al. 1997). Previous studies have reported that inhibin levels are elevated in 
GCTs, where ovarian inhibin secretion is increased resulting in elevated serum levels 
(Yamashita et al. 1997). In order to assess whether inhibin is elevated in APC2-deficient GCT, 
immunostaining of the inhibin α subunit was performed. Results revealed focal cytoplasmic 
staining for inhibin α in 18-month-Apc2+/- and 12-month-Apc2-/- GCTs, with more abundant 
presence in the 12-month-Apc2-/- GCTs (Figure 5.12a,b). 
Activin, another TGFβ growth factor, has been previously shown to contribute to GCT 
development in mice, and is known to bind to activin receptor type II (ACVRII) before 
signalling through activin receptor type I (ACVRI) (Kim et al. 2016). Gene expression analysis 
was performed for Acvr1 in 18-month-Apc2+/- and 12-month-Apc2-/- GCTs, reflecting an 
increased expression in GCTs from both genotypes (Figure 5.13c). However, Acvr1 expression 
was more consistent and elevated in the 12-month-Apc2-/- GCT analysed compared to the 18-
month-Apc2+/- GCT, whose expression reflected a considerable degree of tumour heterogeneity 
(Figure 5.12c). 
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Figure 5.10: Upregulation of FOXL2 in APC2-deficient GCTs. Representative 
photomicrographs of FOXL2 immunostaining in (a) 18-month-old Apc2+/- (n=3), and (b) 12-
month-old Apc2-/- (n=1) sections. Scale bar 500 µm. Insets show GCT at 5X original 
magnification. (c) Gene expression analysis of Foxl2 in APC2-deficient tumours (T) were 
performed and compared to age-matched Apc2+/+ ovaries using qRT-PCR and normalized to 
Actb expression. n=3 for 12-months and 18-months Apc2+/+ groups. n=1 for 12-months       
Apc2-/- and 18 months Apc2+/- tumours (results display 2 independent samples of the same 
tumour). T:tumour.  
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Figure 5.11: Expression of estrogen receptors in APC2-deficient GCTs. Representative 
photomicrographs of ERα immunohistochemical staining in (a) 18-month-old Apc2+/- (n=3), 
and (b) 12-month-old Apc2-/- (n=1) sections. Scale bar 500 µm. Insets show GCT at 5X original 
magnification. Gene expression analysis of (c) Esr1, and (d) Esr2 in APC2-deficient tumours 
(T) were performed and compared to age-matched Apc2+/+ ovaries using qRT-PCR and 
normalized to Actb expression. n=3 for 12-months and 18-months Apc2+/+ groups. n=1 for 12-
months Apc2-/- and 18 months Apc2+/- tumours (results display 2 independent samples of the 
same tumour). T:tumour. 
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Figure 5.12: Expression analysis of members of TGFβ family of growth factors in APC2-
deficient GCTs. Representative photomicrographs of inhibin α immunostaining in (a) 18-
month-old Apc2+/- (n=3), and (b) 12-month-old Apc2-/- (n=1) sections. Scale bar 500 µm. Insets 
show GCT at 5X original magnification. (c) Gene expression analysis of Acvr1 in APC2-
deficient tumours (T) were performed and compared to age-matched Apc2+/+ ovaries using 
qRT-PCR and normalized to Actb expression. n=3 for 12-months and 18-months Apc2+/+ 
groups. n=1 for 12-months Apc2-/- and 18 months Apc2+/- tumours (results display 2 
independent samples of the same tumour). T:tumour.  
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5.2.5. PI3K/AKT signalling does not contribute to GCT formation in APC2-
deficient mice 
In a previously-published adult GCT mouse model driven by WNT signalling 
activation, it was observed that activation of PI3K/AKT signalling via Pten deletion enhances 
GCT development and progression (Lague et al. 2008; Richards et al. 2012). 
Immunohistochemical staining for p-AKT and its downstream target p-FOXO1/3/4 were 
performed to analyze whether PI3K/AKT signalling contributes to tumour formation in the 
current study. Both p-AKT (Figure 5.13a,b) and p-FOXO1/3/4 (Figure 5.13c,d) proteins were 
completely absent in APC2-deficient tumours, in contrast to growing follicles present in the 
same ovarian section. 
PTEN is a tumour suppressor which acts as a negative regulator for PI3K/AKT 
signalling by converting the active phosphatidyl inositol triphosphate PIP3 to the inactive 
phosphatidyl inositol biphosphate PIP2 (Georgescu 2010). Immunohistochemical staining and 
quantitative RT-PCR were performed on APC2-deficient tumours to quantify the expression 
of PTEN at the protein and gene level, respectively. PTEN protein was strongly expressed in 
APC2-deficient tumours. In 18-month-old Apc2+/- tumours, the protein showed frequent 
nuclear staining, estimated to range from 50% to 100% of all the tumour cells (Figure 5.14a). 
However, in the 12-month Apc2-/- tumour, the protein was expressed mainly in the cytoplasm 
with the presence of occasional nuclear staining estimated at 10% of the cells (Figure 5.14b). 
The mRNA expression level of Pten was increased in only one of the two samples analysed 
from the 12-month-Apc2-/- tumour, but was not changed in the 18-month-Apc2+/- tumour 
samples (Figure 5.14c). 
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Figure 5.13: PI3K/AKT signalling does not contribute to adult GCT formation in APC2-
deficient tumours. Representative photomicrographs of p-AKT immunohistochemical staining 
in (a) 18-month-old Apc2+/- (n=3), and (b) 12-month-old Apc2-/- (n=1) sections. Representative 
photomicrographs of p-FOXO1/3/4 immunohistochemical staining in (c) 18-month-old Apc2+/- 
(n=3), and (d) 12-month-old Apc2-/- (n=1) sections. Scale bar 500 µm. Insets show GCTs at 5X 
original magnification. Black arrows: growing follicles.  
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Figure 5.14: Upregulation of PTEN in APC2-deficient GCTs. Representative 
photomicrographs of PTEN immunohistochemical staining in (a) 18-month-old Apc2+/- (n=3), 
and (b) 12-month-old Apc2-/- (n=1) sections. Scale bar 500 µm. Insets show GCTs at 5X 
original magnification. (c) Gene expression analysis of Pten in APC2-deficient tumours (T) 
were compared to age-matched Apc2+/+ ovaries using qRT-PCR and normalized to Actb 
expression. n=3 for 12-months and 18-months Apc2+/+ groups. n=1 for 12-months Apc2-/- and 
18 months Apc2+/- tumours (results display 2 independent samples of the same tumour). 
T:tumour. 
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  5.2.6. Granulosa cell differentiation is compromised in APC2-deficient GCTs 
Functional differentiation of granulosa cells was shown to be impaired in previously 
published GEMMs of adult GCT (Richards et al. 2012; Liu et al. 2015; Gao et al. 2016). To 
investigate whether granulosa cell differentiation was disrupted in the current study, 
quantitative RT-PCR was used to determine the expression level of a subset of genes known to 
control steroidogenesis (Cyp11a1 and Cyp19a1, Figure 5.15a,b), response to gonadotrophins 
(Fshr and Lhcgr, Figure 5.16a,b) and hormone receptors (Pgr and Ar, Figure 5.16c,b). The 
expression levels of these six genes were downregulated in both tumours, apart from Pgr levels 
in the 12-month-old Apc2-/- tumour, which was highly variable. A degree of variability was 
present in expression levels of these genes in control mice (Apc2+/+), which might be interpreted 
in light of loss of cyclicity due to menopause, causing severe reductions or loss of follicles in 
ovaries collected at 12 months and 18 months of age, respectively. 
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Figure 5.15: Impairment of granulosa cell-steroidogenic machinery in GCTs. Gene expression 
analysis of (a) Cyp11a1 and (b) Cyp19a1 in APC2-deficient tumours (T) were performed and 
compared to age-matched Apc2+/+ ovaries using qRT-PCR and normalized to Actb expression. 
n=3 for 12-months and 18-months Apc2+/+ groups. n=1 for 12-months Apc2-/- and 18 months 
Apc2+/- tumours (results display 2 independent samples of the same tumour). T:tumour. 
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Figure 5.16: Impairment of granulosa cell-hormone response receptors in GCTs. Gene 
expression analysis of (a) Fshr, (b) Lhcgr, (c) Pgr and (d) Ar in APC2-deficient tumours (T) 
were compared to age-matched Apc2+/+ ovaries using qRT-PCR and normalized to Actb 
expression. n=3 for 12-months and 18-months Apc2+/+ groups. n=1 for 12-months Apc2-/- and 
18 months Apc2+/- tumours (results display 2 independent samples of the same tumour). 
T:tumour. 
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5.2.7. Ovarian morphology is disrupted after GCT development 
Recent reports of adult GCT GEMM revealed the presence of cells expressing epithelial 
markers within the tumour, in addition to their normal presence in the OSE (Liu et al. 2015; 
De Cian et al. 2016; Gao et al. 2016). Immunohistochemistry for the epithelial marker E-
cadherin (Figure 5.17a,b) was performed to determine the localization of epithelial cells. E-
cadherin was present in some parts of the OSE but completely absent elsewhere.  
In the current study, apart from one tumour (Figure 5.2a), all tumours analysed caused 
the disruption of the ovarian architecture (Figure 5.2b-e) and replaced normal ovarian 
compartments such as follicles and corpora lutea. Molecular markers for some ovarian 
compartments were assessed using quantitative RT-PCR. The expression levels of Gdf9 
(oocyte marker, Figure 5.18a), Cyp17a1 (theca cell marker, Figure 5.18b) and Cdh1 (epithelial 
marker, Figure 5.18c) were reduced in both GCTs analysed, apart from Cdh1 in 12-month 
Apc2-/- GCT. Again, a degree of variability was evident among control Apc2+/+ mice which 
might be caused by age-related menopause.  
 
Figure 5.17: Characterizing epithelial traits of APC2-deficient GCTs. Representative 
photomicrographs of E-cadherin immunohistochemical staining in (a) 18-month-old Apc2+/- 
(n=3), and (b) 12-month-old Apc2-/- (n=1) sections. Insets show ovarian surface epithelium at 
5X original magnification.. Scale bar: 500 µm. Black arrows: OSE.   
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Figure 5.18: Disruption of normal ovarian architecture in APC2-deficient GCTs. Gene 
expression analysis of (a) Gdf9, (b) Cyp17a1 and (c) Cdh1 were performed in APC2-deficient 
tumours (T) and compared to age-matched Apc2+/+ ovaries using qRT-PCR and normalized to 
Actb expression. n=3 for 12-months and 18-months Apc2+/+ groups. n=1 for 12-months       
Apc2-/- and 18 months Apc2+/- tumours (results display 2 independent samples of the same 
tumour). T:tumour.  
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5.2.8. Characterizing the GCT developing in an Apcfl/fl mouse with intact APC2 
As mentioned earlier, one of the 18-month-Apc2+/+ mice (on the background of non-
induced Apcfl/fl) developed a small GCT (Table 5.2). The non-induced hypomorphic Apcfl/fl 
allele was previously shown to initiate hepatocellular carcinoma in mice with 100% penetrance 
by 400 days of age (Daly 2013). In order to investigate whether this tumour was WNT-driven, 
an immunohistochemical staining for β-catenin was performed, and showed high nuclear β-
catenin staining (Figure 5.19). PI3K/AKT did not contribute to tumourigenesis as reflected by 
immunohistochemical staining for p-AKT and p-FOXO1/3/4 (Figure 5.20). Unlike APC2-
deficient tumours, PTEN expression in the Apc2+/+ tumour was minimal (Figure 5.20). This 
tumour phenocopied the APC2-deficient GCTs, being highly proliferative (Ki67), vascular 
(CD34), non-epithelial (E-cadherin), and non-apoptotic (cleaved caspase 3 and FOXO1) 
(Figure 5.21). Molecular signature of human GCT was retained in the 18-month-Apc2+/+ 
tumour as reflected by the high expression of FOXL2 and inhibin α protein, but not the ERα 
(Figure 5.22).  
 
Figure 5.19: Expression of β-catenin protein in 18-month-Apcfl/fl ovaries. Representative 
photomicrographs of β-catenin immunohistochemistry in (a) normal ovary (inset showing 
membraneous staining for β-catenin in granulosa cells of follicles), and (b) GCT (inset showing 
nuclear staining for β-catenin in granulosa cells of the tumour). Scale bar 500 µm. Black arrow: 
ovarian follicles. Insets show 5X original magnification. O:ovary, T: tumour. 
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Figure 5.20: PI3K/AKT signalling does not contribute to tumourigenesis in 18-month-Apcfl/fl 
GCT. Representative photomicrographs of (a,b) p-AKT, (c,d) p-FOXO1/3/4, and (e,f) PTEN 
immunohistochemistry in 18-month-Apcfl/fl/Apc2+/+ (a,c,e) normal ovary (insets show staining 
in granulosa cells of follicles, 5X original magnification), and (b,d,f) GCT (insets show staining 
in tumour cells, 5X original magnification). Scale bar 500 µm. Black arrow: ovarian follicles. 
O:ovary, T: tumour. 
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Figure 5.21: The 18-month-Apcfl/fl/Apc2+/+ tumour phenocopied APC2-deficient GCTs. 
Representative photomicrographs of (a,b) Ki67, (c,d) CD34, (e,f) e-cadherin, (g,h) cleaved 
caspase 3 and (i,j) FOXO1 immunohistochemistry in 18-month-Apcfl/fl/Apc2+/+ (a,c,e,g,i) 
normal ovary (insets show staining in granulosa cells of follicles, 5X original magnification, 
apart from e where inset shows OSE) and (b,d,f,h,j) GCT (insets show staining in tumour cells, 
5X original magnification). Scale bar 500 µm. Black arrow: ovarian follicles. Red arrow: atretic 
follicle. O:ovary, T: tumour. 
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Figure 5.22: Molecular signature of 18-month-Apcfl/fl/Apc2+/+ tumour. Representative 
photomicrographs of (a,b) FOXL2, (c,d) Inhibin-α and (e,f)  ERα immunohistochemistry in 
18-month-Apcfl/fl/Apc2+/+ (a,c,e) normal ovary (insets show staining in granulosa cells of 
follicles, 5X original magnification) and (b,d,f) GCT (insets show staining in tumour cells, 5X 
original magnification). Scale bar 500 µm. Black arrow: ovarian follicles. O:ovary, T: tumour. 
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5.3 Discussion 
5.3.1. Reduction or loss of APC2 protein drives ovarian granulosa cell tumour 
formation in aging mice. 
Activation of canonical WNT signalling has been previously shown to drive ovarian 
GCT formation in two genetically-engineered mouse models; the degradation-resistant β-
catenin model (Boerboom et al. 2005), and the R-spondin1 gain-of-function model (De Cian 
et al. 2016). In both models, WNT signalling activation was evident and resulted in early-onset 
subfertility with 100% penetrance (Boerboom et al. 2005; De Cian et al. 2016). However, 
tumour formation was delayed and was only evident in a subset of mice. Pre-tumour lesions 
were identified in both models (Boerboom et al. 2005; De Cian et al. 2016). 
WNT signalling was highly activated in GCT of APC2-deficient mice, as reflected by 
the strong nuclear expression of β-catenin protein in the tumour areas (Figure 5.4). This high 
level of WNT signalling activation caused the elevation of Wnt target genes Axin1 and Wif1 
(Figure 5.5), which function to downregulate the pathway. This expression profile is similar to 
that described by Richards et al. in the ovarian GCTs developing in mice expressing 
degradation-resistant β-catenin along with Pten deletion or Kras activation (Richards et al. 
2012). Although this pattern of expression was retained in both Apc2-/- and Apc2+/- tumours, a 
dose-dependent increase in the expression of these WNT signalling pathway members was 
observed in Apc2-/- tumours. However, the main limitation of the current study is the number 
of samples used to perform the analysis. These gene expression data represent only one tumour 
collected at 2 different time points and from 2 different genotypes. Whether the changes 
observed are merely due to the genotype dosage or whether the age is playing a role remains 
unclear. More samples will be needed to unravel these ambiguities. 
  
198 
 
In the current study, APC2 deletion caused subfertility with 100% penetrance 
(Discussed in Chapter 4). Tumour formation was evident in at least 20% of the mice starting 
at the age of 12 months (Table 5.2, Figure 5.2). Although all the aging mice in the different 
Apc2 cohorts carried the hypomorphic Apcfl allele, only one 18-month-old Apcfl/fl mouse with 
intact APC2 developed an ovarian tumour. It was previously shown that mRNA levels of Apc 
were reduced in non-recombined Apcfl/fl brain and intestines, but APC protein levels were not 
affected (Shibata et al. 1997). However, mRNA and protein levels of Apc in Apcfl/fl ovary were 
not previously characterized and remain unknown. No ovarian GCT formation was reported in 
previous studies aging the hypomorphic Apcfl/fl mouse after inducing recombination 
exclusively in the OSE (Wu et al. 2011; Tanwar et al. 2013). GCT formation is not common 
in mice although incidence increases with age and has been shown to be strain-specific (Mahler 
et al. 1996; Dixon et al. 2014). 
This percentage of GCT formation in APC2-deficient mice is lower than the frequency 
resulting from expression of degradation-resistant β-catenin (57%, (Boerboom et al. 2005)), 
but higher than that reported after activating R-spondin1 (12.5%, (De Cian et al. 2016)). 
Tumour formation was evident in 44% of 6-month-old mice in the β-catenin model (Boerboom 
et al. 2005). However, tumour formation was delayed to 12 months in the R-spondin1 model 
(De Cian et al. 2016), similar to the APC2-deficient model. These discrepancies in frequency 
and onset of tumour formation could be related to the different functions of these three proteins 
in WNT signalling. It is expected that over-expression of β-catenin, the main effector of the 
WNT signalling pathway (Sakanaka et al. 2000), would result in the highest frequency and 
earliest onset of tumour formation. Both APC2 and R-spondin1 differentially regulate WNT 
signalling, the first through downregulating β-catenin (Van Es et al. 1999; Ahmed et al. 2002) 
and the other by positively modulating the pathway via preventing the internalization of the 
Wnt coreceptor LPR6 (Binnerts et al. 2007). Whether the higher prevalence of tumour 
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formation in APC2-deficient mice compared to R-spondin1 activation is caused by differences 
in the intensity of WNT signalling activation remains unclear. 
In the current study, pre-tumour lesions in the form of solid nests of follicle-like 
structures with disorganized granulosa cells, previously described in the other models 
(Boerboom et al. 2005; De Cian et al. 2016), were not evident. The use of serial sections within 
the current study to characterize ovaries enabled the discrimination between real cystic lesions 
and growing follicles. Both Apc2+/+ and Apc2-/- ovaries developed cysts at 6 months, but the 
type of cysts formed were different between both genotypes (Table 5.1, Figure 5.1). 
Exclusively in the 6-month-old Apc2-/- cohort, mice developed follicular cysts with 40% 
penetrance, and small epithelial cysts with 20% penetrance. We propose that a proportion of 
these follicular cysts progressed to form GCTs later on, while the epithelial cysts progressed to 
form the large fluid-filled cysts only present in one 18-month-old Apc2+/- mouse in the current 
study, but occasionally observed in previous aging APC2-deficient mice in the Clarke lab 
(Figure 5.3). 
5.3.2. Other signalling pathways contributing to GCT formation in APC2-
deficient mice. 
It was previously shown in section 4.2.6. that in 10-week-old Apc2-/- ovaries, granulosa 
cells had higher apoptotic rates as compared to those of Apc2+/+ ovaries. However, in the GCTs, 
complete absence of apoptosis was evident in APC2-deficient tumours. In the 10-week-old 
Apc2-/- ovaries, higher levels of Foxo1 and downstream targets were found as compared to 
Apc2+/+ mice. However, in the GCTs, gene and protein expression levels of Foxo1 were 
markedly reduced (Figure 5.9). This may indicate the need for silencing Foxo1 to switch from 
apoptosis to tumour formation. This conclusion is in agreement with the results reported by 
Liu et al. using a Foxo1/Foxo3 double knockout mouse model, where 20% of the mice 
developed granulosa cell tumours starting at 6 months of age (Liu et al. 2015). 
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As discussed in section 4.2.7, Lhcgr was highly expressed in 10-week-old Apc2-/- 
ovaries. Overexpression of Lhcgr expression at this early stage might have contributed to GCT 
formation. This hypothesis could be supported by the development of ovarian GCTs in 50% of 
24-week-old mice bearing a gain-of-function mutation in Lhcgr (Hai et al. 2015). Although the 
expression levels were almost absent in APC2-deficient GCTs (Figure 5.16), this may reflect 
the impaired differentiation of granulosa cells in the formed tumours. 
The molecular pathogenesis of adult GCTs of the ovary has been linked to a somatic 
missense mutation in FOXL2 gene detected in 97% of human cases (Shah et al. 2009). This 
missense mutation results in the production of a mutant protein, where a cysteine amino acid 
at position 134 is replaced by tryptophan. The mechanism by which this mutation drives GCT 
development has been recently described as a sensitization to phosphorylation of the mutant 
protein at the S33 phosphorylation site, leading to hyperphosphorylation and subsequent 
degradation of FOXL2 protein (Kim et al. 2014a). In the current study, APC2-deficient GCTs 
highly expressed FOXL2 protein (Figure 5.10), similar to the finding previously reported in 
other GEMMs of ovarian adult GCTs (Hai et al. 2015; Gao et al. 2016). However, due to the 
unavailability of a commercial antibody targeting phospho-S33 FOXL2 protein, the 
phosphorylation status of FOXL2 protein detected in the current study, as well as other studies, 
cannot be confirmed. It remains unclear whether the high FOXL2 protein level detected in the 
GCTs of our APC2-deficient mice is contributing to tumourigenesis, or is a nascent marker of 
granulosa cell differentiation which is retained by the tumour cells. 
When the expression of a dominant-stable β-catenin or the deletion of Foxo1/3 was 
accompanied by Pten deletion, GCT formation was accelerated (Lague et al. 2008; Richards 
et al. 2012; Liu et al. 2015). In the current study, expression of PTEN protein was highly 
elevated, although the Pten mRNA levels were only slightly altered (Figure 5.14). The protein 
level was higher in 18-month-Apc2+/- GCTs as compared to the 12-month-Apc2-/- GCT. PTEN 
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has been previously identified as a downstream target of WNT signalling (Ahmad et al. 2011) 
in bladder cancer. Ahmad et al. have shown that PTEN expression is markedly increased post-
WNT signalling activation via APC deletion, GSK3 deletion or β-catenin activation (Ahmad 
et al. 2011), and proposed this as a mechanism for delaying tumour progression in their model. 
In the APC2-deficient GCTs, the elevated PTEN protein together with the complete absence 
of p-AKT protein (Figure 5.13) could reflect a part of a defensive/negative feedback 
mechanism by which the cells try to counteract the activated WNT signalling by silencing 
PI3K/AKT to prevent tumour progression. This is similar to the blocking effect of PTEN 
protein on bladder cancer progression (Ahmad et al. 2011) and mammary tumour formation 
(Zhao et al. 2005) post-WNT signalling activation reported previously.  
In conclusion, although WNT signalling is the main driver of GCT formation in APC2-
deficient ovaries, the contribution of other signalling pathways cannot be excluded. Whether 
perturbation of these signalling pathways are consequences of tumour formation rather than 
contributing factors cannot be ignored either. More research is required to clarify these 
complex mechanisms. 
5.3.3. Ovarian GCTs of APC2-deficient mice recapitulates human adult GCT 
histological features and molecular signature 
For GEMMs to be useful as a tool in preclinical studies, genotypic and phenotypic 
similarity between the animal model and the corresponding human tumour need to be present. 
Although somatic mutation of the FOXL2 gene remains the main molecular genetic alteration 
found in adult GCTs in human, a mouse model carrying an equivalent mutation in the mouse 
Foxl2 gene has not yet been developed. Thus it is crucial to validate the available mouse models 
as tools to study tumour pathogenesis and as preclinical models for drug testing. 
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 WNT signalling activation, defined by increased β-catenin expression, has been 
previously described in a subset of human GCTs of the ovary (Boerboom et al. 2005; Stewart 
et al. 2013; Kilonzo et al. 2015). In the current study, WNT signalling activation resulting from 
APC2-deficiency caused the formation of adult GCTs of the ovary, which recapitulate many 
histologic features of human adults GCTs. A range of histologic patterns described previously 
in human adult GCTs (Stenwig et al. 1979; Kanthan et al. 2012; Vani et al. 2014) were present 
in the GCTs formed in APC2-deficient mice (Figure 5.2). However, more than one histological 
pattern was present in the same tumour, and histological patterns varied among tumours. The 
cause of this variability is unclear, but is similar to previous reports describing more than one 
histological pattern in a single adult human GCT (Stenwig et al. 1979; Vani et al. 2014). Other 
histologic features which are diagnostic markers for adult GCTs in human ovaries were also 
retained in our APC2-deficient GCTs, such as the presence of Call-Exner bodies, mitotic 
figures and coffee-bean-shaped nuclei (Schumer and Cannistra 2003). The recapitulation of 
these features is similar to those seen in the degradation-resistant β-catenin model (Boerboom 
et al. 2005) as well as in the non-WNT signalling GEMMs such as the Foxo1/Foxo3 double 
knockout model (Liu et al. 2015) and the constitutively-active TGF β receptor-1 model (Gao 
et al. 2016). 
Other features described in human GCTs were retained in APC2-deficient GCTs. For 
example, high proliferation was evident as reflected by Ki67 immunostaining (Figure 5.6). 
Increased proliferation is one of the hallmarks of tumour progression (Hanahan and Weinberg 
2011). The increased proliferation of granulosa cells could be partly caused by the 
downregulation of Esr2 (Figure 5.11), a tumour suppressor gene in the granulosa cells whose 
expression needs to be suppressed in order to enhance granulosa cell proliferation (Wang et al. 
2015c). Again, whether this is a consequence of tumourigenesis or contributing to it is not 
clear. Ovarian GCT development was reported in 2-year-old constitutive Esr2 knockout mice 
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(Fan et al. 2010b). The same group reported the absence of tumour formation in Esr1 or 
Esr1/Esr2 double knockout mice (Fan et al. 2010b), suggesting the contribution of estrogen 
receptor alpha in GCT development. This is in line with the findings of the current study; GCTs 
developing in APC2-deficient mice showed downregulation of Esr2 but upregulation of Esr1 
and the presence of nuclear ERα in tumour cells (Figure 5.11). 
Increased angiogenesis is another hallmark of tumour formation, which was retained in 
GCTs formed in APC2-deficient mice (Figure 5.7). New blood vessel formation, visualized in 
the current study by CD34 immunostaining, is similar to those reported in other GEMMs of 
ovarian GCTs (Gao et al. 2016) as well as in human adult GCTs (Kusamura et al. 2003; 
Färkkilä et al. 2011). The interaction between activated canonical WNT signalling, elevated 
Fgf1 expression (evident only in Apc2-/- tumours) and Vegfa expression may account for the 
prevalent microvessel formation present in APC2-deficient tumours (Carmeliet and Jain 2011). 
In conclusion, GCTs in our APC2-deficient mouse model human ovarian adult GCTs, 
retaining the histologic features as well as the molecular signature (FOXL2, inhibin and ERα 
expression). 
5.3.4. Differentiation is impaired in APC2-deficient GCTs 
In the setting of tumour development, where the tumour replaces the normal ovarian 
tissue, it is expected that most of the ovarian compartment will be lost. This was evident in the 
microscopic examination of the tissue, where the presence of corpora lutea and follicles was 
much reduced (Figure 5.2). Although loss of these functional ovarian elements is expected in 
aging mice, even their remnants were absent due to replacement by tumour tissue. In order to 
confirm this finding, expression analyses of Gdf9, Cyp17a1 and Cdh1 (along with E-cadherin 
immunostaining) were chosen as molecular markers of oocytes, theca cells and epithelial cells 
respectively (Figure 5.17-5.18). The expression levels of these markers were all reduced in 
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GCTs of APC2-deficient mice. Of note in GCTs developing in APC2-deficient mice that the 
expression of E-cadherin was limited to the ovarian surface epithelium (Figure 5.17). Recent 
GEMMs of GCTs have described the presence of epithelial markers within the tumours, which 
was explained by dedifferentiation of tumour cells to progenitor epithelial cells (the only cell 
type harbouring stem cells in the ovary) (Liu et al. 2015; De Cian et al. 2016), or migration of 
epithelial cells into the tumour (initiating the tumour)(Gao et al. 2016). APC2-deficient GCTs 
are not reproducing this epithelial phenotype. It is worth mentioning that the cell of origin of 
ovarian granulosa cells is still not clearly defined, as it is still controversial whether they 
originate from coelomic epithelium or mesenchymal precursors (Kottarathil et al. 2013). 
Gdf9 was previously shown to downregulate Kitlg in both cumulus cells and KGN, a 
granulosa cell tumour cell line (Tuck et al. 2015). The downregulation of Gdf9 observed in the 
current study (Figure 5.18) might explain the upregulation of Kitlg (Figure 5.9), which in turn 
might account for the inhibition of apoptosis (Figure 5.8) observed in GCTs (Abdi et al. 2015). 
Differentiation of granulosa cells in the tumours was impaired as well. Although tumour 
cells retained the expression of some early granulosa cell markers such as FOXL2 (Figure 
5.10), the expression of granulosa cell functional marker (Cyp19a1, Fshr, Ar, Esr2) as well as 
markers of terminal differentiation (Lhcgr, Pgr, Cyp11a1) were compromised (Figure 5.11, 
5.15-5.16). The limited capability of full differentiation of granulosa cells in the tumours has 
been reported in other GEMMs of adult GCT (Richards et al. 2012; Liu et al. 2015; Gao et al. 
2016). 
Throughout the study, a degree of heterogeneity was observed in the expression levels 
of genes from the 12-month-Apc2-/- tumour compared to the 18-month-Apc2+/- tumour. The 
reason of this heterogeneity is not clear, owing to the limited number of samples processed. 
However, one explanation might be the size of the tumour. The tumour collected from the 12-
  
205 
 
month-Apc2-/- was a small one, and if compared to tumours of similar size, which were 
examined microscopically, it cannot be excluded that a part of the normal ovarian tissue is 
present. As the sampling was done blindly, one of the samples could represent the tumour bulk 
while the other represent the tumour periphery or tumour/normal tissue interphase. On the other 
hand, the 18-month-Apc2+/- tumour was the largest one collected in the current study. As it was 
divided into 2 parts, one for histological assessment and the other for gene expression analysis, 
it is apparent from the microscopic examination that all the tissue was replaced by the tumour. 
5.3.5. Conclusion and future work 
For the first time, roles of the APC2 protein in aging ovaries have been established. It 
has been shown that APC2 is an important tumour suppressor protein in ovarian granulosa 
cells. APC2-deficient mice developed GCTs due to activation of WNT signalling, however, 
the contribution of other signalling pathways cannot be excluded. We propose that the late 
formation of the tumours as well as the low incidence is caused by upregulation of PTEN. We 
hypothesize that deleting PTEN simultaneously with APC2 will accelerate tumour formation 
and progression. The GCTs formed in APC2-deficient mice recapitulate human adult GCT 
histology and molecular signature, and thus can be successfully used as a model to study 
tumour biology and in preclinical drug testing. 
Some questions remain to be answered. The APC2-deficient mouse used in the current 
study is a constitutive knockout mouse. Whether ovarian cells, other than granulosa cells, are 
contributing to tumour development is not clear. In order to dissect the cell of origin of the 
tumour, conditional deletion of APC2 in granulosa cells as well as in other cellular 
compartments (e.g. oocytes, theca cells) using a cre recombining exclusively in each of these 
cells would be useful. To the best of our knowledge, a conditional APC2 mouse strain is 
currently not available and would need to be developed and characterized first before this 
question could be answered. 
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Another important question is the interaction between APC and APC2 proteins in GCT 
development and progression. In the previous work performed in the Clarke lab, APC2 loss 
caused tumour formation in APC-deficient mice in the mammary glands (Daly et al. 2016), but 
attenuated tumour formation in the liver (Daly 2013). Whether complete silencing of both APC 
proteins in the granulosa cells would have a synergistic or antagonistic effect on tumour 
formation remains unanswered.  
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6. Roles of APC2 in epithelial ovarian tumourigenesis 
6.1. Introduction 
6.1.1. OSE as an origin for EOC  
As discussed in section 1.2.3.1., the cell of origin of EOC is still unclear, and many 
theories have been postulated based on clinical evidence or mouse models. Historically, it was 
believed that EOC originates from OSE, the only epithelial cells in the ovary. This theory has 
been questioned because of the differences in histology and embryonic origin between OSE 
(single layer of squamous to cuboidal mesothelial cells) and EOC (resembles müllerian duct-
derived epithelium). Although no clinical data support this hypothesis, mouse models have 
been developed driven by deletion of a number of genes exclusively in the OSE, modelling the 
4 main histotypes of EOC (serous, endometrioid, mucinous and clear cell) (Wu et al. 2007; 
Szabova et al. 2012; Chandler et al. 2015; Ren et al. 2016), thus providing some support for 
this theory. 
According to the theory, epithelial cells at the site of continuous rupture and repair, are 
highly susceptible to mutations, and if trapped inside the ovary during ovulation, may form 
inclusion cysts. Supported by paracrine signals coming from the surrounding niche 
(inflammatory mediators and steroidal hormones), as well as autocrine signals from inside 
cells, they accumulate mutations and undergo metaplastic transformation into müllerian 
epithelium, a pre-requisite for neoplasia. Genes mutated, as well as factors present in the 
surrounding niche, determine the histotype of EOC (Dubeau 2008; Kurman and Shih Ie 2010).  
With the recent isolation and characterization of stem cells from the OSE, this theory 
has been refined, with the differentiating abilities of stem cells explaining the differences in 
histology between the originating OSE and the developing EOC (Ng and Barker 2015).  
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6.1.2. APC genes in human epithelial ovarian cancer 
Mutations and copy number alterations of APC and APC2 have been previously 
characterized in human EOC. Inactivating mutations of APC were present in just 1.4% (1/72) 
human OEA (Wu et al. 2007). However, using the COSMIC database, 10.94% (7/64) human 
OEA showed inactivating mutations in APC, of which 3 were homozygous (Forbes et al. 2016). 
In contrast, only 1.88% (13/693) of human serous carcinoma cases had mutations in APC, 
which were mostly heterozygous (Forbes et al. 2016). No APC mutations were detected in 
mucinous or clear cell carcinoma, however, the datasets were small (10 cases/histotype). In the 
cBioPortal database, only 2 EOC datasets were available, both for serous ovarian carcinoma 
cases. In one cBioPortal dataset, APC mutations were evident in 1.3% (4/310) and copy number 
alterations (deletions) in 3.2% (10/310) of cases, while in the other dataset mutations were 
evident in 1.9% (6/316) and deletions in 0.6% (2/316) cases (CGARN 2011). These findings 
could support the notion that WNT signalling plays a role in OEA pathogenesis, as well as 
being implicated in the pathogenesis of ovarian serous adenocarcinoma.  
Shortly after its discovery, APC2 allelic imbalance was reported in 19/20 human 
ovarian cancer samples, but histotypes of these tumours were not reported (Jarrett et al. 2001). 
Data extracted from cBioPortal showed that APC2 was deleted in 5.1% (16/311) cases in a 
human serous ovarian carcinoma dataset, while being deleted in 1.3% (4/316) of cases in the 
second dataset of the same histotype (CGARN 2011). In the COSMIC database, APC2 copy 
number alteration was present in one dataset representing human serous ovarian carcinoma, in 
which 1.56% (9/576) of samples had deletions (Forbes et al. 2016). 
Data extracted from the COSMIC database did not reveal any epigenetic alteration 
(hypo or hypermethylation) of either APC or APC2 in the different datasets assessed.  
Interestingly, in one serous carcinoma dataset of cBioPortal, 0.96% (3/311) of cases showed 
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homozygous deletion of both genes, while 0.32% (1/311) showed homozygous deletion of 
APC2 in addition to a missense mutation in APC. 
6.1.3. Aims, hypothesis and highlights 
The aims of this chapter were to characterize the role of APC2 in OSE homeostasis and 
whether loss of APC2 contributes to epithelial tumourigenesis, either alone or in combination 
with other tumour suppressors (APC and/or PTEN). The hypothesis was that APC2 is a tumour 
suppressor for epithelial tumourigenesis, and that loss of APC2 would disrupt the OSE, leading 
to formation of epithelial cysts and predisposing to epithelial tumours. However, the findings 
did not support this hypothesis and revealed that APC2 is dispensable for OSE homeostasis. 
Unlike the previous observation in the Clarke lab, Apc2-/- female mice did not develop ovarian 
cysts. Combined loss of APC2 with APC or PTEN in the OSE failed to initiate epithelial 
tumour formation. Surprisingly, the presence of intact APC2 protein delayed the initiation of 
OEA development in adenovirus-cre-induced Ptenfl/fl/Apcfl/fl ovaries, but enhanced tumour 
growth. This suggests a dualistic role of APC2 protein in WNT-driven OEA, where it acts as a 
tumour suppressor for tumour initiation but an oncoprotein for tumour progression. APC2 
presence does not inhibit OEA tumourigenesis, and its loss might be considered a passive event 
happening to suppress tumour growth.  
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6.2. Results 
6.2.1. APC2 loss is not disruptive to the ovarian surface epithelium 
The OSE is a single layer of squamous to cuboidal epithelium that covers the ovary and 
is subjected to tear and subsequent repair after ovulation (Auersperg et al. 2001). In order to 
investigate whether APC2-deficiency affects OSE integrity and functionality, a series of 
histologic, immunohistochemical and ex-vivo assays were performed. Histologic examination 
of H&E-stained 10-week-old Apc2+/+ and Apc2-/- ovarian sections collected at diestrus stage 
showed no signs of unrepaired tears, epithelial cysts, clefts, hyperplasia or metaplastic changes 
(shifting to columnar epithelium) in either genotype (Figure 6.1). 
 
Figure 6.1: OSE integrity is not affected by APC2-deficiency. Photomicrographs of ovaries 
collected from 10-week-old (a) Apc2+/+ and (b) Apc2-/- mice, showing smooth OSE (black 
arrows) formed of squamous epithelial cells. n=4. Scale bars 500 μm. Insets show OSE at 5X 
original magnification. 
Being a primitive mesothelium, OSE displays both epithelial and mesenchymal features 
(Auersperg et al. 2001). To test whether these features were affected by APC2-deficiency, 
immunohistochemistry for epithelial markers (CK18 and E-cadherin) and a mesenchymal 
marker (vimentin) were performed, but no differences were observed in their intensity or 
localization between the 2 experimental genotypes (Figure 6.2).  
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As previously mentioned in section 4.2.4., APC2 deletion caused a trend of increase in 
proliferation and significantly increased apoptosis in follicle granulosa cells. To investigate 
whether APC2-deficiency affects proliferation and apoptosis of OSE, immunohistochemistry 
was performed using Ki67 and cleaved caspase 3 antibodies, respectively. No apoptotic cells 
were evident in the OSE from either genotype (Figure 6.3a,b), and there was a non significant 
decrease in proliferation in Apc2-/-  vs. Apc2+/+ OSE (23.25±13.1 Apc2+/+ vs. 14.25±4.6 Apc2-/-
, Figure 6.3c-e).  
In order to study effects of APC2-deficiency on proliferation, migration and stemness 
in more depth, ex-vivo assays were performed on OSE isolated from 10-week-old Apc2+/+ and 
Apc2-/- ovaries. Cell Titer-Glo® viability assay revealed no significant differences in the 
number of viable cells in the cultured OSE from Apc2-/- mice compared to those from Apc2+/+ 
mice (Figure 6.4). A scratch assay was used to assess the migratory capabilities of OSE cells. 
No significant differences in migration were observed between cells isolated from the two 
genotypes (Figure 6.5). A non-adherent sphere formation (anoikis resistance) assay was used 
to quantify stem cells (Wang et al. 2015a) and showed no significant difference between the 2 
genotypes in the number of spheres >50 µm in diameter, although sphere formation was highly 
variable in Apc2+/+ OSE cells (Figure 6.6).  
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Figure 6.2: APC2-deficiency did not affect epithelial/mesenchymal features of OSE. 
Photomicrographs of ovaries collected from 10-week-old mice, for immunohistochemistry of 
CK18 in (a) Apc2+/+ and (b) Apc2-/- ovaries (black arrows: staining in OSE), E-cadherin in (c) 
Apc2+/+ and (d) Apc2-/- ovaries (staining is present exclusively in OSE), and vimentin in (e) 
Apc2+/+ and (f) Apc2-/- ovaries (black arrows: OSE, note that vimentin is present in all ovarian 
compartments apart from growing follicles). n=4. Scale bars 500μm. Insets show OSE at 5X 
original magnification. CK18: cytokeratin 18. E-cadh: E-cadherin. Vim: vimentin. 
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Figure 6.3: Proliferation and apoptosis are not altered in Apc2-/- ovaries. Photomicrographs of 
ovaries collected from 10-week-old mice, showing immunohistochenical staining for cleaved 
caspase-3 in (a) Apc2+/+ and (b) Apc2-/- mice (red arrows show positively-stained granulosa 
cells in atretic follicles), and Ki67 in (c) Apc2+/+ and (d) Apc2-/- mice (black arrows show 
positively stained-cells in the OSE). (e) Histogram for Ki67 immunostaining in OSE. n=4. 
Scale bars 500μm. Insets show OSE at 5X original magnification. 
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Figure 6.4: APC2-deficiency did not affect proliferation of cultured OSE. Photomicrographs 
of OSE in culture at confluency, isolated from (a) Apc2+/+ and (b) Apc2-/- ovaries. (c) 
Proliferation of OSE cells measured as luminescent signal from viable cells by Cell Titer-Glo®. 
n=3. Results are displayed as mean±S.E. 
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Figure 6.5: Migration of OSE cells in APC2-deficient ovaries. (a) Photomicrographs showing 
nearly confluent OSE from Apc2+/+ (left panel) and Apc2-/- (right panel) ovaries taken just after 
the scratch (0 hour, upper panel) and 24 hours later (lower panel). (b) Histogram showing 
migration rates measured from the differences in scratch width at time of scratch and 24 hours 
later. n=3. Results are displayed as mean±S.E. 
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Figure 6.6: OSE cells separated from Apc2+/+ and Apc2-/- form small spheres in suspension cell 
cultures. Photomicrographs of spheres formed in (a) Apc2+/+ and (b) Apc2-/- OSE suspension 
cultures.  Orange arrows: large spheres. Scale bar 50µm. (c) Histogram showing number of 
large spheres (>50 µm) formed per well, and reflecting high degree of variability in Apc2+/+ 
cultures. n=3. Results are displayed as mean±S.E. 
6.2.2. Conditional deletion of APC in the OSE of APC2-deficient mice did not 
initiate epithelial tumour formation 
As shown in section 6.2.1., loss of APC2 protein does not disrupt OSE homeostasis. 
Whether compensation between APC2 and its homologue APC is protecting the OSE is not 
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clear. In order to address this, constitutive APC2-deficiency was combined with conditional 
APC deficiency, by recombining a floxed Apc allele exclusively in the OSE using intrabursal 
injection of adenovirus-cre, performed in 10-week-old mice. Ovaries were either collected 8- 
weeks post-induction (early time point), or when mice were 12-months old (late time point) 
(Table 6.1). Histopathological examination was performed, along with immunohistochemical 
characterization of proliferation, WNT signalling activation and epithelial integrity. 
Table 6.1.: Numbers of mice analysed in experimental cohorts injected intrabursally by 
adenovirus-cre for studying compensation between APC proteins. 
Genotype/ 
Time of dissection 
WT Apcfl/fl  
 
Apc2-/- Apcfl/fl 
Apc2-/- 
Early time point  
(8-weeks post-induction) 
n=4 n=4 n=3 n=3 
Late time point 
(age of 12 months) 
n=7 n=7 n=0 n=3 
 
Preliminary experiments performed by Dr. Carl Daly in the Clarke lab, have shown that 
adenovirus-cre injection causes recombination of floxed genes exclusively in the OSE 
(Appendix 5). The experimental cohorts outlined in Table 6.1 were induced by intrabursal 
adenovirus-cre injections of both ovaries, in order to minimize the number of mice needed in 
the study. From each mouse, one ovary was fixed and used for 
histopathology/immunohistochemical characterization while the other was snap frozen. Wild 
type mice (WT, with intact APC and APC2 proteins) were injected to determine whether the 
procedure itself might affect OSE homeostasis. Ovarian sections were stained with H&E and 
histopathological analysis was performed to determine any abnormalities in the OSE in the 
experimental cohorts. 
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In the wild type cohort (Apc+/+/Apc2+/+), no signs of OSE lesions were observed 8-
weeks post-induction (early point). However, age-related OSE irregularities were observed in 
6/7 of induced wild type mice aged to 12 months (late point). Invagination was seen in 1/7 
ovary (together with slight stromal infiltration and minimal shedding), hyperplasia and multi-
layering in 1/7 ovary, slight stromal infiltration in 2/7 ovaries and minimal shedding in 2/7 
ovaries (Figure 6.7, Table 6.2). 
However, in the induced Apcfl/fl cohort, OSE irregularities appeared in 50% of mice 
(2/4) as early as 8-weeks post-induction. In a cohort of 4 ovaries examined microscopically, 
1/4 had a deep invagination, with shedding and stromal infiltration (Figure 6.8a). Micro-
papillary formation was noted in 1/4 ovary. In the 12-month-old mice, a range of ovarian 
abnormalities were observed in 6/7 ovaries. A large cyst which distorted the overall ovarian 
structure was present in 1/7 ovary (Figure 6.8b). In addition, micro-papillary growth was 
evident in 1/7 ovary (Figure 6.8c), shedding in 1/7 ovary (Figure 6.8d), multi-layering in 1/7 
ovaries (Figure 6.8e). In addition, 1/7 ovary developed micro-papillary growth, OSE shedding 
and slight invagination. Another 1/7 ovary displayed micro-papillary growth, and multi-
layering (Table 6.2a,b). 
Due to the subfertility phenotype discussed in details in Chapter 4, we had difficulty 
generating sufficient mouse numbers for the Apc2-/- genotype cohorts. For this analysis, 3  
Apc2-/- mice were induced and ovaries collected 8-weeks post-induction, but we were unable 
to generate a cohort of this genotype for the late time point. At 8-weeks post-induction, no 
signs of OSE irregularities were observed (Figure 6.9), similar to wild type mice collected at 
the same time point (Figure 6.7a), and to the non-induced Apc2-/- cohorts analysed at 10 weeks 
(Figure 6.1). 
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In contrast to induced Apcfl/fl cohorts, no OSE abnormalities were recorded in 
Apcfl/fl/Apc2-/- cohort 8-weeks post-induction (Figure 6.10a), and slight stromal invasion was 
recorded in only 1/3 of the late time point cohort (Figure 6.10b, Table 6.2).  
These results are collectively summarized in table 6.2 and indicate that loss of APC 
protein in the epithelium disrupts OSE homeostasis, but that this is insufficient to initiate 
tumourigenesis. Importantly, additional APC2 loss rescues the OSE from disruption. However, 
this interpretation should be treated with caution due to the limited number of ovaries that were 
available for the analysis. 
Table 6.2: (a) OSE disruptions in 12-month-old induced APC/APC2 experimental cohorts. (b) 
Individual phenotypic characterization of epithelial lesions in ovaries of Apcfl/fl cohort.  
(a) Genotype 
/histologic feature 
WT Apcfl/fl Apcfl/fl /Apc2-/- 
Number of ovaries with 
OSE disruptions 
6/7 6/7 1/3 
Invagination 1/7 1/7 (slight) 0/3 
Multi-layering 1/7 2/7 0/3 
Stromal infiltration 3/7 (slight) 0/7 1/3 (slight) 
OSE shedding 3/7 2/7 0/3 
Cyst  0/7 1/7 0/3 
Micro-papillary growth 0/7 3/7 0/3 
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b) Apcfl/fl mouse  
 
Invagination Multi-
layering 
OSE 
shedding 
Cyst  Micro-
papillary 
growth 
1st  No No No Yes  No 
2nd  No No No No Yes  
3rd  No No Yes  No No 
4th  No Yes  No No No 
5th  Yes  No Yes  No Yes  
6th  No Yes  No No Yes  
7th  No No No No No 
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Figure 6.7: OSE homeostasis is disrupted in aging mice. Photomicrographs of H&E-stained 
ovarian sections at (a) 8-weeks post-induction/early point (EP, inset 5X original 
magnification), and (b) 12 months of age (9.5 months post-induction/Late point (LP)). Scale 
bar 500 µm. (c) 5X original magnification of squared area in (b). Inset 2X original 
magnification. SI: infiltration. M: multi-layering. S: shedding. Scale bar 100 µm. n=4 for EP 
cohort. n=7 for LP cohort. 
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Figure 6.8: OSE abnormalities seen in Apcfl/fl ovaries post-induction. Photomicrographs of 
H&E staining for ovarian sections (a) 8-weeks post-induction/early point (EP, n=4), showing 
the presence of deep invagination and stromal infiltration, and (b) 12 months of age/late point 
(LP), showing an ovarian cyst. Scale bar 500 µm. Insets show 5X original magnification. Other 
OSE irregularities observed in LP (n=7) included (c) micro-papillary formation, (d) epithelial 
shedding, and (e) epithelial multi-layering. Scale bar in (c-e) 100 µm. I: invagination. SI: 
stromal infiltration. C: cyst. P: micro-papillary epithelium. S: shedding. M: multi-layering.  
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Figure 6.9: OSE irregularities are not evident in Apc2-/- mice 8-weeks post-induction. 
Photomicrograph showing smooth OSE covering the whole ovary. Inset show OSE at 5X 
original magnification. Scale bar 500 µm. n=3. 
 
 
Figure 6.10: Minimal OSE disruption caused after loss of both APC proteins. 
Photomicrographs of H&E staining for ovarian sections (a) 8-weeks post-induction/early point 
(EP), with no OSE irregularities observed, and (b) at 12-months of age/late point (LP), with a 
small stromal infiltration (SI) observed. Scale bar 500 µm. Insets show 5X original 
magnification. n=3. 
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In any cellular system, the balance between proliferation and death is an important 
determinant in homeostasis. In order to assess whether this balance was disrupted after 
combined loss of APC and APC2 proteins in the epithelium, IHC analysis was performed using 
cleaved caspase-3 (apoptosis) and Ki67 (proliferation) antibodies respectively, and the number 
of positive nuclei were counted. It is known that the OSE resists apoptosis, and it is only ever 
evident in the post-ovulatory site during estrus stage (Slot et al. 2006). No apoptotic cells were 
present in the OSE in any of the experimental cohorts studied at either time point. Ki67 staining 
was not significantly altered in Apcfl/fl ovaries at both time points (Figure 6.11-12). Additional 
loss of APC2 did not alter the proliferation observed in the OSE of Apcfl/fl ovaries (Figure 6.11-
12). It was noted that OSE proliferation decreased with age in all the cohorts, and was absent 
in the multi-layering lesions previously recorded (Figure 6.7-6.10). 
In order to determine the level of WNT signalling activation in the OSE of mice in these 
cohorts, β-catenin IHC was performed and cells expressing nuclear β-catenin were counted 
(Figure 6.13-14). At 8-weeks post-induction, nuclear β-catenin was not evident in the OSE of 
wild type or Apc2-/- ovaries. However, when Apc was deleted, either alone or in combination 
with Apc2, nuclear β-catenin was present in cells of the OSE. Although the same pattern was 
found in aged mice, nuclear β-catenin levels were much reduced in OSE of Apcfl/fl ovaries, but 
remained high in double null ovaries. In multi-layering events, nuclear β-catenin was absent.  
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Figure 6.11: Proliferation is not significantly altered after combined loss of APC and APC2 
proteins in the OSE. Histogram showing the number of Ki67-positive cells in the OSE. Data 
are presented as mean±S.E. n=3-4. EP: early point. LP: late point. Apc-/-: Apcfl/fl 
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Figure 6.12: Proliferation after combined loss of APC and APC2 proteins in the OSE. 
Photomicrographs of Ki67 immunostaining in experimental cohorts (a) 8-weeks post-
induction, and (b) at 12-months of age; upper panel showing positive cells in the OSE, and 
lower panel showing absence of positive cells in multi-layering events. Black arrows: Ki67-
positive cells in the OSE. Scale bar 100 µm. Insets show OSE at 2X original magnification. 
n=3-4. EP: early point. LP: late point. Apc-/-: Apcfl/fl   
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Figure 6.13: β-catenin nuclear staining is evident only after APC loss. Histogram showing the 
number of nuclear β-catenin positive cells in the OSE. Data are presented as mean±S.E.          
EP: early point. LP: late point.  n=3-4. * denotes significance from age-matched Apc2+/+ at 
p<0.05. Apc-/-: Apcfl/fl 
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Figure 6.14: Activation of WNT signalling post-APC loss in the OSE. Photomicrographs of   
β-catenin immunostaining in experimental cohorts at (a) 8-weeks post-induction, and (b) 12-
months of age; upper panel shows positive cells in the OSE, and lower panel shows absence of 
positive cells in multi-layering events. Scale bar 100 µm. Insets show OSE at 2X original 
magnification. EP: early point. LP: late point. Apc-/-: Apcfl/fl . n=3-4.  
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It has been previously reported that E-cadherin is differentially expressed in OSE cells 
according to their morphology, being absent in squamous cells and present in cuboidal and 
columnar cells, and was linked to metaplasia preceding tumour formation (Maines-Bandiera 
and Auersperg 1997). To examine the effectof loss of APC proteins on E-cadherin expression, 
IHC was performed and the percentage of E-cadherin positive OSE was quantified (Figure 
6.15-16). No significant differences were observed between the experimental cohorts at 8-
weeks post-induction; however, levels were significantly increased in the double mutant mice 
at the late time point compared to all other groups (p<0.05). This was accompanied by stromal 
infiltration of E-cadherin positive cells (Figure 6.16). 
 
Figure 6.15.  E-cadherin staining is elevated in OSE of aged mice after combined loss of both 
APC and APC2 proteins. Histogram showing the percentage of E-cadherin positive OSE. Data 
are presented as mean±S.E. EP: early point. LP: late point. Apc-/-: Apcfl/fl. n=3-4. * denotes 
significance from all other groups at p<0.05. 
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Figure 6.16: E-cadherin immunohistochemical staining in Ad-cre induced Apcfl/fl ovaries. 
Photomicrographs of E-cadherin immunostaining in experimental cohorts (a) 8-weeks post-
induction, and (b) at 12-months of age. Staining exclusively present in the OSE, except in LP 
Apc-/-/Apc2-/-, where E-cadherin positive cells infiltrated the stroma under the OSE. Scale bar 
100 µm. Insets show OSE at 2X original magnification. EP: early point. LP: late point. Apc-/-: 
Apcfl/fl. n=3-4. 
In conclusion, deleting APC in the OSE, either alone or in combination with APC2, did 
not cause tumour development in the ovaries. 
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6.2.3. Conditional deletion of PTEN in the OSE of APC2-deficient mice is not 
enough to initiate tumourigenesis. 
It has been shown, both in growing follicles and in GCTs, that PTEN protein expression 
is elevated in APC2-deficient ovaries (Sections 4.2.6 and 5.2.5). In addition, it has been 
previously reported that combined deletion of PTEN and APC in the OSE by intrabursal 
adenovirus-cre induction, initiates OEAs with 100% penetrance as early as 6-weeks post-
induction (Wu et al. 2007). In order to test whether the same is true with APC2 deletion rather 
than APC, Apc2-/- mice were crossed with Ptenfl/fl mice, and intrabursal injection of adenovirus-
cre was used to induce recombination of the floxed Pten gene exclusively in the surface 
epithelium of ovaries in 10-week-old mice. Ovaries were collected 8 weeks later and subjected 
to histopathological and IHC analysis. An outline of experimental groups induced by 
adenovirus-cre in this experiment is shown in Table 6.3. 
Table 6.3: Experimental cohorts injected intrabursally with adenovirus-cre to characterize 
effects of combined deletion of APC2 and PTEN in the OSE. 
Genotype/ 
Time of dissection 
Ptenfl/fl  Ptenfl/fl /Apc2-/- 
Early time point  
(8-weeks post-induction) 
n=5 n=3 
Late time point 
(age of 12 months) 
n=6 n=4 
(not analysed, still alive) 
When Ptenfl/fl ovaries were induced and collected 8 weeks later, a range of OSE 
pathologies were observed in 4/5 mice (Table 6.4, Figure 6.17). Multi-layering together with 
invagination was evident in 1/5 ovary, stromal infiltration together with glandular formation 
and micro-papillary growth in 1/5 ovary, OSE shedding in 1/5, and invagination in 1/5 of 
ovaries analysed (Table 6.4, Figure 6.17). When induced Ptenfl/fl mice were left to age and 
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ovaries collected at 12-month, 5/6 showed severe disruption of the epithelium with 2/6 (33.3%) 
developing OEA, 1/6 (16.7%) developing pre-tumour lesions (serous papillary hyperplasia) 
and 1/6 (16.7%) displaying a large bursal cyst (accompanied with oviductal tumour), which 
enclosed the ovary (Table 6.4, Figure 6.17). Stromal infiltration, which ranged from slight to 
deep, was observed in all the ovaries analysed (100%). Shedding, multi-layering, micro-
papillary growth and small glands were observed in 5/6 ovaries (83.3%). Out of 3 ovaries 
examined 8-weeks post-combined loss of PTEN and APC2 in OSE, one did not show any 
pathologic alterations. Of the other 2 ovaries, one displayed shedding, and the other one 
displayed shedding in addition to multi-layering and deep invagination (Table 6.4, Figure 
6.18). Due to the subfertility of Apc2-/- mice, generating Ptenfl/fl /Apc2-/- female mice took 
longer than anticipated. This caused delays in the induction of this cohort assigned to age until 
12 months, making it unavailable for analysis at the time of writing.  
Table 6.4: OSE disruptions observed in PTEN/APC2 experimental cohorts. EP: early point, 8-
weeks post-induction. LP: late point, at 12 months of age. 
Experimental group 
/histologic feature 
Ptenfl/fl EP Ptenfl/fl/Apc2-/- EP Ptenfl/fl LP 
Total OSE disruptions 4/5 2/3 5/6 
Invagination 2/5 1/3 0/6 
Multi-layering 1/5 1/3 5/6 
Stromal infiltration 1/5 0/3 6/6 
OSE shedding 1/5 2/3 5/6 
Gland formation 1/5 0/3 5/6 
Micro-papillary growth  1/5 0/3 5/6 
Poorly  differentiated OEA 0/5 0/3 2/6 
Pre-tumour lesions 0/5 0/3 1/6 
Cyst 0/5 0/3 1/6 
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Figure 6.17: A subset of induced Ptenfl/fl ovaries display tumourigenesis upon aging. 
Photomicrographs displaying abnormalities observed in Ptenfl/fl OSE at (a) 8-weeks post-
induction (Scale bar 100 µm, n=5) and (b) 12 months of age (n=6). In (b), the upper panel 
shows an OEA, Left panel is 5X original magnification. Inset shows highly metaplastic cells 
at 10X original magnification, scale bar 100 µm. Lower left panel shows serous papillary 
hyperplasia, scale bar 100 µm, right panel shows a bursal cyst and oviductal tumour, scale bar 
1 mm. EP: early point, LP: late point. I: invagination, M: multi-layering, P: micro-papillary 
formation, PO: papillary outgrowth, S: shedding, T:tumour, G: gland, EC: epithelial cyst, PT: 
pre-tumour lesion, SI: stromal infiltration, CB: bursal cyst, OvT: oviductal tumour. 
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Figure 6.18: OSE is disrupted following combined APC2 and PTEN loss in the epithelium. 
Photomicrograph displaying a range of abnormalities observed in Ptenfl/fl /Apc2-/- OSE 8-weeks 
post-induction (Scale bar 100 µm, n=3) I: invagination, M: multi-layering, S: shedding. 
 In order to assess the level of activation of PI3K/AKT signalling post-PTEN deletion, 
IHC for p-AKT (Ser473) was performed. In the Ptenfl/fl ovaries collected 8-weeks post-
induction, p-AKT levels were variable and ranged from weak (2/3) to moderate (1/3) staining 
in the OSE without involvement of the underlying stroma (Figure 6.19). However, in the aged 
cohort, p-AKT immunostaining was high in the OSE and in the lesions previously described, 
apart from the oviductal tumour (Figure 6.19). In the Ptenfl/fl/Apc2-/- ovaries collected 8-weeks 
post-induction, p-AKT staining ranged from weak (2/3) to strong (1/3) staining in the OSE 
(Figure 6.19). 
Ki67 immunohistochemistry was used to quantify differences in OSE proliferation 
between Ptenfl/fl/Apc2-/- and Ptenfl/fl ovaries, 8-weeks post-induction, and there was a non-
significant increase in proliferation in Ptenfl/fl/Apc2-/- ovaries (Figure 6.20). When Ki67 
immunostaining was assessed in the Ptenfl/fl aged ovaries, the tumour and pre-tumour lesions 
were not highly proliferative (Figure 6.20). 
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Figure 6.19: p-AKT is differentially expressed post PTEN-loss in Apc2+/+ and Apc2-/- ovaries. 
Representative photomicrographs of p-AKT (Ser473) immunostaining in the OSE/lesions in 
(a) Ptenfl/fl ovaries 8-weeks post-induction; scale bar 100 µm; insets show OSE at 2X original 
magnification, (b) induced Ptenfl/fl ovaries aged to 12 months, scale bar 500 µm, insets show 
black squares at 5X original magnification, and (c) Ptenfl/fl /Apc2-/- ovaries 8-weeks post-
induction, scale bar 100 µm, insets show OSE at 2X original magnification EP: early point. 
LP: late point.  
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Figure 6.20: Lesions in Ptenfl/fl-aged ovaries are not highly proliferative. (a) Photomicrographs 
of Ki67 immunohistochemistry in Ptenfl/fl and Ptenfl/fl/Apc2-/- ovaries 8-weeks post-induction 
(Scale bar 100 µm, n=3). (b) Histogram of Ki67-positive cells in the OSE at early time point 
(mean±S.E).  Photomicrographs of Ki67 immunohistochemistry in (c) a pre-tumour lesion and 
(d) OEA tumours of aged Ptenfl/fl ovaries. Scale bars 200 µm. Insets 2X original magnification. 
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E-cadherin immunostaining was performed and the percentage of positively stained 
OSE quantified in Ptenfl/fl/Apc2-/- and Ptenfl/fl ovaries, at 8-weeks post-induction. Similar to 
Ki67 immunostaining, a non-significant increase of E-cadherin expression was observed in 
Ptenfl/fl/Apc2-/- (Figure 6.21). In both groups, the expression of E-cadherin was confined to the 
OSE, with no apparent stromal infiltration. However, in aged Ptenfl/fl ovaries, E-cadherin 
expression was present in the OSE as well as the pre-tumour lesions, tumours and the lining of 
the bursal cyst described previously (Figure 6.22). 
 
 
Figure 6.21: E-cadherin expression in Apc2+/+ and Apc2-/- ovaries 8-weeks after PTEN-loss. 
Photomicrographs of E-cadherin immunohistochemistry in (a) Ptenfl/fl and (b) Ptenfl/fl/Apc2-/- 
ovaries 8-weeks post-induction. Scale bar 100 µm. Insets are 2X original magnification. (c) 
Histogram of % of E-cadherin-positive OSE (mean±S.E.).  n=3. Pten-/-: Ptenfl/fl 
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Figure 6.22: E-cadherin expression in Ptenfl/fl - aged ovarian lesions. Photomicrographs of E-
cadherin IHC in (a) pre-tumour lesion (serous hyperplasia of the OSE), (b,c) OEA tumours, 
and (d) bursal cyst. Scale bars: 100 µm (a,b), 200 µm (c,d). Black arrows: areas of E-cadherin-
positivity in the lesions. Insets show higher magnification for the black arrow area (2X for a,b, 
4X for c,d). SH: serous hyperplasia. T: tumour. CB: Bursal cyst. 
In conclusion, unlike with APC (Wu et al. 2007), the combined loss of PTEN with APC2 in 
the OSE was insufficient to initiate tumour formation 8-weeks post-adenovirus-cre induction.  
6.2.4. Loss of APC2 promotes initiation of OEA 
As previously mentioned, deep deletions in APC2 sequence were detected in 5.1% 
cases in one dataset of human serous ovarian carcinoma (TCGA). In addition, copy number 
alterations (deletions) have been shown in 19/20 ovarian tumour samples analysed (Jarrett et 
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al. 2001). It has been proposed that APC2 could be a potential epithelial tumour suppressor in 
the ovary (Jarrett et al. 2001), although it is not known whether APC2 loss contributes to 
tumourigenesis or results from it. In order to shed some light on this unexplored field, tumour 
initiation was assessed in adenovirus-cre-induced Ptenfl/fl/Apcfl/fl mice, which were either wild 
type, heterozygous or homozygous for the Apc2 gene (Apc2+/+, Apc2+/- or Apc2-/- respectively). 
Ovaries were collected 15-days post-induction (n=3), and examined microscopically for the 
presence of pre-tumour lesions (tumourlets), which have previously been described at 3 weeks 
post-induction in the Ptenfl/fl/Apcfl/fl model (Wu et al. 2011). In the Apc2+/+ cohort, no tumourlets 
developed (Figure 6.23). However, in both the Apc2+/- and Apc2-/- cohorts, 2/3 ovaries (66.67%) 
developed tumourlets (mean number = 9 tumourlets in both cohorts), which were mostly 
small/medium surface/sub-surface lesions, apart from one ovary in the Apc2-/- cohort which 
developed a larger stromal tumourlet as well as regional metastasis of tumour tissue to outside 
the ovary (Figure 6.23). IHC showed high levels of expression of -catenin in these structures 
(Figure 6.23). Collectively, these results indicate that loss of APC2 accelerates tumour 
formation in the adenovirus-cre-induced Ptenfl/fl/Apcfl/fl OEA model.  
To further characterize this phenotype, IHC for Ki67, E-cadherin, and p-AKT were also 
carried out. Proliferation (Ki67 staining) was counted in OSE as well as in tumourlets when 
present, as it was very difficult to distinguish OSE in these pre-tumour lesions post-neoplastic 
transformation (Figure 6.24a,b). As a result of the high variability among data of the 3 groups, 
the increase in proliferation seen in APC2-deficient cohorts was not significant. All the 
tumourlets observed in APC2-deficient cohorts were highly proliferative (Figure 6.24a). A 
non-significant increase in E-cadherin immunostaining was observed in OSE from APC2-
deficient mice (Figure 6.24a,b). It is noteworthy that not all cells in the tumourlets were 
expressing E-cadherin (Figure 6.24a). 
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Figure 6.23: APC2 delays tumour initiation in adenovirus-cre-induced Ptenfl/fl/Apcfl/fl OEA 
model. Photomicrographs of H&E staining (left panel) and β-catenin staining (right panel) of 
ovaries dissected from the 3 experimental groups, 15-days post-induction. n=3. Black arrows 
indicate tumourlets. Scale bars 500 µm. 
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Figure 6.24a: Effect of APC2-deficiency on proliferation and epithelial differentiation in Ptenfl/fl/Apcfl/fl ovaries collected 15-days post-induction. 
Photomicrographs of Ki67 (upper panel), and E-cadherin (lower panel) in Apc2+/+ (left panel), Apc2+/- (middle panel) and Apc2-/- (right panel) Ad-
cre Ptenfl/fl/Apcfl/fl ovaries. Black arrows: tumourlets. n=3. Scale bar 100 µm. Insets show OSE/tumourlet at 2X original magnification. 
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Figure 6.24b: Quantitative analysis of proliferation and OSE epithelial differentiation in APC2-
deficient Ptenfl/fl/Apcfl/fl ovaries 15 days post-induction. Histograms of Ki67 positive cells in the 
OSE (left panel) and % of E-cadherin positive OSE (right panel). Data are shown as mean±S.E. 
n=3. Ad-cre Pten/Apc: Ad-cre Ptenfl/fl/Apcfl/fl. 
Nuclear β-catenin and p-AKT IHC were used to assess activation of WNT signalling 
and PI3K/AKT signalling, respectively, in the 3 cohorts (Figure 6.25). 1/3 (33.3%) 
ovaries/cohort did not show nuclear β-catenin immunostaining, but intense cytoplasmic 
staining was present in some parts of the OSE. In the Apc2+/+ cohort, nuclear β-catenin staining 
was variable in the 2 mice which did show positivity (40% of OSE cells in one and 100% in 
the other). In the APC2-deficient cohorts, nuclear staining was also evident in the OSE, and 
much more strongly in the tumourlets (Figure 6.25). p-AKT expression was variable in the 
OSE of all the studied cohorts, but was highly expressed in the tumourlets of APC2-deficient 
mice (Figure 6.25). 
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Figure 6.25: WNT signalling and PI3K/AKT signalling are activated in APC2-deficient OSE and tumourlets of Ptenfl/fl/Apcfl/fl ovaries 15-days 
post-induction. Photomicrographs of β-catenin (upper panel), and p-AKT (lower panel) in Apc2+/+ (left panel), Apc2+/- (middle panel) and Apc2-/- 
(right panel) cohorts. Black arrows: tumourlets. Red arrows: OSE. Scale bar 100 µm. Insets show OSE/tumourlet at 2X original magnification. 
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6.2.5. Loss of APC2 attenuates OEA growth 
In order to further define roles of APC2 in OEA, tumour burden was assessed in the 
same cohorts of mice, but ovaries were collected at a later time point of 8-weeks post-induction 
(n=3 for Apc2+/+ and Apc2-/-, n=6 for Apc2+/-). At the time of dissection, ovarian dimensions 
were measured by callipers, and used to calculate ovarian volume (Section 3.4.2). In the 
Apc2+/+ tumour cohort, dissected ovaries were significantly larger than those collected from 
either Apc2+/- or Apc2-/- cohorts (p<0.05, Figure 6.26). Although ovaries collected from      
Apc2-/- tumour cohort were smaller than those from the Apc2+/- tumour cohort, this difference 
was not statistically significant by ANOVA/LSD test (Figure 6.26).  
 
Figure 6.26: Volume of ovaries collected from Apc2+/+ (n=3), Apc2+/- (n=6) and Apc2-/- (n=3) 
Ptenfl/fl/Apcfl/fl mice at 8-weeks post-induction. Data are presented as mean±S.E. Statistical 
significance between groups was determined using ANOVA test followed by LSD test 
(variance between experimental groups was homogenous, tested by Levene’s test). * denotes 
significance from Apc2+/+ at p<0.05. Ad-cre Pten/Apc: Ad-cre Ptenfl/fl/Apcfl/fl. 
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Ovaries were examined microscopically for the presence of OEA, as previously 
described at 6-weeks post-induction in the Ptenfl/fl/Apcfl/fl model (Wu et al. 2007). OEA with 
100% penetrance was evident in both the Apc2+/+and Apc2+/- tumour cohorts. However, in the 
Apc2-/- cohort, only 2/3 (66.67%) of ovaries showed OEA formation, with 1/3 (33.33%) 
showing just pre-tumour lesions (tumourlets), similar to the ones described at 15-days post-
induction. OEA completely replaced the ovarian tissue in 2/3 (66.67%) of Apc2+/+ ovaries and 
1/6 (16.67%) of Apc2+/- ovaries, but failed to do so in any of the Apc2-/- (0/3) ovaries (Figure 
6.27a-c). Large blood cysts were evident in 2/3 (66.67%) of Apc2+/+ and 2/6 (33.33%) of 
Apc2+/-, but were absent in Apc2-/- (0/3) (Figure 6.27d). 66.67% of Apc2+/+ and Apc2+/- tumours 
were formed of many separate tumour lobules (6.27e), which were not evident in any of the 
Apc2-/- tumours. Squamous differentiation and focal keratinization were minimal in Apc+/+ 
tumours (forming 7% of the whole section), but were more evident in Apc2+/- and Apc2-/- 
tumours, forming 20% and 40% of the whole sections analysed respectively (Figures 6.27f, 
6.30b). Gland formation (frequently filled with mucin) was evident in all tumours analysed, 
apart from the Apc2-/- ovary with tumourlets. However, glands were more abundant, present in 
groups and packed closely together in Apc2+/+ tumours (Figure 6.27g). Glandular stromal 
invasion was evident in all Apc2+/+ and Apc2+/- tumours, but was only seen in 1/3 Apc2-/- 
tumours (Figure 6.27h). Cancer-associated fibroblasts were evident in all tumour cohorts, but 
were present at higher levels in the Apc2+/+ tumours, surrounding tumour lobules (Figure 
6.27i). Tumour-infiltrating immune cells were present in all Apc+/+ tumours, but were absent 
in both Apc2+/- and Apc2-/- tumours (Figure 6.27j). Large undifferentiated tumour areas, 
staining negatively for E-cadherin, were observed in 1/3 (33.33%) of Apc2+/+ tumours and 2/3 
(66.67%) of Apc2-/- tumours respectively (Figure 6.27k-l). A summary of this histologic 
characterization of tumours is outlined in table 6.5.  
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Figure 6.27: Histologic characterization of OEA formed in Apc2 experimental cohorts of 
Ptenfl/fl/Apcfl/fl ovaries 8-weeks post-induction. Representative photomicrographs of H&E 
staining showing (a) Apc2+/+ tumour replacing normal ovarian structures, (b) Apc2+/-, and (c) 
Apc2-/- tumours where ovarian structures are still present (black arrow: follicle), (d) blood cyst, 
(e) tumour lobules, (f) squamous differentiation and focal keratinization, (g) packed mucin-
filled glands (black arrow), (h) epithelial glands invading stroma (black arrow), (i) cancer-
associated fibroblasts (black arrow), and (j) immune cell infiltration (black arrow: immune 
cells). (k,l) non-epithelial differentiated tumour (black arrow: epithelial differentiation) stained 
with H&E (h) and E-cadherin antibody (i). Scale bar 100 µm. Insets show 2.5X original 
magnification.
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Table 6.5: Summary of histologic features characterized in OEA developing in ovaries of Apc2 
experimental cohorts of Ad-cre Ptenfl/fl/Apcfl/fl female mice at 8-weeks post-induction. 
Apc2 Genotype 
 /histologic feature 
Apc2+/+ Apc2+/- Apc2-/- 
Tumour penetrance 100% (3/3) 100% (6/6) 66.67 (2/3) 
Fully replace normal ovarian tissue 66.67% (2/3) 16.67% (1/6) 0% (0/3) 
Blood cysts 66.67% (2/3) 33.33% (2/6) 0% (0/3) 
Tumour lobules 66.67% (2/3) 66.67% (4/6) 0% (0/3) 
Squamous differentiation & focal 
keratinization (% tumour/tumourlet 
area) 
7% 21% 36.67% 
Gland stromal invasion 100% (3/3) 100% (6/6) 33.33% (1/3) 
Tumour-infiltrating immune cells 100% (3/3) 0% (0/6) 0% (0/3) 
Large epithelial-undifferentiated 
areas 
33.33% (1/3) 0% (0/6) 66.67% (2/3) 
 
Unlike the early time point (15-days post-induction), when APC2 presence delayed 
tumour formation in adenovirus-cre induced Ptenfl/fl/Apcfl/fl ovaries, the presence of APC2 
promoted tumour growth in ovaries collected 8-weeks post-induction. This difference may be 
caused by a disruption in the balance between proliferation and apoptosis. In order to 
investigate these mechanisms, immunohistochemistry for Ki67 and cleaved caspase 3 were 
performed. Quantification in 3 different tumour areas/ovary (whenever possible) revealed no 
significant differences in proliferation or apoptosis between the 3 cohorts (Figure 6.28). It was 
observed that cleaved caspase 3 was higher in larger tumours compared to smaller ones, 
irrespective of genotype. 
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Figure 6.28: Proliferation and apoptosis are not significantly-changed in APC2-deficient 
tumours of Ad-cre Ptenfl/fl/Apcfl/fl ovaries 8-weeks post-induction. Histograms showing the 
number of positively-stained cells for (a) Ki67, and (b) cleaved caspase 3 in tumour cohorts. 
n=3 for Apc2+/+ and Apc2-/- groups. n=5 for Apc2+/- group. Data are presented as mean±S.E. 
(c) Representative photomicrographs of Ki67 (upper panel), and cleaved caspase3 (lower 
panel) in experimental cohorts. Black arrow: positively-stained cells. Scale bar 100 µm. 
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Upon histologic examination of tumours, the presence of blood-filled cysts was 
observed only in the Apc2+/+ and Apc2+/- cohorts. As shown previously, Apc2+/+ tumours 
developed the largest tumours in all experimental cohorts, which was not caused by increased 
proliferation or decreased apoptosis. However, it might be caused by increased new blood 
vessels formation (angiogenesis), providing the tumour with nutrients and oxygen required for 
tumour growth (Nishida et al. 2006). In order to investigate whether this was the mechanism 
causing enhanced tumour growth in Apc2+/+ cohort, CD34 immunostaining was performed. 
Analysis of the CD34 immunostaining revealed enhanced vascularity in all tumours and 
tumourlets, which was comparable among all experimental cohorts (Figure 6.29). 
 
Figure 6.29: Representative photomicrographs of CD34 immunohistochemical staining 
performed on sections from different Apc2 experimental cohorts of Ad-cre Ptenfl/fl/Apcfl/fl 
ovaries 8-weeks post-induction. Scale bar 100 µm. 
It was observed that tumours developing in Apc2+/+ Ad-cre Ptenfl/fl/Apcfl/fl more 
frequently form epithelial glands, which were more packed together and invading the stroma, 
compared to the other cohorts. In order to investigate whether APC2 presence enhances 
epithelial differentiation, E-cadherin immunostaining was performed and the percentage of 
area staining positively for E-cadherin was calculated. The analysis revealed that Apc2+/+ 
tumours were expressing significantly higher levels of E-cadherin compared to Apc2-/- tumours 
(Figure 6.30), as larger areas of the Apc2-/- tumours had keratinized areas with minimal 
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squamous differentiation (Figure 6.30). Epithelial differentiation was slightly lower in Apc2+/- 
tumours compared to Apc2+/+ tumours, but not significantly (Figure 6.30). 
Simultaneous activation of WNT signalling and PI3K/AKT signalling pathways drives 
OEA development in adenovirus-cre-induced Ptenfl/fl/Apcfl/fl ovaries (Wu et al. 2007). Whether 
APC2 loss altered the level of activation of these pathways, thus impacting on tumour 
progression in the Apc2-/- tumour cohort, was evaluated by IHC for β-catenin and p-AKT, the 
main effectors of WNT and PI3K signalling pathways, respectively. All tumours, irrespective 
of genotype, showed intense staining for β-catenin, which was mostly cytoplasmic but 
frequently nuclear (Figure 6.31). p-AKT staining was focal, ranging from membranous to 
cytoplasmic, and was comparable across tumours of all cohorts (Figure 6.31). 
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Figure 6.30: APC2 presence enhances epithelial differentiation of OEA developing in Ad-cre 
Ptenfl/fl/Apcfl/fl ovaries at 8-weeks post-induction. Histogram showing % tumour area (a) 
positively-staining for E-cadherin, and (b) keratinized with squamous differentiation. n=3 for 
Apc2+/+ and Apc2-/- groups. n=6 for Apc2+/- group. Data are presented as mean±S.E. 
Representative photomicrographs of (c) E-cadherin immunostaining, and (d) areas of focal 
keratinization/squamous differentiation in experimental cohorts. Scale bar 100 µm. Insets show 
tumour areas at 4X original magnification. 
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Figure 6.31: WNT signalling and PI3K signalling pathways are activated in OEA formed in 
Ad-cre Ptenfl/fl/Apcfl/fl ovaries at 8-weeks post-induction irrespective of Apc2 genotype. 
Representative photomicrographs of IHC for (a) β-catenin, and (b) p-AKT (ser473) in different 
tumour cohorts. n=3 for Apc2+/+ and Apc2-/- groups, n=4 for Apc2+/- group. Scale bar 100 µm. 
Insets show tumour at 4X original magnification. 
6.2.6. Transcriptome analysis of Apc2+/+ and Apc2-/- Ad-cre Ptenfl/fl/Apcfl/fl ovaries 
In order to explore in more depth how APC2 loss acts as a suppressor of OEA tumour 
progression, RNA sequencing was performed on RNA extracted from ovaries collected at 8-
weeks post-induction from Ptenfl/fl/Apcfl/fl/Apc2+/+ and Ptenfl/fl/Apcfl/fl/Apc2-/- mice (3 
mice/cohort). From 35,156 transcripts analysed, 289 with false discovery rate (FDR) <0.05 
were differentially-expressed in Apc2+/+ tumours, as compared to Apc2-/- tumours (Table 6.6). 
36 were significantly upregulated in Apc2+/+ tumours (Table 6.7), while 253 were significantly 
downregulated in Apc2+/+ tumours (and therefor upregulated in Apc2-/- tumours) (Table 6.8). 
It is of note that many of the Apc2+/+ downregulated (Apc2-/- upregulated) transcripts are 
involved in normal ovarian functions, which might be due to the presence of more normal 
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ovarian tissue in Apc2-/- tumours compared to the large tumours in Apc+/+ ovaries, which 
replace most or all of the normal tissue. Protein-protein interactions between the most 
differentially regulated genes (FDR<0.05) in Apc2+/+ vs. Apc2-/- Ad-cre Ptenfl/fl/Apcfl/fl tumours 
were analysed using the STRING v.10.5 online tool (Szklarczyk et al. 2017). Only known 
interactions extracted from curated experiments or databases were used to analyse the data. 
Few interactions were found in the Apc+/+ upregulated gene list, with only one important hub 
identified (LRGUK, Figure 6.32a). Proteins identified from the Apc2+/+ downregulated    
(Apc2-/- upregulated) gene list, however, were more closely connected, with many hubs 
identified (Figure 6.32b). The largest hubs were ESR2, BMPR1b, TRIB2, CCNO, ASZ1 and 
FBXW family, with most of them being known as regulators of normal ovarian functions. A 
network showing all interactive proteins was prepared using Cytoscape v.3.4.0. Software 
(Lopes et al. 2010)(Figure 6.32c). This revealed the additional presence of interactions between 
Apc2+/+ upregulated and downregulated proteins, with new hubs identified (e.g. Hunk). 
Table 6.6: Global differential expression analysis of Ad-cre Ptenfl/fl/Apcfl/fl/Apc2+/+ (n=3) vs. 
Ptenfl/fl/Apcfl/fl/Apc2-/- (n=3) ovaries 8-weeks post-induction   
Global differential expression analysis 
Total 
number of 
transcripts 
Significantly 
differentially 
expressed transcripts 
(FDR <0.05) 
Significantly 
downregulated 
transcripts in Apc2+/+ 
vs. Apc2-/- 
(FDR <0.05) 
Significantly upregulated 
transcripts 
in Apc2+/+ vs. Apc2-/- 
(FDR <0.05) 
 
35 156 
Number Percentage Number Percentage Number Percentage 
289  0.82% 253  0.72% 36 0.102% 
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Table 6.7: List of upregulated gene transcripts in Apc2+/+ (n=3) vs. Apc2-/- (n=3) Ad-cre 
Ptenfl/fl/Apcfl/fl ovaries 8-weeks post-induction 
Gene ID Target gene Log2 fold 
change 
Apc2+/+ 
ovaries vs. 
Apc2-/- 
ovaries 
 
Fold 
change  
Apc2
+/+
 
ovaries 
vs. Apc2
-/-
 
ovaries 
P-value FDR
 
 
NM_010401 Histidine ammonia lyase 
(Hal) 
3.69 12.86 7.27E-23 1.99E-18 
NM_007969 WAP four-disulfide core 
domain 18 (Wfdc18) 
2.19 4.58 3.24E-07 2.79E-04 
NM_010743, 
NM_001294171 
Interleukin 1 receptor-
like 1 (Il1rl1) 
1.84 3.58 1.55E-05 3.8E-03 
NM_009160 Surfactant associated 
protein D (Sftpd) 
1.83 3.57 2.02E-05 4.4E-03 
NM_178924 Uroplakin 1B (Upk1b) 1.81 3.5 6.81E-07 4.3E-04 
NM_026323 WAP four-disulfide core 
domain 2 (Wfdc2) 
1.78 3.43 1.69E-06 8.5E-04 
NM_021382 Tachykinin receptor 3 
(Tacr3) 
1.78 3.43 1.25E-06 6.58E-04 
NM_009474 Urate oxidase (Uox) 1.76 3.38 4.27E-05 8.1E-03 
NM_021443 Chemokine (C-C motif) 
ligand 8 (Ccl8) 
1.73 3.32 5.88E-05 9.94E-03 
NM_001112702, 
NM_021467 
Troponin I, skeletal, slow 
1 (Tnni1) 
1.68 3.22 5.58E-05 9.8E-03 
NM_009778 Complement component 
3 (C3) 
1.67 3.21 5.95E-05 9.94E-03 
NM_008522 Lactotransferrin (Ltf) 1.62 3.18 1.85E-04 2.3E-02 
NR_073011 Spermatogenesis 
associated glutamate (E)-
rich protein pseudogene 
(4930572O03Rik) 
1.58 3.07 1.41E-04 1.91E-02 
NM_001308501, 
NM_010340 
G-protein-coupled 
receptor 50 (Gpr50) 
1.56 
 
2.95 3.25E-04 3.5E-02 
NR_028262 Rhabdomyosarcoma 2 
associated transcript 
(non-coding RNA)(Rmst) 
1.56 2.94 2.47E-04 2.8E-02 
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Table 6.8: List of downregulated gene transcripts in Apc2+/+ (n=3) vs. Apc2-/- (n=3) Ad-cre 
Ptenfl/fl/Apcfl/fl ovaries 8-weeks post-induction. 
 
Gene ID 
 
Target gene 
Log2 
fold 
change 
Apc2
+/+
 
ovaries 
vs.  
Apc2
-/-
 
ovaries 
Fold 
change  
Apc2
+/+
 
ovaries 
vs.  
Apc2
-/-
 
ovaries 
 
P-value 
 
FDR
 
 
NM_001005371 Predicted gene 13084 
(Gm13084) 
-2.41 0.188 1.66E-08 3.76E-05 
NM_001165965, 
NM_177091 
Fibronectin type III 
domain containing 7 
(Fndc7) 
1.54 2.92 2.67E-04 3.02E-02 
NM_001109751, 
NM_173004, 
NM_001109749 
Contactin 4 (Cntn4) 1.54 2.89 4.01E-04 4.11E-02 
NM_001002898 Signal-regulatory protein 
beta 1A (Sirpb1a) 
1.49 2.81 5.14E-04 4.7E-02 
NM_001167828, 
NM_199146 
Tripartite motif-
containing 30D 
(Trim30d) 
1.46 2.74 1.19E-08 2.96E-05 
NM_018857 Mesothelin (Msln) 1.45 2.68 4.67E-05 8.6E-03 
NM_001271809, 
NR_073451, 
NR_073452, 
NM_001271810 
Protocadherin 11 X-
linked (Pcdh11x) 
1.38 2.6 2.23E-04 2.6E-02 
NM_001081957 WAP four-disulfide core 
domain 17 (Wfdc17) 
1.25 2.38 2.21E-06 9.5E-04 
NM_028886 Leucine-rich repeats and 
guanylate kinase domain 
containing (Lrguk) 
1.22 2.33 4.2E-04 4.2E-02 
NM_010197 Fibroblast growth factor 
1 (Fgf1) 
1.21 2.32 1.5E-04 1.96E-02 
NR_002897 Small nucleolar RNA, 
H/ACA box 64 
(Snora64) 
1.2 2.3 1.16E-04 1.6E-02 
NM_015755 Hormonally upregulated 
Neu-associated kinase 
(Hunk) 
0.914 1.88 2.34E-04 2.71E-02 
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NM_145708 Oocyte specific homeobox 2 
(Obox2) 
-2.38 0.193 3.09E-09 1.06E-05 
NM_010564 Inhibin alpha (Inha) -2.32 0.200 6.82E-09 1.87E-05 
NM_175290 NLR family, pyrin domain 
containing 14 (Nlrp14) 
-2.32 0.201 4.15E-08 6.29E-05 
NM_172479 Solute carrier family 38, 
member 5 (Slc38a5) 
-2.31 0.201 3.05E-09 1.06E-05 
NM_172953 Serine (or cysteine) peptidase 
inhibitor, clade A, member 5 
(Serpina5) 
-2.30 0.203 1.15E-09 5.24E-06 
NM_001033214 RIKEN cDNA E330034G19 
gene (E330034G19Rik) 
-2.29 0.205 1.78E-08 3.76E-05 
NM_019977 Myo-inositol oxygenase (Miox) -2.27 0.207 3.00E-08 5.47E-05 
NM_001243837 Complement component 7 (C7) -2.23 0.213 1.11E-11 7.60E-08 
NR_121593, 
NR_121595, 
NR_121596, 
NR_121594 
Predicted gene 1965 (Gm1965) -2.18 0.221 4.34E-07 3.20E-04 
NR_131241, 
NM_001039143, 
NR_131242, 
NM_001305857, 
NM_011860 
NLR family, pyrin domain 
containing 5 (Nlrp5) 
-2.18 0.221 4.07E-08 6.29E-05 
NM_001014395 F-box and WD-40 domain 
protein 22 (Fbxw22) 
-2.17 0.222 5.10E-07 3.41E-04 
NM_153106 Peptidyl arginine deaminase, 
type VI (Padi6) 
-2.17 0.223 1.81E-07 1.91E-04 
NR_015609 Expressed sequence C86187 
(C86187) 
-2.16 0.223 4.74E-07 3.25E-04 
NM_001166065 Glucosaminyl (N-acetyl) 
transferase 4, core 2 (beta-1,6-
N-
acetylglucosaminyltransferase) 
(Gcnt4) 
-2.12 0.230 1.58E-07 1.81E-04 
NM_010933 Natriuretic peptide type C 
(Nppc) 
-2.12 0.230 6.67E-07 4.34E-04 
NM_138311 H1 histone family, member O, 
oocyte-specific (H1foo) 
-2.12 0.231 4.17E-07 3.20E-04 
NM_001201390 RIKEN cDNA E330021D16 
gene (E330021D16Rik) 
-2.12 0.231 3.65E-07 3.03E-04 
NM_001270792 Predicted gene 2042 (Gm2042) -2.11 0.232 1.76E-07 1.91E-04 
NM_178657 Oogenesin 1 (Oog1) -2.08 0.236 1.95E-07 1.91E-04 
NM_001122678, 
NM_001167793_3 
Predicted gene 3286 (Gm3286) -2.08 0.236 8.84E-07 5.14E-04 
NM_001122668 RIKEN cDNA E330014E10 
gene (E330014E10Rik) 
-2.07 0.239 1.17E-06 6.39E-04 
NM_011776 Zona pellucida glycoprotein 3 
(Zp3) 
-2.07 0.239 1.30E-06 6.72E-04 
NM_001122678, 
NM_001167793, 
NM_001167792 
Predicted gene 3286 (Gm3286) -2.06 0.239 1.42E-06 6.84E-04 
NM_177069 F-box and WD-40 domain 
protein 21 (Fbxw21) 
-2.06 0.239 1.63E-06 7.34E-04 
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NM_001105254 Predicted gene 10436 
(Gm10436) 
-2.06 0.240 3.05E-07 2.79E-04 
NM_001164523, 
NM_001111286 
Oocyte maturation, alpha 
(Omt2a) 
-2.03 0.244 2.60E-06 1.08E-03 
NM_027802 Oocyte specific homeobox 1 
(Obox1) 
-2.03 0.244 1.06E-06 5.94E-04 
NM_008181 Glutathione S-transferase, alpha 
1 (Ya)(Gsta1) 
-2.02 0.247 2.69E-06 1.10E-03 
NM_201258 Oogenesin 3 (Oog3) -2.01 0.248 1.62E-06 7.34E-04 
NM_001002894 NLR family, pyrin domain 
containing 14 (Nlrp14) 
-2.01 0.248 8.53E-07 5.14E-04 
NM_001309485, 
NM_001289468, 
NM_001309484, 
NR_110339, 
NM_009337 
T cell lymphoma breakpoint 1 
(Tcl1) 
-2.01 0.249 2.88E-06 1.15E-03 
NM_177070 F-box and WD-40 domain 
protein 16 (Fbxw16) 
-2.00 0.249 3.47E-06 1.26E-03 
NM_001113187 KH domain containing 1B 
(Khdc1b) 
-1.99 0.252 1.40E-06 6.84E-04 
NM_019493 B cell translocation gene 4 
(Btg4) 
-1.99 0.252 1.53E-06 7.11E-04 
NM_008458 Serine (or cysteine) peptidase 
inhibitor, clade A, member 3C 
(Serpina3c) 
-1.97 0.256 4.88E-09 1.49E-05 
NM_001098799 TOX high mobility group box 
family member 2 (Tox2) 
-1.96 0.257 6.37E-06 1.92E-03 
NM_008032 AF4/FMR2 family, member 2 
(Aff2) 
-1.96 0.258 9.01E-07 5.14E-04 
NM_008182 Glutathione S-transferase, alpha 
2 (Yc2) (Gsta2) 
-1.94 0.260 6.59E-06 1.96E-03 
NM_172896, 
NM_175290 
NLR family, pyrin domain 
containing 4A (Nlrp4a) 
-1.94 0.261 6.33E-06 1.92E-03 
NR_003564 Transcription elongation factor 
B (SIII), polypeptide 2 
pseudogene (Gm15698) 
-1.93 0.262 6.07E-06 1.91E-03 
NM_007996, 
NM_001301728 
Ferredoxin 1 (Fdx1) -1.92 0.265 1.21E-06 6.51E-04 
NM_010701 Leukocyte cell derived 
chemotaxin 1 (Lect1) 
-1.92 0.265 4.47E-06 1.53E-03 
NM_145947 Solute carrier family 26, 
member 7 (Slc26a7) 
-1.91 0.267 1.51E-06 7.11E-04 
NM_001033404 Predicted gene 813 (Gm813) -1.90 0.268 1.13E-05 2.99E-03 
NM_172925 Kelch-like 31 (Klhl31) -1.90 0.268 1.13E-05 2.99E-03 
NM_009580 Zona pellucida glycoprotein 1 
(Zp1) 
-1.89 0.269 8.37E-06 2.39E-03 
NM_013479 Bcl2-like 10 (Bcl2l10) -1.88 0.271 1.01E-05 2.76E-03 
NM_010720 Lipase, endothelial (Lipg) -1.87 0.274 5.73E-06 1.84E-03 
NM_130869 NOBOX oogenesis homeobox 
(Nobox) 
-1.86 0.275 1.33E-05 3.44E-03 
NM_145210 2'-5' oligoadenylate synthetase 
1E (Oas1e) 
-1.86 0.275 1.54E-05 3.80E-03 
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NM_001033269, 
NM_001039683, 
NR_104407, 
NM_001286180, 
NM_001286178, 
NM_001286179 
Eukaryotic translation initiation 
factor 4E family member 1B 
(Eif4e1b) 
-1.86 0.276 1.80E-05 4.15E-03 
NM_172673 FERM domain containing 5 
(Frmd5) 
-1.85 0.278 3.08E-06 1.17E-03 
NM_175011 RIKEN cDNA E330017A01 
gene (E330017A01Rik) 
-1.84 0.280 2.21E-05 4.76E-03 
NM_027664 Ribosomal modification protein 
rimK-like family member B 
(Rimklb) 
-1.84 0.280 4.52E-06 1.53E-03 
NM_013523 Follicle stimulating hormone 
receptor (Fshr) 
-1.83 0.282 2.47E-05 5.24E-03 
NM_019779 Cytochrome P450, family 11, 
subfamily a, polypeptide 1 
(Cyp11a1) 
-1.83 0.282 1.71E-05 4.01E-03 
NM_027582 Aldo-keto reductase family 1, 
member C-like (Akr1cl) 
-1.83 0.282 3.40E-06 1.26E-03 
NM_011077 Phosphate regulating 
endopeptidase homolog, X-
linked (Phex) 
-1.82 0.283 2.79E-08 5.46E-05 
NM_011169, 
NM_001253782, 
NM_001253781 
Prolactin receptor (Prlr) -1.82 0.283 3.53E-06 1.26E-03 
NM_133893 2'-5' oligoadenylate synthetase 
1D (Oas1d) 
-1.81 0.285 2.22E-05 4.76E-03 
NM_133353 Oocyte secreted protein 1 
(Oosp1) 
-1.79 0.289 1.54E-05 3.80E-03 
NM_146879 Olfactory receptor 330 
(Olfr330) 
-1.79 0.290 3.18E-05 6.45E-03 
NM_007468 Apolipoprotein A-IV( Apoa4) -1.78 0.291 1.02E-05 2.76E-03 
NM_001199218, 
NM_023805, 
NM_001199217 
Solute carrier family 38, 
member 3 (Slc38a3) 
-1.78 0.292 1.68E-05 4.01E-03 
NM_177571 Predicted gene 13103 
(Gm13103) 
-1.78 0.292 4.06E-05 7.90E-03 
NM_001042612 NLR family, pyrin domain 
containing 9C (Nlrp9c) 
-1.77 0.292 4.24E-05 8.13E-03 
NM_001267625, 
NM_058212, 
NM_001267626 
D4, zinc and double PH.D. 
fingers, family 3 (Dpf3) 
-1.77 0.293 1.99E-05 4.39E-03 
NM_009757 Bone morphogenetic protein 15 
(Bmp15) 
-1.77 0.294 6.34E-06 1.92E-03 
NM_015793 F-box and WD-40 domain 
protein 14 (Fbxw14) 
-1.75 0.297 5.29E-05 9.47E-03 
NM_198661 Oogenesin 2 (Oog2) -1.75 0.298 5.65E-05 9.80E-03 
NM_207707, 
NR_104386, 
NM_010157 
Estrogen receptor 2 (beta) 
(Esr2) 
-1.74 0.299 6.31E-06 1.92E-03 
NM_001122660 Predicted gene 10639 
(Gm10639) 
-1.74 0.299 5.78E-05 9.87E-03 
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NM_153110, 
NM_001177551 
Tripartite motif-containing 61 
(Trim61) 
-1.73 0.301 3.41E-05 6.82E-03 
NM_153529 Neuritin 1 (Nrn1) -1.73 0.301 1.69E-05 4.01E-03 
NM_001159627, 
NM_001159628, 
NM_010417, 
NM_181273 
Hephaestin (Heph) -1.73 0.301 1.26E-07 1.51E-04 
NM_173773 Oogenesin 4 (Oog4) -1.73 0.302 6.87E-05 1.09E-02 
NM_001007077 Predicted gene 13023 
(Gm13023) 
-1.72 0.303 6.05E-05 9.99E-03 
NM_001004145 NLR family, pyrin domain 
containing 4G (Nlrp4g) 
-1.72 0.303 7.05E-05 1.12E-02 
NM_011775 Zona pellucida glycoprotein 2 
(Zp2) 
-1.70 0.307 1.93E-05 4.29E-03 
NM_001271798, 
NM_001271800, 
NM_001081377, 
NM_001081377 
Protocadherin 9 (Pcdh9) -1.69 0.309 8.00E-06 2.33E-03 
NM_027741, 
NM_001305882 
Maestro (Mro) -1.69 0.311 9.70E-06 2.71E-03 
NM_199036 F-box and WD-40 domain 
protein 15 (Fbxw15) 
-1.68 0.312 1.02E-04 1.46E-02 
NM_001177542 Expressed sequence C87977 
(C87977) 
-1.68 0.312 9.69E-05 1.41E-02 
NM_031387, 
NM_001002241, 
NM_001002238, 
NM_001002240 
Tudor domain containing 1 
(Tdrd1) 
-1.68 0.312 8.98E-05 1.34E-02 
NM_029948 PRAME family member 12 
(Pramef12) 
-1.68 0.313 9.39E-05 1.38E-02 
NM_194058 NLR family, pyrin domain 
containing 9B (Nlrp9b) 
-1.66 0.316 1.26E-04 1.75E-02 
NM_001267625, 
NM_058212, 
NM_001267626 
D4, zinc and double PH.D. 
fingers, family 3 (Dpf3) 
-1.66 0.317 5.62E-05 9.80E-03 
NM_001143683 Metallophosphoesterase domain 
containing 2 (Mpped2) 
-1.66 0.317 1.33E-04 1.82E-02 
NM_001164284 Expressed sequence C87414 
(C87414) 
-1.65 0.319 1.30E-04 1.79E-02 
NM_001177419, 
NM_001177420 
F-box and WD-40 domain 
protein 28 (Fbxw28) 
-1.65 0.320 1.48E-04 1.97E-02 
NM_001008428 F-box and WD-40 domain 
protein 20 (Fbxw20) 
-1.64 0.322 1.60E-04 2.06E-02 
NM_053171 CUB and Sushi multiple 
domains 1 (Csmd1) 
-1.63 0.323 1.42E-06 6.84E-04 
NM_001166433, 
NM_001033211 
expressed sequence 
AU022751(AU022751) 
-1.62 0.324 1.79E-04 2.25E-02 
NM_177598 F-box and WD-40 domain 
protein 13 (Fbxw13) 
-1.62 0.325 1.58E-04 2.06E-02 
NM_027022 CKLF-like MARVEL 
transmembrane domain 
containing 2A (Cmtm2a) 
-1.62 0.325 1.41E-04 1.91E-02 
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NM_001277218, 
NM_001277216, 
NM_001277220, 
NM_007560 
Bone morphogenetic protein 
receptor, type 1B (Bmpr1b) 
-1.61 0.327 4.69E-05 8.62E-03 
NM_053242, 
NM_001286607, 
NM_212435 
Forkhead box P2 (Foxp2) -1.61 0.327 1.45E-05 3.70E-03 
NM_145981 Phytanoyl-CoA hydroxylase 
interacting protein (Phyhip) 
-1.61 0.327 1.86E-04 2.31E-02 
NM_026436 Transmembrane protein 86A 
(Tmem86a) 
-1.61 0.328 1.73E-05 4.03E-03 
NR_015524 Centrosomal protein 83, 
opposite strand (Cep83os) 
-1.61 0.328 5.01E-06 1.67E-03 
NM_139218 Developmental pluripotency-
associated 3 (Dppa3) 
-1.61 0.329 1.51E-04 2.00E-02 
NM_153409, 
NM_001290665, 
NM_178634, 
NM_178634 
Cysteine-serine-rich nuclear 
protein 3 (Csrnp3) 
-1.60 0.329 5.54E-05 9.80E-03 
NM_026480 Oocyte expressed protein 
(Ooep) 
-1.60 0.331 9.82E-05 1.42E-02 
NM_201370 WEE1 homolog 2 (S. pombe) 
(Wee2) 
-1.59 0.331 1.66E-04 2.13E-02 
NR_027385, 
NM_198663 
Expressed sequence C87499 
(C87499) 
-1.59 0.333 2.35E-04 2.71E-02 
NM_009692 Apolipoprotein A-I (Apoa1) -1.59 0.333 8.52E-05 1.29E-02 
NM_001271704, 
NM_181317 
K+ voltage-gated channel, 
subfamily S, 2 (Kcns2) 
-1.58 0.334 1.67E-04 2.13E-02 
NR_037571 Predicted gene 7056 (Gm7056) -1.58 0.334 2.54E-04 2.89E-02 
NM_029837 Metallophosphoesterase domain 
containing 2 (Mpped2) 
-1.58 0.334 1.49E-04 1.98E-02 
NM_001033794 F-box and WD-40 domain 
protein 18 (Fbxw18) 
-1.58 0.335 2.35E-04 2.71E-02 
NM_008807, 
NM_001290998, 
NM_001290996, 
NM_001290999, 
NM_001045555 
Tubby-like protein 2 (Tulp2) -1.58 0.336 4.15E-05 8.00E-03 
NM_011824 Gremlin 1, DAN family BMP 
antagonist (Grem1) 
-1.57 0.337 1.89E-05 4.28E-03 
NR_033577 Apolipoprotein L 7c 
pseudogene (Gm8221) 
-1.57 0.338 3.07E-04 3.35E-02 
NM_001167938, 
NM_001167937 
DNA segment, Chr 6, ERATO 
Doi 527, expressed 
(D6Ertd527e) 
-1.55 0.342 3.37E-04 3.59E-02 
NM_029416 Kruppel-like factor 17 (Klf17) -1.55 0.342 2.15E-04 2.57E-02 
NM_001168589 Vertebrae development 
associated (Vrtn) 
-1.54 0.343 3.75E-04 3.95E-02 
NM_172815 R-spondin 2 (Rspo2) -1.54 0.344 3.84E-04 4.00E-02 
NM_007445 Anti-Mullerian hormone (Amh) -1.54 0.344 3.80E-04 3.99E-02 
NM_145144 Allograft inflammatory factor 
1-like (Aif1l) 
-1.54 0.344 2.75E-04 3.08E-02 
NM_001081062 Cyclin O (Ccno) -1.54 0.345 3.93E-04 4.08E-02 
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NM_144551 Tribbles pseudokinase 2 (Trib2) -1.54 0.345 4.29E-06 1.49E-03 
NM_026763 Collagen, type VI, alpha 4 
(Col6a4) 
-1.52 0.348 9.62E-05 1.41E-02 
NM_001164284 Expressed sequence C87414 
(C87414) 
-1.52 0.348 4.09E-04 4.16E-02 
NM_007762 Corticotropin releasing 
hormone receptor 1 (Crhr1) 
-1.52 0.348 4.30E-04 4.22E-02 
NM_053123, 
NM_001290708 
SWI/SNF related, matrix 
associated, actin dependent 
regulator of chromatin, 
subfamily a, member 1 
(Smarca1) 
-1.52 0.349 7.40E-05 1.16E-02 
NM_010934 Neuropeptide Y receptor Y1 
(Npy1r) 
-1.52 0.350 1.14E-04 1.62E-02 
NM_011158 Protein kinase, cAMP 
dependent regulatory, type II 
beta (Prkar2b) 
-1.51 0.351 1.67E-04 2.13E-02 
NM_015764, 
NM_001252071 
Gene regulated by estrogen in 
breast cancer protein (Greb1) 
-1.51 0.352 1.15E-04 1.62E-02 
NM_010582 Inter-alpha trypsin inhibitor, 
heavy chain 2 (Itih2) 
-1.50 0.354 5.08E-04 4.70E-02 
NR_044992 Predicted gene 6367 (Gm6367) -1.50 0.354 4.13E-04 4.16E-02 
NM_001013774 Karyopherin alpha 7 (importin 
alpha 8) (Kpna7) 
-1.50 0.354 4.92E-04 4.65E-02 
NR_040604 RIKEN cDNA 4930590L20 
gene (4930590L20Rik) 
-1.48 0.359 3.19E-04 3.47E-02 
NM_023729 Ankyrin repeat, SAM and basic 
leucine zipper domain 
containing 1 (Asz1) 
-1.47 0.361 5.25E-04 4.81E-02 
NM_001195048, 
NM_001195046, 
NM_001195049, 
NM_001195047, 
NM_008778 
p21 protein (Cdc42/Rac)-
activated kinase 3 (Pak3) 
-1.46 0.364 4.16E-04 4.16E-02 
NM_001113399, 
NM_001113400, 
NM_178723 
Zinc finger protein 385B 
(Zfp385b) 
-1.45 0.365 2.41E-04 2.76E-02 
NM_001080781 RIKEN cDNA 1700029H14 
gene (1700029H14Rik) 
-1.45 0.367 5.30E-04 4.83E-02 
NM_178678 Leucine rich repeat 
transmembrane neuronal 3 
(Lrrtm3) 
-1.44 0.369 4.22E-04 4.16E-02 
NM_001033220 Expressed sequence AU021092 
(AU021092) 
-1.42 0.373 2.14E-04 2.57E-02 
NM_007741 Collagen, type IX, alpha 2 
(Col9a2) 
-1.42 0.374 2.78E-04 3.10E-02 
NM_001083628 Growth regulation by estrogen 
in breast cancer-like (Greb1l) 
-1.42 0.375 2.37E-06 1.00E-03 
NR_038184, 
NR_038185 
RIKEN cDNA C430049B03 
gene (C430049B03Rik) 
-1.41 0.375 2.23E-04 2.63E-02 
NM_011485 Steroidogenic acute regulatory 
protein (Star) 
-1.41 0.376 2.07E-04 2.51E-02 
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NM_001146045, 
NM_001100458 
Family with sequence similarity 
169, member A (Fam169a) 
-1.38 0.384 9.85E-05 1.42E-02 
NM_134072 Aldo-keto reductase family 1, 
member C14 (Akr1c14) 
-1.38 0.385 4.05E-04 4.14E-02 
NM_011825 Gremlin 2, DAN family BMP 
antagonist (Grem2) 
-1.38 0.385 2.98E-04 3.29E-02 
NM_011516 Synaptonemal complex protein 
1 (Sycp1) 
-1.36 0.391 7.18E-11 3.94E-07 
NM_001285841 Syntabulin (syntaxin-
interacting) (Sybu) 
-1.35 0.394 3.30E-04 3.56E-02 
NM_001005510 Spectrin repeat containing, 
nuclear envelope 2 (Syne2) 
-1.32 0.402 1.27E-04 1.75E-02 
NM_153574 Family with sequence similarity 
13, member A (Fam13a) 
-1.31 0.402 4.47E-04 4.33E-02 
NM_026247, 
NR_037145 
Asparagine-linked 
glycosylation 13 (Alg13) 
-1.26 0.418 1.79E-12 2.46E-08 
NM_008149 Glycerol-3-phosphate 
acyltransferase, mitochondrial 
(Gpam) 
-1.26 0.419 5.27E-04 4.81E-02 
NM_001277730, 
NM_001134741 
Tudor domain containing 5 
(Tdrd5) 
-1.24 0.423 2.76E-04 3.08E-02 
NM_207663, 
NM_183312, 
NM_201639 
Synemin, intermediate filament 
protein (Synm) 
-1.24 0.423 3.32E-04 3.57E-02 
NM_175526 C-type lectin domain family 1, 
member a (Clec1a) 
-1.19 0.438 3.53E-04 3.74E-02 
NM_019699 Fatty acid desaturase 2 (Fads2) -1.18 0.441 3.84E-04 4.00E-02 
NM_010295 Glutamate-cysteine ligase, 
catalytic subunit (Gclc) 
-1.14 0.455 4.86E-04 4.62E-02 
NM_008256 3-hydroxy-3-methylglutaryl-
Coenzyme A synthase 2 
(Hmgcs2) 
-1.12 0.460 4.40E-04 4.29E-02 
NM_001291184 Proprotein convertase 
subtilisin/kexin type 6 (Pcsk6) 
-1.10 0.468 5.13E-04 4.72E-02 
NR_073123, 
NM_172960 
AarF domain containing kinase 
5 (Adck5) 
-1.09 0.470 7.55E-05 1.18E-02 
NM_001286062, 
NM_009640 
Angiopoietin 1 (Angpt1) -1.07 0.477 5.07E-04 4.70E-02 
NM_012026 Rho guanine nucleotide 
exchange factor (GEF) 28 
(Arhgef28) 
-1.06 0.481 3.07E-05 6.28E-03 
NM_177595 Mohawk homeobox (Mkx) -1.05 0.483 4.87E-04 4.62E-02 
NM_001252489, 
NM_001252490, 
NR_045524, 
NM_207530 
Oxysterol binding protein-like 
1A (Osbpl1a) 
-1.03 0.489 3.98E-04 4.10E-02 
NM_001253751 Farnesyl diphosphate synthetase 
(Fdps) 
-1.02 0.494 1.59E-04 2.06E-02 
NM_146006 Lanosterol synthase (Lss) -0.99 0.505 6.21E-05 1.01E-02 
NR_037964 RIKEN cDNA 2610507I01 
gene (2610507I01Rik) 
-0.97 0.509 2.55E-04 2.89E-02 
NM_011183, 
NM_001128605 
Presenilin 2 (Psen2) -0.94 0.522 5.92E-05 9.94E-03 
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Figure 6.32: Protein-protein interaction networks of (a-b) differentially-expressed genes, with 
FDR<0.05 generated by STRING (a) upregulated genes, (b) downregulated genes (on next 
page) in Apc2+/+ vs. Apc2-/- Ad-cre Ptenfl/fl/Apcfl/fl ovaries 8-weeks post-induction. Small nodes 
(circles): proteins of unknown 3D structures. Large nodes (circles): some 3D protein structure 
is known or predicted. Turquoise lines: known interactions from curated databases. Purple 
lines: experimentally-determined interactions. Red arrows: highly-connected hubs. (c) 
Network of interactive proteins of most differentially-expressed genes (on the following page) 
generated by Cytoscape. Yellow nodes: upregulated, blue nodes: downregulated. 
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A heat map was generated for the genes with FDR<0.05. It is of note that the 3 ovaries 
collected from each of the 2 experimental cohorts, clustered together (Figure 6.33). 
 
Figure 6.33: Partial heat maps of differentially-expressed genes, showing the clustering of 
Apc2+/+ and Apc2-/- Ad-cre Ptenfl/fl/Apcfl/fl ovaries into 2 distinct clusters. Red indicates high 
expression, green indicates low expression. n=3. 
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Gene ontology analysis was performed for all upregulated genes in Apc2+/+ tumours with 
FDR<0.1 and biological processes regulated were identified using DAVID Bioinformatics 
Resources 6.8 (Huang da et al. 2009) and selecting for GOTERM BP DIRECT database for 
functional annotation (Table 6.9). It can be seen that upregulated genes are mostly those 
involved in processes such as inflammation, chemotaxis, immune response, proteolysis, ERK 
and other signalling events. 
 Table 6.9: Identifying biological processes enriched in Apc2+/+ (n=3) vs. Apc2-/- (n=3) Ad-cre 
Ptenfl/fl/Apcfl/fl ovaries 8-weeks post-induction. 
Biological process P-Value Genes 
Positive regulation of 
inflammatory response 
2.04E-04 NM_009139, NM_021443, NM_001294171, 
NM_011338, NM_010743 
Lymphocyte chemotaxis 0.00165 NM_009139, NM_021443, NM_011338 
Monocyte chemotaxis 0.0024 NM_009139, NM_021443, NM_011338 
Positive regulation of 
phagocytosis 
0.0035 NM_001002898, NM_009160, NM_009778 
Chemokine-mediated signalling 
pathway 
0.0045 NM_009139, NM_021443, NM_011338 
Positive regulation of ERK1 and 
ERK2 cascade 
0.0048 NM_009139, NM_021443, NM_011338, 
NM_009778 
Regulation of angiotensin levels in 
blood 
0.0055 NM_010779, NM_007753 
Cellular response to interferon-
gamma 
0.0068 NM_009139, NM_021443, NM_011338 
Neutrophil chemotaxis 0.007 NM_009139, NM_021443, NM_011338 
Cell chemotaxis 0.0089 NM_009139, NM_021443, NM_011338 
Cellular response to interleukin-1 0.0093 NM_009139, NM_021443, NM_011338 
Immune response 0.013 NM_009139, NM_021443, NM_010779, 
NM_011338 
Cellular response to tumour 
necrosis factor 
0.017 NM_009139, NM_021443, NM_011338 
Complement activation, 
alternative pathway 
0.018 NM_001142706, NM_009778, NM_008198 
Chemotaxis 0.0195 NM_009139, NM_021443, NM_011338 
Inflammatory response 0.024 NM_009139, NM_021443, NM_011338, 
NM_009778 
Complement activation 0.027 NM_001142706, NM_009778, NM_008198 
Positive regulation of GTPase 
activity 
0.029 NM_009139, NM_021443, NM_011338 
Immune system process 0.032 NM_001142706, NM_008522, NM_009160, 
NM_009778, NM_008198 
Positive regulation of protein 
phosphorylation 
0.044 NM_009778, NM_198111, NM_010197 
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Cell surface receptor signalling 
pathway 
0.06 NM_001308501, NM_001080815, 
NM_178924, NM_010340 
GO:0006508~proteolysis 0.08887667 NM_001142706, NM_008522, NM_010779, 
NM_007753, NM_008198 
A similar analysis was performed for the downregulated genes in Apc2+/+ vs. Apc2-/- 
Ad-cre Ptenfl/fl/Apcfl/fl ovaries with FDR<0.1. As expected, most of the cellular pathways 
identified regulate normal ovarian homeostasis e.g. folliculogenesis and steroidogenesis (Table 
6.10). 
Table 6.10: Identifying biological processes downregulated in Apc2+/+ (n=3) vs. Apc2-/- (n=3) Ad-
cre Ptenfl/fl/Apcfl/fl ovaries 8-weeks post-induction. 
Term P-Value Genes 
Negative regulation of cell 
differentiation 
7.29E-13 NM_198661, NM_001007077, NM_029948, 
NM_198663, NM_001270792, NM_001167793, 
NM_001270793, NR_027385, NM_178657, 
NM_001005371, NM_201258, NM_001177542, 
NM_001164285, NM_173773, NM_001164284, 
NM_001122678, NM_001105254, NM_001122668, 
NM_177571, NM_001167792 
Negative regulation of 
apoptotic process 
6.02E-08 NM_198661, NM_001007077, NM_010295, 
NM_029948, NM_198663, NM_001270792, 
NM_001167793, NM_001270793, NR_027385, 
NM_009640, NM_019739, NM_011824, NM_178657, 
NM_001005371, NM_011562, NM_201258, 
NM_001177542, NM_001164285, NM_173773, 
NM_001164284, NM_001122678, NM_001105254, 
NM_001122668, NM_001286062, NM_177571, 
NM_001167792, NM_013479 
Negative regulation of 
transcription, DNA-
templated 
4.12E-07 NM_198661, NM_001007077, NM_010295, 
NM_029948, NM_001270792, NM_212435, 
NM_198663, NM_001167793, NM_001270793, 
NM_001286607, NR_027385, NM_011824, 
NM_001005371, NM_178657, NM_011776, 
NM_201258, NM_001177542, NM_001164285, 
NM_173773, NM_001164284, NM_001122678, 
NM_001105254, NM_001122668, NM_177571, 
NM_053242, NM_001167792, NM_027022 
Ovarian follicle 
development 
8.14E-06 NM_010157, NM_133893, NM_130869, NM_009757, 
NM_009640, NM_013523, NM_207707, NR_104386, 
NM_001286062, NM_010564 
Steroid biosynthetic 
process 
1.33E-05 NM_008256, NM_001012306, NM_019779, 
NM_001253751, NM_146006, NM_007996, 
NM_001301728, NM_134469, NM_011485 
Positive regulation of cell 
proliferation 
1.36E-05 NM_198661, NM_001007077, NM_029948, 
NM_198663, NM_001270792, NM_001167793, 
NM_001270793, NR_027385, NM_011824, 
NM_178657, NM_001005371, NM_011562, 
NM_201258, NM_001177542, NM_001164285, 
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NM_173773, NM_001164284, NM_001122678, 
NM_001105254, NM_001122668, NM_177571, 
NM_001167792 
Cholesterol metabolic 
process 
1.05E-04 NM_009692, NM_008256, NM_019779, 
NM_001253751, NM_007468, NM_007996, 
NM_001301728, NM_134469, NM_011485 
Cholesterol biosynthetic 
process 
1.44E-04 NM_009692, NM_008256, NM_001253751, 
NM_007468, NM_146006, NM_134469 
Meiotic cell cycle 1.50E-04 NM_011516, NM_001002240, NM_001145885, 
NM_001002241, NM_183015, NM_031387, 
NM_023729, NM_010029, NM_201370, 
NM_001002238, NM_138311 
DNA methylation 
involved in gamete 
generation 
4.33E-04 NM_001002240, NM_001145885, NM_001002241, 
NM_001277730, NM_031387, NM_023729, 
NM_010029, NM_001002238, NM_001134741 
Phospholipid homeostasis 0.003 NM_009692, NM_008149, NM_010720 
Response to nutrient 0.0033 NM_010295, NM_009692, NM_170778, NM_010720, 
NM_011485 
Reverse cholesterol 
transport 
0.0052 NM_009692, NM_007468, NM_010720 
Steroid metabolic process 0.0055 NM_009692, NM_008256, NM_019779, 
NM_001253751, NM_007996, NM_001301728, 
NM_134469 
Cell differentiation 0.0145 NM_001002240, NM_001002241, NM_001277730, 
NM_031387, NM_023729, NM_130869, NM_009640, 
NM_019739, NM_012026, NM_001134741, 
NM_007560, NM_011562, NM_001145885, 
NM_007445, NM_001277216, NM_153519, 
NM_010029, NM_001277220, NM_001002238, 
NM_001286062, NM_001146002, NM_001277218, 
NM_001002894, NM_010701 
Lipid metabolic process 0.0157 NM_009692, NM_008256, NM_019779, NM_019699, 
NM_001253751, NM_146006, NM_007996, 
NM_001301728, NM_134469, NM_008149, 
NM_010720, NM_053178 
Iron ion transport 0.0172 NM_001159627, NM_010417, NM_181273, 
NM_175011, NM_001033404, NM_001159628 
Positive regulation of 
proteasomal ubiquitin-
dependent protein 
catabolic process 
0.0174 NM_010295, NM_001033214, NM_144551, 
NM_001128605, NM_011183 
Response to stilbenoid 0.0186 NM_008181, NM_008182, NM_007468 
Spermatogenesis 0.0219 NM_001002240, NM_001277730, NM_001002241, 
NM_031387, NM_023729, NM_001134741, 
NM_011516, NM_001145885, NM_153519, 
NM_010029, NM_013523, NM_001002238, 
NM_001146002, NM_172953, NM_001002894 
piRNA metabolic process 0.0246 NM_001002240, NM_001145885, NM_001002241, 
NM_031387, NM_023729, NM_010029, 
NM_001002238 
Cellular response to 
fibroblast growth factor 
stimulus 
0.0262 NM_010295, NM_011562, NM_011485 
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Cellular response to 
insulin stimulus 
0.0381 NM_010295, NM_019739, NM_008149, NM_011485 
Negative regulation of 
cytokine secretion 
involved in immune 
response 
0.0413 NM_009692, NM_009640, NM_001286062 
Activation of 
transmembrane receptor 
protein tyrosine kinase 
activity 
0.0413 NM_001253781, NM_001253782, NM_009640, 
NM_011169, NM_001286062 
Negative regulation of 
oocyte maturation 
0.0413 NM_201370, NM_010933 
Regulation of intestinal 
cholesterol absorption 
0.0413 NM_009692, NM_007468 
Metabolic process 0.0421 NM_001195049, NM_001195048, NM_008256, 
NM_008778, NM_023913, NM_053178, 
NM_001195047, NM_001195046, NM_008182, 
NM_001122660, NM_001012306, NR_037145, 
NM_008149, NM_026247 
Glucocorticoid metabolic 
process 
0.0493 NM_009692, NM_011485 
Sperm chromatin 
condensation 
0.0493 NM_011516, NM_013523 
Determination of dorsal 
identity 
0.0493 NM_011825, NM_011824 
 
As positive regulation of the ERK signalling was enriched in Apc2+/+ vs. Apc2-/- Ad-cre 
Ptenfl/fl/Apcfl/fl ovaries in this analysis, IHC was used to determine the levels of phospho-
ERK1/2 protein in Apc2+/+ and Apc2-/- Ad-cre Ptenfl/fl/Apcfl/fl ovaries. High cytoplasmic/nuclear 
focal staining was frequently observed in Apc2+/+ Ad-cre Ptenfl/fl/Apcfl/fl tumour-bearing 
ovaries, at both the periphery as well as within tumours (Figure 6.34). However, staining was 
only evident in 1/3 Apc2-/- Ad-cre Ptenfl/fl/Apcfl/fl tumours and was confined to the tumour 
periphery. In the Apc2-/- Ad-cre Ptenfl/fl/Apcfl/fl ovary with tumourlets, high expression was 
observed exclusively in the OSE (Figure 6.34).  
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Figure 6.34: p-ERK1/2 is upregulated in Apc2+/+ Ad-cre induced Ptenfl/fl/Apcfl/fl tumours. 
Photomicrographs of p-ERK1/2 immunostaining in Apc2+/+ (left) and Apc2-/- (middle) 
tumours, as well as OSE of Apc2-/- non-tumour ovary (right) (on background of Ad-cre 
Ptenfl/fl/Apcfl/fl and collected 8-weeks post-induction). Scale bar 100µm. n=3. 
 
Detailed analysis of genes with FDR<1X10-4 (Table 6.11) showed that the most 
differentially regulated gene was histidine ammonia lyase (HAL), which was nearly 13-fold 
over-expressed in Apc2+/+ Ad-cre Ptenfl/fl/Apcfl/fl tumours. It catalyses the degradation of L-
histidine to L-glutamine, an important nutrient for ovarian cancer cells (Yuan et al. 2015). 
Apart from the Trim30d gene, which was upregulated in Apc2+/+ tumours, all other genes were 
downregulated in Apc2+/+ tumours (upregulated in Apc2-/- tumours, Table 6.11). Most of these 
genes are exclusively expressed in normal ovarian tissue or regulate ovarian homeostasis. 
However, the list also includes C7,which represses important genes such as MYC, and 2 
serine/cysteine peptidase inhibitors, which prevent inhibition of peptidases with important 
roles during tumour progression (Mason and Joyce 2011) (Table 6.11). Function categories 
were extracted from SP Comment tool of the DAVID Bioinformatics Resources 6.8.  
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Table 6.11: Functions of genes most differentially regulated (FDR<1X10-4) in Apc2+/+ (n=3) vs. 
Apc2-/- (n=3) Ad-cre Ptenfl/fl/Apcfl/fl ovaries. Red denotes upregulated genes. 
Gene P value FDR p Fold 
change 
Function 
Histidine 
ammonia lyase 
(Hal) 
7.27E-23 1.99E-18 12.86 L-histidine degradation into L-glutamate 
Asparagine-
linked 
glycosylation 13 
(Alg13) 
1.79E-12 2.46E-08 0.4179 Involved in protein N-glycosylation. 
Essential for the second step of the 
dolichol-linked oligosaccharide pathway 
Complement 
component 7 (C7) 
1.11E-11 7.6E-08 0.2135 Component of heterochromatin. 
Recognizes and binds histone H3 tails 
methylated at 'Lys-9', leading to epigenetic 
repression. Probably involved in the 
repression of many genes located in 
euchromatin, such as E2F1, MYC and 
CDC25A.  
Synaptonemal 
complex protein 
1 (Sycp1) 
 
7.18E-11 3.94E-07 0.3907 Major component of the transverse 
filaments of synaptonemal complexes 
(SCS), formed between homologous 
chromosomes during meiotic 
prophase.  
Serine (or 
cysteine) 
peptidase 
inhibitor, clade 
A, member 5 
(Serpina5) 
1.15E-09 5.24E-06 0.2027 Inhibits activated protein C as well as 
plasminogen activators.  
Solute carrier 
family 38, 
member 5 
(Slc38a5) 
 
3.05E-09 1.06E-05 0.2013 Functions as a sodium-dependent 
amino acid transporter which counter 
transport protons. Mediates the 
saturable, pH-sensitive, and 
electrogenic cotransport of several 
neutral amino acids including glycine, 
asparagine, alanine, serine, glutamine 
and histidine with sodium.  
Oocyte specific 
homeobox 2 
(Obox2) 
3.09E-09 1.06E-05 0.1927 Regulation of oocyte transcription 
Serine (or 
cysteine) 
peptidase 
inhibitor, clade 
A, member 3C 
(Serpina3c) 
 
4.88E-09 1.49E-05 0.2557 The reactive center loop (RCL) extends 
out from the body of the protein and 
directs binding to the target protease. 
The protease cleaves the serpin at the 
reactive site within the RCL, 
  
273 
 
establishing a covalent linkage 
between the serpin reactive site and the 
protease. The resulting inactive serpin-
protease complex is highly stable  
Inhibin alpha 
(Inha) 
 
6.82E-09 1.87E-05 0.2003 Inhibins and activins inhibit and activate, 
respectively, the secretion of follitropin by 
the pituitary gland. Inhibins/activins are 
involved in regulating a number of diverse 
functions such as hypothalamic and 
pituitary hormone secretion, gonadal 
hormone secretion, germ cell development 
and maturation, erythroid differentiation, 
insulin secretion, nerve cell survival, 
embryonic axial development or bone 
growth, depending on their subunit 
composition. Inhibins appear to oppose the 
functions of activins. Belongs to the TGF-
beta family. 
Tripartite motif-
containing 30D 
(Trim30d) 
1.19E-08 2.96E-05 2.7440  
RIKEN cDNA 
E330034G19 
gene 
(E330034G19Rik) 
1.78E-08 3.76E-05 0.2051 Positive regulation of proteasomal 
ubiquitin-dependent protein catabolic 
processes. 
Predicted gene 
13084 (Gm13084) 
1.66E-08 3.76E-05 0.1883 Present in the ovary 
Phosphate 
regulating 
endopeptidase 
homolog, X-
linked (Phex) 
2.79E-08 5.46E-05 0.2826 Binds 1 zinc ion per subunit. Probably 
involved in bone and dentin 
mineralization and renal phosphate 
reabsorption.  
Myo-inositol 
oxygenase (Miox) 
 
3E-08 5.47E-05 0.2066 Polyol metabolism; myo-inositol 
degradation into D-glucuronic acid; D-
glucuronic acid from myo-inositol. 
NLR family, 
pyrin domain 
containing 5 
(Nlrp5) 
 
4.36E-08 6.29E-05 0.2237 Expression is first detected in oocytes 
of type 3A primary follicles. 
Transcripts accumulate during 
oogenesis. During meiotic maturation, 
the vast majority of the transcripts are 
degraded and virtually none is detected 
by 2-cell stage embryogenesis.  
NLR family, 
pyrin domain 
containing 4F 
(Nlrp4f) 
4.15E-08 6.29E-05 0.2008 May be involved in inflammation. 
Highly expressed in the ovaries. 
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6.3. Discussion 
6.3.1. APC2 is dispensable for OSE homeostasis 
The aim of the current study was to characterize roles of the APC2 protein in the OSE using 
the constitutive Apc2-/- mouse, which was achieved by performing in vivo and ex vivo assays. 
The results described here clearly show that APC2 is dispensable for OSE homeostasis in early 
adulthood; APC2 loss did not impair the wound repairing capabilities of the OSE, affect 
proliferation or differentiation, or initiate metaplastic changes (Figures 6.1-6.6). WNT 
signalling was not activated in the OSE following APC2 loss, as reflected by comparable 
membranous β-catenin staining in both Apc2+/+ and Apc2-/- ovaries (Figure 4.2), and similar 
expression levels of genes of the WNT signalling cascade in cultured OSE (Appendix 4). β-
catenin has been previously shown to localize to the cell membrane within the OSE of mouse 
adult ovary (Usongo et al. 2013). Here, APC2 deletion failed to activate WNT signalling and 
re-locate β-catenin to the nucleus. This is different form the effect of  canonical WNT signalling 
activators LiCl and Wnt3a, which did cause nuclear localization in OSE cultures, but failed to 
activate downstream TCF/LEF complexes (Usongo et al. 2013). Ex-vivo assays of OSE 
isolated from Apc2+/+ and Apc2-/- ovaries did not reveal any changes in epithelial morphology, 
proliferation, migration or sphere forming abilities (Figure 6.4-6.6). Again, this differs from 
the phenotype seen post-LiCl or Wnt3a treatment of OSE, where increased proliferation 
(measured by Brdu), and impaired differentiation (seen as morphological changes of cells to 
an elongated shape, together with decreased E-cadherin expression) were evident (Usongo et 
al. 2013). 
 Genetic alterations in oncogenes or tumour suppressor genes in the WNT signalling 
pathway have been previously shown to cause OSE-related pathologies. Mutation of APC 
caused different phenotypes depending on the method utilized to induce recombination of the 
floxed Apc allele. When adenovirus-cre was used, 18% of Apcfl/fl mice developed endometriosis 
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by the age of 12 months (Wu et al. 2011). However, when Amhr2-cre was used, 35% of mice 
developed OEAs by the age of 11 months (Tanwar et al. 2013). Tumour formation was more 
pronounced when degradation-resistant β-catenin was expressed in the OSE, causing the 
formation of tumours, mostly OEAs, in 50% of mice aged 8-12 months (Tanwar et al. 2011a). 
In the current study, when Apc2+/+, Apc2+/- and Apc2-/- female mice (on the background of non-
induced hypomorph Apcfl allele) were aged to 18 months, only one Apc2+/- mouse developed a 
cyst. Other than this, no OSE pathologies were observed in APC2-deficient mice and epithelial 
tumour formation was not evident. 
In conclusion, loss of APC2 is not disruptive to the OSE. Importantly, as no phenotypic 
changes were observed in the OSE of 10-week-old ovaries, this time point could be used to 
explore the effect of combining APC2 loss with deletion of APC or PTEN in the OSE.   
6.3.2. Combining APC2 loss with APC loss is not sufficient to initiate tumourigenesis 
Functional redundancy/compensation between APC and APC2 proteins has been 
previously described in the mammary gland, where tumour formation was only evident after 
deleting both APC proteins in the epithelium (Daly et al. 2016). A similar approach was 
performed here to see whether deletion of both proteins would drive EOC formation. We used 
intrabursal injection of adenovirus-cre to recombine the Apc gene, as it has been successfully 
used by other groups, and because it only recombines genes in the OSE (Flesken-Nikitin et al. 
2003; Wu et al. 2007; Tirodkar et al. 2014), unlike Amhr2-cre, which causes recombination in 
granulosa cells as well as in the OSE (Connolly et al. 2003; Tanwar et al. 2013). It has been 
previously reported that 90% of OSE cells were infected post-adenovirus cre, and that the 
recombination rate (detected using LacZ reporter mice) ranged from 60-80% of OSE cells 
(Flesken-Nikitin et al. 2003). When this technique was applied in the current study, neither 
APC deletion on its own, nor combined APC/APC2 deletion, were enough to initiate epithelial 
tumourigenesis. Indeed, additional loss of APC2 in Ad-cre Apcfl/fl ovaries protected the 
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epithelium from age-related and/or APC-loss-related OSE disruption in aging mice (Figures 
6.8-6.10). 
 The decrease in nuclear β-catenin in aging Ad-cre Apcfl/fl mice compared to 8-weeks 
post-induction (Figure 6.13) was not expected, especially with the higher incidence of OSE 
disruptions and pathologies seen in the older group. However, using a β-catenin-responsive 
reporter construct (Mohamed et al. 2004), it was previously reported that the number of OSE 
cells showing β-catenin/TCF signalling does decrease with age (Usongo and Farookhi 2012). 
One possible explanation for the higher levels at 8-weeks post-induction, is that the loss of 
APC, which would be driving activation of WNT signalling, had only recently happened, in 
contrast to the late time point. As such, cells expressing nuclear -catenin were lost as 
previously described (Usongo and Farookhi 2012). It is not known why the β-catenin active 
cells are lost with age, but one possible explanation may be that these cells are lost during 
ovulation and are replaced by neighboring cells, with lower/normal -catenin expression levels. 
As such cells have been described as potential stem cells in the OSE (Usongo and Farookhi 
2012), another explanation might be that they are differentiating into non β-catenin-active cells, 
which might explain why the multi-layering, seen in aging Apcfl/fl ovaries, are not expressing 
nuclear β-catenin. 
However, in the Ad-cre Apcfl/fl/Apc2-/- aging cohort, higher levels of nuclear β-catenin 
were observed, when compared to the Ad-cre Apcfl/fl aging group, but this was not accompanied 
by OSE disruptions (Figure 6.13). As APC2-deficiency is due to constitutive gene knockout in 
these mice, this might suggest an essential interaction between β-catenin-positive epithelial 
clones and the surrounding stroma, which might be disrupted post-APC2 deletion. The role of 
APC2 in the stroma is not yet explored, but we have shown that APC2 loss affects ovarian 
angiogenesis, folliculogenesis and steroidogenesis. It has been previously proposed that 
ovarian epithelial metaplasia requires inflammatory mediators and steroidogenic hormones 
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(Wei et al. 2011). With the finding that both Cyp17a1 and Cyp19a1 were downregulated in 
Apc2-/- ovaries (Figure 4.21), it might be expected that intra-ovarian levels of estradiol would 
be lower in Ad-cre Apcfl/fl/Apc2-/- ovaries as compared to Ad-cre Apcfl/fl or wild type ovaries, 
thus protecting the OSE from metaplastic changes resulting from the interaction between 
mutational hits and hormones. If these β-catenin positive cells in the OSE are stem cells, as 
previously proposed (Usongo and Farookhi 2012), then signals from the surrounding 
microenvironment would dictate whether they remain quiescent, self-renew or differentiate 
(Jones and Wagers 2008). It is known that ovarian steroids are required for normal functioning 
of mammary stem cells and that estrogen deprivation decreases their repopulating frequency 
and outgrowth potential post-transplantation into fat pads (Asselin-Labat et al. 2010). Whether 
the same is true for ovarian stem cells remains to be explored. 
6.3.3. Combining APC2 loss with PTEN loss is not sufficient to initiate tumourigenesis 
Combining APC and PTEN loss in the OSE of the mouse leads to the development of 
OEA with 100% penetrance by 6-weeks post-genes deletion (Wu et al. 2007). Based on the 
structural similarity between APC and APC2 proteins, a similar outcome might be expected 
when both PTEN and APC2 are deleted in the OSE. However, we have shown that in mice 
with a constitutive Apc2 knockout, deletion of PTEN in the OSE is not sufficient to initiate 
OEA by 8-weeks post-induction. This might be explained by functional differences between 
APC and APC2 in the regulation of WNT signalling. As discussed previously (Section 1.3.1.3), 
in vivo WNT signalling activation post-APC deletion is reproducible in many organs, including 
the ovaries. However, in vivo WNT signalling activation post-APC2 deletion is tissue and 
context-specific (Section 4.3.1). In the current study, constitutive loss of APC2 did not cause 
WNT signalling activation in the OSE (Appendix 4).  In addition, due to the constitutive nature 
of APC2 deletion, signals coming from the stroma are dissimilar in the 2 models, which may 
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affect the metaplastic potential of the OSE post-APC2 deletion, in a similar way to that 
discussed in section 6.3.2. 
It is not unusual that bimutational hits in the OSE are not enough to initiate epithelial 
ovarian tumourigenesis. For instance, combining ARID1A loss and PIK3CA activation in the 
OSE failed to induce tumourigenesis in mice followed until the age of 12 months (Zhai et al. 
2016). In another study, however, the same genetic alterations led to the development of 
ovarian clear cell carcinoma (Chandler et al. 2015), and this was attributed to the difference in 
the mutant Pik3ca alleles used (Zhai et al. 2016). Similarly, combined deletion of PTEN and 
activation of PIK3CA in the OSE failed to initiate epithelial tumourigenesis, but caused the 
development of non-epithelial tumours and micropapillary OSE proliferation in 82% and 100% 
of mice respectively (Wu et al. 2013). However, in another study, the same mutational 
alterations lead to the development of ovarian tumours, of which 67% were serous 
adenocarcinoma (Kinross et al. 2012).  
Here, Ptenfl/fl ovaries collected at 12 months of age showed a range of OSE 
abnormalities and pathologies (Table 6.4). Pre-tumour lesions, in the form of serous 
hyperplasia or epithelial cysts, were evident in 33% (2/6) of the mice, and poorly-differentiated 
small OEA were also evident in 33% (2/6) of the mice. These pathologies, although of higher 
percentage of tumour development in the current study, have been previously reported; firstly, 
where 62% of mice developed endometrial glandular lesions and 7.5% ovarian tumours 
(Dinulescu et al. 2005), and secondly, where 83.3% developed serous papillary hyperplasia 
(Kinross et al. 2012). However, our results are different from a previous report in which only 
2% (1/47) of mice, of a similar age, showed endometriosis (Wu et al. 2011). In all of these 
studies, adenovirus-cre injection was the method used to induce recombination of the floxed 
Pten allele; however, the dose that was used varied between studies, ranging from as high as 
2.4x108 pfu  in our study and 2x108 pfu  (Kinross et al. 2012), to 5x107 pfu (Wu et al. 2011) and 
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as low as 2.5x107 pfu (Dinulescu et al. 2005). In our study, the loxP sites flank exons 4 and 5 
of Pten, which is similar to the allele used by the Wu group, but different from the one used by 
Dinulescu and Kinross groups, which flanked only exon 5. Comparing and contrasting these 
studies suggest that the higher percentage of tumourigenesis observed in the current study may 
be caused by the combination of a high viral dose used in the induction and a bigger deletion 
in the Pten gene (floxing both exons 4 and 5). Characterization of PTEN exon 4 deletion in 
humans revealed a 37% reduction of PTEN protein, and marked increase in p-AKT, suggestive 
of a lipid phosphatase activity for exon 4 (Agrawal et al. 2005), which might in our case, 
synergize with the attenuated phosphatase activity arising from exon 5 deletion (Suzuki et al. 
2001) 
One of the induced Ptenfl/fl mice of the aged cohort developed an oviductal tumour 
(Figure 6.17). This might be explained in terms of the limitation of the intrabursal viral 
injection technique discussed earlier (Section 1.4.4.1). In the current study, we chose to inject 
the adenovirus-cre directly into the ovarian bursa rather than performing the trans-infundibular 
intra-oviductal injection used by others (Dinulescu et al. 2005; Wu et al. 2007) to try to avoid 
any possible recombination in the oviduct. However, owing to the anatomical location of the 
infundibulum, which directly opens into the bursa, recombination within the oviduct cannot be 
excluded.  As p-AKT levels were surprisingly low in this lesion, there is the possibility that 
another-spontaneous- mutation had arisen and was driving this oviductal tumour; however, this 
possibility has not been explored. 
6.3.4. APC2 loss promotes OEA initiation in Ptenfl/fl/Apcfl/fl mice 
A previous study reported that ovarian tumour initiation, as indicated by the 
development of tumourlets, was not evident in the first 2 weeks following Ad-cre induction of 
Ptenfl/fl/Apcfl/fl mice, but was present in 6/10 of mice 3-weeks post-induction (Wu et al. 2011). 
In the current study, the choice of 15 days post-induction as an early time point was made based 
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on these reported data, to characterize the early events preceding tumour formation. Our results 
reproduced what has been published before, as no tumourlets were evident 2-weeks post-
induction in Apc2+/+ adenovirus-cre-induced Ptenfl/fl/Apcfl/fl ovaries. However, when APC2 
protein was reduced or lost, in Apc2+/- or Apc2-/- cohorts, respectively, tumourlet formation was 
evident in 66.7% of the mice at this timepoint (Figure 6.23). Both clonal expansion (in the form 
of tumourlets) and invasion of basement membrane were observed, reflecting an earlier 
initiation of tumour development in APC2-deficient Ad-cre Ptenfl/fl/Apcfl/fl mice. As the Apc2- 
allele is constitutive in nature, it is difficult to know whether this effect is due to loss of APC2 
in transformed epithelial cells, the surrounding microenvironment or even cells outside the 
ovary. 
One explanation for the early initiation of tumourigenesis following APC2 loss in Ad-
cre Ptenfl/fl/Apcfl/fl mice could be a disruption in immunoediting of transformed epithelial cells. 
According to the immunoediting hypothesis, innate immune cells recognize proliferative 
neoplastic cells and an adaptive tumour immunity develops, leading to their elimination (Dunn 
et al. 2004). If the elimination is not complete, it is followed by an ‘equilibrium’ phase, where 
more immune-resistant tumour cells are produced and an equilibrium exists between immune 
cells and tumour cells, resulting in reduced-immunogenic tumour clones which stay dormant 
for long periods before they can completely ‘escape’ immune defence mechanisms and grow 
(Dunn et al. 2004). Both innate and adaptive immune responses are required for initiating this 
tumour-specific immunity, and T-cells have been shown to play important roles during the 
‘elimination’ phase (Dunn et al. 2004). WNT signalling activation, by inhibiting GSK3 or 
using Wnt3a, has been previously shown to reduce T-cell expansion and disrupt T-cell 
functions, by preventing the differentiation of naïve T-cells into mature effector T-cells 
(Muralidharan et al. 2011). Whether APC2 loss activates WNT signalling in T-cells in a similar 
manner, thus disrupting tumour cell immunoediting, is unknown and remains to be explored. 
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The early invasion seen post-APC2 loss could be explained, at least in part, by the basal 
epithelial cell extrusion hypothesis (Slattum and Rosenblatt 2014). The normal extrusion 
direction of the cells is apical, and in the ovaries would result in shedding of transformed cells 
outside the ovary. However, when the extrusion is basally-shifted, the transformed cells would 
breach the basement membrane and invade the ovary (Slattum and Rosenblatt 2014). It has 
been shown that apical extrusion needs coupling between microtubules and actin filaments, 
and that a shift to basal extrusion happens post-APC truncating mutations due to disruption of 
microtubule dynamics (Slattum and Rosenblatt 2014). A previous study has shown defective 
neuronal migration post-APC2 deletion in the brain, caused by defects in actin and microtubule 
dynamics (Shintani et al. 2012). APC2 was shown to be distributed along microtubules, 
causing their stability when overexpressed in cultured chick retina, and APC2 knockdown 
impaired microtubule stability (Shintani et al. 2009). It is possible that a similar disruption of 
microtubule dynamics may have been affected in the absence of APC2 in the transformed cells 
of Ad-cre Apcfl/fl/Ptenfl/fl ovaries, thus facilitating the basal extrusion of cells and enabling 
tumourlet invasion to take place. 
6.3.5. APC2 is required for OEA progression 
Before starting this project, we hypothesized that APC2 acts as a tumour suppressor for 
epithelial ovarian tumourigenesis, and that APC2-deficiency would cause the development of 
larger tumours in the Ad-cre Apcfl/fl/Ptenfl/fl ovarian model. This was based on assumptions 
from previous studies, which demonstrated APC2 allelic imbalance in human ovarian tumours 
(Jarrett et al. 2001), as well as copy number alterations (deletions) in human and murine high 
grade serous ovarian carcinoma (Perets et al. 2013). However, we unexpectedly found that, 
following the initial rapid development of tumourlets when APC2 was absent in Ad-cre 
Ptenfl/fl/Apcfl/fl ovaries, confirming that it is a tumour suppressor for tumour initiation, tumour 
progression at 8-weeks post-induction was actually hampered by APC2 loss (Figure 6.26), 
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suggesting it was acting as an oncoprotein.  This is similar to the attenuation of hepatocellular 
carcinoma found when APC2 was deleted in Apcfl/fl mice; only micro-adenomas were present 
in the livers of Apcfl/fl/Apc2-/- mice in contrast to hepatocellular carcinoma developing in Apcfl/fl 
at 400 days of age (Daly 2013). This has been seen in the ovarian setting as well, when Arid1a, 
another gene believed to be a tumour suppressor for ovarian epithelial tumourigenesis, was 
deleted using the same OEA model used in the current study (Zhai et al. 2016). Arid1a silencing 
prolonged survival and enhanced glandular epithelial differentiation of tumours (Zhai et al. 
2016). Although different from our findings, that smaller tumours develop post APC2-loss, 
ARID1A-deficiency caused larger tumour formation, which was unexpectedly associated with 
prolonged survival (Zhai et al. 2016). In the current study, survival was not evaluated; however, 
a recent study analysing data for high grade serous ovarian cancer cases from The Cancer 
Genome Atlas, showed that elevated APC2 levels are associated with decreased overall, as well 
as, progression-free survival following chemotherapy (Seagle et al. 2016). 
In the current study, APC2-deficiency in Ad-cre Apcfl/fl/Ptenfl/fl ovaries collected 8-
weeks post-induction did not enhance glandular epithelial differentiation, in fact, it was 
reduced, and differentiation into keratinizing squamous cell carcinoma was observed (Figure 
6.30). The presence of discrete areas of focal squamous differentiation and keratinization has 
previously been described in tumours developing in Ad-cre Ptenfl/fl/Apcfl/fl ovaries 6-weeks 
post-induction (Wu et al. 2007). However, the large keratinized areas, resembling ovarian 
squamous cell carcinoma seen in our APC2-deficient tumours, have not been previously 
described. Although ovarian squamous cell carcinoma is rare, and originates from teratoma or 
endometriosis, a recent case report presented an ovarian squamous cell carcinoma arising from 
OEA (Shoji et al. 2016), although the molecular driver of this differentiation was not 
characterized. WNT signalling activation has been shown to play important roles in the 
pathogenesis of squamous cell carcinoma in a number of organs (Aminuddin and Ng 2016; 
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Sherwood and Leigh 2016; Shiah et al. 2016). Extracting data from the Cancer Genome Atlas 
revealed that APC2 is mutated (missense mutations) in 2.24%, 1.73% and 1.57% of squamous 
cell carcinomas of lung, cervix and head and neck respectively. In addition, downregulation of 
Apc2 was recently shown in a rat model of oral squamous cell carcinoma (Peng et al. 2015). 
Whether a higher level of WNT signalling disruption is required for ovarian squamous cell 
metaplasia is unknown, but it could be hypothesized that partial compensation between APC 
and APC2 protects ovarian epithelial cells from squamous metaplasia and keratinization when 
only APC (as well as PTEN) is deficient, and that simultaneous loss of both APC proteins 
facilitates the squamous metaplasia. This hypothesis might be supported by results of Axin2 
RNAscope analysis (performed shortly before thesis submission), which revealed lower 
expression of Axin2 RNA in areas where abundant packed epithelial gland formation was 
evident in Apc2+/+ Ad-cre Apcfl/fl/Ptenfl/fl tumours, as compared to other areas of the tumour as 
well as to Apc2-/- Ad-cre Apcfl/fl/Ptenfl/fl tumours (Appendix 7). 
No significant differences were observed between Apc2+/+ and Apc2-/- Ad-cre 
Apcfl/fl/Ptenfl/fl tumours in terms of proliferation or apoptosis (Figure 6.28). This was 
unexpected, as the presence of APC2 resulted in the formation of larger tumours, suggesting 
an imbalance between the two processes. It is known that Ki67 marks proliferative cells in all 
stages of the cell cycle (Scholzen and Gerdes 2000), meaning that it is marking all cycling cells 
whether or not they will finally reach the mitotic phase. However, if the cells enter the cell 
cycle and become arrested later on, or if mitosis fails, this cannot be visualized using Ki67 
immunostaining. IHC for phospho-histone 3 protein, which marks the fraction of proliferating 
cells undergoing mitosis (Pérez-Cadahía et al. 2009), revealed a significant decrease in mitotic 
cells in Apc2-/- tumours compared to Apc2+/+ tumours (24.1±2.2 vs. 48.5±1.99, mean±S.E., 
p<0.05), which may explain the decreased size of tumours in which APC2 levels were reduced 
or absent. Previous work with Drosophila embryos identified a small yet significant increase 
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in mitotic defects post-APC2 loss caused by chromosome segregation errors (Poulton et al. 
2013). An interesting finding was that although all the squamous-differentiated cells present in 
keratin pools were Ki67 positive, they were not mitotic (phospho-histone 3 negative, Appendix 
6). This may indicate that differentiation of tumour cells into the squamous morphology post-
APC2-deficiency is one of the mechanisms by which tumour growth is arrested following rapid 
initiation. 
6.3.6. Identifying possible molecular mechanisms of APC2-dependent tumour 
progression 
RNA sequencing was performed to compare the transcriptome of tumours developing 
in Ad-cre Ptenfl/fl/Apcfl/fl ovaries at 8-weeks post-induction, either when APC2 protein was 
present (Apc2+/+) or absent (Apc2-/-). One of the main limitations of this study was that the 
RNA used for sequencing was extracted from whole ovaries. Histological analysis of the other 
ovary from each mouse showed that normal ovarian tissue was always present in tumours 
lacking APC2, due to the decreased tumour progression in animals of this genotype (Table 
6.5). These facts need to be taken into consideration when interpreting the data, especially for 
genes which are downregulated in Apc2+/+ as compared to Apc2-/- tumours.  
The most significantly differentially-regulated gene, when comparing Apc2+/+ with 
Apc2-/- Ad-cre Apcfl/fl/Ptenfl/fl tumours, was Histidine ammonia lyase (Hal), also known as 
histidase, which was 13-fold upregulated (Table 6.7,6.11), and catalyses the first step in 
histidine catabolism (Kawai et al. 2005). While its deficiency is known to cause histidinemia 
or histidinurea, which are characterized by mental impairment (Kawai et al. 2005), the 
pathogenesis of HAL overexpression is not yet fully characterized. A recent study in amphibian 
metamorphosis reported that HAL expression is increased during intestinal stem cell 
development, especially in proliferating stem cells (Luu et al. 2017), suggesting a role for HAL 
in regulating intestinal stem cell proliferation and function. Whether HAL plays similar roles 
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in adult stem cells in other organs, or in cancer stem cells, remains to be investigated. Normally, 
HAL is not expressed in the ovaries, but is highly expressed in EOC, including OEAs (data 
extracted from The Human Protein Atlas database, (Uhlen et al. 2015)). The end product of 
histidine catabolism is glutamine, which has been previously shown to promote ovarian cancer 
cell proliferation when used as a nutrient by cultured cells (Yuan et al. 2015). In addition, 
glutamine-dependent ovarian cancer cells have been reported as highly invasive, when 
compared to glucose-dependent cancer cells (Yang et al. 2014). It would be interesting to 
further explore the role of HAL in EOC, particularly whether its upregulation contributes to 
tumourigenesis and whether it may be a potential therapeutic target. 
Of the most significantly downregulated genes in Apc2+/+ vs. Apc2-/- Ad-cre 
Ptenfl/fl/Apcfl/fl ovaries, Serpina5, Serpina3c and C7 could all potentially be linked to 
tumourigenesis (Table 6.8, 6.11).  Serpina5 (serine protease inhibitor, clade A, member 5) 
encodes a protein which inhibits peptidase activity and has been shown to suppress serous 
ovarian tumour formation (Sieben et al. 2005), probably by inhibiting  MAPK signalling (Lee 
et al. 2013). Serpina3c,  another serine protease inhibitor, has been shown to be downregulated 
in human colorectal cancer tissue, and localizes to epithelial tumour cells, as well as 
surrounding stroma (Dimberg et al. 2011). C7, which codes for complement component 7 
protein, is a potential tumour suppressor whose expression is decreased in ovarian cancer (Ying 
et al. 2016), as well as in other cancers such as oesophageal, kidney and colorectal (Oka et al. 
2001). 
Protein-protein interaction were visualized with STRING and Cytoscape tools in order 
to identify the highly connected/most interacting proteins, named protein hubs, which are 
proposed to play more central roles in developing the phenotype (Vallabhajosyula et al. 2009), 
tumour progression in our case, compared to other less-essential proteins. When protein-protein 
interactions were plotted from the list of genes significantly upregulated (FDR<0.05) in Apc2+/+ 
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vs. Apc2-/- Ad-cre Apcfl/fl/Ptenfl/fl ovaries, only one hub (LRGUK) was identified (Figure 6.32a). 
Cytoscape plotting (Figure 6.32c) revealed that it regulates PCDH11x and is regulated by 
HUNK and HAL. Little is known about the LRGUK (leucine rich repeats and guanylate kinase 
domain containing) protein, but according to The Human Protein Atlas, it is not expressed in 
normal ovaries but is expressed in ovarian cancers, including OEAs (Uhlen et al. 2015). GUK 
(guanylate kinase), a paralogue of LRGUK, has been shown to be a target for 6-thioguanine 
and 8-azaguanine cancer chemotherapeutic agents (Stolworthy and Black 2001). 
Many hubs were identified when protein-protein interactions of genes significantly 
downregulated (FDR<0.05) in Apc2+/+ vs. Apc2-/- Ad-cre Apcfl/fl/Ptenfl/fl ovaries were plotted 
(Figure 6.32b). The most connected hubs were BMPR1b, ASZ1, TRIB2, ESR2 and members 
of FBXW family. BMPR1b (bone morphogenetic protein receptor 1b) expression is decreased 
in EOC, which correlates with poor survival (Ma et al. 2010). ASZ1 (ankyrin repeat, SAM and 
basic leucine zipper domain containing 1, also known as GASZ) is a germ cell-specific protein 
(Yan et al. 2002), whose reduction would be expected when oocytes are absent. Whether it has 
other roles, or whether its expression is disrupted in cancer, is not yet known. TRIB2 (Tribbles 
2) is a pseudokinase whose expression is decreased in platinum-resistant EOC and is associated 
with poor survival (Kritsch et al. 2017). ESR2 (estrogen receptor beta) is known to have tumour 
suppressor roles for EOC both in vitro and in vivo (Bossard et al. 2012), and ESR2 agonists 
were successfully proven to inhibit the proliferation of EOC cells in vitro (Liu et al. 2017; 
Schuler-Toprak et al. 2017). FBXW (F-box and WD-40 domain) proteins, shown to be 
downregulated in the current study, are highly expressed in normal mouse ovaries (Yue et al. 
2014); however, they clustered separately when protein-protein interactions were plotted 
(Figure 6.32b,c), meaning that they are only predicted to interact with each other, and their 
function is unknown. Whether their reduced expression is caused by the absence of normal 
ovarian tissue in Apc2+/+ tumours, or whether they play a role in tumourigenesis, is not known. 
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FBXW7, another family member, which was not significantly decreased in the current study, 
is a tumour suppressor in EOC and is downregulated in the 4 main histotypes (Kitade et al. 
2016). 
Plotting the protein-protein interactions of differentially expressed interacting genes 
(extracted from the protein-protein interaction analysis performed for upregulated (Figure 
6.32a) and downregulated (Figure 6.32b) genes), to visualize protein-protein interactions 
between upregulated and downregulated protein-coding genes (Figure 6.35c), lead to the 
identification of an important new hub in the network, the HUNK (Hormonally Up-regulated 
Neu-associated Kinase) protein, which was significantly upregulated in Apc2+/+ Ad-cre 
Apcfl/fl/Ptenfl/fl tumours. Extracting data from the Human Protein Atlas revealed that it is 
moderately expressed in EOC, including OEAs, in a pattern similar to that seen in breast cancer 
(Uhlen et al. 2015). HUNK function has not been characterized in EOC, but in breast cancer it 
plays pivotal roles in tumourigenesis, and is involved in resistance to inhibitors in HER2+ 
(ERBB2+) breast cancer through regulation of autophagy (Zambrano et al. 2017).  
When biological pathway analysis was performed for the most downregulated genes in 
Apc2+/+ vs. Apc2-/- Ad-cre Apcfl/fl/Ptenfl/fl tumours, pathways most represented were those 
regulating normal ovarian homeostasis (Table 6.10). However, analysis of biological pathways 
of upregulated genes revealed an enrichment in pathways regulating inflammatory responses, 
immune responses, cellular responses to interferon gamma, interleukin 1 and tumour necrosis 
factor (Table 6.9). In addition, immune infiltration was only evident in Apc2+/+ Ad-cre 
Apcfl/fl/Ptenfl/fl tumours (Table 6.5). Historically, EOC has been hypothesized to originate from 
the OSE, which undergoes metaplastic changes caused by inflammation taking place during 
ovulation at the site of rupture (Ness and Cottreau 1999). EOC progression has been shown to 
be governed by the interaction between tumour cells and the surrounding microenvironment, 
mainly immune cells and inflammatory cytokines and chemokines (Maccio and Madeddu 
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2012). Chemokines (e.g. Ccl8), which encode for small proteins secreted by tumour and 
stromal cells (Balkwill 2004), as well as growth factors (e.g. Fgf1) and cytokine receptors (e.g. 
Il1rl1), were upregulated in Apc2+/+ Ad-cre Apcfl/fl/Ptenfl/fl tumours. Although little effort has 
been made previously to unravel the inflammatory cytokine/immune status in OEA mouse 
models and their contribution to tumour initiation and progression, these roles have been 
characterized in an ovarian clear cell carcinoma mouse model arising from the deletion of 
Arid1a and activation of Pik3ca in the OSE (Chandler et al. 2015). In this model, tumour 
progression was mediated by high IL-6 levels, which activated pro-tumourigenic cytokine 
signalling (Chandler et al. 2015). Because of the time constraint, further characterization of 
immune/inflammatory status and tumour microenvironment were not performed in the current 
study, but are highly recommended for future investigation. 
One of the limitations of the current study was that results of RNA sequencing analysis 
were not confirmed by qRT-PCR because of the limited tumour samples collected. However, 
positive regulation of ERK1/2 signalling one of the upregulated biological pathways in Apc2+/+ 
vs. Apc2-/- Ad-cre Apcfl/fl/Ptenfl/fl tumours (Table 6.9), was confirmed by immunohistochemical 
analysis of p-ERK1/2 (Figure 6.34). ERK (extracellular signal–regulated kinase, also known as 
MAPK) is downstream of KRAS, which is mutated in 10.65% (44/413) OEA human cases, as 
extracted from COSMIC database. Interestingly, the first OEA mouse model was based on 
deleting Pten and expression of an active mutant of Kras in the OSE (Dinulescu et al. 2005). 
KRAS/BRAF/MEK/ERK canonical signalling is activated in many cancers, including EOC 
(Samatar and Poulikakos 2014), with accumulating evidence that activation of the pathway is 
needed for EOC progression (Wilhelm et al. 2004; Bourguignon et al. 2005). The presence of 
p-ERK1/2 positive cells inside the tumours in Apc2+/+ Ad-cre Apcfl/fl/Ptenfl/fl tumours compared 
to their peripheral localization, if any, in the Apc2-/- Ad-cre Apcfl/fl/Ptenfl/fl tumours (Figure 6.34) 
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might indicate that the presence of ERK1/2-positive clones is needed for tumour invasion and 
progression in the Ptenfl/fl/Apcfl/fl model. 
6.3.7. Conclusion and future directions 
Results of the current study have shown that APC2 is dispensable for OSE homeostasis. 
APC2 loss on its own, or in combination with APC or PTEN loss in the OSE, failed to initiate 
EOC. When APC2 loss was introduced to the Ad-cre Ptenfl/fl/Apcfl/fl tumour model, early 
initiation of tumourigenesis was observed, but reduced progression was evident, as reflected 
by ovarian volumes 8-weeks post-induction. Several mechanisms were shown to be responsible 
for this tumour growth restriction, including differentiation to squamous phenotype with 
hyperkeratinisation, decreased mitosis, decreased p-ERK1/2 expression and disrupted 
immune/inflammatory signalling. Owing to the constitutive nature of the Apc2- allele, both 
tumour cell autonomous and non-autonomous (from stromal cells) mechanisms could be 
contributing to the observed phenotype. In conclusion, the assumption that APC2 protein is a 
tumour suppressor for growth of OEA histotype of EOC is not supported by the findings of the 
current study. Instead, APC2 played a dualistic function in Wnt-driven OEA, a tumour 
suppressor for initiation but an oncoprotein for progression. However, although this is true in 
the current study, it needs to be tested in a non-Wnt ovarian tumour model, and in a model 
representing serous adenocarcinoma histotype before it could be extended, generalized or used 
to determine its relevance to human data. 
Dissecting autonomous and/or non-autonomous contributions of APC2 to phenotypes 
observed in the current study, could be tested by intrabursal injection of adenovirus-cre 
together with short hairpin RNA vector targeting Apc2 to the OSE of Ptenfl/fl/Apcfl/fl ovary. 
Comparing and contrasting tumours developing in this model with tumours generated in the 
current study might help to clearly unravel roles of APC2 in neoplastic OSE. 
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To understand the clinical significance of the current data, it would be crucial to define 
APC2 loss in terms of tumour size, stage, sensitivity/resistance to chemotherapy, whether it 
happens in association with certain mutations, in certain histotypes and whether it is present in 
the tumour cells and/or stromal cells. With the recent report that increased APC2 expression in 
HGSOC is correlated with poor survival (Seagle et al. 2016), and stemming from results of the 
current study, more work should be directed to unravel contributions of APC2 protein in EOC 
before deciding whether targeting APC2 could be considered as a therapeutic intervention. 
Out of the functional analysis performed in the current study, 2 targets appear very 
attractive to be considered for future projects, namely HAL and HUNK. With the data present 
in the Human Protein Atlas showing that they are overexpressed in epithelial ovarian tumours, 
irrespective of histotype, and with lack of information in literature regarding their roles in EOC, 
proposed future work would be phenotypically characterizing them first in vitro, through 
knockdown and overexpression in EOC cell lines, before phenotypic characterization of the 
produced cells in vivo using transplantation models. These targets could then be judged for 
usefulness as therapeutic interventions for treating EOC.
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7. General discussion 
The work presented in this thesis set out to determine roles for APC2 in ovarian WNT 
signalling activation, homeostasis, fertility and tumourigenesis. This study has revealed, for 
the first time, that APC2-deficiency activates WNT signalling in the ovary during early 
adulthood, which subsequently disrupts ovarian homeostasis and causes subfertility originating 
from an ovarian defect. Follicle growth was perturbed in APC2-deficient mice secondary to 
defective response to gonadotrophins, reduced follicular vascularity, downregulation of genes 
coding for steroidogenic enzymes and upregulation of Foxo1 expression, which contributed to 
increased apoptosis of granulosa cells in APC2-deficient follicles. The second major finding 
of the current study was the development of WNT-driven adult GCT in at least 20% of APC2-
deficient female mice (on the background of non-induced Apcfl/fl) as early as 12 months. These 
tumours recapitulated human adult GCT histology and molecular signature. One of the 
significant findings that emerged from this study is that APC2 loss does not contribute to 
ovarian epithelial tumourigenesis (as distinct from sex cord-originating GCTs); epithelial 
tumour formation was not evident when APC2 was lost on its own, or combined with APC or 
PTEN loss. On the contrary, OSE disruption caused by age and/or APC loss in the epithelium 
was attenuated post-APC2 loss. APC2-deficiency in Ad-cre Ptenfl/fl/Apcfl/fl OEA model 
attenuated tumour growth, although this attenuation was preceded by earlier initiation. Taken 
together, these results suggest that APC2 is an important regulator of ovarian WNT signalling 
and plays essential roles in ovarian homeostasis and fertility. In addition, it is a tumour 
suppressor for GCT development, but plays a dualistic role in WNT-driven OEA: a tumour 
suppressor for initiation and an oncoprotein for progression. 
The findings from this study make several distinct contributions of fundamental new 
knowledge to the current literature, being the first to highlight the role of APC2 as an important 
regulator of WNT signalling in the ovary. Initial studies performed in Drosophila and on cell 
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lines to functionally-characterize APC2 demonstrated the presence of β-catenin and Axin1 
binding sites in APC2, which enable it to regulate WNT signalling (Hamada et al. 1999; Van 
Es et al. 1999; Ahmed et al. 2002; Akong et al. 2002; McCartney et al. 2006; Roberts et al. 
2012). However, in an in vivo setting, APC2 regulation of WNT signalling is tissue specific, 
with WNT signalling activation post-APC2 loss only evident in the small intestine and liver 
but not the mammary glands (Daly 2013; Daly et al. 2016).   
The current findings also extend our knowledge of deleterious effects of WNT 
signalling activation on ovarian homeostasis and fertility, which had previously been suggested 
from studies investigating WNT signalling activation and ovarian subfertility in mice 
(Boerboom et al. 2005; Fan et al. 2010a; Abedini et al. 2016; De Cian et al. 2016). Results 
presented here have clearly shown that reduced ovulation observed in APC2-deficient mice is 
not caused by defects in ovulation and terminal differentiation of granulosa cells (which happen 
when WNT signalling is activated in antral follicles), but rather caused by restricted follicular 
growth and failure to reach the pre-ovulatory stage. This phenotype is similar to previous 
phenotypes published when WNT signalling was activated in pre-antral follicles (Boerboom et 
al. 2005; Abedini et al. 2016), implying that APC2 is expressed in growing follicles as early 
as the pre-antral stage. 
In addition, this research provides additional evidence with respect to roles of WNT 
signalling activation in the pathogenesis of ovarian GCT. Accumulating evidence from clinical 
data has pointed to this role of WNT signalling (Boerboom et al. 2005; Stewart et al. 2013; 
Kilonzo et al. 2015; Xu et al. 2016), and GEMMs proved that WNT signalling activation on 
its own is sufficient to initiate ovarian GCTs (Boerboom et al. 2005; De Cian et al. 2016). 
The findings in this study provide a new understanding of roles of APC2 in ovarian 
epithelial tumourigenesis. Reports from previous work (Jarrett et al. 2001; Perets et al. 2013), 
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as well as data extracted from cBioPortal database have shown loss of APC2 (allelic imbalance 
or mutational deletions) in human ovarian carcinoma. In addition, the role of WNT signalling 
in human OEA pathogenesis (Wu et al. 2001; Tanwar et al. 2013), and in different GEMMs 
developing OEAs post-WNT signalling activation alone (Tanwar et al. 2011a; Tanwar et al. 
2013; van der Horst et al. 2014), or in combination with PTEN-loss (Wu et al. 2007; Tanwar 
et al. 2011a; Wu et al. 2011; Zhai et al. 2016), led to the hypothesis that APC2 was a tumour 
suppressor for ovarian epithelial tumourigenesis. However, findings of the current study do not 
support this hypothesis. Instead, they suggest that APC2 is an oncoprotein for WNT-driven 
OEA progression, similar to its role in WNT-driven hepatocellular carcinoma (Daly 2013). 
This new hypothesis is supported by a recent finding that increased APC2 levels in human 
HGSOC are associated with decreased overall survival as well as progression-free survival 
post-chemotherapy (Seagle et al. 2016). 
One important feature of tumours developing in APC2-deficient Ptenfl/fl/Apcfl/fl -induced 
ovaries, as compared to Apc+/+ tumours, was squamous metaplasia and keratinization with 
reduced mitotic capacities. This could be explained in terms of the ‘just right’ hypothesis of 
WNT signalling activation  According to the hypothesis, a ‘moderate’ dose of WNT signalling 
activation is required for tumourigenesis. However, if this dose is exceeded, tumourigenesis is 
attenuated as tumour cells undergo abnormal differentiation rather than proliferation. This was 
evident in intestinal tumours (Bordonaro et al. 2008), and in mammary gland organoids (Jardé 
et al. 2016), where hyper-induction of WNT signalling caused increased apoptosis or squamous 
metaplasia, respectively. Using the ‘just right’ hypothesis to explain the findings of the current 
study (Figure 6.1), one can postulate that WNT signalling activation post APC2-loss was 
‘counteracted’ by other signalling pathways in granulosa cells of ovaries during early 
adulthood so as to reach a ‘just right’ level to cause GCT formation only in a subset of aging 
mice. However, it never reached the ‘just right’ level needed to induce epithelial ovarian 
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tumourigenesis even when the dose was ‘increased’ post APC-loss. In contrast, in the 
Ptenfl/fl/Apcfl/fl tumour model, APC/APC2 loss combined with PI3K pathway activation enabled 
the ‘just right’ level to be reached earlier causing early initiation but was followed by 
‘hyperinduction’, which delayed/prevented tumour growth probably by inducing 
differentiation into non-mitotic squamous keratinized cells (Appendix 6-7). 
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Figure 6.1: Using the ‘just right’ hypothesis of WNT signalling to explain interactions between 
APC and APC2 in tumourigenesis. (a) APC2 loss does not modulate WNT-driven 
tumourigenesis post-APC loss in the intestines, synergize with APC loss to reach the ‘just right’ 
level of WNT activation to drive mammary gland tumourigenesis, but exceeds the ‘just right’ 
level required for hepatocellular carcinoma in non-induced Apcfl/fl mice (reduced APC level) 
(Daly 2013). (b) In the ovary, loss of APC or APC2 alone or in combination in the OSE fails 
to activate WNT signalling to reach the ‘just right’ level for tumourigenesis. However, in 
PTEN-deficient OSE, APC loss is enough to activate WNT signalling to the ‘just right’ level, 
but combined APC/APC2 loss causes hyper-activation of WNT signalling exceeding the ‘just 
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right’ level and attenuating tumour progression. In granulosa cells, reduced APC (non-induced 
Apcfl/fl) was enough to reach the ‘just right’ level of WNT signalling activation to drive 
tumourigenesis in 1/19 mice. However, combined APC2 deficiency with APC reduction 
caused the ‘just right’ level to be reached in 20% of mice, causing GCT formation. 
Given the constitutive nature of the Apc2- allele, both autonomous and non-autonomous 
mechanisms are expected to contribute to the described phenotypes. Results of the current 
study have clearly shown the intra-ovarian origin of the subfertility phenotype described in 
APC2-deficient mice, and that hypothalamic-pituitary regulation of ovarian functions is not 
contributing to the subfertility phenotype. Although the subfertility is caused by increased 
apoptosis of granulosa cells, a contribution of endothelial cells to the phenotype was evident. 
Whether the same phenotype could be reproduced if APC2-deletion was targeted exclusively 
in granulosa cells (using Amhr2 or Cyp19a-cre) remains unknown, due to the unavailability of 
an Apc2- conditional allele. The same applies to GCTs developing in APC2-deficient mice, 
which – in contrast – displayed enhanced angiogenesis. In the case of epithelial tumours 
developing in APC/PTEN-deficient mice, findings of the current study suggest that non-
epithelial cells are contributing to enhanced tumour formation seen when APC2 was intact. 
This was evident by the presence of immune cell infiltrates in tumours, and enrichment of 
immune and inflammatory pathways, which were absent when Apc2 was deleted. This would 
imply that APC2-deficiency in immune cells is disruptive, and may be preventing a positive 
contribution to tumour growth.  In addition, the constitutive nature of Apc2- allele might be 
contributing to the early initiation of tumourigenesis observed in APC2-deficient tumours, by 
modulating T-cell ‘immunoediting’ suppression of tumourigenesis. Furthermore, although the 
current study focused on WNT signalling-regulatory functions of APC2, contributions of non-
WNT functions of APC2 cannot be ignored. Previous studies have pointed to APC2 in 
regulating cytoskeleton and microtubule association (McCartney et al. 1999; Nakagawa et al. 
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2000b; Jarrett et al. 2001; Shintani et al. 2009; Shintani et al. 2012), spindle anchoring during 
mitosis (McCartney et al. 2001), and a possible modulating role of cell cycle progression and 
apoptosis via translocating p53-binding protein 2 (also known as apoptosis-stimulating protein 
2 of p53 ASPP2) to the perinucleus (Nakagawa et al. 2000a). Disruption of these roles, 
although not explored in the current study, might have contributed to GCT formation in APC2-
deficient mice, and to early initiation of tumourigenesis happening in APC2-deficient 
Ptenfl/fl/Apcfl/fl adenovirus-cre induced ovaries. 
Also, it is naïve to think that WNT signalling activation is the sole driver of the reported 
phenotypes, or to ignore the cross talk between WNT signalling and other signalling pathways. 
For example, unlike early adulthood, FOXO1 expression was absent in APC2-deficient GCT, 
implying a need to silence FOXO1 and to stop FOXO1-driven granulosa cell apoptosis as a 
prerequisite for tumourigenesis. However, the cause of the ‘switch’ from present 
FOXO1/granulosa cell apoptosis to absent FOXO1/granulosa cell proliferation and 
tumourigenesis was not identified and needs to be characterized. This question needs to be 
extended to WNT-driven tumourigenesis in other organs to determine whether it is associated 
with silencing FOXO1. Answering this question might help in identifying new targets for 
cancer treatment. It is noteworthy to mention here that PTEN levels remained elevated in 
granulosa cells at early adulthood and in granulosa cell tumours, which means that the control 
of FOXO1 expression is not solely happening through PTEN/p-AKT axis, which is typically 
thought to regulate FOXO1 nuclear localisation. The high levels of PTEN in granulosa cells of 
growing follicles might have contributed to increased apoptosis by inhibiting the translocation 
of FOXO1 outside the nucleus and thus ensuring FOXO1 activates pro-apoptotic target genes. 
In addition, high PTEN expression levels found in GCT of APC2-deficient ovaries might be 
responsible for the late development of tumourigenesis, as previously described in other models 
(Lague et al. 2008; Richards et al. 2012; Liu et al. 2015). It is thus possible to hypothesize that, 
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similar to previously published models, deleting Pten in granulosa cells of APC2-deficient 
ovaries would lead to rapid tumour development. The upregulation of ERK signalling in large 
tumours developing in Ptenfl/fl/Apcfl/fl/Apc2+/+- induced ovaries is another example of 
contribution of different signalling pathways to tumourigenesis, which was not explored in 
detail in the current work due to time constraints. 
Given the very low expression of APC2 in the ovary, an important role in regulating 
ovarian homeostasis is perhaps unexpected. However, in the mouse mammary gland, where 
the expression of APC2 is lower than that of the ovary, combined loss of APC2 and APC 
initiated tumourigenesis, in contrast to failure of APC loss on its own to do so (Daly et al. 
2016). In contrast, loss of APC2 on a background of floxed APC attenuated hepatocellular 
carcinoma developing in Apcfl/fl aging mouse liver (Daly 2013). This raises the question about 
defining the functional interaction between both APC proteins in the ovary. There are clear 
discrepancies between the subfertility phenotype described post-APC2 deletion in the current 
study and the absence of ovarian defects in APC-deficient mice, despite WNT signalling 
activation (Tanwar et al. 2013). Similarly, it is noteworthy that aged Apcfl/fl mice have not been 
previously reported to develop GCTs (Buchert et al. 2010; Wu et al. 2011), as confirmed in 
the cohorts collected at 12 months in the current study (both non-induced and adenovirus-cre- 
induced Apcfl/fl cohorts did not develop GCTs). Even when Amhr2-cre was used to induce 
recombination of Apcfl/fl in the OSE and granulosa cells, female mice developed OEA by 11 
months of age, but none developed GCTs (Tanwar et al. 2013). Taking into account that 20% 
of Apc2-/- mice (on a non-induced Apcfl/fl background) developed GCT at the age of 12 months, 
and none developed OEA by the age of 18 months, and that APC2 loss attenuates OEA growth 
in Ad-cre Ptenfl/fl/Apcfl/fl ovaries, it could be proposed that APC and APC2 play distinct and 
antagonistic roles in the OSE and in granulosa cells of growing follicles (similar to their 
functional antagonism in the liver, but different from their functional compensation in the 
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mammary gland). It is to be noted that one of the non-induced Apcfl/fl mice developed a small 
GCT at the age of 18 months driven by WNT signalling activation. Given the hypomorph 
nature of floxed Apc allele, previously shown in other organs e.g. the liver (Buchert et al. 2010), 
this raises the question of whether loss of APC2 on a wild type Apc background is sufficient to 
drive GCT formation, similar to those developing when floxed Apc background was present. 
This question however remains unanswered and needs to be explored. 
A key aspect of this study was the establishment of consistent methodologies and 
interventions. When characterizing ovarian homeostasis, it is crucial to collect all ovaries at the 
same stage of the oestrous cycle in order to eliminate the cycle stage as a variable. Choosing 
which stage to work with in this study was an important point to be considered. As the main 
goal of the study, initially, was to characterize roles of APC2 in the OSE, ovaries were collected 
at the diestrus stage (which is post-ovulatory), to determine whether APC2 regulates wound 
repair after ovulation. However, the choice of this stage limited the number of pre-ovulatory 
follicles present, which were needed to characterize subfertility. Two methods were used for 
collecting ovaries at a synchronized stage, exogenous gonadotrophin administration and 
manual staging. Gonadotrophin administration partially synchronized female mice, with only 
70% of mice present in the diestrus stage 22-24 hours post-HCG administration. In addition, 
this method interferes with normal ovarian homeostasis, causing unrepairable tears in the OSE 
of all mice, irrespective of the genotype, due to forcing many follicles to ovulate at the same 
time. Although more time-consuming, manually-staging mice using the vaginal cytology 
method (Byers et al. 2012), proved to be more accurate.  
Initial characterisation of ovarian homeostasis by counting follicles and corpora lutea 
in one section/ovary, was found to be unreliable. For example, a pre-ovulatory follicle missing 
an ovum in a section could be mis-regarded as a cyst. In addition, because different follicular 
stages are distributed in the cortex of the whole ovary, counting one section is not enough to 
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represent the number of follicles in the ovary. Characterization of serially-sectioned ovaries, 
by sectioning the ovary into 100 sections 5 µm apart, and staining the 10th section by H&E to 
be examined microscopically, although time consuming, must be carried out for correct 
analysis. However, because most of the organ is then sectioned at one time, preserving antigens 
present in the cut sections placed on poly-l-lysine (PLL) -coated slides for an extended period 
should be considered. In the current study, re-dipping the PLL sections in wax proved to be 
effective in preserving both cytoplasmic and nuclear antigens for years, and is recommended 
for future studies. 
The 3Rs (reduction, replacement, refinement) principles for animal research were 
considered while designing all experiments presented in the thesis. For example, to assess 
fertility, a retrospective analysis of breeders rather than setting mating experiments was the 
chosen method. One limitation here was that the extracted data available for different 
genotypes of female Apc2 mice (Apc2+/+, Apc2+/-, Apc2-/-) represented crossings to males of the 
corresponding genotype, rather than to wild type males. Effects of Apc2-gene dosage on male 
fertility are not yet characterized, with the caveat that male fertility might be affected in APC2-
deficient male mice, and could contribute to the delayed pregnancy and reduced litter size 
observed in APC2-deficient crosses. In order to address this issue, another experiment was 
designed using female mice from the 3 different Apc2 genotypes, where ovulated oocytes post-
gonadotrophin administration were retrieved and counted. This experiment confirmed that 
APC2-deficient mice ovulate less and would be expected to give smaller litter size. Another 
example of considering the 3Rs principles was viral induction of both ovaries to minimize the 
number of animals used in the experiments, in contrast to previous publications which induced 
only one ovary leaving the other ovary to serve as control (Flesken-Nikitin et al. 2003; Wu et 
al. 2007), wherein the current study, external controls (induced wild type mice) were used 
instead. A method refinement was performed, as well, by changing the injection site, through 
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injecting the adenovirus-cre directly into the bursal space via the bursal membrane rather than 
using the trans-infundibular intra-oviductal route (Flesken-Nikitin et al. 2003; Wu et al. 2007). 
This refinement was employed to avoid recombination of floxed genes in the oviducts, by 
avoiding direct injection into their infundibular ends. Despite this, one of the aged Ptenfl/fl-
induced mice displayed an oviductal tumour, which might be explained in terms of the 
anatomical location of the oviduct, which directly opens into the bursa, and the leakage of virus 
from bursa to oviduct. 
In order to dissect contributions of APC2 in EOC development, APC2 loss was 
introduced to an established mouse model of OEA and a comparative study between tumours 
formed with/without APC2 were performed. The Ptenfl/fl/Apcfl/fl adenovirus-cre induced OEA 
model (Wu et al. 2007) was chosen because it is based on WNT signalling activation through 
APC loss, and was successfully used previously to elucidate contributions of oncogenes (Wu 
et al. 2013), or tumour suppressors (Zhai et al. 2016) to ovarian epithelial tumourigenesis. 
However, the OEA histotype is different from the serous adenocarcinoma histotype where 
APC2 loss has been reported (Perets et al. 2013). Whether the phenotypes reported here would 
be reproducible if APC2 loss was introduced to a serous carcinoma tumour model [e.g. Pax8-
driven deletions of Brca/Tp53/Pten model (Perets et al. 2013)], or to a non-WNT driven OEA 
model [e.g. Mucin1-expressing/Kras activated/ Pten deleted model (Tirodkar et al. 2014)] 
needs to be unravelled before oncogenic roles of Apc2 could be generalized to all ovarian 
epithelial tumours.  
An important limitation in the current study was the absence of an APC2 antibody 
which could be used for immunohistochemistry to differentiate between Apc2+/+ and Apc2-/- 
tissues. The antibody previously used by Dr Carl Daly was discontinued by the manufacturer. 
For this study, 3 different antibodies were tested, but none were reliable for use in 
immunohistochemistry (although an Abcam antibody could differentiate between APC2 levels 
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in western blot of protein extract from brains), with similar staining patterns observed in 
Apc2+/+ and Apc2-/- ovaries (Appendix 2). This meant the inability to define, for instance, at 
which follicular stage APC2 is expressed. In order to bypass this limitation, all possible 
phenotypes previously published in the setting of WNT signalling activation and ovarian 
subfertility in mice were analysed in the APC2 null mice (Boerboom et al. 2005; Fan et al. 
2010a; Abedini et al. 2016; De Cian et al. 2016). An alternative approach was to design 
RNAscope probes by which Apc2 mRNA could be hybridized and visualized in situ. However, 
this was hampered by the lack of information regarding the genetic engineering of the Apc2- 
allele. Many attempts were made over the course of this work, using a number of different 
approaches, to sequence the engineered allele. Only a partial sequence was obtained in-house. 
To confirm the partial results and, potentially, to unravel the full sequence, a walking primer 
project was performed by Eurofins Genomics and results have become available shortly before 
submission of this thesis (Appendix 3). The difficulties in obtaining a full sequence of the allele 
are due to secondary structures and the formation of multiple hairpins, which Eurofins also had 
difficulties with. However, the sequencing did reveal 60 bases were deleted in exon 14 of Apc2 
mutant gene, resulting in a frameshift mutation and a pre-mature stop codon, translated into a 
truncated non-functional protein (Appendix 3). The western blot showed a loss of the 240 kDa 
APC2 band in Apc2-/- mice, and did not detect a smaller truncated fragment in Apc2-/- when an 
antibody binding to the truncated region was used (Appendix 2). However, this small difference 
in the nucleotide sequence makes designing RNAscope probes impossible, at least 300 bases 
need to be unique in order to design probes which can faithfully show differences between 
Apc2+/+ and Apc2-/- genotypes. The newly-developed BaseScope assay, which can detect short 
RNA targets down to 50 bases, could be considered instead. 
Delays in inducing cohorts needed in Chapter 6 as a result of technical/administrative 
reasons (amending project licence to allow for intrabursal injections, preparing a surgical suite 
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with class II biological safety cabinet to perform inductions, health and safety approvals for 
viral injections, practicing intrabursal injection by the technician), as well as the sad death of 
Professor Alan Clarke resulted in most of this work happening late in the project, which limited 
the time available for the analysis. For instance, the non-autonomous contributions of the 
constitutive Apc2- allele in modulating inflammatory and immune responses, impacting on 
tumour initiation and progression, were not fully characterized. Another important limitation 
is the small cohort sizes used in here to characterize roles of APC2 in OEA tumourigenesis. 
More mice have been induced in the Apc2+/+ and Apc2-/- tumour cohorts to be collected 8 weeks 
post-induction (which will be after thesis submission). Tumours collected from these mice will 
add more weight to the data presented here, and will enable the confirmation of the RNAseq 
data by performing qRT-PCR on independent samples. 
In conclusion, the findings of the current study provide fundamental new knowledge 
on the role of APC2 in regulating ovarian WNT signalling, homeostasis and tumourigenesis.  
The finding that WNT signalling activation in growing follicles impairs ovulation raises the 
importance of the assessment of WNT signalling activation in the setting of human female 
subfertility/infertility. This could provide new insights into the molecular pathogenesis of this 
condition, and may help in designing new treatment interventions for these patients. In 
addition, the clinical relevance of data gathered from the GEMMs in this study needs to be 
investigated. As shown here, and as previously reported (Boerboom et al. 2005; Hai et al. 2015; 
Liu et al. 2015; De Cian et al. 2016), mutations which cause female subfertility or infertility in 
early adulthood in mice are followed by development of GCT upon aging. Is this the case in 
human females?  
In addition, the study has led to a potential paradigm shift in our understanding of APC2 
roles in epithelial ovarian tumourigenesis. The findings have shown that Apc2 can be either an 
oncogene or a tumour suppressor gene depending on context. Furthermore, the RNA seq 
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analysis performed in the current study on Apc2+/+ and Apc2-/- Ptenfl/fl/Apcfl/fl–induced ovaries, 
together with literature searching enabled the identification of genes/proteins which are 
upregulated in epithelial ovarian tumours such as HAL and HUNK. Roles of these proteins in 
epithelial ovarian cancer have not yet been characterized and are highly recommended for 
future work. Downregulation of Esr2 was evident in GCT developing in APC2-deficient 
female mice, as well as in large OEAs developing in Apc2+/+ vs. Apc2-/- Ptenfl/fl/Apcfl/fl –induced 
ovaries. This raises the question of whether downregulation of Esr2 is required for ovarian 
tumourigenesis, irrespective of tumour type. Recent work exploring treatment interventions to 
make use of ESR2 as a possible ovarian tumour suppressor, by using estrogen receptor β-
agonist (synthetic agonists or phytoestrogens) has proven its efficacy in decreasing OC cell 
growth  (Schuler-Toprak et al. 2017), and in sensitizing resistant OC cells to chemotherapy 
(Liu et al. 2017). 
With OC standing as the most lethal gynaecological malignancy accounting for 4128 
deaths in UK in 2014, equivalent to 56% of cases diagnosed in that year (CancerResearchUK 
2017), the current study provided important contributions to our fundamental understanding of 
the pathogenesis of this highly-heterogeneous ill-defined group of tumours. 
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9. Appendices 
Appendix 1: List of preparations used in the Material and Methods section 
1X Tris Borate EDTA (TBE) buffer  
10.8 gram Tris base (Fisher Bioreagents, USA) + 5.5 gram Boric acid (Riedel-de Haen, 
Germany) + 0.585 gram EDTA (Sigma-Aldrich, USA) in 1000 ml ultrapure water (Sigma, 
USA), pH: 8 
Sterile saline solution 
0.9 g of sodium chloride (Sigma, USA) dissolved in 100 ml distilled water and autoclaved 
1X Citrate buffer 
2.94 g Sodium citrate tribasic dihydrate (Sigma, USA) in 1000 ml distilled water, pH: 6 
1X TBST buffer 
6.05 gram of tris base (Fisher Bio reagents, USA) + 8.76 gram of sodium chloride (Sigma, 
USA) in 1000 ml distilled water+ 1 ml of Tween 20 (Sigma, USA) , pH: 7.4 
0.1% sterile gelatine solution 
 100 mg gelatine (Sigma, USA) dissolved in 100 ml of sterile 1X PBS (Gibco, Life 
Technologies, USA), sterilized by autoclaving 
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Appendix 2: Expression levels of APC2 in Apc2+/+ and Apc2-/- mice 
Upon starting this project, knowing that the only antibody previously used by Dr. Carl 
Daly to differentiate between Apc2 different genotypes by immunohistochemistry was 
discontinued by the manufacturer, many techniques were attempted. The Apc2-/- mouse was a 
gift from the Clevers lab who did not reveal the exact genetic structure of the Apc2- construct 
inserted into the mouse embryonic cells. Dr. Karen Reed personal communication with the 
Clevers group revealed uncertainty about the method and the site of the genetic alteration in 
the Apc2 gene. However, they suggested that the genetic alteration they had performed was in 
Apc2 exon 13, a 215 bp exon present before the large terminal exon 14 (4990 bp). 
Gene expression analysis of Apc2 was first attempted. RNA was extracted from ovaries 
and cDNA was used for qRT-PCR assay. The first gene expression analysis performed was a 
Taqman gene expression assay using an Apc2 mouse Taqman probe which spans exon junction 
between exons 13 and 14. This assay confirmed the presence of Apc2 mRNA in the whole 
ovarian tissue. There was a significant change in Apc2 expression between Apc2+/+ and Apc2-/- 
mice, surprisingly a 16-fold increase of Apc2 expression in Apc2-/- mice as compared to Apc2+/+ 
mice. Subsequent gene expression analysis was performed using the SYBR Green gene 
expression assay, which enables the design of primers to target the amplification of specified 
sequences. Gene expression analysis using primers specific for exon 13 (one designed to 
amplify the beginning of the exon, the other one to amplify the end of the exon) of the Apc2 
mRNA resulted in a 10±1 folds increase of Apc2 expression levels in Apc2-/- mice as compared 
to Apc2-/- mice. However, when performing the expression analysis using primers specific for 
exon 14, a comparable expression was observed in the 2 genotypes (Figure A2.1). 
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Figure A2.1: Gene expression levels of Apc2 in Apc2-/- vs. Apc2+/+ ovaries was performed by 
qRT-PCR and normalized to Actb expression using Taqman probe, or primers designed 
specifically for exon 13 (B: beginning, E: end) or exon 14. Data are shown as mean±95% 
confidence intervals of relative mRNA expression levels, n=3-4. Statistical significance was 
determined according to Cumming et al. (Cumming et al. 2007). * denotes significance from 
Apc2+/+ at p<0.05. 
In order to visualize APC2 expression pattern in the ovary, immunohistochemistry was 
attempted using 3 different antibodies (A2.2a). But, because there were no difference in the 
protein expression staining patterns between Apc2+/+ and Apc2-/- ovaries, these antibodies were 
not considered reliable for use in immunohistochemistry, and could not be used to describe 
expression patterns of APC2 in the ovary. These antibodies were then tried for western blotting 
using Hela cells as a positive control. The Abcam APC2 antibody (ab113370) was the only 
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antibody which gave a protein band of the expected size (240 kDa). Protein samples were then 
prepared from Apc2+/+ and Apc2-/- ovaries and used for APC2 protein detection by western 
blotting. However, owing to the very low expression levels of APC2 in the ovaries, no bands 
were detected. Because Apc2- allele is constitutive, brain protein extracts were used to confirm 
differences in APC2 protein levels between Apc2+/+ and Apc2-/-, as APC2 is highly expressed 
in the brain. A band of size equivalent to APC2 protein was detected in Apc2+/+ brain, but not 
in Apc2-/- brain (Figure A2.2b). 
 
Figure A2.2: Protein expression of APC2 in Apc2+/+ and Apc2-/- mice by (a) 
immunohistochemistry of ovaries using 3 different antibodies from Abcam, Invitrogen and 
Santa Cruz. Scale bars: 100 µm. (b) western blotting of brain tissue using Abcam APC2 
antibody. GAPDH was used as a loading control protein.  
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Appendix3: Apc2- allele sequencing 
To characterize the site of genetic manipulation in Apc2- allele, the genotyping primer 
pair provided by the Clevers lab (primer pair 1, Table 3.10) was first blasted using Primer-
Blast program to detect the target template, but no templates were detected, implying that the 
primer is designed specifically to target Apc2- genetic construct. Following this, the primer pair 
was used to amplify genomic DNA extracted from Apc2-/- mouse, and the amplified DNA was 
sent to Eurofins genomic services for sequencing (Figure A3.1a). Blasting sequencing results 
revealed that the sequence was mostly aligned to exon 14 (starting at base 265 and ending at 
base 762) of mouse Apc2, apart from the first 15 bp which were not aligned to exon 14. Instead, 
this short fragment showed 100% alignment with a range of cloning vectors, suggesting that 
the cloning vector insert is present in exon 14. 
To determine the sequence of the insert used for cloning to define its effect on Apc2 
gene and protein production  in the ‘Apc2-/-’  mouse, another forward primer complementary to 
exon 13 was designed and used together with the same reverse primer (designed by Clevers 
lab) to amplify genomic DNA from Apc2-/- mouse (primer pair 2, Table 3.10). Gel 
electrophoresis revealed that the size of this region was approximately 4500 bp, 1800 bp larger 
than the Apc2+/+ amplicon (Figure A3.1b). The amplified DNA was sent to Eurofins genomic 
services for sequencing, and sequence results revealed that the first half of intron 13-14 is intact 
and completely aligned to the published mouse Apc2 gene sequence. Forward primers 
complementary to the intron were designed and used together with the same reverse primer to 
further amplify and sequence this region. However, either multiple bands or no bands were 
detected. As a result, a primer-walking project was performed by Eurofins genomic 
sequencing, and the full length of the amplified region (starting at exon 13 and ending by base 
762 of exon 14) was sequenced (Figure A3.2). Sequencing results revealed that the full length 
of exon 13, intron 13-14 and first 204 bases of exon 14 were intact. However, a targeting vector 
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(containing a neomycin cassette and 2 loxP sites) was inserted following base 204 of exon 14. 
60 bases of exon 14 were deleted in the Apc2- allele (base 205-264), after which the remaining 
sequence aligned again with Apc2 exon 14 mouse sequence (base 265-762) (Figure A3.3). 
Gene targeting caused a frame shift mutation resulting in pre-mature stop codon in the mRNA, 
consequently translated to a truncated protein (formed of the first 671 (of 2274) amino acids of 
mouse APC2 protein) (Figure A3.4). This truncated protein lacked important functional 
conserved domains such as one of the six armadillo repeats (mediate interaction between APC2 
and β-catenin), SAMP motif (binds to Axin), and APC basic domain (interacts with 
microtubules), as extracted from conserved domain database (Marchler-Bauer et al. 2017) 
(Figure A3.5). 
 
 
 
 
 
 
 
 
Figure A3.1: Gel electrophoresis of Apc2 DNA amplified using (a) the genotyping primers 
(Primer pair 1, Table 3.10), and (b) primers designed to amplify the sequence beginning from 
exon 13 to exon 14 (primer pair 2, Table 3.10).Yellow arrowhead: Apc+ PCR fragment (size: 
580 bp). Red arrowhead: Apc- PCR fragment (size 495: bp). Picture (a) was produced by Dr. 
Carl Daly  
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ctgtcagcacacagcacagagaacaaggcagccatctgccaggtagatggtgcactgggtttcctggtgagcaccctcacataccgtt
gccaagggaactccctggcagtcatcgagagtggcggtgggatcctgcgcaacgtgtcaagcctcattgccacacgggaggactac
aggtcagctcccatcacgatccacccaaatcacagaggccgggaatgggagatggtgggggagcagtggctgctcttgcagagaa
cctgggtttggttgtcagcactgcatggtgacacacaaacacccttaactccagttccacgggatcctgtgccctcttcttacatccgtgg
gcaccaggcacacatgtggcacacagacaaacatccaggcataacaaccatacacagagtataacataaaccacattactagataat
gttcataataaggcagacgtggcagggcgtgatccccatcccagcacccgggaagcagagagaggatgccctacaagtctaaggc
cagcctggtttctagcaagttctaggccagtcaggactgtcaaatgagatctttcctcaaggccaggtatggtgtgtgtctcagtaactgt
ccatatgtgccactttgttcccagcactcgggggtgggcggctcaccacatgtgacttcagttccagggccctgccactcccttctgctg
ctggtgggcacttcacacatggtgcacagacagacacacacccgtacacatgaaataaaatgacaggaattttaaagttgggctgaag
agatggctcagtggttaagagcactgactgctcttccaaaggtcctgagttcagttcccagcaaccacatggtgtctcacaaccatctgt
aatgggatctgatgtcctcttctggtgcatcttatacataaaatcataaaataaataaataattttttttttggttttttgagacccctagctgtctt
ggaactcattctgtagaccaggcttgcctcaaactcagaaatctgcctgtctctgcctcccaagtgctgggattaaaggtgtgcgacacc
actgcccagaaaataaatctttttaaaaaaatacttttaaaattaagtcttaaaaacaaatgagccgggcgtggtggcacacacctttaatc
ccagcacttgggaggcagagacaggcggattttggagtccgaggccatcctggtctatagagtgagtttcaggacagcgagggctac
acagagaaaccttgtctcgaaaaacaaaaaagtcttaaaaacaaaccaaatatataacccagatatggaggtacaggacacacaccta
taaacctggcacaggaaagccaccttcagctagctatggagtttaaagttagcctcggcttgctcagacccttcctcaaaacaaaacaa
acccaaacagctgcggggaatcacgcagcgcggctgggaaagcttacggtatagctattttatttttttctcaaattcacacctaaaggat
ggacattttaatctgctatagaggttctagtcttgtgtggtgggcggggcgtgtaggggcatggctaagccttgctagcaagctggggtc
gttcagctagtgggggtaaagtggaggtgggcatggttgagcacaggcttgacaggtcggtatggaccgggcggggcggggcgg
ggcggggcaagccaaggggcatagcgaggcagtgttgtgattggctgagcggggtcatcacaggcaggggtgaacctgatttactt
ggttggctaagagttcagcaaggtagaggtgagtatagcggagatggggatatgggtgggcatgactgaacaaagggcatagctag
gctagaggagtggctgagtcaggcaagcatggctgggctggggctgctgggctggggaccttgggagaggagctctcatgtagggt
gtggcaggaatggcagtgtgatgtggatggtgagcactgcaggactggagtaaagcccacctttttttcctctgggtttccccaggcag
gtgctccgtgaccacaactgcctgcagacactgctgcagcacctcacatcacacagtttgaccatcgtgagcaatgcctgtggcaccct
ctggaacctgtctgcccgcagcccccgcgatcaggaactgttgtgggacctgggggccgtgggcatgctacgcaacctcgtccactc
caaacacaagatgatcgccatgggccgctctagctagaactagtggatccggaacccttaatataacttcgtataatgtatgctatacga
agttattaggtccctcgacctgcagcccaagctgatcctctagtcgagccccagctggttctttccgcctcagaagccatagagcccac
cgcatccccagcatgcctgctattgtcttcccaatcctcccccttgctgtcctgccccaccccaccccccagaatagaatgacacctact
cagacaatgcgatgcaatttcctcattttattaggaaaggacagtgggagtggcaccttccagggtcaaggaaggcacgggggaggg
gcaaacaacagatggctggcaactagaaggcacagtcgaggctgatcagcgagctctagctagagaattgatcccctcagaagaact
cgtcaagaaggcgatagaaggcgatgcgctgcgaatcgggagcggcgataccgtaaagcacgaggaagcggtcagcccattcgc
cgccaagctcttcagcaatatcacgggtagccaacgctatgtcctgatagcggtccgccacacccagccggccacagtcgatgaatc
cagaaaagcggccattttccaccatgatattcggcaagcaggcatcgccatgggtcacgacgagatcatcgccgtcgggcatgcgcg
ccttgagcctggcgaacagttcggctggcgcgagcccctgatgctcttcgtccagatcatcctgatcgacaagaccggcttccatccg
agtacgtgctcgctcgatgcgatgtttcgcttggtggtcgaatgggcaggtagccggatcaagcgtatgcagccgccgcattgcatca
gccatgatggatactttctcggcaggagcaaggtgagatgacaggagatcctgccccggcacttcgcccaatagcagccagtcccttc
ccgcttcagtgacaacgtcgagcacagctgcgcaaggaacgcccgtcgtggccagccacgatagccgcgctgcctcgtcctgcagt
tcattcagggcaccggacaggtcggtcttgacaaaaagaaccgggcgcccctgcgctgacagccggaacacggcggcatcagagc
agccgattgtctgttgtgcccagtcatagccgaatagcctctccacccaagcggccggagaacctgcgtgcaatccatcttgttcaatg
gccgatcccatattggctgcaggtcgaaaggcccggagatgaggaagaggagaacagcgcggcagacgtgcgcttttgaagcgtg
cagaatgccgggcctccggaggaccttcgggcgcccgccccgcccctgagcccgcccctgagcccgcccccggacccacccctt
cccagcctctgagcccagaaagcgaaggagcaaagctgctattggccgctgccccaaaggcctacccgcttccattgctcagcggtg
ctgtccatctgcacgagactagtgagacgtgctacttccatttgtcacgtcctgcacgacgcgagctgcggggcgggggggaacttcc
tgactaggggaggagtagaaggtggcgcgaaggggccaccaaagaacggagccggttggcgcctaccggtggatgtggaatgtg
tgcgaggccagaggccacttgtgtagcgccaagtgcccagcggggctgctaaagcgcatgctccagactgccttgggaaaagcgc
ctcccctacccggtagaattccgatcatattcaataacccttaatataacttcgtataatgtatgctatacgaagttattaggtctgaagagg
agtttacgtccagccaagcttatcgataccgtcgacctcgacatggctgtctccccaggcacctgcgtgcccagtctttacgtccgcaag
cagagggctctggaagctgagttggacactcggcacctggtgcatgcactcggtcacttagagaagcagagtctgcctgaggcaga
gaccacttcaaagaagcccctgccacccctccgccacctggacgggctggtgcaggactatgcctctgattctggctgctttgacgat
gatgatgcaccatccctggctgctgctgccaccacagctgagcccgccagcccagcagtgatgtctatgttccttggcggtcccttcctt
cagggccaggcactggcccgcaccccacctgcccgccagggtggcctagaagccgagaaggaggctggtggggaggcagctgt
ggctgccaaggccaaggccaagctggcgttggctgtggctcggatcgacagattggtggaggacatctctgccctgcacacctcatc 
 
Figure A3.2: Sequence of Apc2- region amplified using primer pair 2 (See Table 3.10) 
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Figure A3.3: Schematic diagram of the structure of Apc2 wild type (Apc2+) and mutant (Apc2-
) alleles. Orange line: place of stop codon. Green triangles: loxP sites. Yellow: Target vector 
construct. Neo: Neomycin. 
 
MTSSMASYEQLVRQVEALKAENTHLRQELRDNSSHLSKLETETSGMKEVLKHLQGK
LEQEARVLVSSGQTEVLEQLKALQTDISSLYNLKFHAPALGPEPAARTPEGSPVHGSG
PSKDSFGELSRATIRLLEELDQERCFLLSEIEKEEKEKLWYYSQLQGLSKRLDELPHV
DTFSMQMDLIRQQLEFEAQHIRSLMEERFGTSDEMVQRAQIRASRLEQIDKELLEAQ
DRVQQTEPQALLAVKPVAVEEEQEAEVPTHPEDGTPQPGNSKVEVVFWLLSMLATR
DQEDTARTLLAMSSSPESCVAMRRSGCLPLLLQILHGTEAGSVGRAGIPGAPGAKDA
RMRANAALHNIVFSQPDQGLARKEMRVLHVLEQIRAYCETCWDWLQARDSGTETP
VPIEPQICQATCAVMKLSFDEEYRRAMNELGGLQAVAELLQVDYEMHKMTRDPLNL
ALRRYAGMTLTNLTFGDVANKATLCARRGCMEAIVAQLGSESEELHQVVSSILRNLS
WRADINSKKVLREVGSMTALMECVLRASKESTLKSVLSALWNLSAHSTENKAAICQ
VDGALGFLVSTLTYRCQGNSLAVIESGGGILRNVSSLIATREDYSLQTLLQHLTSHSL
TIVSNACGTLWNLSARSPRDQELLWDLGAVGMLRNLVHSKHKMIAMGRSS* 
Figure A3.4: Amino acid sequence of truncated APC2 protein formed in Apc2-/- mice. Amino 
acids in red are those translated because of the frame shift mutation.* denotes end of protein 
(equivalent to stop codon) 
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Figure A3.5: Conserved domains of mouse APC2 protein in (a) first 1000 amino acid sequence of the APC2 protein. Red line: Place of truncation 
in APC2 protein produced by Apc2-/- mouse, and (b) remaining amino acid sequence of the APC2 protein. APC-: coiled-coil N-terminus of APC. 
Suppress: APC suppressor protein. ARM/Arm: armadillo/β-catenin-like repeats. SAM: SAMP motif. APC basic: APC basic domain.(Marchler-
Bauer et al. 2017)
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Appendix 4: Expression levels of Wnt-target genes in the OSE 
In order to determine whether APC2 loss activates WNT signalling in the OSE, 
expression levels of a subset of Wnt target genes were identified. OSE was isolated from 
Apc2+/+ and Apc2-/- ovaries (Section 3.4.8), and cultured for 3-4 days until reaching confluency 
(Section 3.9.1). Cells were trypsinized, washed (Section 3.9.2) and collected in Eppendorf 
tubes. RNA was extracted from these cells using RNeasy plus micro kit (Qiagen, USA). The 
extracted RNA was used to prepare cDNA prior to performing gene expression analysis 
(Section 3.6). No significant differences were observed in the expression levels of all genes 
analysed (Figure A4.1) 
 
Figure A4.1:  APC2 loss does not activate canonical WNT signalling in the OSE. Expression 
levels of a subset of Wnt-target genes were compared between Apc2+/+ and Apc2-/- OSE extracts 
using qRT-PCR and normalized to Actb expression. Data are shown as mean±S.E. n=3. 
Statistical significance was determined by t-test. 
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Appendix 5: Recombination of floxed genes in the OSE post-adenovirus-cre injection 
(Previous work performed by Dr. Carl Daly) 
Preliminary experiments were performed by Dr. Carl Daly to confirm that 
recombination of floxed genes post adenovirus-cre intrabursal injections are confined to the 
OSE. First, a ROSA26 cre reporter strain (Soriano 1999) was induced by intrabursal 
adenovirus-cre injection to check cre-mediated recombination in the OSE, which induces the 
expression of a lacZ (β-galactosidase) gene. Whole ovaries were dissected and incubated with 
X-gal to check for lacZ activity. LacZ positivity (blue staining) indicated that recombination 
events had occurred in the ovarian surface post-induction (Figure A5.1 left panel). Fluorescent 
immunohistochemistry with a β-galactosidase antibody revealed recombination had occurred 
exclusively in the OSE (Figure A5.2 right panel). Following this, an Apcfl/fl mouse was induced 
by intrabursal injection of adenovirus-cre to check recombination of floxed Apc. Fluorescent 
immunohistochemistry against APC on sections from Apcfl/fl ovaries post-adenovirus cre 
induction reflected the loss of APC protein exclusively in cells of the OSE (Figure A5.2). 
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Figure A5.1: Intrabursal injection of adenovirus-cre successfully induced the recombination of 
floxed β-galactosidase gene in Rosa26 reporter mice. Whole mount ovaries (left panel) 
showing blue staining with post X-gal incubation only in adenovirus-cre injected ovary. Scale 
bar 2 mm. Fluorescent immunohistochemistry (right panel) post-adenovirus cre injection 
revealed that β-galactosidase staining was only present in the OSE compartment of the ovary. 
Scale bar 200µm. All pictures were produced by Dr. Carl Daly. 
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Figure A5.2: APC protein is absent from the OSE post-adenovirus cre injection.  APC protein 
is present in the OSE of non-induced Apcfl/fl ovaries (middle upper panel). However, it is lost 
post-adenovirus cre injection (middle lower panel). Scale bar 100 µm. All pictures were 
produced by Dr. Carl Daly. 
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Appendix 6: phospho-histone 3 protein expression analysis in Ad-cre Ptenfl/fl/Apcfl/fl OEA 
post-APC2 loss 
As illustrated in Figure 6.28, there were no significant differences in proliferation 
between Apc2+/+ and Apc2-/- Ad-cre Ptenfl/fl/Apcfl/fl tumours when assessed by Ki67 
immunohistochemistry. It is known that Ki67 marks cells at any stage of the cell cycle, which 
does not necessarily mean that these cells are mitotic (Scholzen and Gerdes 2000). In order to 
visualize and quantify mitotic cells, phospho-histone 3 (pH3) immunohistochemistry was 
performed. A 2-fold change was observed in the number of mitotic cells in Apc2+/+ vs. Apc2-/- 
Ad-cre Ptenfl/fl/Apcfl/fl tumours (48.5±1.99 vs. 24.1±2.2, mean±S.E., n=3, p<0.05, Figure A6.1). 
It was observed that cells with squamous differentiation present in keratinized areas of Apc2-/- 
Ad-cre Ptenfl/fl/Apcfl/fl tumours, although positively staining for Ki67, are not mitotic 
(negatively staining for pH3) (Figure A6.2). This might indicate that squamous metaplasia of 
OEA cells post-APC2 loss is one of the mechanisms causing reduced tumour growth, by 
inhibiting mitosis. 
 
Figure A6.1: phospho-histone 3 expression is reduced in Ad-cre Ptenfl/fl/Apcfl/fl tumours post-
APC2 loss. Representative photomicrographs of phospho-histone 3 in (a) Apc2+/+, and (b) 
Apc2-/- Ad-cre Ptenfl/fl/Apcfl/fl tumours collected 8-weeks post-induction. n=3. Scale bar 200 
µm. 
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Figure A6.2: Squamous differentiated cells in keratinized areas in APC2-deficient Ad-cre 
Ptenfl/fl/Apcfl/fl tumours are not mitotic. Representative photomicrographs of (a) Ki67, and (b) 
pH3 immunohistochemistry in Apc2-/- Ad-cre Ptenfl/fl/Apcfl/fl tumours. Black arrows: Ki67 
positive cells. Insets show 2X original magnification. n=3. Scale bars 200 µm. 
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Appendix 7: Axin2 RNAscope in Ad-cre Ptenfl/fl/Apcfl/fl OEA. 
As illustrated in Figure 6.31, β-catenin immunostaining was very intense in all tumours 
irrespective of genotype. Another way of visualizing WNT signalling activation in tumours 
was attempted, by visualizing Axin2 RNA expression patterns using the novel in situ 
hybridization technology RNA scope (ACD Biotechne, Canada). Apc2+/+ and Apc2-/- Ad-cre 
Ptenfl/fl/Apcfl/fl tumour tissue sections were hybridized to mouse Axin2 RNAscope probe (ACD 
biotechne, catalogue number 400331). Expression analysis revealed comparable expression of 
Axin2 in Apc2+/+ and Apc2-/- tumours, which was intense and patchy, irrespective of genotype 
(Figure A7.1). As mentioned previously (Section 6.2.5), epithelial glands were more abundant 
and packed together in areas of Apc2+/+ Ad-cre Ptenfl/fl/Apcfl/fl tumours, in contrast to Apc2-/- 
Ad-cre Ptenfl/fl/Apcfl/fl tumours which mostly displayed reduced discrete glands. It was observed 
that areas of glandular differentiation in Apc2+/+ Ad-cre Ptenfl/fl/Apcfl/fl tumours display reduced 
Axin2 expression, as compared to Apc2-/- Ad-cre Ptenfl/fl/Apcfl/fl tumours (Figure A7.1). This 
might indicate that sustained levels of activated WNT signalling in Apc2-/- Ad-cre 
Ptenfl/fl/Apcfl/fl tumours attenuates epithelial glandular differentiation.  
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Figure A7.1: Axin2 RNAscope of Ad-cre Ptenfl/fl/Apcfl/fl tumours. Representative 
photomicrographs of Axin2 RNAscope in Apc2+/+ (upper panels), and Apc2-/- Ad-cre 
Ptenfl/fl/Apcfl/fl tumours (lower panels). Right panels represent 5X magnification of black 
rectangles in left panels. Black arrows: Axin2 positive staining in glands. n=3. Scale bars 500 
µm left panel, 100 µm right panel. 
 
 
